

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/48337 A2(51) International Patent Classification⁷: C12N 14/47,
15/12, A01K 67/027, A61K 38/17, 39/395, C07K 16/18,
C12Q 1/68, G01N 33/50, 33/53

(21) International Application Number: PCT/US01/48517

(22) International Filing Date:
12 December 2001 (12.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/255,639 13 December 2000 (13.12.2000) US
60/257,852 21 December 2000 (21.12.2000) US
60/260,105 5 January 2001 (05.01.2001) US
60/262,932 18 January 2001 (18.01.2001) US
60/263,096 18 January 2001 (18.01.2001) US
60/263,090 19 January 2001 (19.01.2001) US
60/265,926 2 February 2001 (02.02.2001) US(71) Applicant (for all designated States except US): INCYTE
GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo
Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GRIFFIN, Jennifer,
A. [US/US]; 33691 Mello Way, Fremont, CA 94555
(US). YAO, Monique, G. [US/US]; 1189 Woodgate
Drive, Carmel, IN 46033 (US). DUGGAN, Brendan, M.
[AU/US]; 243 Buena Vista Avenue #306, Sunnyvale, CA
94086 (US). YUE, Henry [US/US]; 826 Lois Avenue,
Sunnyvale, CA 94087 (US). DING, Li [CN/US]; 3353
Alma Street #146, Palo Alto, CA 94306 (US). LAL,
Preeti, G. [IN/US]; P.O. Box 5142, Santa Clara, CA
95056 (US). LEE, Ernestine, A. [US/US]; 624 Kains
Street, Albany, CA 94706 (US). RAMKUMAR, Jay-
alaxmi [IN/US]; 34359 Maybird Circle, Fremont, CA
94555 (US). THANGAVELU, Kavitha [US/US]; 1950
Montecito Avenue #23, Mountain View, CA 94043 (US).
XU, Yuming [US/US]; 1739 Walnut Drive, Mountain
View, CA 94040 (US). LEE, Sally [US/US]; 825 East
Evelyn, #425, Sunnyvale, CA 94086 (US). TANG, Y.,
Tom [US/US]; 4230 Ranwick Court, San Jose, CA 95118
(US). NGUYEN, Danniell, B. [US/US]; 1403 Ridgwood
Drive, San Jose, CA 95118 (US). WARREN, Bridget, A.
[US/US]; 10130 Parkwood Drive #2, Cupertino, CA 95014(US). HONCHELL, Cynthia, D. [US/US]; 400 Laurel
Street #203, San Carlos, CA 94070 (US). GIETZEN,
Kimberly, J. [US/US]; 691 Los Huecos Drive, San Jose,
CA 95123 (US). BAUGHN, Mariah, R. [US/US]; 14244
Santiago Road, San Leandro, CA 94577 (US). GANDHI,
Ameena, R. [US/US]; 705 5th Avenue, San Francisco, CA
94118 (US). ARVIZU, Chandra [US/US]; 490 Sherwood
Way #1, Menlo Park, CA 94025 (US). WALIA, Narinder,
K. [US/US]; 890 Davis Street, #205, San Leandro, CA
94577 (US). LU, Yan [CN/US]; 3885 Corrina Way, Palo
Alto, CA 94303 (US). ELLIOTT, Vicki, W. [US/US];
3770 Polton Place Way, San Jose, CA 95121 (US). LU,
Dyung, Aina, M. [US/US]; 233 Coy Drive, San Jose, CA
95123 (US). HAFALIA, April, J., A. [US/US]; 2227 Calle
de Primavera, Santa Clara, CA 95054 (US). AZIMZAI,
Yalda [US/US]; 5518 Boulder Canyon Drive, Castro
Valley, CA 94552 (US). KHAN, Farrah, A. [IN/US];
9445 Harrison Street, Des Plaines, IL 60016 (US). TRAN,
Uyen, K. [US/US]; 2638 Mabury Square, San Jose, CA
95133 (US).(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics,
Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SECRETED PROTEINS

(57) Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

SECRETED PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of secreted proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of secreted proteins.

BACKGROUND OF THE INVENTION

Protein transport and secretion are essential for cellular function. Protein transport is mediated by a signal peptide located at the amino terminus of the protein to be transported or secreted. The signal peptide is comprised of about ten to twenty hydrophobic amino acids which target the nascent protein from the ribosome to a particular membrane bound compartment such as the endoplasmic reticulum (ER). Proteins targeted to the ER may either proceed through the secretory pathway or remain in any of the secretory organelles such as the ER, Golgi apparatus, or lysosomes. Proteins that transit through the secretory pathway are either secreted into the extracellular space or retained in the plasma membrane. Proteins that are retained in the plasma membrane contain one or more transmembrane domains, each comprised of about 20 hydrophobic amino acid residues.

Secreted proteins are generally synthesized as inactive precursors that are activated by post-translational processing events during transit through the secretory pathway. Such events include glycosylation, proteolysis, and removal of the signal peptide by a signal peptidase. Other events that may occur during protein transport include chaperone-dependent unfolding and folding of the nascent protein and interaction of the protein with a receptor or pore complex. Examples of secreted proteins with amino terminal signal peptides are discussed below and include proteins with important roles in cell-to-cell signaling. Such proteins include transmembrane receptors and cell surface markers, extracellular matrix molecules, cytokines, hormones, growth and differentiation factors, enzymes, neuropeptides, vasomediators, cell surface markers, and antigen recognition molecules. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, New York, NY, pp. 557-560, 582-592.)

Cell surface markers include cell surface antigens identified on leukocytic cells of the immune system. These antigens have been identified using systematic, monoclonal antibody (mAb)-based "shot gun" techniques. These techniques have resulted in the production of hundreds of mAbs directed against unknown cell surface leukocytic antigens. These antigens have been grouped into "clusters of differentiation" based on common immunocytochemical localization patterns in various

differentiated and undifferentiated leukocytic cell types. Antigens in a given cluster are presumed to identify a single cell surface protein and are assigned a "cluster of differentiation" or "CD" designation. Some of the genes encoding proteins identified by CD antigens have been cloned and verified by standard molecular biology techniques. CD antigens have been characterized as both
5 transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI). (Reviewed in Barclay, A.N. et al. (1995) The Leucocyte Antigen Facts Book, Academic Press, San Diego, CA, pp. 17-20.)

Matrix proteins (MPs) are transmembrane and extracellular proteins which function in
10 formation, growth, remodeling, and maintenance of tissues and as important mediators and regulators of the inflammatory response. The expression and balance of MPs may be perturbed by biochemical changes that result from congenital, epigenetic, or infectious diseases. In addition, MPs affect leukocyte migration, proliferation, differentiation, and activation in the immune response. MPs are frequently characterized by the presence of one or more domains which may include collagen-like
15 domains, EGF-like domains, immunoglobulin-like domains, and fibronectin-like domains. In addition, MPs may be heavily glycosylated and may contain an Arginine-Glycine-Aspartate (RGD) tripeptide motif which may play a role in adhesive interactions. MPs include extracellular proteins such as fibronectin, collagen, galectin, vitronectin and its proteolytic derivative somatomedin B; and cell adhesion receptors such as cell adhesion molecules (CAMs), cadherins, and integrins. (Reviewed
20 in Ayad, S. et al. (1994) The Extracellular Matrix Facts Book, Academic Press, San Diego, CA, pp. 2-16; Ruoslahti, E. (1997) *Kidney Int.* 51:1413-1417; Sjaastad, M.D. and Nelson, W.J. (1997) *BioEssays* 19:47-55.)

Mucins are highly glycosylated glycoproteins that are the major structural component of the mucus gel. The physiological functions of mucins are cytoprotection, mechanical protection,
25 maintenance of viscosity in secretions, and cellular recognition. MUC6 is a human gastric mucin that is also found in gall bladder, pancreas, seminal vesicles, and female reproductive tract (Toribara, N.W. et al. (1997) *J. Biol. Chem.* 272:16398-16403). The MUC6 gene has been mapped to human chromosome 11 (Toribara, N.W. et al. (1993) *J. Biol. Chem.* 268:5879-5885). Hemomucin is a novel Drosophila surface mucin that may be involved in the induction of antibacterial effector molecules
30 (Theopold, U. et al. (1996) *J. Biol. Chem.* 271:12708-12715).

Tuftelins are one of four different enamel matrix proteins that have been identified so far. The other three known enamel matrix proteins are the amelogenins, enamelin and ameloblastin. Assembly of the enamel extracellular matrix from these component proteins is believed to be critical in producing a matrix competent to undergo mineral replacement. (Paine, C.T. et al. (1998) *Connect*
35 *Tissue Res.* 38:257-267). Tuftelin mRNA has been found to be expressed in human ameloblastoma

tumor, a non-mineralized odontogenic tumor (Deutsch, D. et al. (1998) Connect. Tissue Res. 39:177-184).

Olfactomedin-related proteins are extracellular matrix, secreted glycoproteins with conserved C-terminal motifs. They are expressed in a wide variety of tissues and in broad range of species, from *Caenorhabditis elegans* to *Homo sapiens*. Olfactomedin-related proteins comprise a gene family with at least 5 family members in humans. One of the five, TIGR/myocilin protein, is expressed in the eye and is associated with the pathogenesis of glaucoma (Kulkarni, N.H. et al. (2000) Genet. Res. 76:41-50). Research by Yokoyama et al. (1996) found a 135-amino acid protein, termed AMY, having 96% sequence identity with rat neuronal olfactomedin-related ER localized protein in a neuroblastoma cell line cDNA library, suggesting an essential role for AMY in nerve tissue (Yokoyama, M. et al. (1996) DNA Res. 3:311-320). Neuron-specific olfactomedin-related glycoproteins isolated from rat brain cDNA libraries show strong sequence similarity with olfactomedin. This similarity is suggestive of a matrix-related function of these glycoproteins in neurons and neurosecretory cells (Danielson, P.E. et al. (1994) J. Neurosci. Res. 38:468-478).

Mac-2 binding protein is a 90-kD serum protein (90K), a secreted glycoprotein isolated from both the human breast carcinoma cell line SK-BR-3, and human breast milk. It specifically binds to a human macrophage-associated lectin, Mac-2. Structurally, the mature protein is 567 amino acids in length and is preceded by an 18-amino acid leader. There are 16 cysteines and seven potential N-linked glycosylation sites. The first 106 amino acids represent a domain very similar to an ancient protein superfamily defined by a macrophage scavenger receptor cysteine-rich domain (Koths, K. et al. (1993) J. Biol. Chem. 268:14245-14249). 90K is elevated in the serum of subpopulations of AIDS patients and is expressed at varying levels in primary tumor samples and tumor cell lines. Ullrich et al. (1994) have demonstrated that 90K stimulates host defense systems and can induce interleukin-2 secretion. This immune stimulation is proposed to be a result of oncogenic transformation, viral infection or pathogenic invasion (Ullrich, A. et al. (1994) J. Biol. Chem. 269:18401-18407).

Semaphorins are a large group of axonal guidance molecules consisting of at least 30 different members and are found in vertebrates, invertebrates, and even certain viruses. All semaphorins contain the sema domain which is approximately 500 amino acids in length. Neuropilin, a semaphorin receptor, has been shown to promote neurite outgrowth in vitro. The extracellular region of neuropilins consists of three different domains: CUB, discoidin, and MAM domains. The CUB and the MAM motifs of neuropilin have been suggested to have roles in protein-protein interactions and are thought to be involved in the binding of semaphorins through the sema and the C-terminal domains (reviewed in Raper, J.A. (2000) Curr. Opin. Neurobiol. 10:88-94). Plexins are neuronal cell surface molecules that mediate cell adhesion via a homophilic binding mechanism in the presence of calcium ions. Plexins have been shown to be expressed in the receptors and neurons of

particular sensory systems (Ohta, K. et al. (1995) Cell 14:1189-1199). There is evidence that suggests that some plexins function to control motor and CNS axon guidance in the developing nervous system. Plexins, which themselves contain complete semaphorin domains, may be both the ancestors of classical semaphorins and binding partners for semaphorins (Winberg, M.L. et al (1998) Cell 95:903-916).

Human pregnancy-specific beta 1-glycoprotein (PSG) is a family of closely related glycoproteins of molecular weights of 72 KDa, 64KDa, 62KDa, and 54KDa. Together with the carcinoembryonic antigen, they comprise a subfamily within the immunoglobulin superfamily (Plouzek, C.A. and Chou, J.Y. (1991) Endocrinology 129:950-958) Different subpopulations of PSG have been found to be produced by the trophoblasts of the human placenta, and the amnionic and chorionic membranes (Plouzek, C.A. et al. (1993) Placenta 14:277-285).

Autocrine motility factor (AMF) is one of the motility cytokines regulating tumor cell migration; therefore identification of the signaling pathway coupled with it has critical importance. Autocrine motility factor receptor (AMFR) expression has been found to be associated with tumor progression in thymoma (Ohta Y. et al. (2000) Int. J. Oncol. 17:259-264). AMFR is a cell surface glycoprotein of molecular weight 78KDa.

Hormones are signaling molecules that coordinately regulate basic physiological processes from embryogenesis throughout adulthood. These processes include metabolism, respiration, reproduction, excretion, fetal tissue differentiation and organogenesis, growth and development, homeostasis, and the stress response. Hormonal secretions and the nervous system are tightly integrated and interdependent. Hormones are secreted by endocrine glands, primarily the hypothalamus and pituitary, the thyroid and parathyroid, the pancreas, the adrenal glands, and the ovaries and testes.

The secretion of hormones into the circulation is tightly controlled. Hormones are often secreted in diurnal, pulsatile, and cyclic patterns. Hormone secretion is regulated by perturbations in blood biochemistry, by other upstream-acting hormones, by neural impulses, and by negative feedback loops. Blood hormone concentrations are constantly monitored and adjusted to maintain optimal, steady-state levels. Once secreted, hormones act only on those target cells that express specific receptors.

Most disorders of the endocrine system are caused by either hyposecretion or hypersecretion of hormones. Hyposecretion often occurs when a hormone's gland of origin is damaged or otherwise impaired. Hypersecretion often results from the proliferation of tumors derived from hormone-secreting cells. Inappropriate hormone levels may also be caused by defects in regulatory feedback loops or in the processing of hormone precursors. Endocrine malfunction may also occur when the target cell fails to respond to the hormone.

Hormones can be classified biochemically as polypeptides, steroids, eicosanoids, or amines. Polypeptide hormones, which include diverse hormones such as insulin and growth hormone, vary in size and function and are often synthesized as inactive precursors that are processed intracellularly into mature, active forms. Amine hormones, which include epinephrine and dopamine, are amino acid derivatives that function in neuroendocrine signaling. Steroid hormones, which include the cholesterol-derived hormones estrogen and testosterone, function in sexual development and reproduction. Eicosanoid hormones, which include prostaglandins and prostacyclins, are fatty acid derivatives that function in a variety of processes. Most polypeptide hormones and some amine hormones are soluble in the circulation where they are highly susceptible to proteolytic degradation within seconds after their secretion. Steroid hormones and eicosanoid hormones are insoluble and must be transported in the circulation by carrier proteins. The following discussion will focus primarily on polypeptide hormones.

Hormones secreted by the hypothalamus and pituitary gland play a critical role in endocrine function by coordinately regulating hormonal secretions from other endocrine glands in response to neural signals. Hypothalamic hormones include thyrotropin-releasing hormone, gonadotropin-releasing hormone, somatostatin, growth-hormone releasing factor, corticotropin-releasing hormone, substance P, dopamine, and prolactin-releasing hormone. These hormones directly regulate the secretion of hormones from the anterior lobe of the pituitary. Hormones secreted by the anterior pituitary include adrenocorticotrophic hormone (ACTH), melanocyte-stimulating hormone, somatotrophic hormones such as growth hormone and prolactin, glycoprotein hormones such as thyroid-stimulating hormone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), β -lipotropin, and β -endorphins. These hormones regulate hormonal secretions from the thyroid, pancreas, and adrenal glands, and act directly on the reproductive organs to stimulate ovulation and spermatogenesis. The posterior pituitary synthesizes and secretes antidiuretic hormone (ADH, vasopressin) and oxytocin.

Disorders of the hypothalamus and pituitary often result from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma. Such disorders have profound effects on the function of other endocrine glands. Disorders associated with hypopituitarism include hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism. Disorders associated with hyperpituitarism include acromegaly, gigantism, and syndrome of inappropriate ADH secretion (SIADH), often caused by benign adenomas.

Hormones secreted by the thyroid and parathyroid primarily control metabolic rates and the regulation of serum calcium levels, respectively. Thyroid hormones include calcitonin, somatostatin,

and thyroid hormone. The parathyroid secretes parathyroid hormone. Disorders associated with hypothyroidism include goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism. Disorders associated with hyperthyroidism include thyrotoxicosis and its various
5 forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease. Disorders associated with hyperparathyroidism include Conn disease (chronic hypercalcemia) leading to bone resorption and parathyroid hyperplasia.

Hormones secreted by the pancreas regulate blood glucose levels by modulating the rates of carbohydrate, fat, and protein metabolism. Pancreatic hormones include insulin, glucagon, amylin, γ -
10 aminobutyric acid, gastrin, somatostatin, and pancreatic polypeptide. The principal disorder associated with pancreatic dysfunction is diabetes mellitus caused by insufficient insulin activity. Diabetes mellitus is generally classified as either Type I (insulin-dependent, juvenile diabetes) or Type II (non-insulin-dependent, adult diabetes). The treatment of both forms by insulin replacement therapy is well known. Diabetes mellitus often leads to acute complications such as hypoglycemia
15 (insulin shock), coma, diabetic ketoacidosis, lactic acidosis, and chronic complications leading to disorders of the eye, kidney, skin, bone, joint, cardiovascular system, nervous system, and to decreased resistance to infection.

The anatomy, physiology, and diseases related to hormonal function are reviewed in McCance, K. L. and Huether, S. E. (1994) Pathophysiology: The Biological Basis for Disease in
20 Adults and Children, Mosby-Year Book, Inc., St. Louis, MO; Greenspan, F. S. and Baxter, J. D. (1994) Basic and Clinical Endocrinology, Appleton and Lange, East Norwalk, CT.

Growth factors are secreted proteins that mediate intercellular communication. Unlike hormones, which travel great distances via the circulatory system, most growth factors are primarily local mediators that act on neighboring cells. Most growth factors contain a hydrophobic N-terminal
25 signal peptide sequence which directs the growth factor into the secretory pathway. Most growth factors also undergo post-translational modifications within the secretory pathway. These modifications can include proteolysis, glycosylation, phosphorylation, and intramolecular disulfide bond formation. Once secreted, growth factors bind to specific receptors on the surfaces of neighboring target cells, and the bound receptors trigger intracellular signal transduction pathways.
30 These signal transduction pathways elicit specific cellular responses in the target cells. These responses can include the modulation of gene expression and the stimulation or inhibition of cell division, cell differentiation, and cell motility.

Growth factors fall into at least two broad and overlapping classes. The broadest class includes the large polypeptide growth factors, which are wide-ranging in their effects. These factors
35 include epidermal growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor- β

(TGF- β), insulin-like growth factor (IGF), nerve growth factor (NGF), and platelet-derived growth factor (PDGF), each defining a family of numerous related factors. The large polypeptide growth factors, with the exception of NGF, act as mitogens on diverse cell types to stimulate wound healing, bone synthesis and remodeling, extracellular matrix synthesis, and proliferation of epithelial, epidermal, and connective tissues. Members of the TGF- β , EGF, and FGF families also function as inductive signals in the differentiation of embryonic tissue. NGF functions specifically as a neurotrophic factor, promoting neuronal growth and differentiation.

Another class of growth factors includes the hematopoietic growth factors, which are narrow in their target specificity. These factors stimulate the proliferation and differentiation of blood cells such as B-lymphocytes, T-lymphocytes, erythrocytes, platelets, eosinophils, basophils, neutrophils, macrophages, and their stem cell precursors. These factors include the colony-stimulating factors (G-CSF, M-CSF, GM-CSF, and CSF1-3), erythropoietin, and the cytokines. The cytokines are specialized hematopoietic factors secreted by cells of the immune system and are discussed in detail below.

Hormones travel through the circulation and bind to specific receptors on the surface of, or within, target cells. Although they have diverse biochemical compositions and mechanisms of action, hormones can be grouped into two categories. One category includes small lipophilic hormones that diffuse through the plasma membrane of target cells, bind to cytosolic or nuclear receptors, and form a complex that alters gene expression. Examples of these molecules include retinoic acid, thyroxine, and the cholesterol-derived steroid hormones such as progesterone, estrogen, testosterone, cortisol, and aldosterone. The second category includes hydrophilic hormones that function by binding to cell surface receptors that transduce signals across the plasma membrane. Examples of such hormones include amino acid derivatives such as catecholamines (epinephrine, norepinephrine) and histamine, and peptide hormones such as glucagon, insulin, gastrin, secretin, cholecystokinin, adrenocorticotrophic hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating hormone, and vasopressin. (See, for example, Lodish et al. (1995) Molecular Cell Biology, Scientific American Books Inc., New York, NY, pp. 856-864.)

Pro-opiomelanocortin (POMC) is the precursor polypeptide of corticotropin (ACTH), a hormone synthesized by the anterior pituitary gland, which functions in the stimulation of the adrenal cortex. POMC is also the precursor polypeptide of the hormone beta-lipotropin (beta-LPH). Each hormone includes smaller peptides with distinct biological activities: alpha-melanotropin (alpha-MSH) and corticotropin-like intermediate lobe peptide (CLIP) are formed from ACTH; gamma-lipotropin (gamma-LPH) and beta-endorphin are peptide components of beta-LPH; while beta-MSH is contained within gamma-LPH. Adrenal insufficiency due to ACTH deficiency, resulting from a genetic mutation in exons 2 and 3 of POMC results in an endocrine disorder characterized by early-

onset obesity, adrenal insufficiency, and red hair pigmentation (Chretien, M. et al. (1979) Can. J. Biochem. 57:1111-1121; Krude, H. et al. (1998) Nat. Genet. 19:155-157; Online Mendelian Inheritance in Man (OMIM) 176830).

Growth and differentiation factors are secreted proteins which function in intercellular communication. Some factors require oligomerization or association with membrane proteins for activity. Complex interactions among these factors and their receptors trigger intracellular signal transduction pathways that stimulate or inhibit cell division, cell differentiation, cell signaling, and cell motility. Most growth and differentiation factors act on cells in their local environment (paracrine signaling). There are three broad classes of growth and differentiation factors. The first class includes the large polypeptide growth factors such as epidermal growth factor (EGF), fibroblast growth factor, transforming growth factor, insulin-like growth factor (IGF), and platelet-derived growth factor. EGF includes a 30-40 residue EGF repeat domain, composed of conserved cysteine and glycine residues, found in a variety of proteins involved in cell proliferation, including the leukocyte antigen CD97 and the Notch family proteins (Greener, M. (2000) Mol. Med. Today 6:139-140). IGF forms a heterotrimeric complex with IGF-binding-protein 3 and the acid-labile subunit (ALS). ALS is largely composed of 18-20 leucine-rich repeats of 24 amino acids (Leong, S.R. et al. (1992) Mol. Endocrinol. 6:870-876). The second class includes the hematopoietic growth factors such as the colony stimulating factors (CSFs). Hematopoietic growth factors stimulate the proliferation and differentiation of blood cells such as B-lymphocytes, T-lymphocytes, erythrocytes, platelets, eosinophils, basophils, neutrophils, macrophages, and their stem cell precursors. The third class includes small peptide factors such as bombesin, vasopressin, oxytocin, endothelin, transferrin, angiotensin II, vasoactive intestinal peptide, and bradykinin, which function as hormones to regulate cellular functions other than proliferation.

Growth and differentiation factors play critical roles in neoplastic transformation of cells in vitro and in tumor progression in vivo. Inappropriate expression of growth factors by tumor cells may contribute to vascularization and metastasis of tumors. During hematopoiesis, growth factor misregulation can result in anemias, leukemias, and lymphomas. Certain growth factors such as interferon are cytotoxic to tumor cells both in vivo and in vitro. Moreover, some growth factors and growth factor receptors are related both structurally and functionally to oncoproteins. In addition, growth factors affect transcriptional regulation of both proto-oncogenes and oncosuppressor genes. (Reviewed in Pimentel, E. (1994) Handbook of Growth Factors, CRC Press, Ann Arbor, MI, pp. 1-9.)

In addition, some of the large polypeptide growth factors play crucial roles in the induction of the primordial germ layers in the developing embryo. This induction ultimately results in the formation of the embryonic mesoderm, ectoderm, and endoderm which in turn provide the framework for the entire adult body plan. Disruption of this inductive process would be catastrophic

to embryonic development. One such growth factor, wnt, is a secreted glycoprotein that has activity as both a short-range inducer and as a long-range morphogen (for a review, see Howes, R. and S. Bray (2000) *Current Biology* 10:R222-R226). Wnt signaling is implicated in diseases including cancer and Alzheimer's Disease (Bienz, M. and H. Clevers (2000) *Cell* 103:311-320; Polakis, P. (2000) *Genes Dev.* 14:1837-1851; De Ferrari, G.V. and N.C. Inestrosa (2000) *Brain Res. Brain. Res. Rev.* 33:1-12). Chordin is a developmental protein that binds to ventralizing TGF-beta-like bone morphogenetic proteins (BMPs) and sequesters them in latent complexes, causing dorsalization of tissue (Pappano, W. N. et al. (1998) *Genomics* 52:236-239). Other developmental proteins that regulate BMPs include noggin, cerberus, dan, and gremlin (Schmitt, J.M. et al. (1999) *J. Orthop. Res.* 17:269-278).

The Slit protein, first identified in *Drosophila*, is critical in central nervous system midline formation and potentially in nervous tissue histogenesis and axonal pathfinding. Itoh et al. ((1998) *Brain Res. Mol. Brain Res.* 62:175-186) have identified mammalian homologues of the slit gene (human Slit-1, Slit-2, Slit-3 and rat Slit-1). The encoded proteins are putative secreted proteins containing EGF-like motifs and leucine-rich repeats, both of which are conserved protein-protein interaction domains. Slit-1, -2, and -3 mRNAs are expressed in the brain, spinal cord, and thyroid, respectively (Itoh, A. et al., *supra*). The Slit family of proteins are indicated to be functional ligands of glypican-1 in nervous tissue and it is suggested that their interactions may be critical in certain stages during central nervous system histogenesis (Liang, Y. et al. (1999) *J. Biol. Chem.* 274:17885-17892).

Neuropeptides and vasomediators (NP/VM) comprise a large family of endogenous signaling molecules. Included in this family are neuropeptides and neuropeptide hormones such as bombesin, neuropeptide Y, neurotensin, neuromedin N, melanocortins, opioids, galanin, somatostatin, tachykinins, urotensin II and related peptides involved in smooth muscle stimulation, vasopressin, vasoactive intestinal peptide, and circulatory system-borne signaling molecules such as angiotensin, complement, calcitonin, endothelins, formyl-methionyl peptides, glucagon, cholecystokinin and gastrin. NP/VMs can transduce signals directly, modulate the activity or release of other neurotransmitters and hormones, and act as catalytic enzymes in cascades. The effects of NP/VMs range from extremely brief to long-lasting. (Reviewed in Martin, C.R. et al. (1985) *Endocrine Physiology*, Oxford University Press, New York, NY, pp. 57-62.)

NP/VMs are involved in numerous neurological and cardiovascular disorders. For example, neuropeptide Y is involved in hypertension, congestive heart failure, affective disorders, and appetite regulation. Somatostatin inhibits secretion of growth hormone and prolactin in the anterior pituitary, as well as inhibiting secretion in intestine, pancreatic acinar cells, and pancreatic beta-cells. A reduction in somatostatin levels has been reported in Alzheimer's disease and Parkinson's disease.

Vasopressin acts in the kidney to increase water and sodium absorption, and in higher concentrations stimulates contraction of vascular smooth muscle, platelet activation, and glycogen breakdown in the liver. Vasopressin and its analogues are used clinically to treat diabetes insipidus. Endothelin and angiotensin are involved in hypertension, and drugs, such as captopril, which reduce plasma levels of
5 angiotensin, are used to reduce blood pressure (Watson, S. and S. Arkininstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 194; 252; 284; 55; 111).

Neuropeptides have also been shown to have roles in nociception (pain). Vasoactive intestinal peptide appears to play an important role in chronic neuropathic pain. Nociceptin, an endogenous ligand for the opioid receptor-like 1 receptor, is thought to have a predominantly anti-
10 nociceptive effect, and has been shown to have analgesic properties in different animal models of tonic or chronic pain (Dickinson, T. and Fleetwood-Walker, S.M. (1998) *Trends Pharmacol. Sci.* 19:346-348).

Cytokines comprise a family of signaling molecules that modulate the immune system and the inflammatory response. Cytokines are usually secreted by leukocytes, or white blood cells, in
15 response to injury or infection. Cytokines function as growth and differentiation factors that act primarily on cells of the immune system such as B- and T-lymphocytes, monocytes, macrophages, and granulocytes. Like other signaling molecules, cytokines bind to specific plasma membrane receptors and trigger intracellular signal transduction pathways which alter gene expression patterns. There is considerable potential for the use of cytokines in the treatment of inflammation and immune
20 system disorders.

Cytokine structure and function have been extensively characterized in vitro. Most cytokines are small polypeptides of about 30 kilodaltons or less. Over 50 cytokines have been identified from human and rodent sources. Examples of cytokine subfamilies include the interferons (IFN- α , - β , and - γ), the interleukins (IL1-IL13), the tumor necrosis factors (TNF- α and - β), and the chemokines.
25 Many cytokines have been produced using recombinant DNA techniques, and the activities of individual cytokines have been determined in vitro. These activities include regulation of leukocyte proliferation, differentiation, and motility.

The activity of an individual cytokine in vitro may not reflect the full scope of that cytokine's activity in vivo. Cytokines are not expressed individually in vivo but are instead expressed in
30 combination with a multitude of other cytokines when the organism is challenged with a stimulus. Together, these cytokines collectively modulate the immune response in a manner appropriate for that particular stimulus. Therefore, the physiological activity of a cytokine is determined by the stimulus itself and by complex interactive networks among co-expressed cytokines which may demonstrate both synergistic and antagonistic relationships.

35 Chemokines comprise a cytokine subfamily with over 30 members. (Reviewed in Wells, T.

N. C. and Peitsch, M. C. (1997) *J. Leukoc. Biol.* 61:545-550.) Chemokines were initially identified as chemotactic proteins that recruit monocytes and macrophages to sites of inflammation. Recent evidence indicates that chemokines may also play key roles in hematopoiesis and HIV-1 infection. Chemokines are small proteins which range from about 6-15 kilodaltons in molecular weight.

- 5 Chemokines are further classified as C, CC, CXC, or CX₃C based on the number and position of critical cysteine residues. The CC chemokines, for example, each contain a conserved motif consisting of two consecutive cysteines followed by two additional cysteines which occur downstream at 24- and 16-residue intervals, respectively (ExPASy PROSITE database, documents PS00472 and PDOC00434). The presence and spacing of these four cysteine residues are highly
- 10 conserved, whereas the intervening residues diverge significantly. However, a conserved tyrosine located about 15 residues downstream of the cysteine doublet seems to be important for chemotactic activity. Most of the human genes encoding CC chemokines are clustered on chromosome 17, although there are a few examples of CC chemokine genes that map elsewhere. Other chemokines include lymphotactin (C chemokine); macrophage chemotactic and activating factor (MCAF/MCP-1;
- 15 CC chemokine); platelet factor 4 and IL-8 (CXC chemokines); and fractalkine and neurotractin (CX₃C chemokines). (Reviewed in Luster, A. D. (1998) *N. Engl. J. Med.* 338:436-445.)

- Other proteins that contain signal peptides include secreted proteins with enzymatic activity. Such activity includes, for example, oxidoreductase/dehydrogenase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, or ligase activity. For example, matrix
- 20 metalloproteinases are secreted hydrolytic enzymes that degrade the extracellular matrix and thus play an important role in tumor metastasis, tissue morphogenesis, and arthritis (Reponen, P. et al. (1995) *Dev. Dyn.* 202:388-396; Firestein, G.S. (1992) *Curr. Opin. Rheumatol.* 4:348-354; Ray, J.M. and Stetler-Stevenson, W.G. (1994) *Eur. Respir. J.* 7:2062-2072; and Mignatti, P. and Rifkin, D.B. (1993) *Physiol. Rev.* 73:161-195). The catalytic protein disulfide isomerase (PDI) is found in
- 25 membrane-bound eukaryotic compartments such as the endoplasmic reticulum (ER). It facilitates disulfide bond exchange as well as correct glycosylation. Edman et al. (1995; *Nature* 317:267-70) reported that rat PDI is useful for the *in vitro* production and folding of recombinant human proteins. Likewise, purified PDI is also commercially useful for the production and folding of recombinant, therapeutic human proteins such as tissue plasminogen activator (tPA). Ceruloplasmin is a serum
- 30 multicopper oxidase which plays a role in iron metabolism. Aceruloplasminemia is characterized by diabetes, retinal degeneration, and neurologic symptoms (for a review, see Gitlin, J.D. (1998) *Pediatr. Res.* 4:271-276). Additional examples are the acetyl-CoA synthetases which activate acetate for use in lipid synthesis or energy generation (Luong, A. et al. (2000) *J. Biol. Chem.* 275:26458-26466). The result of acetyl-CoA synthetase activity is the formation of acetyl-CoA from acetate and CoA.
- 35 Acetyl-CoA synthetases share a region of sequence similarity identified as the AMP-binding domain

signature. Acetyl-CoA synthetase has been shown to be associated with hypertension (Toh, H. (1991) Protein Seq. Data Anal. 4:111-117; and Iwai, N. et al. (1994) Hypertension 23:375-380).

A number of isomerases catalyze steps in protein folding, phototransduction, and various anabolic and catabolic pathways. One class of isomerases is known as peptidyl-prolyl *cis-trans* isomerases (PPIases). PPIases catalyze the *cis* to *trans* isomerization of certain proline imidic bonds in proteins. Two families of PPIases are the FK506 binding proteins (FKBPs), and cyclophilins (CyPs). FKBPs bind the potent immunosuppressants FK506 and rapamycin, thereby inhibiting signaling pathways in T-cells. Specifically, the PPIase activity of FKBPs is inhibited by binding of FK506 or rapamycin. There are five members of the FKBP family which are named according to their calculated molecular masses (FKBP12, FKBP13, FKBP25, FKBP52, and FKBP65), and localized to different regions of the cell where they associate with different protein complexes (Coss, M. et al. (1995) J. Biol. Chem. 270:29336-29341; Schreiber, S.L. (1991) Science 251:283-287).

The peptidyl-prolyl isomerase activity of CyP may be part of the signaling pathway that leads to T-cell activation. CyP isomerase activity is associated with protein folding and protein trafficking, and may also be involved in assembly/disassembly of protein complexes and regulation of protein activity. For example, in *Drosophila*, the CyP NinaA is required for correct localization of rhodopsins, while a mammalian CyP (Cyp40) is part of the Hsp90/Hsc70 complex that binds steroid receptors. The mammalian CypA has been shown to bind the *gag* protein from human immunodeficiency virus 1 (HIV-1), an interaction that can be inhibited by cyclosporin. Since cyclosporin has potent anti-HIV-1 activity, CypA may play an essential function in HIV-1 replication. Finally, Cyp40 has been shown to bind and inactivate the transcription factor c-Myb, an effect that is reversed by cyclosporin. This effect implicates CyPs in the regulation of transcription, transformation, and differentiation (Bergsma, D.J. et al (1991) J. Biol. Chem. 266:23204-23214; Hunter, T. (1998) Cell 92:141-143; and Levenson, J.D. and Ness, S.A. (1998) Mol. Cell. 1:203-211).

Gamma-carboxyglutamic acid (Gla) proteins rich in proline (PRGPs) are members of a family of vitamin K-dependent single-pass integral membrane proteins. These proteins are characterized by an extracellular amino terminal domain of approximately 45 amino acids rich in Gla. The intracellular carboxyl terminal region contains one or two copies of the sequence PPXY, a motif present in a variety of proteins involved in such diverse cellular functions as signal transduction, cell cycle progression, and protein turnover (Kulman, J.D. et al. (2001) Proc. Natl. Acad. Sci. USA 98:1370-1375). The process of post-translational modification of glutamic residues to form Gla is Vitamin K-dependent carboxylation. Proteins which contain Gla include plasma proteins involved in blood coagulation. These proteins are prothrombin, proteins C, S, and Z, and coagulation factors VII, IX, and X. Osteocalcin (bone-Gla protein, BGP) and matrix Gla-protein (MGP) also contain Gla (Friedman, P.A. and C.T. Przysiecki (1987) Int. J. Biochem. 19:1-7; C. Vermeer (1990) Biochem. J.

266:625-636).

Immunoglobulins

Antigen recognition molecules are key players in the sophisticated and complex immune systems which all vertebrates have developed to provide protection from viral, bacterial, fungal, and parasitic infections. A key feature of the immune system is its ability to distinguish foreign molecules, or antigens, from "self" molecules. This ability is mediated primarily by secreted and transmembrane proteins expressed by leukocytes (white blood cells) such as lymphocytes, granulocytes, and monocytes. Most of these proteins belong to the immunoglobulin (Ig) superfamily, members of which contain one or more repeats of a conserved structural domain. This Ig domain is comprised of antiparallel β sheets joined by a disulfide bond in an arrangement called the Ig fold. The criteria for a protein to be a member of the Ig superfamily is to have one or more Ig domains, which are regions of 70-110 amino acid residues in length homologous to either Ig variable-like (V) or Ig constant-like (C) domains. Members of the Ig superfamily include antibodies (Ab), T cell receptors (TCRs), class I and II major histocompatibility (MHC) proteins and immune cell-specific surface markers such as the "cluster of differentiation" or CD antigens, CD2, CD3, CD4, CD8, poly-Ig receptors, Fc receptors, neural cell-adhesion molecule (NCAM) and platelet-derived growth factor receptor (PDGFR).

Ig domains (V and C) are regions of conserved amino acid residues that give a polypeptide a globular tertiary structure called an immunoglobulin (or antibody) fold, which consists of two approximately parallel layers of β -sheets. Conserved cysteine residues form an intrachain disulfide-bonded loop, 55-75 amino acid residues in length, which connects the two layers of β -sheets. Each β -sheet has three or four anti-parallel β -strands of 5-10 amino acid residues. Hydrophobic and hydrophilic interactions of amino acid residues within the β -strands stabilize the Ig fold (hydrophobic on inward facing amino acid residues and hydrophilic on the amino acid residues in the outward facing portion of the strands). A V domain consists of a longer polypeptide than a C domain, with an additional pair of β -strands in the Ig fold.

A consistent feature of Ig superfamily genes is that each sequence of an Ig domain is encoded by a single exon. It is possible that the superfamily evolved from a gene coding for a single Ig domain involved in mediating cell-cell interactions. New members of the superfamily then arose by exon and gene duplications. Modern Ig superfamily proteins contain different numbers of V and/or C domains. Another evolutionary feature of this superfamily is the ability to undergo DNA rearrangements, a unique feature retained by the antigen receptor members of the family.

Many members of the Ig superfamily are integral plasma membrane proteins with extracellular Ig domains. The hydrophobic amino acid residues of their transmembrane domains and

their cytoplasmic tails are very diverse, with little or no homology among Ig family members or to known signal-transducing structures. There are exceptions to this general superfamily description. For example, the cytoplasmic tail of PDGFR has tyrosine kinase activity. In addition Thy-1 is a glycoprotein found on thymocytes and T cells. This protein has no cytoplasmic tail, but is instead
5 attached to the plasma membrane by a covalent glycoposphatidylinositol linkage.

Another common feature of many Ig superfamily proteins is the interactions between Ig domains which are essential for the function of these molecules. Interactions between Ig domains of a multimeric protein can be either homophilic or heterophilic (i.e., between the same or different Ig domains). Antibodies are multimeric proteins which have both homophilic and heterophilic
10 interactions between Ig domains. Pairing of constant regions of heavy chains forms the Fc region of an antibody and pairing of variable regions of light and heavy chains form the antigen binding site of an antibody. Heterophilic interactions also occur between Ig domains of different molecules. These interactions provide adhesion between cells for significant cell-cell interactions in the immune system and in the developing and mature nervous system. (Reviewed in Abbas, A.K. et al. (1991) Cellular
15 and Molecular Immunology, W.B. Saunders Company, Philadelphia, PA, pp.142-145.)

Antibodies

MHC proteins are cell surface markers that bind to and present foreign antigens to T cells. MHC molecules are classified as either class I or class II. Class I MHC molecules (MHC I) are expressed on the surface of almost all cells and are involved in the presentation of antigen to
20 cytotoxic T cells. For example, a cell infected with virus will degrade intracellular viral proteins and express the protein fragments bound to MHC I molecules on the cell surface. The MHC I/antigen complex is recognized by cytotoxic T-cells which destroy the infected cell and the virus within. Class II MHC molecules are expressed primarily on specialized antigen-presenting cells of the immune system, such as B-cells and macrophages. These cells ingest foreign proteins from the
25 extracellular fluid and express MHC II/antigen complex on the cell surface. This complex activates helper T-cells, which then secrete cytokines and other factors that stimulate the immune response. MHC molecules also play an important role in organ rejection following transplantation. Rejection occurs when the recipient's T-cells respond to foreign MHC molecules on the transplanted organ in the same way as to self MHC molecules bound to foreign antigen. (Reviewed in Alberts, B. et al.
30 (1994) Molecular Biology of the Cell, Garland Publishing, New York, NY, pp. 1229-1246.)

Antibodies are multimeric members of the Ig superfamily which are either expressed on the surface of B-cells or secreted by B-cells into the circulation. Antibodies bind and neutralize foreign antigens in the blood and other extracellular fluids. The prototypical antibody is a tetramer consisting of two identical heavy polypeptide chains (H-chains) and two identical light polypeptide chains (L-
35 chains) interlinked by disulfide bonds. This arrangement confers the characteristic Y-shape to

antibody molecules. Antibodies are classified based on their H-chain composition. The five antibody classes, IgA, IgD, IgE, IgG and IgM, are defined by the α , δ , ϵ , γ , and μ H-chain types. There are two types of L-chains, κ and λ , either of which may associate as a pair with any H-chain pair. IgG, the most common class of antibody found in the circulation, is tetrameric, while the other classes of antibodies are generally variants or multimers of this basic structure.

H-chains and L-chains each contain an N-terminal variable region and a C-terminal constant region. The constant region consists of about 110 amino acids in L-chains and about 330 or 440 amino acids in H-chains. The amino acid sequence of the constant region is nearly identical among H- or L-chains of a particular class. The variable region consists of about 110 amino acids in both H- and L-chains. However, the amino acid sequence of the variable region differs among H- or L-chains of a particular class. Within each H- or L-chain variable region are three hypervariable regions of extensive sequence diversity, each consisting of about 5 to 10 amino acids. In the antibody molecule, the H- and L-chain hypervariable regions come together to form the antigen recognition site. (Reviewed in Alberts, B. et al. supra, pp. 1206-1213 and 1216-1217.)

Both H-chains and L-chains contain the repeated Ig domains of members of the Ig superfamily. For example, a typical H-chain contains four Ig domains, three of which occur within the constant region and one of which occurs within the variable region and contributes to the formation of the antigen recognition site. Likewise, a typical L-chain contains two Ig domains, one of which occurs within the constant region and one of which occurs within the variable region.

The immune system is capable of recognizing and responding to any foreign molecule that enters the body. Therefore, the immune system must be armed with a full repertoire of antibodies against all potential antigens. Such antibody diversity is generated by somatic rearrangement of gene segments encoding variable and constant regions. These gene segments are joined together by site-specific recombination which occurs between highly conserved DNA sequences that flank each gene segment. Because there are hundreds of different gene segments, millions of unique genes can be generated combinatorially. In addition, imprecise joining of these segments and an unusually high rate of somatic mutation within these segments further contribute to the generation of a diverse antibody population.

The discovery of new secreted proteins, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of secreted proteins.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, secreted proteins, referred to collectively as "SECP" and individually as "SECP-1," "SECP-2," "SECP-3," "SECP-4," "SECP-5," "SECP-6," "SECP-7," "SECP-8," "SECP-9," "SECP-10," "SECP-11," "SECP-12," "SECP-13," "SECP-14," "SECP-15," "SECP-16," "SECP-17," "SECP-18," "SECP-19," "SECP-20," "SECP-21," "SECP-22," "SECP-23," "SECP-24," "SECP-25," "SECP-26," "SECP-27," "SECP-28," "SECP-29," "SECP-30," "SECP-31," "SECP-32," "SECP-33," "SECP-34," "SECP-35," "SECP-36," "SECP-37," "SECP-38," "SECP-39," "SECP-40," "SECP-41," "SECP-42," "SECP-43," "SECP-44," "SECP-45," "SECP-46," "SECP-47," "SECP-48," "SECP-49," "SECP-50," "SECP-51," "SECP-52," "SECP-53," and "SECP-54." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-54.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-54. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:55-108.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the

invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a naturally occurring amino acid sequence at least
5 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is
10 transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a
15 naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54.

The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID
20 NO:55-108, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group
30 consisting of SEQ ID NO:55-108, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous
35 nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and

which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous

5 nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at
10 least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target
15 polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected
20 from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-
25 54. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional SECP, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected
30 from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54. The method comprises a) exposing a sample comprising the
35

polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional SECP, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional SECP, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group

consisting of SEQ ID NO:1-54. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability scores for the matches between each polypeptide and its homolog(s) are also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing

the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

5 “SECP” refers to the amino acid sequences of substantially purified SECP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

 The term “agonist” refers to a molecule which intensifies or mimics the biological activity of SECP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other
10 compound or composition which modulates the activity of SECP either by directly interacting with SECP or by acting on components of the biological pathway in which SECP participates.

 An “allelic variant” is an alternative form of the gene encoding SECP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or
15 many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

 “Altered” nucleic acid sequences encoding SECP include those sequences with deletions,
20 insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as SECP or a polypeptide with at least one functional characteristic of SECP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding SECP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding
25 SECP. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent SECP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of SECP is retained. For example,
30 negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

35 The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide,

polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

5 “Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of SECP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small
10 molecules, or any other compound or composition which modulates the activity of SECP either by directly interacting with SECP or by acting on components of the biological pathway in which SECP participates.

The term “antibody” refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant.
15 Antibodies that bind SECP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin,
20 and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term “antigenic determinant” refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures
25 on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term “aptamer” refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Patent No.
30 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH₂), which may improve a desired property, e.g.,
35 resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules,

e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E.N. and L. Gold (2000) J. Biotechnol. 74:5-13.)

5 The term "intramer" refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).

The term "spiegelmer" refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on
10 substrates containing right-handed nucleotides.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified
15 sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or
20 translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic SECP, or of any oligopeptide thereof,
25 to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

30 A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding SECP or fragments of SECP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be
35 associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be

deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
15	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
20	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
25	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
30	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
35	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide.

Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A “detectable label” refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

“Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

“Exon shuffling” refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

A “fragment” is a unique portion of SECP or the polynucleotide encoding SECP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:55-108 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:55-108, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:55-108 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:55-108 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:55-108 and the region of SEQ ID NO:55-108 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-54 is encoded by a fragment of SEQ ID NO:55-108. A

fragment of SEQ ID NO:1-54 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-54. For example, a fragment of SEQ ID NO:1-54 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-54. The precise length of a fragment of SEQ ID NO:1-54 and the region of SEQ ID NO:1-54 to which the
5 fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

10 "Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps
15 in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of
20 molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent
25 similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at

30 <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>.

35 The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST

programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

5 *Reward for match: 1*

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

10 *Word Size: 11*

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at
15 least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode
20 similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a
25 standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default
30 parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by
35 CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

5 *Matrix: BLOSUM62*
 Open Gap: 11 and Extension Gap: 1 penalties
 Gap x drop-off: 50
 Expect: 10
 Word Size: 3
10 *Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least
15 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for
20 chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a
25 complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific
30 binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about
35 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of SECP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of SECP which is useful in any of the antibody production methods disclosed herein or known in the

art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other
5 chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of SECP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of SECP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide,
10 polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably
15 linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of
20 amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an SECP may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in
25 the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of SECP.

"Probe" refers to nucleic acid sequences encoding SECP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule.

30 Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

35 Probes and primers as used in the present invention typically comprise at least 15 contiguous

nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques
5 such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

10 Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions
15 (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and
20 other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

25 The term "sample" is used in its broadest sense. A sample suspected of containing SECP, nucleic acids encoding SECP, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a
30 protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A
35 and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

5 A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells,
10 trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" or "expression profile" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods
15 well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term
"transformed cells" includes stably transformed cells in which the inserted DNA is capable of
20 replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the
25 art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria,
30 cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

35 A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having

at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human secreted proteins (SECP), the polynucleotides encoding SECP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders.

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is

denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (GenBank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability scores for the matches between each polypeptide and its homolog(s). Column 5 shows the annotation of the GenBank homolog(s) along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs, including the locations of signal peptides (as indicated by "Signal Peptide" and/or "signal_cleavage"). Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are secreted proteins. For example, SEQ ID NO:2 is 99% identical to a novel human AMP-binding enzyme similar to acetyl-coenzyme A synthetase (acetate-coA ligase) (GenBank ID g6996429) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $5.8e-262$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:2 also contains an AMP-binding domain signature as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:2 is an AMP-binding enzyme (note that "AMP-binding domains" are shared regions of sequence similarity within a number of prokaryotic and eukaryotic enzymes which most likely act via an ATP-dependent covalent binding of AMP to their substrate, PROSITE:PDOC00427).

As a further example, SEQ ID NO:3 is 33% identical from residues E44 to L530 to bovine PDI (protein disulfide isomerase) (GenBank ID g163497) as determined by the Basic Local

Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $1.1\text{e-}70$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:3 also contains a thioredoxin domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:3 is a protein disulfide isomerase.

As a further example, SEQ ID NO:4 is 56% identical to human preceruloplasmin (GenBank ID g180256) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:4 contains a signal peptide and a multicopper oxidase active site domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) The presence of this domain is confirmed by BLIMPS, MOTIFS, and PROFILESCAN analyses, providing further corroborative evidence that SEQ ID NO:4 is a secreted multicopper oxidase.

In another example, SEQ ID NO:16 is 79% identical to human growth hormone hGH-V2 (GenBank ID g183178) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $5.6\text{e-}106$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:16 also contains a signal peptide and a somatotropin hormone family signature as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) The presence of these motifs is confirmed by BLIMPS, MOTIFS, SPSCAN, and PROFILESCAN analyses, providing further corroborative evidence that SEQ ID NO:16 is a secreted hormone.

As a further example, SEQ ID NO:27 is 49% identical to mouse Fca/m receptor (GenBank ID g11071950) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $2.2\text{e-}115$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:27 also contains an immunoglobulin domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from additional BLAST analyses provide further corroborative evidence that SEQ ID NO:27 is an immunoglobulin domain-containing receptor.

In another example, SEQ ID NO:41 is 99% identical to human chordin (GenBank ID g3822218) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:41 also contains a von Willebrand factor growth

regulator domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from MOTIFS analyses provide further corroborative evidence that SEQ ID NO:41 is a growth regulation molecule.

5 SEQ ID NO:50 contains a signal peptide as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 2.) The presence of the signal peptide is confirmed by data from SPSCAN. SEQ ID NO:1, SEQ ID NO:5-15, SEQ ID NO:17-26, SEQ ID NO:28-40, SEQ ID NO:42-49 and SEQ ID NO:51-54, which were analyzed and annotated in a similar manner, all contain signal
10 peptides as determined by SPSCAN or HMMER analysis. The algorithms and parameters for the analysis of SEQ ID NO:1-54 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Column 1 lists the polynucleotide sequence
15 identification number (Polynucleotide SEQ ID NO:), the corresponding Incyte polynucleotide consensus sequence number (Incyte ID) for each polynucleotide of the invention, and the length of each polynucleotide sequence in basepairs. Column 2 shows the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences used to assemble the full length polynucleotide sequences of the invention, and of fragments of the polynucleotide sequences which are useful, for
20 example, in hybridization or amplification technologies that identify SEQ ID NO:55-108 or that distinguish between SEQ ID NO:55-108 and related polynucleotide sequences.

The polynucleotide fragments described in Column 2 of Table 4 may refer specifically, for example, to Incyte cDNAs derived from tissue-specific cDNA libraries or from pooled cDNA libraries. Alternatively, the polynucleotide fragments described in column 2 may refer to GenBank
25 cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. In addition, the polynucleotide fragments described in column 2 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the polynucleotide fragments described in column 2 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences
30 including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the designation "NP"). Alternatively, the polynucleotide fragments described in column 2 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, a polynucleotide sequence identified as
FL_XXXXXX_N₁_N₂_YYYYY_N₃_N₄ represents a "stitched" sequence in which XXXXXX is the
35 identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is

the number of the prediction generated by the algorithm, and $N_{1,2,3...}$ if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the polynucleotide fragments in column 2 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, a polynucleotide sequence identified as

5 FLXXXXXX_gAAAAA_gBBBBB_1_N is a "stretched" sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and *N* referring to specific exons (See Example V). In instances where a RefSeq
10 sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, gBBBBB).

Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis
15 methods associated with the prefixes (see Example IV and Example V).

Prefix	Type of analysis and/or examples of programs
GNN, GFG, ENST	Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI	Hand-edited analysis of genomic sequences.
FL	Stitched or stretched genomic sequences (see Example V).
INCY	Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in Table 4 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA
25 identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors
30 which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses SECP variants. A preferred SECP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid

sequence identity to the SECP amino acid sequence, and which contains at least one functional or structural characteristic of SECP.

The invention also encompasses polynucleotides which encode SECP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected
5 from the group consisting of SEQ ID NO:55-108, which encodes SECP. The polynucleotide sequences of SEQ ID NO:55-108, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding SECP. In
10 particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding SECP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:55-108 which has at least about 70%, or alternatively at least about 85%, or even at least about
15 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:55-108. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of SECP.

In addition, or in the alternative, a polynucleotide variant of the invention is a splice variant of a polynucleotide sequence encoding SECP. A splice variant may have portions which have
20 significant sequence identity to the polynucleotide sequence encoding SECP, but will generally have a greater or lesser number of polynucleotides due to additions or deletions of blocks of sequence arising from alternate splicing of exons during mRNA processing. A splice variant may have less than about 70%, or alternatively less than about 60%, or alternatively less than about 50% polynucleotide sequence identity to the polynucleotide sequence encoding SECP over its entire
25 length; however, portions of the splice variant will have at least about 70%, or alternatively at least about 85%, or alternatively at least about 95%, or alternatively 100% polynucleotide sequence identity to portions of the polynucleotide sequence encoding SECP. For example, a polynucleotide comprising a sequence of SEQ ID NO:108 is a splice variant of a polynucleotide comprising a sequence of SEQ ID NO:94. Any one of the splice variants described above can encode an amino
30 acid sequence which contains at least one functional or structural characteristic of SECP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding SECP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide
35 sequence that could be made by selecting combinations based on possible codon choices. These

combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring SECP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode SECP and its variants are generally capable of
5 hybridizing to the nucleotide sequence of the naturally occurring SECP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding SECP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which
10 particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding SECP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode SECP and
15 SECP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding SECP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of
20 hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:55-108 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

25 Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE
30 amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system
35 (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences

are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding SECP may be extended utilizing a partial nucleotide
5 sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.)

Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown
10 sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme
15 digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries
20 and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

25 When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

30 Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate
35 software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire

process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode SECP may be cloned in recombinant DNA molecules that direct expression of SECP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express SECP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter SECP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of SECP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding SECP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.)

Alternatively, SECP itself or a fragment thereof may be synthesized using chemical methods. For

example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of SECP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.)

The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active SECP, the nucleotide sequences encoding SECP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding SECP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding SECP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding SECP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding SECP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding SECP. These include, but are not limited to, microorganisms such as bacteria transformed

with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding SECP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding SECP can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding SECP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of SECP are needed, e.g. for the production of antibodies, vectors which direct high level expression of SECP may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of SECP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of SECP. Transcription of sequences encoding SECP may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding SECP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses SECP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of SECP in cell lines is preferred. For example, sequences encoding SECP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk*⁻ and *apv*⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic,

or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding SECP is inserted within a marker gene sequence, transformed cells containing sequences encoding SECP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding SECP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding SECP and that express SECP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of SECP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on SECP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled

hybridization or PCR probes for detecting sequences related to polynucleotides encoding SECP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding SECP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding SECP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode SECP may be designed to contain signal sequences which direct secretion of SECP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding SECP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric SECP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of SECP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and

metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the SECP encoding sequence and the heterologous protein sequence, so that SECP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled SECP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

SECP of the present invention or fragments thereof may be used to screen for compounds that specifically bind to SECP. At least one and up to a plurality of test compounds may be screened for specific binding to SECP. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of SECP, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which SECP binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express SECP, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing SECP or cell membrane fractions which contain SECP are then contacted with a test compound and binding, stimulation, or inhibition of activity of either SECP or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with SECP, either in solution or affixed to a solid support, and detecting the binding of SECP to the compound.

Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a

solid support.

SECP of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of SECP. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for SECP activity, wherein SECP is combined with at least one test compound, and the activity of SECP in the presence of a test compound is compared with the activity of SECP in the absence of the test compound. A change in the activity of SECP in the presence of the test compound is indicative of a compound that modulates the activity of SECP. Alternatively, a test compound is combined with an in vitro or cell-free system comprising SECP under conditions suitable for SECP activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of SECP may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding SECP or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding SECP may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding SECP can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a

region of a polynucleotide encoding SECP is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease.

- 5 Alternatively, a mammal inbred to overexpress SECP, e.g., by secreting SECP in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) *Biotechnol. Annu. Rev.* 4:55-74).

THERAPEUTICS

- Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of SECP and secreted proteins. In addition, the expression of SECP is closely
10 associated with breast, reproductive, digestive, urinary, fibroblastic, diseased, tumorous, testicular, pituitary, adenoid, lymph node, monocyte, ileum, coronary artery endothelium, uterine endometrial and brain tissues. Examples can also be found in Table 6. Therefore, SECP appears to play a role in cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders. In the treatment of disorders associated with increased SECP expression or activity, it is
15 desirable to decrease the expression or activity of SECP. In the treatment of disorders associated with decreased SECP expression or activity, it is desirable to increase the expression or activity of SECP.

- Therefore, in one embodiment, SECP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or
20 activity of SECP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of
25 the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis,
30 autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis,
35 hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or

pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, 5 fungal, parasitic, protozoal, and helminthic infections, and trauma; a cardiovascular disorder such as congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus 10 erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, complications of cardiac transplantation, arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery; a neurological 15 disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, 20 suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central 25 nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), 30 akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; and a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, 35 and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary

mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss.

5 In another embodiment, a vector capable of expressing SECP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of SECP including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified SECP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent
10 a disorder associated with decreased expression or activity of SECP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of SECP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of SECP including, but not limited to, those listed above.

15 In a further embodiment, an antagonist of SECP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of SECP. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders described above. In one aspect, an antibody which specifically binds SECP may be used directly as an antagonist or indirectly as a
20 targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express SECP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding SECP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of SECP including, but not limited to, those described above.

25 In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the
30 various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of SECP may be produced using methods which are generally known in the art. In particular, purified SECP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind SECP. Antibodies to SECP may also
35 be generated using methods that are well known in the art. Such antibodies may include, but are not

limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with SECP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to SECP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of SECP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to SECP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce SECP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for SECP may also be generated. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between SECP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering SECP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for SECP. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of SECP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple SECP epitopes, represents the average affinity, or avidity, of the antibodies for SECP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular SECP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the SECP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of SECP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of SECP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding SECP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding SECP. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding SECP. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding SECP may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the

case where a genetic deficiency in SECP expression or regulation causes disease, the expression of SECP from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in SECP are treated by constructing mammalian expression vectors encoding SECP and introducing these vectors by mechanical means into SECP-deficient cells. Mechanical transfer technologies for use with cells *in vivo* or *ex vitro* include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev. Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr. Opin. Biotechnol.* 9:445-450).

Expression vectors that may be effective for the expression of SECP include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). SECP may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Gossen, M. et al. (1995) *Science* 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) *Curr. Opin. Biotechnol.* 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and H.M. Blau, *supra*), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding SECP from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to SECP expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding SECP under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive

element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent No. 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding SECP to cells which have one or more genetic abnormalities with respect to the expression of SECP. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent No. 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding SECP to target cells which have one or more genetic abnormalities with respect to the expression of SECP. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing SECP to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S.

Patent No. 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding SECP to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for SECP into the alphavirus genome in place of the capsid-coding region results in the production of a large number of SECP-coding RNAs and the synthesis of high levels of SECP in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the introduction of SECP into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using

triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

5 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding SECP.

10 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of
15 candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

 Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis.
20 Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding SECP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

25 RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine,
30 queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

 An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding SECP. Compounds
35 which may be effective in altering expression of a specific polynucleotide may include, but are not

limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased SECP expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding SECP may be therapeutically useful, and in the treatment of disorders associated with decreased SECP expression or activity, a compound which specifically promotes expression of the polynucleotide encoding SECP may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding SECP is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding SECP are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding SECP. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a *Schizosaccharomyces pombe* gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruce, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruce, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable

for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.

5 Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

10 An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of SECP, antibodies to SECP, and mimetics, agonists, antagonists, or inhibitors of SECP.

15 The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form.
20 These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton,
25 J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

30 Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising SECP or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, SECP or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to
35 transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et

al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example SECP or fragments thereof, antibodies of SECP, and agonists, antagonists or inhibitors of SECP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about $0.1 \mu\text{g}$ to $100,000 \mu\text{g}$, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind SECP may be used for the diagnosis of disorders characterized by expression of SECP, or in assays to monitor patients being treated with SECP or agonists, antagonists, or inhibitors of SECP. Antibodies useful for diagnostic

purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for SECP include methods which utilize the antibody and a label to detect SECP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring SECP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of SECP expression. Normal or standard values for SECP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to SECP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of SECP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding SECP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of SECP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of SECP, and to monitor regulation of SECP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding SECP or closely related molecules may be used to identify nucleic acid sequences which encode SECP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding SECP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the SECP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:55-108 or from genomic sequences including promoters, enhancers, and introns of the SECP gene.

Means for producing specific hybridization probes for DNAs encoding SECP include the cloning of polynucleotide sequences encoding SECP or SECP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a

variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding SECP may be used for the diagnosis of disorders associated with expression of SECP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cardiovascular disorder such as congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, complications of cardiac transplantation, arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease,

dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and
5 radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal
10 disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive
15 dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; and a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-
20 Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss. The polynucleotide sequences encoding SECP may be used in Southern or northern
25 analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered SECP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding SECP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide
30 sequences encoding SECP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding SECP in the
35 sample indicates the presence of the associated disorder. Such assays may also be used to evaluate

the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of SECP, a normal or standard profile for expression is established. This may be accomplished by combining
5 body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding SECP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from
10 samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from
15 successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance
20 of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding SECP may involve the use of PCR. These oligomers may be chemically synthesized, generated
25 enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding SECP, or a fragment of a polynucleotide complementary to the polynucleotide encoding SECP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

30 In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding SECP may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP,
35 oligonucleotide primers derived from the polynucleotide sequences encoding SECP are used to

amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of SECP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, SECP, fragments of SECP, or antibodies specific for SECP may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to

generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent No.

5 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The
10 resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present
15 invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson
20 (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is
25 not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to
30 prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological
35 sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the

treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for SECP to quantify the levels of SECP expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoz, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and

should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which
5 alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated
10 biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the
15 polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological
20 sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.
25

In another embodiment of the invention, nucleic acid sequences encoding SECP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal
35 mapping. The sequences may be mapped to a particular chromosome, to a specific region of a

chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355; Price, C.M. (1993) *Blood Rev.* 7:127-134; and Trask, B.J. (1991) *Trends Genet.* 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) *Proc. Natl. Acad. Sci. USA* 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding SECP on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) *Nature* 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, SECP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between SECP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with SECP, or fragments thereof, and washed. Bound SECP is then detected by methods well known in the art. Purified SECP can

also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

5 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding SECP specifically compete with a test compound for binding SECP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with SECP.

10 In additional embodiments, the nucleotide sequences which encode SECP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure
15 in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, including U.S. Ser. No. 60/262,932, U.S. Ser. No. 60/265,926, U.S. Ser. No. 60/255,639, U.S. Ser. No. 60/257,852, U.S. Ser. No. 60/260,105, U.S. Ser. No. 60/263,090 and U.S. Ser. No. 60/263,096 are expressly incorporated by reference herein.

20

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA). Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of
25 denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

30 Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA
35 purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPO1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the

MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM; PROTEOME databases with sequences from Homo sapiens, Rattus norvegicus, Mus musculus, Caenorhabditis elegans, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Candida albicans (Incyte Genomics, Palo Alto CA); and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, the PROTEOME databases, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence

alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:55-108. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 2.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative secreted proteins were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode secreted proteins, the encoded polypeptides were analyzed by querying against PFAM models for secreted proteins. Potential secreted proteins were also identified by homology to Incyte cDNA sequences that had been annotated as secreted proteins. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly

process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

5 Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpi public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

25 Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The

resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of SECP Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:55-108 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:55-108 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

In this manner, SEQ ID NO:58 was mapped to chromosome 3 within the interval from 160.0 to 187.1 centiMorgans. SEQ ID NO:59 was mapped to chromosome 15 within the interval from 59.3 centiMorgans to the q-terminus. SEQ ID NO:60 was mapped to chromosome 15 within the interval from 39.5 to 59.3 centiMorgans. SEQ ID NO:61 was mapped to chromosome 3 within the interval from 67.9 to 77.4 centiMorgans. SEQ ID NO:62 was mapped to chromosome 16 at 473.44 centiMorgans. SEQ ID NO:63 was mapped to chromosome 9 within the interval from 75.8 to 136.7 centiMorgans. SEQ ID NO:64 was mapped to chromosome 19. SEQ ID NO:65 was mapped to chromosome 1 within the interval from 196.5 to 205.1 centiMorgans. SEQ ID NO:66 was mapped to chromosome 5 within the interval from 138.7 to 141.4 centiMorgans. SEQ ID NO:67 was mapped to chromosome 2 within the interval from 223.1 to 231.8 centiMorgans. SEQ ID NO:68 was mapped to chromosome 2 within the interval from 223.1 to 231.8 centiMorgans. SEQ ID NO:69 was mapped to chromosome 17 within the interval from 62.2 centiMorgans to the q-terminus. SEQ ID NO:75 was mapped to chromosome 15 within the interval from 59.3 centiMorgans to the q terminus. SEQ ID NO:76 was mapped to chromosome 13 within the interval from the p-terminus to 36.6 centiMorgans.

SEQ ID NO:77 was mapped to the short arm of chromosome 8 within the cytogenetic band 23.3.

SEQ ID NO:78 was mapped to chromosome 11 within the interval from 102.6 to 131.7 centiMorgans.

SEQ ID NO:79 was mapped to chromosome 3 within the interval from 49.5 to 64.4 centiMorgans.

SEQ ID NO:80 was mapped to chromosome 5 within the interval from 104.5 to 121.4 centiMorgans.

5 VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

10 Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

15

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

The product score takes into account both the degree of similarity between two sequences and the
 20 length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by
 25 gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the
 30 other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding SECP are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA
 35 sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is

classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding SECP. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of SECP Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar,

Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:55-108 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a

SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

5 The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and
10 compared.

X. Microarrays

 The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the
15 aforementioned technologies should be uniform and solid with a non-porous surface (Skena (1999), supra.). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to
20 those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Skena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

 Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be
25 selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser
30 desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

35 Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and

poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

15 Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in U.S. Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in

0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital

(A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the SECP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring SECP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of SECP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the SECP-encoding transcript.

XII. Expression of SECP

Expression and purification of SECP is achieved using bacterial or virus-based expression systems. For expression of SECP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express SECP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of SECP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding SECP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K.

et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, SECP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from SECP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified SECP obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.

XIII. Functional Assays

SECP function is assessed by expressing the sequences encoding SECP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are

discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of SECP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding SECP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding SECP and other genes of interest can be analyzed by northern analysis or microarray techniques.

10 **XIV. Production of SECP Specific Antibodies**

SECP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the SECP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-SECP activity by, for example, binding the peptide or SECP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring SECP Using Specific Antibodies

Naturally occurring or recombinant SECP is substantially purified by immunoaffinity chromatography using antibodies specific for SECP. An immunoaffinity column is constructed by covalently coupling anti-SECP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing SECP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of SECP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt

antibody/SECP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and SECP is collected.

XVI. Identification of Molecules Which Interact with SECP

SECP, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton, A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled SECP, washed, and any wells with labeled SECP complex are assayed. Data obtained using different concentrations of SECP are used to calculate values for the number, affinity, and association of SECP with the candidate molecules.

Alternatively, molecules interacting with SECP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) *Nature* 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

SECP may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

XVII. Demonstration of SECP Activity

An assay for growth stimulating or inhibiting activity of SECP measures the amount of DNA synthesis in Swiss mouse 3T3 cells (McKay, I. and Leigh, I., eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York, NY). In this assay, varying amounts of SECP are added to quiescent 3T3 cultured cells in the presence of [^3H]thymidine, a radioactive DNA precursor. SECP for this assay can be obtained by recombinant means or from biochemical preparations. Incorporation of [^3H]thymidine into acid-precipitable DNA is measured over an appropriate time interval, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold SECP concentration range is indicative of growth modulating activity. One unit of activity per milliliter is defined as the concentration of SECP producing a 50% response level, where 100% represents maximal incorporation of [^3H]thymidine into acid-precipitable DNA.

Alternatively, an assay for SECP activity measures the stimulation or inhibition of neurotransmission in cultured cells. Cultured CHO fibroblasts are exposed to SECP. Following endocytic uptake of SECP, the cells are washed with fresh culture medium, and a whole cell voltage-clamped *Xenopus* myocyte is manipulated into contact with one of the fibroblasts in SECP-free medium. Membrane currents are recorded from the myocyte. Increased or decreased current relative to control values are indicative of neuromodulatory effects of SECP (Morimoto, T. et al. (1995) *Neuron* 15:689-696).

Alternatively, an assay for SECP activity measures the amount of SECP in secretory, membrane-bound organelles. Transfected cells as described above are harvested and lysed. The lysate is fractionated using methods known to those of skill in the art, for example, sucrose gradient ultracentrifugation. Such methods allow the isolation of subcellular components such as the Golgi apparatus, ER, small membrane-bound vesicles, and other secretory organelles.

Immunoprecipitations from fractionated and total cell lysates are performed using SECP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The concentration of SECP in secretory organelles relative to SECP in total cell lysate is proportional to the amount of SECP in transit through the secretory pathway.

Alternatively, AMP binding activity is measured by combining SECP with ^{32}P -labeled AMP. The reaction is incubated at 37°C and terminated by addition of trichloroacetic acid. The acid extract is neutralized and subjected to gel electrophoresis to remove unbound label. The radioactivity retained in the gel is proportional to SECP activity.

Alternatively, the activity of purified SECP can be tested by introducing the molecule into an *in vitro* production system for tissue plasminogen activator (tPA). Any statistically significant improvement of correctly folded tPA in the presence as compared to the absence of SECP would indicate that SECP is active and functioning correctly.

Alternatively, SECP activity may be measured by the enzymatic activity they possess. For SEQ ID NO:4, for example, SECP activity is measured as ferroxidase activity at pH 6 in 0.3 M acetate buffer. The appearance of ferric ions is monitored at 315 nm (Bonomi, F. et al. (1996) J. Biol. Inorg. Chem. 1:67-72). For SEQ ID NO:6, for example, SECP activity is measured by the phosphorylation of galactose. SECP is incubated for 5 minutes in a 100 μl reaction containing 200 μM ^3H -galactose (30,000 cpm), 5 mM ATP, 5 mM MgCl_2 , 5 mM NaF, 100 mM Tris-HCl buffer, pH 8.5. The reaction is stopped by heating at 100°C for 1 min, and the incubation mixture applied to a DE52 column. The column is washed with at least 5 column volumes of 10 mM $(\text{NH}_4)\text{HCO}_3$ to remove unbound material. Galactose-P is eluted with 500 mM $(\text{NH}_4)\text{HCO}_3$ and assayed for radioactive content by scintillation counting (Pastuszak, I. et al. (1996) J. Biol. Chem.

271:23653-23656). For SEQ ID NO:9, for example, SECP activity is measured by the amount of cobalamin bound using the isotope dilution method of Nexø, and Gimsing, employing human IF as the binding protein (1981, Scand. J. Clin. Lab. Invest. 41:465-468). For SEQ ID NO:10, for example, SECP activity is measured by the hydrolysis of appropriate synthetic peptide substrates conjugated with various chromogenic molecules in which the degree of hydrolysis is quantified by spectrophotometric (or fluorometric) absorption of the released chromophore (Beynon, R.J. and J.S. Bond (1994) Proteolytic Enzymes: A Practical Approach, Oxford University Press, New York, NY, pp.25-55). Peptide substrates are designed according to the category of protease activity as

endopeptidase (serine, cysteine, aspartic proteases, or metalloproteases), aminopeptidase (leucine aminopeptidase), or carboxypeptidase (carboxypeptidases A and B, procollagen C-proteinase). Commonly used chromogens are 2-naphthylamine, 4-nitroaniline, and furylacrylic acid. Assays are performed at ambient temperature and contain an aliquot of the enzyme and the appropriate substrate in a suitable buffer. Reactions are carried out in an optical cuvette, and the increase/decrease in absorbance of the chromogen released during hydrolysis of the peptide substrate is measured. The change in absorbance is proportional to the enzyme activity in the assay.

Alternatively, SECP activity can be measured as enzyme activity. For SEQ ID NO:20, for example, activity is proportional to the hydrolysis of glucosamine-6-sulfate by SECP which can be measured by the method of Robertson et al. (1992, Biochem. J. 288:539-544).

In another alternative, SECP can be assayed by its interaction with the insulin-like growth factor complex. For SEQ ID NO:17, for example, ¹²⁵I-labeled SECP is incubated for 2 h with 10 ng of IGF-I or-II and a range from 0 to 10 ng of IGFBP-3 in 50 mM sodium phosphate buffer, pH 6.5, at 22 °C (final volume 0.3 ml). SECP complexed to IGFBP-3 is precipitated using IGFBP-3 antiserum and radioactivity in each tube measured (Janosi, J.B.M. et al. (1999) J. Biol. Chem. 274:5292-5298).

XVIII. Demonstration of Immunoglobulin Activity

An assay for SECP activity measures the ability of SECP to recognize and precipitate antigens from serum. This activity can be measured by the quantitative precipitin reaction. (Golub, E.S. et al. (1987) Immunology: A Synthesis, Sinauer Associates, Sunderland, MA, pages 113-115.)

SECP is isotopically labeled using methods known in the art. Various serum concentrations are added to constant amounts of labeled SECP. SECP-antigen complexes precipitate out of solution and are collected by centrifugation. The amount of precipitable SECP-antigen complex is proportional to the amount of radioisotope detected in the precipitate. The amount of precipitable SECP-antigen complex is plotted against the serum concentration. For various serum concentrations, a characteristic precipitin curve is obtained, in which the amount of precipitable SECP-antigen complex initially increases proportionately with increasing serum concentration, peaks at the equivalence point, and then decreases proportionately with further increases in serum concentration. Thus, the amount of precipitable SECP-antigen complex is a measure of SECP activity which is characterized by sensitivity to both limiting and excess quantities of antigen.

Alternatively, an assay for SECP activity measures the expression of SECP on the cell surface. cDNA encoding SECP is transfected into a non-leukocytic cell line. Cell surface proteins are labeled with biotin (de la Fuente, M.A. et al. (1997) Blood 90:2398-2405). Immunoprecipitations are performed using SECP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of SECP expressed on the cell surface.

Alternatively, an assay for SECP activity measures the amount of cell aggregation induced by overexpression of SECP. In this assay, cultured cells such as NIH3T3 are transfected with cDNA encoding SECP contained within a suitable mammalian expression vector under control of a strong promoter. Cotransfection with cDNA encoding a fluorescent marker protein, such as Green Fluorescent Protein (CLONTECH), is useful for identifying stable transfectants. The amount of cell agglutination, or clumping, associated with transfected cells is compared with that associated with untransfected cells. The amount of cell agglutination is a direct measure of SECP activity.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
95765	1	095765CD1	55	095765CB1
6399886	2	6399886CD1	56	6399886CB1
6024420	3	6024420CD1	57	6024420CB1
7481067	4	7481067CD1	58	7481067CB1
3378720	5	3378720CD1	59	3378720CB1
938824	6	938824CD1	60	938824CB1
1683721	7	1683721CD1	61	1683721CB1
1694122	8	1694122CD1	62	1694122CB1
1970615	9	1970615CD1	63	1970615CB1
2314152	10	2314152CD1	64	2314152CB1
2886225	11	2886225CD1	65	2886225CB1
6144418	12	6144418CD1	66	6144418CB1
6834184	13	6834184CD1	67	6834184CB1
6951005	14	6951005CD1	68	6951005CB1
7250331	15	7250331CD1	69	7250331CB1
1758413	16	1758413CD1	70	1758413CB1
7011042	17	7011042CD1	71	7011042CB1
7427362	18	7427362CD1	72	7427362CB1
7485304	19	7485304CD1	73	7485304CB1
1422394	20	1422394CD1	74	1422394CB1
1336022	21	1336022CD1	75	1336022CB1
7473674	22	7473674CD1	76	7473674CB1
7475846	23	7475846CD1	77	7475846CB1
7475860	24	7475860CD1	78	7475860CB1
7950941	25	7950941CD1	79	7950941CB1
7485334	26	7485334CD1	80	7485334CB1
7220001	27	7220001CD1	81	7220001CB1
5956275	28	5956275CD1	82	5956275CB1
346472	29	346472CD1	83	346472CB1

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
643526	30	643526CD1	84	643526CB1
1483418	31	1483418CD1	85	1483418CB1
2683477	32	2683477CD1	86	2683477CB1
5580991	33	5580991CD1	87	5580991CB1
5605931	34	5605931CD1	88	5605931CB1
6975241	35	6975241CD1	89	6975241CB1
6988529	36	6988529CD1	90	6988529CB1
6996808	37	6996808CD1	91	6996808CB1
7472689	38	7472689CD1	92	7472689CB1
876751	39	876751CD1	93	876751CB1
2512510	40	2512510CD1	94	2512510CB1
7486326	41	7486326CD1	95	7486326CB1
1221545	42	1221545CD1	96	1221545CB1
124737	43	124737CD1	97	124737CB1
1510784	44	1510784CD1	98	1510784CB1
1901257	45	1901257CD1	99	1901257CB1
2044370	46	2044370CD1	100	2044370CB1
2820933	47	2820933CD1	101	2820933CB1
2902793	48	2902793CD1	102	2902793CB1
7486536	49	7486536CD1	103	7486536CB1
8137305	50	8137305CD1	104	8137305CB1
3793128	51	3793128CD1	105	3793128CB1
4001243	52	4001243CD1	106	4001243CB1
6986717	53	6986717CD1	107	6986717CB1
7503512	54	7503512CD1	108	7503512CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
1	95765CD1	g190183	2.6E-76	[Homo sapiens] opiomelanocortin Krude, H. et al. (1998) Nature Genet. 19:155-157
2	6399886CD1	g6996429	5.8E-262	d1568C11.3 (novel AMP-binding enzyme similar to acetyl-coenzyme A synthetase (acetate-coA ligase)) [Homo sapiens] Luong, A. et al., (2000) J. Biol. Chem. 275:26458-26466
3	6024420CD1	g163497	1.1E-70	[Bos taurus] PDI (E.C.5.3.4.1) (protein disulfide isomerase) Yamauchi, K., et al. (1987) Biochem. Biophys. Res. Commun. 146, 1485-1492
4	7481067CD1	g180256	0	[Homo sapiens] preceruloplasmin (EC 1.16.3.1) Waggoner, D.J. et al. (1999) Neurobiol. Dis. 9:221-230; Hellman, N.E. et al. (2000) Gut 47:858-860
5	3378720CD1	g9859003	9.1E-65	[Homo sapiens] tumor metastasis-suppressor
16	1758413CD1	g183178	5.6E-106	[Homo sapiens] hGH-V2 Cooke, N.E. et al. (1988) J. Biol. Chem. 263:9001-9006
17	7011042CD1	g184808	3.0E-11	[Homo sapiens] insulin-like growth factor binding protein complex, acid-labile subunit Leong, S.R. et al. (1992) Mol. Endocrinol. 6:870-876
18	7427362CD1	g14530679	7.0E-70	WNT3A [Homo sapiens] Saitoh, T., et al (2001) Biochem. Biophys. Res. Commun. 284:1168-1175
19	7485304CD1	g2623871	2.1E-115	[Gallus gallus] Wnt-14 protein Bergstein, I. et al. (1997) Genomics 46:450-458
20	1422394CD1	g15430244	0	N-acetylglucosamine-6-sulfatase [Coturnix coturnix] Dhoot, G.K., et al (2001) Science 293:1663-6.
22	7473674CD1	g13620917	9.0E-46	mitochondrial ribosomal protein bMRP63 [Mus musculus] Suzuki, T., et al (2001) J. Biol. Chem. 276:33181-33195
26	7485334CD1	g10566471	1.2E-73	[Mus musculus] Gliacolin Koide, T. et al. (2000) J. Biol. Chem. 275:27957-27963

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
27	7220001CD1	g11071950	2.2E-115	[Mus musculus] (AB048834) Fca/m receptor Shibuya, A., et al (2000) Nat. Immunol. 1:441-446
28	5956275CD1	g7259265	4.4E-129	[Mus musculus] contains transmembrane (TM) region Inoue, S., et al. (2000) Biochem. Biophys. Res. Commun. 268, 553-561
39	876751CD1	g15430246	0	nephroretin short isoform [Mus musculus] Brandenberger, R., et al (2001) J. Cell Biol. 154:447-458
40	2512510CD1	g14423349	0	membrane glycoprotein LIG-1 [Homo sapiens]
41	7486326CD1	g3822218	0	[Homo sapiens] chordin Pappano, W. N. et al. (1998) Genomics 52:236-239
48	2902793CD1	g15026974	2.0E-36	obscurin [Homo sapiens] Young, P., et al (2001) J. Cell Biol. 154: 123-136
54	7503512CD1	g14423349	0	membrane glycoprotein LIG-1 [Homo sapiens]

Table 3

SEQ ID NO:	Incyré Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	095765CD1	235	S92 S211 Y189	N91	signal_cleavage: M1-E23	SPSCAN
					Signal Peptide: M1-E23, M1-G26, M1-V24, M1-C28, M1-E30	HMMER
					Corticotropin ACTH domain: S106-F144, P188-T220	HMMER_PFAM
					Transmembrane Domain: C6-W27 N-terminus is non-cytosolic	TMAP
					Pro-opiomelanocortin signature PR00383: Y107-P117, V118-E133, D134-E143, A181-W196, W196-M209	BLIMPS_PRINTS
					PRECURSOR CORTICOTROPIN LIPOTROPIN PRO-OPIMELANOCORTIN POMC HORMONE SIGNAL ENDORPHIN CLEAVAGE ON PAIR PD004218:L12-Q68	BLAST_PRODOR
					PRO-OPIMELANOCORTIN POM PRECURSOR SIGNAL PD116389: R101-N229, C28-W84	BLAST_PRODOR
					HORMONE PRECURSOR CORTICOTROPIN LIPOTROPIN PRO-OPIMELANOCORTIN POMC CLEAVAGE ON PAIR OF BASIC PD003250: S106-F144	BLAST_PRODOR
					CORTICOTROPIN LIPOTROPIN PRECURSOR PRO-OPIMELANOCORTIN POMC ENDORPHIN HORMONE CLEAVAGE ON PAIR OF PD029102: D164-N229	BLAST_PRODOR
					CORTICOTROPIN-LIPOTROPIN DM01793[P01190]1-83: M1-W84	BLAST_DOMO

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1 (cont.)					CORTICOTROPIN-LIPOTROPIN DM00964 P01190 I71-264: K145-E235	BLAST_DOMO
					CORTICOTROPIN-LIPOTROPIN DM01793 P19402 I-79: M1-V78	BLAST_DOMO
					CORTICOTROPIN-LIPOTROPIN DM00964 PN0130 I3-90: A167-E235	BLAST_DOMO
2	6399886CD1	689	S16 S409 S415 S486 S601 S640 T89 T97 T142 T150 T156 T318 T438 T546 T663 T664	N109 N492 N554	Signal Peptide: M1-A25 AMP-binding enzyme: T142-V580 Transmembrane Domains: P173-A201, E463-P478 N-terminus is cytosolic Putative AMP-binding domain signature: A272-V322	HMMER HMMER_PFAM TMAP PROFILESKAN
					Putative AMP-binding domain BL00455:Y293-Q308	BLIMPS_BLOCKS
					AMP-binding signature PR00154:E286-S297, T298-H306	BLIMPS_PRINTS
					LIGASE SYNTHETASE PROTEIN ENZYME BIOSYNTHESIS ANTIBIOTIC PHOSPHOPANTETHEINE MULTIFUNCTIONAL REPEAT ACYL-COA PD000070: T142-T438, D482-I581	BLAST_PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
2 (cont.)					SYNTHETASE LIGASE ACETYL COENZYME A ENZYME ACETATE-COA ACETYL-COA PROTEIN ACYL ACTIVATING PD009307: Y58-L146	BLAST_PRODUM
					PUTATIVE AMP-BINDING DOMAIN DM00073 S46276 96-631: L115-R649 P27550 82-615: L115-R649 S52154 15-546: I141-L648 P16928 102-634: L115-R649	BLAST_DOMO
					Putative AMP-binding domain signature M291-K302	MOTIFS
3	6024420CD1	584	S20 S71 S134 S153 S358 S376 S417 S546 S558 T128 T241 T329 T448 T481 T495 T557 Y356	N58 N160 N238 N340 N370 N436 N540	signal_cleavage: M1-S20	SPSCAN
					Signal Peptide: M1-S20; M1-E23, M1-A26	HMMER
					Thioredoxin domain: Q386-D451	HMMER_PFAM
					Transmembrane Domain: P199-H216	TMAP
					N-terminal is non-cytosolic	
					Thioredoxin family active site: L392-I440	PROFILES CAN
					Thioredoxin family proteins signature BL00194: F409-K421	BLIMPS_BLOCKS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
3 (cont.)					ISOMERASE PRECURSOR PROTEIN SIGNAL REDOX ACTIVE CENTER DISULFIDE ENDOPLASMIC RETICULUM REPEAT PD001708: Q55-L367	BLAST_PRODUM
					REDOX ACTIVE CENTER PROTEIN ISOMERASE PRECURSOR THIOREDOXIN SIGNAL DISULFIDE ENDOPLASMIC ELECTRON PD000175: V389-K496	BLAST_PRODUM
					PROTEIN DISULFIDE-ISOMERASE DM00799 P09102 I12-347: L148-D385 DM00799 P54399 I29-364: E167-D385 DM00799 A54757 I27-358: L148-D385	BLAST_DOMO
					THIOREDOXIN FAMILY DM00054 P09102 I349-452: V389-L489	BLAST_DOMO
4	7481067CD1	1049	S38 S180 S221 S241 S317 S318 S383 S551 S604 S638 S736 T155 T184 T198 T203 T208 T222 T311 T389 T414 T430 T452 T515 T570 T589 T661 T688 T783 T855 T1007 T1037 Y134 Y483 Y566 Y715	N111 N137 N169 N245 N270 N392 N460 N475 N549 N575 N781 N829 N830 N908	signal_cleavage: M1-A19	SPSCAN
					Signal Peptide: M1-P16, M1-W18, M1-A19	HMMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
4 (cont.)					Transmembrane Domain: I794-I809	TMAP
					Multicopper oxidase: L900-R1041, L567-C705, L218-C352	HMMER_PFAM
					Multicopper oxidases signatures multicopper_oxidase1.prf: D310-V366, D660-E742, D996-L1050 multicopper_oxidase2.prf: P1001-N1048	PROFILESAN
					Multicopper oxidases signature 1: G680-Y700, G1016-Y1036	MOTIFS
					Multicopper oxidases signature BL00079A: G93-N110, R817-T828, L975-F985, D1014-M1032	BLIMPS_BLOCKS
					FERROXIDASE REPEAT DM00956 P00450 90-336: L89-L334, L438-L684, P838-L1019 DM00956 P00450 445-697: H437-L684, L89-S318, Y819-W1018, H791-S831 DM00956 P00450 804-1038: H791-Y1021, H437-G680, L89-L334 DM00956 P12259 83-308: G90-P249, G439-S577, I794-V992, E252-L334, D595-T675, S538-L552	BLAST_DOMO
					FACTOR PRECURSOR GLYCOPROTEIN PLASMA REPEAT SIGNAL COAGULATION BLOOD VIII CALCIUM PD002090: H368-K559, R22-N205, K707-P893	BLAST_PRODROM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
4 (cont.)					ATP/GTP-binding site motif A (P-loop): G335-S342	MOTIFS
5	3378720CD1	383	S23 S90 S119 S247 S334 S340 T4 T19 T73 T78 T81 T109 Y345	N107	signal_cleavage: M1-E57	SPSCAN
					Transmembrane Domains: H38-A61, C136-Y160, Y181-F198, K201-R229, N261-F281, H294-L314 N terminus is non-cytosolic	TMAP
					PROTEIN TRANSMEMBRANE LONGEVITY ASSURANCE FACTOR UOG1 SIMILAR S CEREVISIAE PD006418: S119-L369	BLAST_PRODOM
6	938824CD1	72			signal_cleavage: M1-A63	SPSCAN
					Signal Peptide: M1-G29	HMIMER
					Transmembrane Domain: P9-A36	TMAP
					N terminus is non-cytosolic	
					Galactokinase signature galactokinase.prf: S17-A67	PROFILESAN
7	1683721CD1	91	S41 T34 T53		signal_cleavage: M1-P23	SPSCAN
					Signal Peptide: M1-P23	HMIMER
8	1694122CD1	160	T19		signal_cleavage: M1-R62	SPSCAN
9	1970615CD1	95	S55		signal_cleavage: M1-A26	SPSCAN
					Signal Peptide: M1-A26, M1-R27, M1-V28, M1-C30	HMIMER
					Transmembrane Domain: Q4-C20 N-terminus is non-cytosolic	TMAP

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9 (cont.)					Eukaryotic cobalamin-binding proteins signature cobalamin_binding.prp: D25-R72	PROFILES CAN
10	2314152CD1	92	S11 S23 S33 S52 T65 Y43		signal_cleavage: M1-S19	SPSCAN
					Signal Peptide: M1-R25, M1-S24	HMIMER
					Endopeptidase Clp active sites clpp_protease_ser.prp: L32-G80	PROFILES CAN
11	2886225CD1	71	S41 T37 Y67		signal_cleavage: M1-L29	SPSCAN
					Signal Peptide: M1-L29	HMIMER
					Transmembrane Domain: H15-C33	TMAP
					N-terminus is non-cytosolic	
					Vitamin K-dependent carboxylation domain glu_carboxylation.prp: M1-G70	PROFILES CAN
12	6144418CD1	100	S46 S69 T50 T60 T84	N67 N85	signal_cleavage: M1-G36	SPSCAN
					Signal Peptide: M1-A29, M1-V31	HMIMER
					Transmembrane Domain: L8-G36	TMAP
					N-terminus is non-cytosolic	
13	6834184CD1	122		N108	signal_cleavage: M1-E38	SPSCAN
					Signal Peptide: M1-G25	HMIMER
					Transmembrane Domain: G8-T36, C81-I105	TMAP
					N-terminus is non-cytosolic	
14	6951005CD1	113	S25 T35 Y81		signal_cleavage: M1-D28	SPSCAN
					Signal Peptide: M1-Q29, M1-D28	HMIMER
					Transmembrane Domain: S50-S72	TMAP
					N-terminus is non-cytosolic	
15	7250331CD1	85			signal_cleavage: M1-L27	SPSCAN

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
15					Signal Peptide: M1-P23, M1-V25, M1-R26, M1-L27, M1-C35	HMMER
(cont.)					Immunoglobulins and major histocompatibility complex proteins signature ig_mhc.prf: L14-L64	PROFILES CAN
16	1758413CD1	256	S88 S97 S111 S132 S181 S194 T53		signal_cleavage: M1-A26	SPSCAN
					Signal Peptide: M1-A26	HMMER
					Transmembrane Domain: T7-L35	TMAP
					N-terminus is non-cytosolic	
					Somatotropin hormone family: L9-M151	HMMER_PFAM
					Somatotropin, prolactin and related hormones	PROFILES CAN
					somatotropin_1.prf: S88-H138	
					Somatotropin, prolactin and related hormones	MOTIFS
					signature 1: C79-W112	
					Somatotropin, prolactin and related hormones	BLIMPS_BLOCKS
					BL00266: L35-Y61, C79-V116, D135-M151, P201-P224	
					Somatotropin hormone family signature PR00836: C79-E92, L101-L119	BLIMPS_PRINTS
					GROWTH HORMONE VARIANT II PRECURSOR	BLAST_PRODROM
					GHV2 PLACENTA SIGNAL ALTERNATIVE SPLICING	
					PD084405: P165-V256	
					HORMONE PRECURSOR SIGNAL PITUITARY	BLAST_PRODROM
					GROWTH SOMATOTROPIN PROLACTIN	
					GLYCOPROTEIN PRL	
					PD000259: T7-M151	

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
16 (cont.)					SOMATOTROPIN, PROLACTIN AND RELATED HORMONES DM00125 P09587 17-227: C17-P228 DM00125 P01243 17-212: C17-G163 DM00125 I67409 17-212: C17-G163 DM00125 P01242 17-212: C17-G163	BLAST_DOMO
17	7011042CD1	287	S16 S46 S91 S147 T76 T105 T214 T242	N42 N176	signal_cleavage: M1-A18	SPSCAN
					Signal Peptide: M1-A18, M1-W17	HMIMER
					Leucine Rich Repeat: N254-P278, Q100-A122, A171-D199, T205-P228, G123-S146, T76-E99, S147-P170, K229-P253	HMIMER_PFAM
					Leucine Rich Repeat PR00019A: L124-L137	BLIMPS_PRINTS
					Leucine zipper pattern: L59-L80, L66-L87	MOTIFS
18	7427362CD1	366	S89 T34 T81 T150 T215 T226 T257 T356 T363	N103	signal_cleavage: M1-A29	SPSCAN
					Signal Peptide: M1-A29	HMIMER
					Transmembrane Domain: P6-L33	TMAP
					N-terminus is non-cytosolic	
					wnt family of developmental signaling proteins: A58-K365	HMIMER_PFAM
					Wnt-1 family signature	PROFILESKAN
					wnt1.prf: M196-K245	
					Wnt-1 family signature: C216-C225	MOTIFS
					Wnt-1 family proteins	BLIMPS_BLOCKS
					BL00246: M196-Y248, N319-C364, A85-C104, G118-D152, W163-E187	

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
18 (cont.)					DEVELOPMENTAL GLYCOPROTEIN PRECURSOR SIGNAL WNT1 WNT5A WNT2 EXTRACELLULAR MATRIX PD000810: C59-A195, E153-K365	BLAST_PRODOM
					WNT-1 FAMILY DM00403 P27467 22-351: K67-K365 DM00403 P21551 32-368: L64-C364 DM00403 P28465 13-351: C59-K365 DM00403 P22727 24-363: A154-C364	BLAST_DOMO
19	7485304CD1	416	S72 S120 S228 S238 T87 T136 T203 T268 T413 Y342	N158	wnt family of developmental signaling proteins: Q113-K415	HMMER_PFAM
					Wnt-1 family signature wnt1.prf: D250-K298	PROFILES CAN
					Wnt-1 family signature: C269-C278	MOTIFS
					Wnt-1 family proteins BL00246: A140-C159, G171-D205, W216-R240, A249-Y301, S369-C414	BLIMPS_BLOCKS
					PROTEIN DEVELOPMENTAL GLYCOPROTEIN PRECURSOR SIGNAL WNT1 WNT5A WNT2 EXTRACELLULAR MATRIX PD000810: L119-A251, D206-K415	BLAST_PRODOM
					WNT-1 FAMILY DM00403 P49340 30-391: L119-S365, A334-C414, S69-Q106 DM00403 P21551 32-368: L119-C414 DM00403 P47793 24-351: C114-K415 DM00403 P22727 24-363: E211-L410, K118-G209	BLAST_DOMO

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
20	1422394CD1	871	S27 S206 S288 S425 S468 S488 S505 S516 S520 S635 T24 T66 T96 T107 T367 T376 T400 T452 T484 T530 T611 T615 T781 Y645	N64 N111 N131 N148 N170 N197 N240 N623 N773 N783	signal_cleavage: M1-C22	SPSCAN
					Signal Peptide: M1-C22	HMMER
					Transmembrane Domain: C5-L21, S353-D370	TMAP
					N-terminus is cytosolic	HMMER_PFAM
					Sulfatase: P43-T467	MOTIFS
					Sulfatases signature 1: P85-G97	BLIMPS_BLOCKS
					Sulfatases proteins BL00523: P43-S59, C87-K98, G134-L144, P214-H225, V289-G318, D363-G373, Y800-Q809	
					ARYLSULFATASE SIGNAL GLYCOPROTEIN LYSOSOME SULPHOHYDROLASE MUCOPOLYSACCHARIDOSIS PD001700: P43-I200, Q279-P378, K330-E392	BLAST_PRODROM
					N-ACETYLGLUCOSAMINE-6-SULFATASE PRECURSOR GLUCOSAMINE-6-SULFATASE HYDROLASE LYSOSOME SIGNAL GLYCOPROTEIN MUCOPOLYSACCHARIDOSIS PD022780: C766-G837	BLAST_PRODROM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
20					SIMILAR TO SULFATASE	BLAST_PRODOM
(cont.)					PD122645: V385-Q487, H700-F765	
					ARYL SULFATASE; SULFATASE; PLANT;	BLAST_DOMO
					DM08669 Q10723 23-520: R280-R490, R42-Q279, N773-P843	
					DM08669 P14217 24-519: L278-G373, R42-P269, S770-P843, E294-Y310	
					DM01026 P08842 24-548: V289-D390, R42-Y143	
					DM01026 P50473 63-522: E273-L389, R42-P153	
21	1336022CD1	100	S3 S72 S93	N5	signal_cleavage: M1-V24	SPSCAN
					Signal Peptide: M1-V24	HMMER
					Transmembrane Domain: V4-P23	TMAP
					N-terminus is non-cytosolic	
22	7473674CD1	102	S28 S102 T79 T98	N96	signal_cleavage: M1-G19	SPSCAN
23	7475846CD1	117			signal_cleavage: M1-C32	SPSCAN
24	7475860CD1	150	S65 T58 T99 T113 T138 Y143	N46 N66	signal_cleavage: M1-A34	SPSCAN
25	7950941CD1	89	S10 S34 S39 S49		Signal Peptide: M1-G24	HMMER
26	7485334CD1	287	S111 S167 S255 T28 T142 T192		signal_cleavage: M1-A15	SPSCAN
					Signal Peptide: M1-A20, M1-A21	HMMER
					Clq domain: A160-L284	HMMER_PFAM
					Clq domain signature: F177-Y207	MOTIFS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
26 (cont.)					Clq domain proteins BL01113: V174-I209, D243-K262, S277-P286, G85-S111	BLIMPS_BLOCKS
					Complement C1Q domain signature PR00007: P168-K194, F195-G214, D243-D264, K275-Y285	BLIMPS_PRINTS
					Collagen triple helix repeat (20 copies): P71-V129	HMMER_PFAM
					Lysosome-associated membrane glycoproteins lamp_2.prf: E145-L175	PROFILESSCAN
					PRECURSOR SIGNAL COLLAGEN REPEAT HYDROXYLATION GLYCOPROTEIN CHAIN PLASMA EXTRACELLULAR MATRIX PD002992: P168-L284	BLAST_PRODROM
					COLLAGEN ALPHA PRECURSOR REPEAT SIGNAL CONNECTIVE TISSUE EXTRACELLULAR MATRIX PD000007: G43-G118	BLAST_PRODROM
					PROCOLLAGEN TYPE XVII ALPHA 1 BULLOUS PEMPHIGOID AUTO-ANTIGEN CELL ADHESION PD071338: G43-G112	BLAST_PRODROM
					PRECOLLAGEN P PRECURSOR SIGNAL PD072959: G43-G128	BLAST_PRODROM
					C1Q DOMAIN DM00777 S23297 465-674: P84-L283 DM00777 P23206 477-673: G88-P286 DM00777 P98085 222-418: G85-D287 DM00777 P27658 551-743: G88-P286	BLAST_DOMO

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
27	722000ICD1	578	S39 S108 S189 S252 S297 S302 S406 S483 S494 S526 T6 T38 T88 T234 T272 T336 T350 T351 T438 T487 T525 T570 Y24	N212 N322	signal_cleavage: M1-A61	SPSCAN
					Signal Peptide: M46-A61, M46-P63, M46-Q64	HMIMER
					Immunoglobulin domain: G120-I200	HMIMER_PFAM
					Transmembrane Domain: S39-P67 R496-R518	TMAP
					N-terminus is cytosolic	
					POLYMERIC IMMUNOGLOBULIN RECEPTOR PRECURSOR PLGR CONTAINS: SECRETORY COMPONENT IMMUNOGLOBULIN FOLD REPEAT PD003917: G120-E203 (P-value = 5.4e-09)	BLAST_PRODOM
					IMMUNOGLOBULIN DM00001 P01833 41-120: H128-G201 DM00001 P15083 41-120: H128-F208 DM00001 P01832 28-125: G120-G201 DM00001 S4884 41-120: H128-G201	BLAST_DOMO
28	5956275CD1	285	S109 S133 S256 T38 T91 T100 T191 Y125		signal_cleavage: M1-A28	SPSCAN
					Signal Peptide: M1-A28	HMIMER
					Immunoglobulin domain: G42-V129	HMIMER_PFAM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
28					Transmembrane Domain: Q3-T31 N-terminus is non-cytosolic	TMAP
(cont.)					Cell attachment sequence: R197-D199	MOTIFS
29	346472CD1	72	S25		signal_cleavage: M1-C14 Signal Peptide: M1-S16, M1-S20, M1-N21, M1-F22, M1-H24, M1-S25, M1-K27	SPSCAN HMMER
					Aminotransferases class-V pyridoxal-phosphate attachment site: S25-S72	PROFILES SCAN
30	643526CD1	72			signal_cleavage: M1-C18 Signal Peptide: M1-C18, M1-S19, M1-E20, M1-S21, M1-G23, M1-S24, M1-P26	SPSCAN HMMER
					Transmembrane Domain: S24-V41	TMAP
31	1483418CD1	149	S65 S70		signal_cleavage: M1-H29 Signal Peptide: M1-G32, M1-V34, M1-S35	SPSCAN HMMER
					Transmembrane Domain: G32-P53 N-terminus is non-cytosolic	TMAP
32	2683477CD1	100	S71 T54 T81	N69	Signal Peptide: M7-L35 Transmembrane Domain: S13-R38 N-terminus is non-cytosolic	HMMER TMAP
33	5580991CD1	78	S50		signal_cleavage: M1-C24 Signal Peptide: M4-S22, M4-C24, M4-P25, M4-S26, M4-S29	SPSCAN HMMER
					Transmembrane Domain: F13-F41 N-terminus is non-cytosolic	TMAP
					CBF/NF-Y subunits signatures: M4-S73	PROFILES SCAN
34	5605931CD1	75	S65		Signal Peptide: M29-A43	HMMER
					Signal Peptide: M1-Q28	HMMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
34 (cont.)					Transmembrane Domain: A5-F25 N-terminus is non-cytosolic	TMAP
35	697524ICD1	111	S6 S51 S75		signal_cleavage: M1-E22 Signal Peptide: M1-E22, M1-K24, M1-K24, M1-G28, M1-I30	SPSCAN HMMER
36	698529CD1	72	S30 T35		signal_cleavage: M1-A15 Signal Peptide: M1-A15, M1-T17, M1-A20	SPSCAN HMMER
37	6996808CD1	90	S34 S42 S68		signal_cleavage: M1-C45 Signal Peptide: M26-C45, M17-L38, M17-S41 Transmembrane Domains: Q12-F40, R44-I72 N-terminus is non-cytosolic	SPSCAN HMMER TMAP
38	7472689CD1	283	S66 S140 S197 T259	N131	Signal Peptide: M21-G38	HMMER
39	876751CD1	566	S111 S238 S407 S485 S556 T167 T176 T308 T312 T316 T320 T346 T527 Y206	N274	Signal_Peptide: M1-A19 Signal Peptide: M1-A18, M1-E20 EGF-like domain: C94-C128, C174-C213, C219-C254, C134-C168, C61-C87 MAM domain: C423-E564 Anaphylatoxin domain proteins BL01177: R99-L117, P163-S180 Calcium-binding EGF-like domain BL01187: C105-Y120, C168-A179	SPSCAN HMMER HMMER_PFAM HMMER_PFAM BLIMPS_BLOCKS BLIMPS_BLOCKS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
39 (cont.)					<p>PRECURSOR GLYCOPROTEIN SIGNAL</p> <p>TRANSMEMBRANE HYDROLASE PROTEIN</p> <p>REPEAT RECEPTOR PHOSPHATASE</p> <p>NEUROFILIN</p> <p>PD001482: W432-E564</p> <p>PROLINE-RICH PROTEIN 3</p> <p>DM00215[P41479]30-111: P297-I369</p> <p>Cell attachment sequence: R383-D385</p> <p>Aspartic acid and asparagine hydroxylation site: C105-C116 C187-C198 C232-C243</p> <p>EGF-like domain signature 1: C76-C87</p> <p>EGF-like domain signature 2: C76-C87 C114-C128 C241-C254</p> <p>Calcium-binding EGF-like domain pattern signature: D90-C114 D170-C196 D215-C241</p>	BLAST_PRODOM
40	2512510CD1	1093	<p>S81 S270 S326</p> <p>S356 S379 S403</p> <p>S473 S588 S705</p> <p>S734 S822 S850</p> <p>S970 S987 S998</p> <p>T192 T214 T320</p> <p>T370 T499 T538</p> <p>T604 T609 T688</p> <p>T736 T771 T818</p> <p>T828 T848 T936</p> <p>Y670</p>	<p>N74 N150 N246</p> <p>N292 N318 N684</p>	Signal Peptide: M1-A33	SPSCAN
					Signal Peptide: M1-A33, M1-A34	HMMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
40 (cont.)					Leucine Rich Repeat: S332-R355, S236-S259, K308-S331, R212-N235, G407-K430, S356-D382, N93-S114, S189-P211, K260-T283, S383-E406, P164-S187, S140-P163, W69-P92, A284-Q307, H116-K136	HMMER_PFAM
					Leucine rich repeat C-terminal domain: D440-D490	HMMER_PFAM
					Immunoglobulin domain: G707-M765, T613-A674, G509-I579	HMMER_PFAM
					Transmembrane Domain: R13-A33 N terminus non-cytosolic	TMAP
					Bee Venom Hyaluronidase PR00847F: R738-V754	BLIMPS_PRINTS
					Leucine-rich repeat signature PR00019 L91-L104, L141-V154	BLIMPS_PRINTS
					MEMBRANE GLYCOPROTEIN PD129774: M765-S1093 PD172109: D491-F583 PD165826: E29-T70	BLAST_PRODOM
					SIMILARITY MULTIPLE LEUCINE RICH PD037237: L432-I610	BLAST_PRODOM
					IMMUNOGLOBULIN DM000001 P35918 668-745: L699-A774 DM000001 A46065 668-745: L699-A774	BLAST_DOMO
					Leucine zipper pattern: L52-L73 L59-L80	MOTIFS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
41	7486326CD1	915	S38 S98 S130 S132 S151 S153 S195 S201 S245 S306 S353 S488 S596 S751 S882 T304 T367 T592 T775 T859 T902 T904 Y152 Y745	N217 N351 N365 N434	Signal_Peptide: M1-P23	SPSCAN
					Signal Peptide: M1-P23, M1-G26	HMMER
					von Willebrand factor (growth regulator) type C domain: C51-C125, C832-C892, C744-C810, C665-C722	HMMER_PFAM
					Transmembrane Domain: P5-R25	TMAP
					N terminus non-cytosolic	
					CHORDIN	BLAST_PRODOM
					PD018424: Q440-L618, G232-Y439, F141-P292, A413-V605	
					PD069130: P811-C892PD015143: P662-D727	
					VON WILLEBRAND FACTOR TYPE C REPEAT	BLAST_DOMO
					DM00551 A55195 22-117: P31-P126	
					DM00551 A55195 752-835: E724-K808, P656-C719	
					DM00551 A55195 637-751: R660-C722, R738-C810, T592-L618	
					DM00551 A55195 836-920: Q809-C892	
					Cell attachment sequence R165-D167	MOTIFS
					VWFC domain signature:	MOTIFS
					C686-C722 C771-C810	

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
41					Leucine zipper pattern: L315-L336	MOTIFS
(cont.)						
42	1221545CD1	113	S66 S71 T44 T100	N88	Signal Peptide: M1-T45	SPSCAN
					Signal Peptide: M1-D18, M1-G20	HMMER
					Transmembrane Domain: T4-R24	TMAP
					N terminus cytosolic	
43	124737CD1	91	S30 S43		Signal Peptide: M1-A26	SPSCAN
					Signal Peptide: M1-A26, M1-L31	HMMER
44	1510784CD1	83	S33 S61 S71		Signal Peptide: M1-S61	SPSCAN
					Signal Peptide: M1-H17, M3-P23	HMMER
					Defensin signature: PR00217A L58-C67	BLIMPS_PRINTS
45	1901257CD1	128	S28 T31 T38		Signal Peptide: M1-S27	SPSCAN
					Signal Peptide: M7-S34, M46-S74	HMMER
					Transmembrane Domain: A4-A25	TMAP
					N terminus non-cytosolic	
46	2044370CD1	84	S31 S49 T22	N38	Signal Peptide: M1-G21	SPSCAN
					Signal Peptide: M1-G21	HMMER
					Transmembrane Domain: L3-Y23	TMAP
					Sushi (SCR complement) domain: PF00084A:C69-P73	BLIMPS_PFAM
47	2820933CD1	109	S33 S52 S97		Signal Peptide: M1-S21	SPSCAN
					Signal Peptide: M1-S21, M1-E31	HMMER
48	2902793CD1	159	S85 S154 T122		Signal Peptide: M1-A23	SPSCAN
					Signal Peptide: M1-C25	HMMER
					Immunoglobulin domain: G54-C112	HMMER_PFAM
					Transmembrane Domain: V4-S21	TMAP
					N terminus non-cytosolic	

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
49	7486536CD1	242	S86 S100 S104 S115 S139 S229 T30 T134 Y176	N76	Signal Peptide: M1-L19, M1-N21	HMMER
					Transmembrane Domain: T6-L29 N terminus non-cytosolic	TMAP
50	8137305CD1	542	S74, S90, S95, S111, S126, T225, Y245, T231, S320, S338, S379, S424, T536	N41, N333	Signal cleavage: M1-F28	SPSCAN
					Signal Peptide: M1-C34	HMMER
					Transmembrane Domain: I7-L32; N-terminus is non-cytoplasmic	TMAP
51	3793128CD1	105	S30, T37	N55	Signal cleavage: M1-R22	SPSCAN
					Signal Peptide: M1-S19	HMMER
					Transmembrane Domain: P7-Y34; N-terminus is non-cytoplasmic	TMAP
52	4001243CD1	102			Signal Peptide: M76-A95, M1-A27	HMMER
53	6986717CD1	129	S31, S77, T125	N83	Signal Peptide: M25-R48, M25-A53, M25-Q51	HMMER
					Transmembrane Domain: P4-R19; N-terminus is non-cytoplasmic	TMAP

Table 3

SEQ ID NO:	Incye Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
54	7503512CD1	1070	S81 S247 S303 S333 S356 S380 S450 S565 S682 S711 S799 S827 S947 S964 S975 T192 T297 T347 T476 T515 T581 T586 T665 T713 T748 T795 T805 T825 T913 Y647	N74 N150 N223 N269 N295 N661	signal_cleavage: M1-A33	SPSCAN
					Signal Peptide: M1-A33, M1-A34	HMMER
					Leucine Rich Repeat: S309-R332, S213-S236, K285-S308, S333-S356, G384-K407, N93-S114, W69-P92, K237-T260, S360-E383, P164-S187, S140-P163, S189-N212, A261-Q284, H116-K136	HMMER_PFAM
					Leucine rich repeat C-terminal domain: D417-D467	HMMER_PFAM
					Leucine rich repeat N-terminal domain: P40-P67	HMMER_PFAM
					Immunoglobulin domain: G684-M742, T590-A651, G486-I556	HMMER_PFAM
					Cytosolic domain: Y793-S1070	TMHMMER
					Transmembrane domain: V770-I792	
					Non-cytosolic domain: M1-T769	
					RECEPTOR INTERLEUKIN-1 P	BLIMPS_PRODUM
					PD02870: F634-V666, L725-P759	

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
54 (cont.)					MEMBRANE GLYCOPROTEIN PD129774: M742-S1070 PD172109: D468-F560 PD165826: E29-T70	BLAST_PRODROM
					KEK1 PRECURSOR T21D12.9 SPLICING SIGNAL ALTERNATIVE KEK2 PD037237: L409-I587	BLAST_PRODROM
					IMMUNOGLOBULIN DM00001 P35918 668-745: L676-A751 DM00001 A46065 668-745: L676-A751	BLAST_DOMO
					Leucine zipper pattern: L52-L73, L59-L80	MOTIFS

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
55/095765CB1/1315	1-68, 1-341, 1-346, 1-359, 1-365, 1-367, 1-435, 1-566, 1-589, 1-625, 1-647, 2-367, 3-365, 3-367, 4-367, 5-367, 6-367, 7-68, 7-367, 9-367, 11-367, 67-367, 154-367, 244-367, 290-358, 361-547, 361-550, 362-957, 363-384, 363-387, 363-394, 363-399, 363-400, 363-403, 363-411, 363-417, 363-418, 363-424, 363-434, 363-436, 363-443, 363-444, 363-446, 363-450, 363-454, 363-459, 363-460, 363-461, 363-464, 363-467, 363-469, 363-473, 363-476, 363-477, 363-480, 363-484, 363-487, 363-489, 363-490, 363-491, 363-492, 363-496, 363-497, 363-498, 363-500, 363-501, 363-504, 363-509, 363-510, 363-511, 363-512, 363-515, 363-517, 363-518, 363-521, 363-526, 363-527, 363-528, 363-529, 363-530, 363-532, 363-533, 363-534, 363-536, 363-538, 363-539, 363-540, 363-541, 363-544, 363-545, 363-547, 363-549, 363-550, 363-551, 363-553, 363-554, 363-555, 363-556, 363-559, 363-560, 363-562, 363-563, 363-564, 363-565, 363-566, 363-567, 363-569, 363-571, 363-572, 363-574, 363-580, 363-582, 363-584, 363-586, 363-590, 363-592, 363-594, 363-595, 363-600, 363-604, 363-608, 363-611, 363-630, 363-925, 363-950, 363-956, 363-957, 365-447, 365-502, 365-510, 365-544, 365-550, 365-554, 365-560, 365-948, 367-443, 367-955, 379-956, 381-956, 388-957, 390-936, 394-956, 401-957, 414-955, 416-950, 421-956, 425-956, 433-554, 442-957, 444-957, 448-957, 451-956, 451-957, 452-955, 456-956, 458-953, 458-955, 461-956, 472-952, 473-957, 477-956, 479-956, 479-957, 484-956, 485-615, 487-956, 491-936, 493-957, 494-956, 495-956, 496-957, 499-954, 499-956, 499-957, 505-956, 505-957, 509-957, 512-949, 516-955, 529-956, 531-957, 537-956, 539-956, 539-957, 541-957, 545-955, 548-947, 548-956, 553-956, 555-953, 563-778, 563-912, 563-957, 564-955, 568-957, 569-965, 572-965, 580-957, 584-1206, 584-1315, 585-957, 586-949, 590-956, 593-956, 593-957, 594-965, 595-734, 595-957, 595-965, 597-743, 601-957, 605-794, 606-710, 607-882, 610-956, 624-954, 629-955, 630-947, 636-957, 641-957, 644-954, 651-921, 655-810, 657-929, 659-777, 659-798, 659-799, 659-940, 664-904, 671-947, 671-957, 678-897, 678-919, 690-835, 705-957, 723-956, 723-957, 729-956, 731-956, 763-955, 775-955, 778-957, 784-957, 805-957, 813-957, 823-957, 836-957, 850-957, 854-957, 881-954, 911-956
56/6399886CB1/3796	1-268, 1-287, 184-830, 186-653, 280-606, 280-753, 280-767, 280-836, 280-852, 280-924, 280-936, 365-765, 365-768, 365-794, 439-1252, 497-916, 571-1252, 621-1286, 645-836, 709-1568, 732-1214, 743-991, 773-1403, 810-1354, 810-1367, 810-1440, 843-1013, 847-1135, 856-1475, 858-1504, 867-1103, 928-1240, 942-1561, 961-1568, 985-1521, 1010-1130, 1010-1451, 1155-1438, 1158-1413, 1207-1495, 1207-1737, 1272-1533, 1272-1729, 1451-1529, 1506-1963, 1531-1871, 1534-1829, 1540-1786, 1543-1737, 1543-1814, 1597-1835, 1649-2212, 1669-2235, 1703-1891, 1711-2149, 1757-2033, 1802-2377, 1883-2433, 1914-2400, 1970-2635, 2001-2230, 2001-2677, 2014-2440, 2036-2249, 2036-2521, 2081-2503, 2086-2350, 2124-2563, 2151-2480, 2177-2453, 2184-2418, 2251-2875, 2257-2524, 2305-2534, 2313-2532, 2313-2938, 2314-3011, 2320-2540, 2331-2799, 2332-2647, 2390-2549, 2415-2612, 2459-2744, 2592-2715, 2602-2830, 2611-2886, 2681-2880, 2681-2928, 2684-2975, 2700-2955, 2710-2998, 2716-3047, 2720-3177, 2725-2947, 2745-2901, 2778-3062, 2792-3019, 2792-3188, 2794-2993, 2808-3112, 2811-3065, 2825-3106, 2826-3084, 2826-3104, 2831-3039, 2868-3094, 2868-3100, 2876-3144, 2883-3112, 2883-3141, 2883-3310, 2904-3133, 2904-3460, 2914-3165, 2951-3227, 2959-3180,

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
56 (cont.)	2977-3227, 2991-3245, 3026-3426, 3027-3314, 3115-3376, 3124-3390, 3129-3730, 3181-3406, 3199-3444, 3204-3445, 3217-3786, 3234-3494, 3240-3488, 3281-3492, 3315-3796, 3327-3775, 3341-3580, 3437-3681, 3483-3711, 3484-3738, 3572-3781, 3629-3796
57/6024420CB1/2983	1-186, 1-286, 1-506, 1-517, 1-631, 1-637, 1-711, 1-787, 2-591, 2-638, 2-667, 3-660, 4-689, 14-650, 70-526, 110-705, 202-837, 272-862, 281-825, 284-883, 298-1007, 319-948, 332-906, 334-884, 346-1151, 403-540, 408-1110, 448-1180, 462-729, 529-1218, 569-1233, 578-1254, 607-852, 608-1341, 612-1232, 664-1503, 668-1227, 714-1339, 740-1382, 781-1404, 811-1688, 882-1650, 914-1605, 916-1611, 931-1462, 947-1202, 955-1479, 998-1585, 999-1798, 1019-1566, 1077-1903, 1078-1637, 1081-1664, 1093-1614, 1127-1943, 1130-1810, 1141-1783, 1147-1873, 1179-1881, 1217-1782, 1264-1829, 1267-1889, 1271-1878, 1294-1918, 1317-1930, 1415-1878, 1709-2983, 1740-2008
58/7481067CB1/3840	1-222, 160-947, 250-418, 514-606, 775-1155, 781-861, 1027-1420, 1086-1379, 1321-1662, 1463-2176, 1463-2964, 1664-1856, 2038-2353, 2248-2294, 2250-2759, 2264-2506, 2423-2507, 2458-2696, 2550-2824, 2571-2825, 2584-3076, 2708-2984, 2713-2753, 2824-3128, 2937-3384, 2970-3384, 3059-3570, 3221-3840
59/3378720CB1/1570	1-293, 1-363, 1-404, 1-437, 1-452, 1-511, 1-521, 1-544, 1-553, 1-557, 1-565, 1-569, 6-276, 41-656, 49-720, 68-639, 89-709, 121-747, 215-841, 219-429, 225-755, 249-864, 296-906, 339-955, 380-934, 423-599, 450-750, 461-739, 634-1045, 647-791, 771-1317, 825-995, 841-1425, 875-1481, 911-1528, 911-1536, 978-1535, 984-1515, 994-1402, 1070-1526, 1093-1316, 1130-1570, 1344-1570
60/938824CB1/409	1-245, 1-294, 1-338, 207-409, 333-393
61/1683721CB1/953	1-189, 1-209, 1-439, 1-470, 1-581, 10-695, 26-658, 209-685, 251-573, 258-536, 269-489, 298-734, 321-839, 324-540, 360-521, 386-862, 388-742, 522-948, 556-953, 646-953
62/1694122CB1/890	1-286, 2-25, 2-479, 25-44, 25-311, 25-314, 25-331, 25-337, 25-338, 25-416, 27-331, 29-110, 51-145, 78-554, 94-529, 96-554, 120-546, 160-439, 160-653, 160-705, 161-435, 164-424, 201-860, 301-554, 301-857, 326-628, 335-621, 336-437, 336-554, 362-487, 362-584, 362-862, 362-881, 362-890, 424-554, 428-554, 445-554, 448-554, 452-693, 452-886, 467-554, 482-725, 516-554, 553-774, 553-807, 553-822, 554-829, 555-869
63/1970615CB1/1960	1-421, 84-333, 117-709, 144-700, 178-360, 178-374, 282-525, 285-709, 286-550, 286-852, 311-555, 423-708, 423-709, 583-736, 598-880, 598-881, 598-1013, 598-1015, 598-1074, 598-1094, 598-1120, 634-1049, 653-1211, 670-921, 678-929, 709-968, 719-1226, 728-1117, 731-978, 740-948, 740-952, 740-1006, 742-965, 742-1294, 747-1016, 762-1213, 850-1163, 869-1053, 922-1173, 922-1186, 983-1255, 1038-1282, 1049-1308, 1049-1327, 1050-1546, 1058-1342, 1060-1546, 1095-1337, 1117-1546, 1117-1603, 1182-1395, 1198-1891, 1202-1447, 1202-1749, 1219-1470, 1226-1466, 1287-1516, 1338-1625, 1351-1590, 1355-1652, 1369-1960, 1447-1640, 1447-1887, 1447-1901, 1472-1774, 1474-1733

Table 4

Polynucleotide SEQ ID NO./ Incye ID/ Sequence Length	Sequence Fragments
64/2314152CB1/832	1-519, 11-466, 13-433, 29-187, 29-476, 29-486, 29-588, 29-628, 32-408, 34-490, 35-239, 35-348, 35-415, 36-655, 36-662, 49-548, 57-457, 58-643, 61-648, 66-760, 77-603, 91-552, 91-598, 94-644, 172-415, 219-832, 412-686, 501-757, 509-832, 525-774
65/2886225CB1/546	1-454, 273-533, 275-546
66/6144418CB1/890	1-123, 1-596, 42-619, 42-630, 60-709, 130-660, 188-658, 188-732, 222-737, 222-778, 222-890, 255-732, 258-686
67/6834184CB1/807	1-554, 1-687, 1-807
68/6951005CB1/677	1-564, 1-643, 4-677
69/7250331CB1/617	1-287, 3-397, 241-532, 269-598, 289-600, 307-497, 344-498, 366-597, 370-617, 441-586, 441-615
70/1758413CB1/795	1-456, 292-768, 292-795, 417-695, 573-707
71/7011042CB1/1677	1-895, 241-1100, 241-1660, 251-753, 896-1043, 920-1043, 1259-1677
72/7427362CB1/1402	1-1268, 268-527, 270-1268, 787-926, 875-1402
73/7485304CB1/1251	1-1251, 73-171, 255-1081
74/1422394CB1/4961	1-493, 34-650, 38-279, 38-311, 39-650, 48-597, 51-590, 304-484, 304-753, 309-899, 421-957, 488-710, 559-633, 582-971, 632-777, 717-1013, 738-1442, 748-1151, 748-1383, 756-951, 958-1606, 1126-1486, 1126-1815, 1273-1817, 1277-1828, 1291-1949, 1322-1922, 1336-1840, 1336-1859, 1336-1908, 1438-1714, 1442-2028, 1509-1757, 1509-2045, 1549-2251, 1754-2257, 1760-2378, 1905-2232, 1905-2438, 1905-2485, 1905-2491, 1905-2571, 1905-2626, 1908-2337, 1925-2480, 1967-2630, 1969-2201, 2010-2503, 2012-2506, 2034-2531, 2037-2626, 2044-2617, 2067-2282, 2070-2350, 2108-2715, 2117-2622, 2132-2324, 2132-2636, 2157-2816, 2183-2689, 2209-2626, 2244-2715, 2278-2790, 2301-2758, 2363-2644, 2363-2647, 2475-2751, 2479-2794, 2479-2884, 2487-2836, 2497-2791, 2498-2827, 2507-2858, 2680-2901, 2680-3121, 2702-3304, 2723-3251, 2774-3063, 2825-3066, 2830-3456, 2837-3405, 2844-3134, 2859-3128, 2861-3141, 2863-3149, 2871-3479, 3077-3336, 3077-3588, 3141-3409, 3141-3601, 3152-3414, 3182-3457, 3260-3554, 3277-3672, 3299-3596, 3299-3602, 3329-3556, 3329-3566, 3349-3612, 3377-3678, 3390-3613, 3408-3634, 3420-3691, 3506-3778, 3519-3673, 3595-4170, 3602-3798, 3625-3922, 3690-3884, 3697-3928, 3716-3979, 3716-4001, 3862-4072, 3865-4142, 3890-4136, 3967-4157, 4002-4269, 4029-4210, 4068-4311, 4070-4381, 4072-4316, 4099-4312, 4152-4403, 4158-4431, 4230-4401, 4230-4750, 4230-4811, 4250-4403, 4277-4817, 4299-4809, 4355-4590, 4355-4603, 4381-4784, 4460-4729, 4460-4816, 4460-4961, 4499-4777, 4501-4645, 4533-4776, 4633-4829, 4639-4874

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
75/1336022CB1/3298	1-494, 217-493, 220-494, 220-613, 220-630, 220-893, 223-831, 226-878, 228-833, 230-934, 234-874, 241-494, 244-613, 269-561, 360-613, 408-885, 465-658, 467-740, 495-1070, 549-1177, 566-827, 577-797, 633-895, 646-1194, 656-953, 668-857, 679-973, 694-885, 705-1428, 721-1177, 758-1079, 781-1362, 782-1009, 797-1044, 812-1122, 825-1101, 831-1122, 836-1108, 842-1070, 866-1100, 917-1125, 919-1610, 939-1177, 944-1561, 947-1222, 966-1234, 967-1134, 970-1436, 979-1535, 996-1232, 1017-1596, 1051-1629, 1074-1621, 1076-1623, 1076-1634, 1085-1345, 1097-1576, 1145-1637, 1159-1366, 1185-1436, 1200-1478, 1228-1671, 1239-1510, 1248-1399, 1249-1888, 1266-1573, 1355-1670, 1374-2001, 1375-1922, 1375-1976, 1424-1961, 1442-2078, 1468-2027, 1497-1977, 1543-2124, 1550-2186, 1624-2160, 1631-2137, 1637-2265, 1661-2205, 1665-2248, 1669-1961, 1678-1954, 1691-1962, 1691-2303, 1699-2305, 1715-2272, 1728-2335, 1740-1962, 1777-2348, 1840-2314, 1856-2086, 1862-2108, 1884-2510, 1885-2515, 1886-2213, 1906-2450, 1910-2426, 1954-1987, 1961-2213, 2017-2460, 2017-2551, 2042-2197, 2048-2507, 2092-2714, 2101-2314, 2167-2678, 2303-2839, 2376-2839, 2479-2895, 2479-2898, 2479-3109, 2538-3144, 2550-3282, 2550-3298, 2588-2879, 2589-2879, 2600-2839, 2603-2839, 2730-3002, 2841-3212
76/7473674CB1/833	1-321, 1-328, 44-463, 44-483, 46-367, 53-519, 68-236, 68-490, 91-537, 114-477, 128-415, 144-290, 269-653, 279-648, 282-485, 282-536, 282-583, 282-609, 282-654, 287-490, 288-654, 289-644, 289-654, 293-653, 300-620, 301-489, 301-645, 301-710, 319-727, 322-496, 323-446, 323-456, 323-470, 323-482, 323-618, 323-628, 323-630, 323-635, 323-637, 323-639, 323-645, 323-646, 323-647, 323-652, 323-653, 323-663, 323-717, 323-730, 323-731, 323-786, 324-647, 326-479, 331-507, 340-647, 341-730, 353-497, 369-497, 395-547, 395-638, 424-647, 426-654, 482-823, 504-654, 567-826, 640-833, 687-823
77/7475846CB1/920	1-920, 199-552
78/7475860CB1/964	1-553, 25-281, 240-535, 243-610, 255-872, 255-873, 268-872, 283-507, 285-849, 289-882, 291-592, 292-578, 293-511, 298-581, 298-722, 300-548, 301-563, 302-594, 309-753, 309-758, 309-760, 314-697, 314-783, 315-580, 315-591, 315-933, 316-678, 316-756, 316-785, 317-518, 317-580, 322-575, 322-586, 324-606, 325-570, 328-579, 330-614, 336-617, 342-623, 346-649, 347-607, 371-898, 377-946, 433-703, 477-820, 484-733, 493-964, 495-804, 512-910, 526-811, 568-807, 639-880, 639-964, 684-832, 762-962, 818-964
79/7950941CB1/701	1-397, 9-701
80/7485334CB1/1742	1-724, 126-1078, 752-995, 752-1279, 896-1188, 1002-1231, 1002-1507, 1038-1619, 1167-1454, 1167-1615, 1167-1742, 1282-1632
81/7220001CB1/2295	1-606, 1-762, 40-275, 149-553, 379-1700, 574-897, 736-1024, 736-1036, 738-1357, 1052-1657, 1117-1681, 1155-1690, 1159-1690, 1193-1839, 1202-1831, 1203-1796, 1226-1771, 1254-1820, 1324-1947, 1324-1969, 1347-1928, 1363-2014, 1367-2014, 1400-1867, 1423-1933, 1425-2084, 1432-2004, 1441-1867, 1499-2176, 1519-1700, 1547-2059, 1599-2093, 1600-2208, 1602-1806, 1605-2295, 1606-2201, 1645-2223, 2257-2285, 2257-2288, 2257-2290, 2257-2291, 2257-2292, 2257-2294, 2257-2295, 2258-2295

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
82/5956275CB1/911	1-676, 60-818, 61-349, 348-911
83/346472CB1/1806	1-259, 1-478, 1-1803, 115-677, 243-606, 292-495, 296-895, 313-977, 325-935, 353-997, 355-851, 361-1061, 362-935, 387-1063, 392-1010, 395-1077, 397-1029, 397-1051, 442-1006, 449-948, 463-979, 479-1190, 534-1032, 534-1100, 534-1102, 539-1042, 541-1191, 577-1094, 602-790, 615-950, 617-1298, 657-1047, 669-1293, 670-1298, 705-1110, 714-1314, 739-1367, 745-1271, 748-1367, 767-1282, 767-1286, 780-1367, 821-1116, 823-1421, 830-1481, 843-1555, 846-1443, 849-1506, 852-1496, 865-1404, 878-1528, 886-1563, 889-1596, 920-1451, 920-1460, 920-1463, 925-1227, 926-1392, 934-1475, 939-1595, 939-1625, 940-1483, 943-1504, 958-1171, 958-1519, 962-1479, 966-1566, 969-1468, 973-1314, 978-1489, 985-1511, 988-1417, 988-1535, 995-1675, 1001-1391, 1013-1286, 1013-1581, 1020-1170, 1122-1765, 1122-1793, 1167-1793, 1172-1443, 1188-1637, 1208-1793, 1214-1806, 1284-1767, 1294-1703, 1408-1684
84/643526CB1/603	1-539, 1-603, 4-603, 44-276, 44-535
85/1483418CB1/1888	1-105, 1-168, 1-193, 1-280, 1-301, 1-394, 1-564, 1-631, 51-522, 89-618, 125-632, 125-644, 125-657, 129-776, 209-717, 211-751, 258-874, 290-680, 297-823, 343-964, 359-1005, 387-561, 396-968, 415-823, 450-507, 460-1056, 470-711, 470-996, 518-1009, 568-1020, 568-1024, 597-764, 606-910, 606-1200, 611-1300, 640-1093, 640-1194, 656-1181, 669-1268, 678-1005, 684-1331, 689-954, 696-1219, 696-1298, 711-1284, 713-1138, 768-1047, 768-1058, 768-1304, 781-1314, 842-1366, 895-1434, 918-1477, 940-1467, 1035-1561, 1112-1664, 1131-1383, 1267-1725, 1307-1554, 1330-1529, 1334-1808, 1340-1528, 1340-1842, 1366-1642, 1407-1679, 1411-1872, 1430-1888
86/2683477CB1/1576	1-254, 1-513, 1-531, 1-557, 1-592, 1-617, 1-641, 1-643, 1-692, 1-713, 1-818, 2-742, 16-717, 27-967, 361-1008, 408-1254, 425-1121, 467-1168, 478-1175, 560-1141, 572-1380, 574-1399, 595-1085, 629-1195, 655-1307, 699-1314, 754-1196, 773-1576, 787-1284, 809-1573, 879-1576, 971-1573, 985-1576, 995-1572, 1060-1576, 1075-1576
87/5580991CB1/415	1-256, 1-415
88/5605931CB1/762	1-705, 66-705, 72-748, 157-705, 166-705, 211-705, 271-762, 275-759, 358-708, 366-701, 454-705, 480-705
89/6975241CB1/654	1-654, 96-653
90/6988529CB1/505	1-464, 1-505
91/6996808CB1/841	1-514, 85-548, 85-745, 85-841

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
92/7472689CB1/1367	1-253, 192-448, 192-769, 192-781, 192-847, 284-331, 387-647, 444-546, 444-553, 444-587, 444-671, 444-674, 444-678, 444-699, 444-731, 444-734, 444-794, 444-810, 445-508, 481-1050, 483-963, 489-977, 490-765, 522-731, 529-863, 530-730, 543-937, 568-688, 572-1125, 604-859, 614-830, 627-1222, 630-1120, 663-1011, 667-1152, 672-1222, 686-1339, 715-1200, 721-927, 721-1259, 729-1290, 735-994, 759-1286, 770-1349, 796-1359, 818-1344, 837-1367, 861-1111, 861-1275, 861-1286, 861-1355, 873-1367, 890-1024, 897-1246, 897-1286, 909-1286, 911-1126, 912-1367, 914-1186, 922-1367, 941-1286, 944-1286, 951-1361, 955-1208, 960-1340, 1001-1304, 1001-1332, 1021-1286, 1028-1286, 1035-1286, 1039-1367, 1041-1351, 1042-1295, 1075-1259, 1084-1286, 1094-1367, 1096-1329, 1101-1286, 1117-1286, 1118-1286, 1144-1286, 1152-1361, 1168-1286, 1180-1286, 1180-1287, 1202-1286, 1239-1286
93/876751CB1/4595	1-594, 248-705, 249-910, 277-740, 289-741, 403-907, 417-988, 440-992, 453-1111, 481-1192, 498-992, 503-1111, 568-812, 568-1066, 599-1188, 642-1192, 665-1303, 675-1202, 997-1564, 1045-1569, 1093-1340, 1093-1658, 1130-1681, 1197-1579, 1330-1617, 1375-1653, 1502-2181, 1507-2168, 1538-2103, 1674-1918, 1675-2130, 1678-2164, 1850-2311, 1890-2119, 1964-2399, 2120-2369, 2120-2746, 2130-2171, 2330-2538, 2330-2804, 2335-2624, 2348-2623, 2356-2650, 2423-2666, 2423-2844, 2447-2637, 2483-3218, 2498-2683, 2501-2670, 2521-2834, 2551-2816, 2563-2757, 2587-3211, 2592-2939, 2597-2878, 2637-3216, 2668-2996, 2694-2939, 2696-2946, 2696-3294, 2725-2994, 2811-3050, 2817-3230, 2839-3111, 2840-3203, 2843-3166, 2892-3145, 2892-3207, 2934-3222, 2945-3099, 2946-3181, 2950-3259, 2966-3244, 2985-3138, 2985-3180, 2995-3223, 2995-3470, 3002-3226, 3021-3324, 3053-3284, 3071-3360, 3080-3367, 3208-3464, 3208-3471, 3208-3720, 3215-3470, 3220-3498, 3233-3522, 3233-3528, 3257-3570, 3294-3845, 3341-3593, 3341-3625, 3350-3606, 3350-3625, 3379-3570, 3390-3653, 3391-3632, 3431-3570, 3432-3734, 3482-3726, 3482-3746, 3492-3730, 3515-3863, 3572-3827, 3572-3829, 3574-3867, 3574-4072, 3593-3852, 3646-3827, 3661-3922, 3661-3931, 3684-3921, 3694-3916, 3711-3981, 3714-3991, 3717-3992, 3743-4032, 3770-4030, 3788-4036, 3789-3948, 3799-4049, 3817-4036, 3820-4053, 3833-4085, 3859-4069, 3863-4027, 3863-4136, 3863-4376, 3866-4106, 3867-4180, 3869-3930, 3870-4126, 3877-4152, 3909-4123, 3940-4566, 3960-4571, 4045-4320, 4088-4379, 4095-4366, 4143-4560, 4160-4390, 4188-4579, 4216-4595, 4246-4465, 4263-4493, 4269-4525, 4366-4595, 4390-4569, 4425-4568, 4428-4574

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
94/2512510CB1/4759	1-218, 124-348, 124-403, 124-474, 124-511, 124-523, 124-529, 124-547, 124-576, 124-595, 124-612, 124-615, 124-621, 124-628, 124-631, 124-645, 124-689, 124-698, 124-713, 124-718, 124-724, 124-731, 124-734, 124-777, 124-778, 124-813, 124-852, 125-709, 126-398, 132-583, 142-594, 142-609, 155-583, 181-663, 197-433, 242-482, 256-561, 338-865, 365-597, 390-656, 436-671, 436-839, 473-882, 475-869, 514-959, 563-806, 689-1241, 813-1483, 833-1469, 945-1339, 946-1492, 973-1329, 1036-1523, 1114-1501, 1139-1426, 1176-1430, 1185-1684, 1212-1883, 1215-1465, 1216-1818, 1250-1811, 1273-1508, 1293-1876, 1313-1929, 1416-1880, 1462-2059, 1494-1803, 1494-1823, 1496-2069, 1512-1691, 1529-2126, 1530-1811, 1565-2214, 1568-2155, 1747-2231, 1808-2326, 1838-2387, 1866-2157, 1883-2594, 1893-2513, 1893-2547, 1901-2071, 2043-2312, 2071-2487, 2100-2372, 2192-2493, 2248-2427, 2272-2528, 2286-2552, 2292-2592, 2432-2722, 2483-2717, 2500-2743, 2538-2831, 2617-2750, 2626-2899, 2653-3239, 2654-2858, 2656-2908, 2730-3003, 2732-2978, 2781-3038, 2781-3316, 2866-3098, 2876-3553, 2887-3045, 2985-3264, 3024-3273, 3039-3276, 3051-3285, 3055-3331, 3075-3281, 3080-3362, 3099-3362, 3141-3440, 3146-3360, 3152-3420, 3153-3427, 3153-3441, 3181-3442, 3241-3496, 3344-3577, 3400-3661, 3400-3665, 3409-3663, 3424-3689, 3431-3762, 3449-3713, 3452-3738, 3460-3729, 3473-3731, 3481-3745, 3502-3775, 3504-3718, 3527-3775, 3528-3752, 3546-3786, 3548-3777, 3570-3853, 3582-3801, 3582-3806, 3617-3813, 3617-3877, 3637-3991, 3669-3877, 3683-3876, 3690-3898, 3707-3947, 3707-3964, 3709-3921, 3738-3994, 3738-4303, 3750-3970, 3783-4044, 3816-4101, 3844-4107, 3943-4256, 3960-4179, 3973-4187, 3973-4190, 3973-4191, 3973-4209, 3973-4374, 3984-4240, 3991-4236, 4000-4271, 4007-4216, 4007-4443, 4057-4295, 4072-4336, 4072-4605, 4072-4733, 4094-4732, 4100-4759, 4102-4369, 4144-4707, 4154-4466, 4155-4393, 4155-4735, 4155-4745, 4165-4747, 4170-4747, 4171-4759, 4179-4444, 4184-4419, 4189-4759, 4205-4759, 4211-4759, 4213-4759, 4239-4748, 4241-4759, 4250-4747, 4258-4740, 4259-4747, 4266-4759, 4272-4754, 4292-4755, 4299-4747, 4300-4749, 4300-4756, 4302-4747, 4304-4747, 4305-4751, 4308-4747, 4313-4751, 4319-4759, 4320-4759, 4321-4740, 4323-4759, 4327-4747, 4329-4749, 4330-4741, 4330-4747, 4334-4753, 4335-4749, 4338-4753, 4338-4759, 4339-4753, 4339-4759, 4340-4740, 4340-4747, 4341-4747, 4343-4747, 4344-4747, 4345-4756, 4350-4747, 4354-4747, 4356-4750, 4360-4759, 4362-4582, 4362-4682, 4362-4710, 4362-4734, 4362-4743, 4375-4751, 4376-4747, 4381-4753, 4388-4748, 4391-4747, 4391-4750, 4396-4738, 4397-4747, 4400-4747, 4401-4751, 4403-4747, 4423-4747, 4423-4747, 4427-4748, 4428-4747, 4429-4741, 4435-4649, 4435-4737, 4435-4738, 4435-4745, 4440-4747, 4444-4754, 4451-4728, 4456-4747, 4456-4753, 4462-4748, 4498-4759, 4503-4748, 4528-4748, 4536-4747, 4538-4752, 4549-4759, 4551-4750, 4551-4759, 4568-4747, 4570-4748, 4576-4759, 4584-4759, 4587-4731, 4604-4747, 4610-4741, 4612-4747, 4622-4748, 4625-4747, 4625-4748, 4640-4747, 4642-4747, 4644-4748, 4650-4747, 4662-4741, 4662-4759, 4678-4747, 4685-4759
95/7486326CB1/3203	1-870, 411-3203

Table 4

Polynucleotide SEQ ID NO./ Incye ID/ Sequence Length	Sequence Fragments
96/1221545CB1/1681	1-580, 69-613, 360-596, 377-763, 545-982, 569-775, 569-803, 583-1202, 657-901, 756-982, 784-1371, 986-1219, 1102-1615, 1204-1681, 1291-1511, 1339-1555, 1400-1614, 1446-1681
97/124737CB1/1207	1-529, 49-529, 309-1007, 319-729, 394-790, 402-566, 402-735, 406-568, 490-753, 502-988, 649-1179, 664-927, 671-1207, 697-963, 710-1092, 740-1175, 744-1092, 749-1092, 755-1015, 755-1207, 762-1207, 769-1179, 817-1008, 838-1092, 880-1092
98/1510784CB1/1544	1-196, 1-805, 316-894, 323-929, 366-783, 374-900, 374-916, 419-681, 446-962, 446-1005, 446-1038, 497-974, 534-886, 553-1008, 594-972, 658-1080, 669-1072, 717-1215, 1094-1523, 1094-1544, 1216-1447
99/1901257CB1/1519	1-248, 1-1519, 4-384, 79-583, 108-761, 481-645, 491-1007, 501-763, 545-1240, 708-1008, 714-1511, 784-1261, 787-1480, 802-1519, 808-1519, 817-1519, 839-1261, 839-1519, 841-1519, 853-1266, 878-1519, 901-1517, 924-1519, 931-1261, 945-1519, 1005-1519, 1007-1266, 1031-1261, 1241-1519
100/2044370CB1/525	1-235, 1-470, 1-525
101/2820933CB1/1062	1-862, 3-870, 431-1006, 440-1034, 440-1062, 443-995, 454-1009, 542-888, 663-966
102/2902793CB1/2155	1-2155, 66-129, 66-159, 66-304, 66-596, 66-653, 66-674, 92-736, 318-859, 318-860, 340-700, 372-973, 379-882, 379-923, 396-973, 405-973, 477-972, 487-937, 487-996, 487-998, 487-1053, 487-1054, 498-1083, 519-1002, 610-1001, 620-1016, 679-1189, 712-1259, 720-1096, 723-1252, 736-1436, 747-1252, 750-1252, 768-1309, 791-1178, 795-1052, 834-1122, 859-1420, 871-1380, 871-1385, 872-1355, 875-1252, 965-1287, 1002-1535, 1018-1597, 1047-1585, 1063-1463, 1157-1779, 1158-1586, 1184-1622, 1219-1704, 1240-1530, 1253-1717, 1253-1726, 1330-1933, 1333-1925, 1342-1977, 1386-1886, 1389-1631, 1394-1944, 1404-1977, 1446-2090, 1458-2078, 1487-2105, 1524-2071, 1621-2062, 1844-2155, 1978-2083
103/7486536CB1/1777	1-239, 1-259, 1-562, 10-255, 13-284, 19-248, 19-325, 19-451, 26-322, 49-265, 49-453, 140-367, 141-383, 148-368, 172-518, 174-553, 176-278, 181-281, 182-430, 182-454, 185-649, 189-449, 196-432, 196-825, 209-328, 217-486, 532-782, 634-914, 634-920, 634-1115, 634-1223, 644-926, 730-1013, 742-1003, 742-1013, 742-1055, 742-1300, 836-1135, 908-1128, 908-1377, 950-1192, 984-1199, 1055-1297, 1110-1390, 1117-1738, 1149-1753, 1171-1754, 1177-1663, 1181-1732, 1222-1733, 1302-1533, 1302-1754, 1302-1777, 1310-1758, 1324-1764, 1327-1622, 1333-1568, 1348-1755, 1454-1756, 1469-1696, 1511-1769, 1587-1765, 1590-1777, 1603-1765

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
104/8137305CB1/2587	1-308, 1-590, 1-899, 2-529, 5-481, 5-706, 27-611, 29-786, 30-611, 40-710, 41-276, 63-603, 87-873, 88-735, 89-688, 175-965, 309-609, 410-925, 481-1028, 550-806, 642-912, 676-1032, 693-936, 693-1024, 813-1102, 875-1451, 1042-1605, 1069-1228, 1170-1692, 1185-1403, 1290-1512, 1317-1947, 1346-1907, 1346-1998, 1381-1968, 1384-2097, 1427-2080, 1431-1686, 1463-1947, 1471-1955, 1548-1845, 1548-1991, 1559-2178, 1560-2068, 1566-1851, 1585-2176, 1592-1909, 1592-2009, 1604-1834, 1611-2217, 1674-2067, 1683-2151, 1689-2119, 1725-2276, 1734-1978, 1734-2119, 1734-2257, 1734-2301, 1734-2587, 1740-2195, 1761-2201, 1775-2134, 1800-2211, 1802-2200
105/3793128CB1/1490	1-278, 1-452, 1-531, 1-534, 1-547, 1-583, 1-625, 1-707, 7-752, 91-728, 103-724, 110-524, 110-554, 110-575, 110-651, 110-677, 110-695, 110-739, 134-796, 193-576, 319-942, 435-1187, 436-970, 437-1067, 454-1190, 488-1163, 541-1134, 595-1270, 642-1173, 647-1162, 661-1280, 668-1271, 685-1271, 703-1376, 743-1435, 753-1286, 753-1454, 840-1490, 887-1349, 915-1374, 959-1484, 962-1484, 968-1437, 1005-1484, 1057-1484, 1073-1484, 1149-1484, 1177-1484, 1332-1484
106/4001243CB1/1174	1-292, 1-406, 1-442, 1-503, 1-570, 1-648, 52-303, 52-723, 86-644, 101-373, 101-583, 101-672, 113-321, 116-663, 285-854, 291-744, 291-898, 305-810, 415-1174, 427-710, 430-945, 436-723, 488-963, 504-720, 695-963
107/6986717CB1/818	1-556, 1-611, 13-546, 83-818
108/7503512CB1/4717	1-4679, 1-4690, 124-403, 124-474, 124-511, 124-523, 124-529, 124-547, 124-576, 124-595, 124-599, 126-398, 132-583, 132-599, 142-594, 142-599, 155-583, 171-360, 197-433, 242-482, 252-357, 252-360, 257-561, 366-478, 396-946, 397-946, 620-1172, 628-1180, 744-1413, 764-1400, 848-1500, 876-1270, 877-1423, 904-1260, 967-1454, 1032-1696, 1038-1658, 1045-1432, 1079-1357, 1107-1361, 1116-1615, 1146-1396, 1147-1749, 1148-1397, 1152-1814, 1181-1742, 1197-1745, 1204-1439, 1224-1806, 1347-1811, 1399-1968, 1418-1492, 1425-1950, 1425-1977, 1427-2000, 1443-1622, 1461-1742, 1496-2145, 1678-2162, 1769-2318, 1809-2230, 2031-2303, 2773-3462, 2797-3170, 2799-3170, 2807-3484, 2820-3351, 2824-3468, 2935-3513, 2955-3204, 2968-3205, 2982-3216, 2986-3262, 2999-3194, 3008-3212, 3011-3293, 3019-3399, 3020-3261, 3022-3553, 3045-3499, 3057-3500, 3059-3500, 3072-3371, 3077-3291, 3084-3494, 3086-3372, 3093-3572, 3096-3532, 3110-3434, 3112-3373, 3120-3468, 3139-3605, 3152-3217, 3166-3290, 3216-3525, 3252-3499, 3276-3508, 3276-3880, 3279-3861, 3326-3572, 3331-3592, 3331-3596, 3340-3536, 3340-3594, 3340-3601, 3355-3620, 3357-3609, 3362-3693, 3379-4037, 3382-4151, 3383-3644, 3383-3669, 3384-3658, 3391-3660, 3396-3913, 3403-3651, 3404-3662,

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
108 (cont.)	3404-3680, 3412-3676, 3433-3706, 3434-3728, 3435-3649, 3443-3683, 3444-3742, 3456-3855, 3458-3694, 3458-3706, 3458-4047, 3459-3683, 3465-3750, 3477-3717, 3479-3708, 3491-4005, 3499-4117, 3501-3784, 3501-4125, 3513-3732, 3513-3737, 3515-3843, 3516-3806, 3528-3606, 3539-3830, 3542-3627, 3542-3807, 3542-3824, 3542-3882, 3542-4149, 3548-3744, 3548-3782, 3548-3808, 3568-3922, 3568-3978, 3571-4320, 3582-4060, 3586-3868, 3586-4184, 3588-4068, 3590-4295, 3600-3808, 3600-4261, 3603-3884, 3603-4075, 3603-4133, 3614-3807, 3621-3829, 3637-4192, 3638-3878, 3638-3895, 3640-3852, 3650-3933, 3654-4176, 3656-4212, 3659-3909, 3660-3950, 3667-3940, 3669-3925, 3669-4234, 3671-4053, 3671-4065, 3681-3901, 3707-4013, 3713-4166, 3714-3975, 3715-3971, 3717-3974, 3720-3873, 3721-3965, 3737-4296, 3738-4125, 3747-4032, 3756-4373, 3770-4118, 3772-4050, 3773-4212, 3775-4038, 3802-4095, 3808-4032, 3809-4390, 3813-4315, 3815-4059, 3815-4496, 3825-4084, 3825-4119, 3825-4120, 3828-4318, 3828-4462, 3829-4016, 3829-4043, 3831-4101, 3832-4343, 3838-4100, 3841-4091, 3847-4480, 3858-4082, 3860-4236, 3860-4303, 3866-4134, 3871-4132, 3874-4634, 3876-4187, 3877-4132, 3878-4164, 3892-4110, 3896-4608, 3901-4188, 3904-4118, 3904-4121, 3904-4122, 3904-4140, 3904-4305, 3904-4320, 3907-4157, 3908-4200, 3915-4171, 3920-4122, 3920-4345, 3922-4167, 3930-4225, 3931-4147, 3931-4186, 3931-4195, 3931-4201, 3931-4202, 3933-4165, 3934-4025, 3938-4147, 3938-4374, 3940-4201, 3942-4245, 3944-4238, 3947-4218, 3953-4561, 3956-4331, 3963-4628, 3967-4223, 3981-4265, 3982-4247, 3988-4226, 3988-4635, 3989-4545, 3990-4247, 3998-4211, 3998-4298, 3998-4673, 4000-4304, 4000-4606, 4003-4265, 4003-4267, 4003-4285, 4003-4536, 4003-4664, 4007-4230, 4013-4306, 4019-4552, 4025-4587, 4025-4631, 4025-4663, 4027-4289, 4031-4288, 4031-4310, 4031-4676, 4031-4705, 4033-4248, 4033-4253, 4033-4300, 4035-4561, 4043-4462, 4046-4341, 4049-4325, 4050-4280, 4052-4532, 4053-4324, 4059-4312, 4059-4356, 4071-4355, 4075-4638, 4084-4357, 4085-4642, 4086-4324, 4086-4676, 4087-4397, 4091-4329, 4094-4386, 4094-4663, 4094-4703, 4095-4346, 4096-4678, 4101-4678, 4103-4624, 4105-4574, 4109-4647, 4110-4375, 4111-4389, 4115-4350, 4115-4387, 4115-4398, 4115-4417, 4117-4359, 4120-4339, 4120-4674, 4128-4417, 4129-4425, 4133-4423, 4135-4367, 4138-4695, 4142-4697, 4144-4693, 4152-4486, 4170-4679, 4172-4711, 4174-4376, 4181-4678, 4189-4671, 4190-4459, 4190-4665, 4190-4678,

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
108 (cont.)	4190-4687, 4191-4363, 4192-4458, 4193-4439, 4197-4630, 4197-4702, 4200-4636, 4203-4685, 4206-4672, 4207-4678, 4212-4490, 4223-4686, 4230-4678, 4231-4676, 4231-4680, 4233-4678, 4235-4678, 4236-4682, 4239-4678, 4243-4619, 4244-4682, 4246-4586, 4250-4678, 4250-4692, 4251-4696, 4252-4671, 4254-4717, 4258-4678, 4260-4680, 4261-4672, 4261-4678, 4265-4684, 4266-4680, 4269-4684, 4269-4703, 4270-4684, 4270-4707, 4271-4671, 4271-4678, 4272-4678, 4274-4678, 4275-4678, 4276-4687, 4281-4678, 4285-4678, 4287-4681, 4289-4529, 4293-4513, 4293-4613, 4293-4641, 4293-4665, 4293-4674, 4295-4541, 4298-4581, 4306-4682, 4307-4678, 4312-4684, 4315-4558, 4319-4679, 4322-4678, 4322-4681, 4323-4597, 4327-4669, 4328-4678, 4331-4678, 4332-4682, 4334-4678, 4344-4597, 4351-4672, 4354-4678, 4355-4581, 4356-4625, 4358-4679, 4359-4678, 4360-4672, 4366-4580, 4366-4668, 4366-4669, 4366-4676, 4369-4655, 4375-4685, 4377-4478, 4377-4663, 4382-4659, 4387-4677, 4389-4668, 4393-4679, 4407-4644, 4429-4705, 4434-4679, 4459-4679, 4467-4678, 4469-4683, 4480-4708, 4482-4643, 4482-4681, 4482-4709, 4486-4575, 4499-4678, 4501-4679, 4515-4702, 4518-4662, 4535-4678, 4541-4672, 4556-4678, 4571-4678, 4573-4678, 4595-4672, 4595-4709, 4609-4678

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID:	Representative Library
55	095765CB1	PITUNOT06
56	6399886CB1	PANCTUT01
57	6024420CB1	TESTNOT11
58	7481067CB1	BRSTNOT07
59	3378720CB1	KERANOT02
60	938824CB1	CERVNOT01
61	1683721CB1	PROSNOT15
62	1694122CB1	COLNNOT23
63	1970615CB1	PROSTUT09
64	2314152CB1	CONUTUT01
65	2886225CB1	UTRSTMR02
66	6144418CB1	BRANDIN01
67	6834184CB1	BRSTNON02
68	6951005CB1	BRAITDR02
69	7250331CB1	KIDNTUT15
71	7011042CB1	BRAZNOT01
72	7427362CB1	BRSTTMR01
73	7485304CB1	SEMTTDE01
74	1422394CB1	MIXDUNB01
75	1336022CB1	COLNNOT13
76	7473674CB1	LUNGNON07
78	7475860CB1	ADRENON04
79	7950941CB1	BRABNOE02
80	7485334CB1	BSTMNON02
81	7220001CB1	COLXTDT01
82	5956275CB1	BRAUNOR01
83	346472CB1	THYMNOT02
84	643526CB1	BRAIFEE05
85	1483418CB1	SINTBST01
86	2683477CB1	SINIUCT01
87	5580991CB1	UTRENON03
88	5605931CB1	MONOTXN03
89	6975241CB1	BRAHTDR04
90	6988529CB1	BRAIFER05
91	6996808CB1	BRAXTDR17
92	7472689CB1	LNODNOT12
93	876751CB1	THYRNOT03
94	2512510CB1	BRAUNOR01
96	1221545CB1	NEUTFMT01
97	124737CB1	THYMNON04
98	1510784CB1	SINTFER03
99	1901257CB1	BRSTTMT02
100	2044370CB1	HIPONON02
101	2820933CB1	ADRETUT06
102	2902793CB1	DRGCNOT01
103	7486536CB1	BRSTNOT05
104	8137305CB1	MIXDTUE01

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID:	Representative Library
105	3793128CB1	BRSTNOT28
106	4001243CB1	PROSTMT03
107	6986717CB1	BRAIFER05
108	7503512CB1	BRSTNOT01

Table 6

Library	Vector	Library Description
ADRENON04	PSPORT1	Normalized library was constructed from 1.36 x 1e6 independent clones from an adrenal tissue library. Starting RNA was made from adrenal gland tissue removed from a 20-year-old Caucasian male, who died from head trauma. The library was normalized in two rounds using conditions adapted from Soares et al. (PNAS (1994) 91:9228-9232) and Ronaldo et al. (Genome Res (1996) 6: 791-806), using a significantly longer (48-hours/round) reannealing hybridization period.
ADRETUT06	pINCY	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.
BRABNOE02	PBK-CMV	This 5' biased random primed library was constructed using RNA isolated from vermiformis tissue removed from a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomenigeal fibrosis and multiple microinfarctions of the cerebral neocortex. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly, and an enlarged spleen and liver. Patient medications included simethicone, Lasix, Digoxin, Colace, Zantac, captopril, and Vasotec.
BRAHTDR04	PCDNA2.1	This random primed library was constructed using RNA isolated archaerect, anterior hippocampus tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver.
BRAIFEE05	PCDNA2.1	This 5' biased random primed library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation.
BRAIFER05	pINCY	Library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation.
BRAITDR02	PCDNA2.1	This random primed library was constructed using RNA isolated from allocortex, neocortex, anterior and frontal cingulate tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver.

Table 6 (cont.)

Library	Vector	Library Description
BRANDIN01	pINCY	This normalized pineal gland tissue library was constructed from .4 million independent clones from a pineal gland tissue library from two different donors. Starting RNA was made from pooled pineal gland tissue removed from two Caucasian females: a 68-year-old (donor A) who died from congestive heart failure and a 79-year-old (donor B) who died from pneumonia. Neuropathology for donor A indicated mild to moderate Alzheimer disease, arteriosclerosis, cerebral amyloid angiopathy and multiple infarctions. Neuropathology for donor B indicated severe Alzheimer disease, arteriosclerosis, cerebral amyloid angiopathy and multiple infarctions. There were diffuse and neuritic amyloid plaques and neurofibrillary tangles throughout the brain sections examined in both donors. Patient history included diabetes mellitus, rheumatoid arthritis, hyperthyroidism, amyloid heart disease, and dementia in donor A; and pseudophakia, gastritis with bleeding, glaucoma, peripheral vascular disease, COPD, delayed onset tonic/clonic seizures, and transient ischemic attack in donor B. The library was normalized in one round using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
BRAUNOR01	pINCY	This random primed library was constructed using RNA isolated from striatum, globus pallidus and posterior putamen tissue removed from an 81-year-old Caucasian female who died from a hemorrhage and ruptured thoracic aorta due to atherosclerosis. Pathology indicated moderate atherosclerosis involving the internal carotids, bilaterally; microscopic infarcts of the frontal cortex and hippocampus; and scattered diffuse amyloid plaques and neurofibrillary tangles, consistent with age. Grossly, the leptomeninges showed only mild thickening and hyalinization along the superior sagittal sinus. The remainder of the leptomeninges was thin and contained some congested blood vessels. Mild atrophy was found mostly in the frontal poles and lobes, and temporal lobes, bilaterally. Microscopically, there were pairs of Alzheimer type II astrocytes within the deep layers of the neocortex. There was increased satellitosis around neurons in the deep gray matter in the middle frontal cortex. The amygdala contained rare diffuse plaques and neurofibrillary tangles. The posterior hippocampus contained a microscopic area of cystic cavitation with hemosiderin-laden macrophages surrounded by reactive gliosis. Patient history included sepsis, cholangitis, post-operative atelectasis, pneumonia CAD, cardiomegaly due to left ventricular hypertrophy, splenomegaly, arteriolonephrosclerosis, nodular colloid goiter, emphysema, CHF, hypothyroidism, and peripheral vascular disease.
BRAXTDR17	PCDNA2.1	This random primed library was constructed using RNA isolated from temporal neocortex tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver.

Table 6 (cont.)

Library	Vector	Library Description
BRAZNOT01	pINCY	Library was constructed using RNA isolated from striatum, globus pallidus and posterior putamen tissue removed from a 45-year-old Caucasian female who died from a dissecting aortic aneurysm and ischemic bowel disease. Pathology indicated mild arteriosclerosis involving the cerebral cortical white matter and basal ganglia. Grossly, there was mild meningeal fibrosis and mild focal atherosclerotic plaque in the middle cerebral artery, as well as vertebral arteries bilaterally. Microscopically, the cerebral hemispheres, brain stem and cerebellum reveal focal areas in the white matter that contain blood vessels that were barrel-shaped, hyalinized, with hemosiderin-laden macrophages in the Virchow-Robin space. In addition, there were scattered neurofibrillary tangles within the basolateral nuclei of the amygdala. Patient history included mild atheromatosis of aorta and coronary arteries, bowel and liver infarct due to aneurysm, physiologic fatty liver associated with obesity, mild diffuse emphysema, thrombosis of mesenteric and portal veins, cardiomegaly due to hypertrophy of left ventricle, arterial hypertension, acute pulmonary edema, splenomegaly, obesity (300 lb.), leiomyoma of uterus, sleep apnea, and iron deficiency anemia.
BRSTNON02	pINCY	This normalized breast tissue library was constructed from 6.2 million independent clones from a pool of two libraries from two different donors. Starting RNA was made from breast tissue removed from a 46-year-old Caucasian female during a bilateral reduction mammoplasty (donor A), and from breast tissue removed from a 60-year-old Caucasian female during a bilateral reduction mammoplasty (donor B). Pathology indicated normal breast parenchyma, bilaterally (A) and bilateral mammary hypertrophy (B). Patient history included hypertrophy of breast, obesity, lumbago, and glaucoma (A) and joint pain in the shoulder, thyroid cyst, colon cancer, normal delivery and cervical cancer (B). Family history included cataract, osteoarthritis, uterine cancer, benign hypertension, hyperlipidemia, and alcoholic cirrhosis of the liver, cerebrovascular disease, and type II diabetes (A) and cerebrovascular accident, atherosclerotic coronary artery disease, colon cancer, type II diabetes, hyperlipidemia, depressive disorder, and Alzheimer's Disease. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
BRSTNOT01	PBLUESCRIPT	Library was constructed using RNA isolated from the breast tissue of a 56-year-old Caucasian female who died in a motor vehicle accident.
BRSTNOT05	PSPORT1	Library was constructed using RNA isolated from breast tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated multicentric invasive grade 4 lobular carcinoma. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular and cardiovascular disease, breast and prostate cancer, and type I diabetes.
BRSTNOT07	pINCY	Library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocystic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, cardiovascular disease, and type II diabetes.

Table 6 (cont.)

Library	Vector	Library Description
BRSTNOT28	pINCY	Library was constructed using RNA isolated from diseased right breast tissue removed from a 40-year-old Caucasian female during a bilateral reduction mammoplasty. Pathology indicated bilateral mild fibrocystic and proliferative changes. Patient history included pure hypercholesterolemia. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, type II diabetes, and prostate cancer.
BRSTTMR01	PCDNA2.1	This random primed library was constructed using RNA isolated from right breast tissue removed from a 62-year-old Caucasian female during open breast biopsy and unilateral extended simple mastectomy. Pathology indicated benign breast parenchyma. Pathology for the matched tumor tissue indicated residual grade 3 (of 4) ductal adenocarcinoma. The patient presented with breast cancer. Patient history included benign neoplasm of the large bowel and leg vein occlusion. Previous surgeries included dilation and curettage and spinal canal exploration. Patient medications included Lozal, Mevacor, and tamoxifen. Family history included heart murmur in the mother; skin cancer in the sibling(s); and prostate cancer in the grandfather.
BRSTTMT02	pINCY	Library was constructed using RNA isolated from diseased right breast tissue removed from a 46-year-old Caucasian female during a unilateral extended simple mastectomy and open breast biopsy. Pathology indicated mildly proliferative fibrocystic change, including intraductal duct ectasia, papilloma formation, and ductal hyperplasia. Pathology for the associated tumor tissue indicated multifocal ductal carcinoma in situ, both comedo and non-comedo types, nuclear grade 2 with extensive intraductal calcifications. Patient history included deficiency anemia, normal delivery, chronic sinusitis, extrinsic asthma, and kidney infection. Family history included type II diabetes, benign hypertension, cerebrovascular disease, skin cancer, and hyperlipidemia.
BSTMNON02	PSPORT1	This normalized brain stem library was constructed from 2.84 million independent clones from a brain stem library. Starting RNA was made from the brain stem tissue of a 72-year-old Caucasian male who died from myocardial infarction. Patient history included coronary artery disease, insulin-dependent diabetes mellitus, and arthritis. Normalization and hybridization conditions were adapted from Soares et al. (PNAS (1994) 91:9228).
CERVNOT01	PSPORT1	Library was constructed using RNA isolated from the uterine cervical tissue of a 35-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. Pathology indicated mild chronic cervicitis. Family history included atherosclerotic coronary artery disease and type II diabetes.
COLNNOT13	pINCY	Library was constructed using RNA isolated from ascending colon tissue of a 28-year-old Caucasian male with moderate chronic ulcerative colitis.
COLNNOT23	pINCY	Library was constructed using RNA isolated from diseased colon tissue removed from a 16-year-old Caucasian male during a total colectomy with abdominal/perineal resection. Pathology indicated gastritis and pancolitis consistent with the acute phase of ulcerative colitis. Inflammation was more severe in the transverse colon, with inflammation confined to the mucosa. There was only mild involvement of the ascending and sigmoid colon, and no significant involvement of the cecum, rectum, or terminal ileum. Family history included irritable bowel syndrome.

Table 6 (cont.)

Library	Vector	Library Description
COLXTDT01	pINCY	Library was constructed using RNA isolated from colon tissue removed from the appendix of a 37-year-old Black female during myomectomy, dilation and curettage, right fimbrial region biopsy, and incidental appendectomy. Pathology indicated an unremarkable appendix. Pathology for the associated tumor tissue indicated multiple (12) uterine leiomyomata. Patient history included premenopausal menorrhagia and sarcoidosis of the lung. Family history included acute myocardial infarction and atherosclerotic coronary artery disease.
CONUTUT01	pINCY	Library was constructed using RNA isolated from sigmoid mesentery tumor tissue obtained from a 61-year-old female during a total abdominal hysterectomy and bilateral salpingo-oophorectomy with regional lymph node excision. Pathology indicated a metastatic grade 4 malignant mixed müllerian tumor present in the sigmoid mesentery at two sites.
DRGCNOT01	pINCY	Library was constructed using RNA isolated from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy. Surgeries included colonoscopy, large intestine biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy; treatment included radiation therapy.
HIPONON02	PSPORT1	This normalized hippocampus library was constructed from 1.13M independent clones from a hippocampus tissue library. RNA was isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from an intracranial bleed. Patient history included nose cancer, hypertension, and arthritis. The normalization and hybridization conditions were adapted from Soares et al. (PNAS (1994) 91:9228).
KERANOT02	PSPORT1	Library was constructed using RNA isolated from epidermal breast keratinocytes (NHEK). NHEK (Clontech #CC-2501) is human breast keratinocyte cell line derived from a 30-year-old black female during breast-reduction surgery.
KIDNTUT15	pINCY	Library was constructed using RNA isolated from left kidney tumor tissue removed from a 65-year-old Caucasian male during an exploratory laparotomy and nephroureterectomy. Pathology indicated grade 1 renal cell carcinoma within the upper pole of the left kidney. Patient history included malignant melanoma of the abdominal skin, benign neoplasm of colon, cerebrovascular disease, and umbilical hernia. Family history included myocardial infarction, atherosclerotic coronary artery disease, and cerebrovascular disease, and prostate cancer.
LNODNOT12	pINCY	Library was constructed using RNA isolated from lymph node tissue obtained from an 11-year-old Caucasian female who died from a motor vehicle accident. Previous surgeries included tonsilectomy.
LUNGNON07	pINCY	This normalized lung tissue library was constructed from 5.1 million independent clones from a lung tissue library. Starting RNA was made from RNA isolated from lung tissue. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.

Table 6 (cont.)

Library	Vector	Library Description
MIXDTUE01	PBK-CMV	This 5' biased random primed library was constructed using pooled cDNA from seven donors. cDNA was generated using mRNA isolated from placental tissue removed from a Caucasian fetus (A), who died after 16 weeks' gestation from fetal demise and hydrocephalus; from placental tissue removed from a Caucasian male fetus (B), who died after 18 weeks' gestation from fetal demise; from an untreated LNCaP cell line, derived from prostate carcinoma with metastasis to the left supraclavicular lymph nodes, removed from a 50-year-old Caucasian male (C); from endometrial tissue removed from a 32-year-old female (D); from diseased right ovary tissue removed from a 45-year-old Caucasian female (E); from diseased right ovary tissue removed from a 47-year-old Caucasian female (donor F) and from right fallopian tube tumor tissue removed from an 85-year-old Caucasian female (donor G). For donor A, patient history included umbilical cord wrapped around the head (3 times) and the shoulders (1 time). Serology was positive for anti-CMV. Family history included multiple pregnancies and live births, and an abortion in the mother. For donor B, serologies were negative. For donor D, pathology indicated the endometrium was in secretory phase. For donor E, pathology indicated stromal hyperthecosis of the right and left ovaries. For donor F, pathology indicated endometriosis. For donor G, pathology indicated poorly differentiated mixed endometrioid (80%) and serous (20%) adenocarcinoma of the right fallopian tube. Patient history included medullary carcinoma of the thyroid.
MIXDUNB01	pINCY	Library was constructed using RNA isolated from myometrium removed from a 41-year-old Caucasian female (A) during vaginal hysterectomy with a dilatation and curettage and untreated smooth muscle cells removed from the renal vein of a 57-year-old Caucasian male. Pathology for donor A indicated the myometrium and cervix were unremarkable. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Pathology for the associated tumor tissue indicated uterine leiomyoma. Medical history included an unspecified menstrual disorder, ventral hernia, normal delivery, a benign ovarian neoplasm, and tobacco abuse in donor A. Previous surgeries included a bilateral destruction of fallopian tubes, removal of a solitary ovary, and an exploratory laparotomy in donor A. Medications included ferrous sulfate in donor A.
MONOTXN03	pINCY	Normalized, treated monocyte tissue library was constructed from 7.6 million independent clones from a treated monocyte library. Starting RNA was made from RNA isolated from treated monocytes from peripheral blood obtained from a 42-year-old female. The cells were treated with anti-interleukin-10 (anti-IL-10) and lipopolysaccharide (LPS). The anti-IL-10 was added at time 0 at 10 ng/ml and LPS was added at 1 hour at 5 ng/ml. The monocytes were isolated from buffy coat by adherence to plastic. Incubation time was 24 hours. cDNA synthesis was initiated using a NotI-anchored oligo(dT) primer. The libraries were normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 -hours/round) reannealing hybridization was used. The libraries were then linearized and recircularized to select for insert containing clones as follows: plasmid DNA was prepped from approximately 1 million clones from the normalized, treated monocyte tissue libraries following soft agar transformation. The DNA was linearized with NotI and insert containing clones were size-selected by agarose gel electrophoresis and recircularized by ligation.

Table 6 (cont.)

Library	Vector	Library Description
NEUTFMT01	PBLUESCRIPT	Library was constructed using total RNA isolated from peripheral blood granulocytes collected by density gradient centrifugation through Ficoll-Hypaque. The cells were isolated from buffy coat units obtained from unrelated male and female donors. Cells were cultured in 10 nM fMLP for 30 minutes, lysed in GuSCN, and spun through CsCl to obtain RNA for library construction. Because this library was made from total RNA, it has an unusually high proportion of unique singleton sequences, which may not all come from polyA RNA species.
PANCTUT01	pINCY	Library was constructed using RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included type II diabetes, osteoarthritis, cardiovascular disease, benign neoplasm in the large bowel, and a cataract. Previous surgeries included a total splenectomy, cholecystectomy, and abdominal hysterectomy. Family history included cardiovascular disease, type II diabetes, and stomach cancer.
PITUNOT06	pINCY	Library was constructed using RNA isolated from pituitary gland tissue removed from a 55-year-old male who died from chronic obstructive pulmonary disease. Neuropathology indicated there were no gross abnormalities, other than mild ventricular enlargement. There was no apparent microscopic abnormality in any of the neocortical areas examined, except for a number of silver positive neurons with apical dendrite staining, particularly in the frontal lobe. The significance of this was undetermined. The only other microscopic abnormality was that there was prominent silver staining with some swollen axons in the CA3 region of the anterior and posterior hippocampus. Microscopic sections of the cerebellum revealed mild Bergmann's gliosis in the Purkinje cell layer. Patient history included schizophrenia.
PROSNOT15	pINCY	Library was constructed using RNA isolated from diseased prostate tissue removed from a 66-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 2+3). The patient presented with elevated prostate specific antigen (PSA). Family history included prostate cancer, secondary bone cancer, and benign hypertension.
PROSTMT03	pINCY	The library was constructed using RNA isolated from right prostate tissue removed from a 68-year-old Caucasian male during a radical prostatectomy and regional lymph node excision. Pathology for the associated tumor indicated adenocarcinoma, Gleason grade 4+3, which formed a predominant mass involving the left side peripherally. The patient presented with elevated prostate specific antigen (PSA) and induration. Patient history included pure hypercholesterolemia, kidney calculus, an unspecified allergy, and atopidermatitis. Family history included colon cancer.
PROSTUT09	pINCY	Library was constructed using RNA isolated from prostate tumor tissue removed from a 66-year-old Caucasian male during a radical prostatectomy, radical cystectomy, and urinary diversion. Pathology indicated grade 3 transitional cell carcinoma. The patient presented with prostatic inflammatory disease. Patient history included lung neoplasm, and benign hypertension. Family history included a malignant breast neoplasm, tuberculosis, cerebrovascular disease, atherosclerotic coronary artery disease and lung cancer.

Table 6 (cont.)

Library	Vector	Library Description
SEMVTE01	PCDNA2.1	This 5' biased random primed library was constructed using RNA isolated from seminal vesicle tissue removed from a 63-year-old Caucasian male during closed prostatic biopsy, radical prostatectomy, and regional lymph node excision. Pathology for the associated tumor tissue indicated Gleason grade 2+3 adenocarcinoma in the right side of the prostate. Adenofibromatous hyperplasia was present. The patient presented with prostate cancer, elevated prostate specific antigen and prostatic hyperplasia. Patient history included kidney calculus, extrinsic asthma, benign bowel neoplasm, backache, tremor, and tobacco abuse in remission. Previous surgeries included adenotomieslectomy. Patient medications included Ventolin and Vancericil. Family history included atherosclerotic coronary artery disease and acute myocardial infarction in the mother; atherosclerotic coronary artery disease and acute myocardial infarction in the father; and stomach cancer and extrinsic asthma in the grandparent(s).
SINIUCT01	pINCY	Library was constructed using RNA isolated from ileum tissue obtained from a 42-year-old Caucasian male during a total intra-abdominal colectomy and endoscopic jejunostomy. Previous surgeries included polypectomy, colonoscopy, and spinal canal exploration. Family history included cerebrovascular disease, benign hypertension, atherosclerotic coronary artery disease, and type II diabetes.
SINTBST01	pINCY	Library was constructed using RNA isolated from ileum tissue obtained from an 18-year-old Caucasian female during bowel anastomosis. Pathology indicated Crohn's disease of the ileum, involving 15 cm of the small bowel. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
SINTFER03	PCDNA2.1	This random primed library was constructed using RNA isolated from small intestine tissue removed from a Caucasian male fetus who died from fetal demise.
TESTNOT11	pINCY	Library was constructed using RNA isolated from testicular tissue removed from a 16-year-old Caucasian male who died from hanging. Patient history included drug use (tobacco, marijuana, and cocaine use), and medications included Lithium, Ritalin, and Paxil.
THYMNON04	PSPORT1	This normalized library was constructed from a thymus tissue library. Starting RNA was made from thymus tissue removed from a 3-year-old Caucasian male, who died from anoxia. Serologies were negative. The patient was not taking any medications. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48-hours/round) reannealing hybridization was used.
THYMNOT02	PBLUESCRIPT	Library was constructed using polyA RNA isolated from thymus tissue removed from a 3-year-old Caucasian male, who died from drowning. Serologies were negative.
THYRNOT03	pINCY	Library was constructed using RNA isolated from thyroid tissue removed from the left thyroid of a 28-year-old Caucasian female during a complete thyroidectomy. Pathology indicated a small nodule of adenomatous hyperplasia present in the left thyroid. Pathology for the associated tumor tissue indicated dominant follicular adenoma, forming a well-encapsulated mass in the left thyroid.

Table 6 (cont.)

Library	Vector	Library Description
UTRENON03	pINCY	<p>This normalized library was constructed from 1.2×10^7 independent clones from a uterine endometrial tissue library. Starting RNA was made from uterine endometrium tissue obtained from a 29-year-old Caucasian female during a vaginal hysterectomy and cystocele repair. Pathology indicated the endometrium was secretory and the cervix showed mild chronic cervicitis with focal squamous metaplasia. Pathology for the associated tumor tissue indicated an intramural uterine leiomyoma. Patient history included hypothyroidism, pelvic floor relaxation, incomplete T-12 injury (due to a motor vehicle accident) causing paraplegia and self catheterization. Previous surgeries included a normal delivery, a laminectomy, and a rhinoplasty. Family history included benign hypertension, type II diabetes, and hyperlipidemia. The libraries were normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.</p>
UTRSTMR02	PCDNA2.1	<p>This random primed library was constructed using pooled cDNA from two different donors. cDNA was generated using mRNA isolated from endometrial tissue removed from a 32-year-old female (donor A) and using mRNA isolated from myometrium removed from a 45-year-old female (donor B) during vaginal hysterectomy and bilateral salpingo-oophorectomy. In donor A, pathology indicated the endometrium was secretory phase. The cervix showed severe dysplasia (CIN III) focally involving the squamocolumnar junction at the 1, 6 and 7 o'clock positions. Mild koilocytotic dysplasia was also identified within the cervix. In donor B, pathology for the matched tumor tissue indicated multiple (23) subserosal, intramural, and submucosal leiomyomata. Patient history included stress incontinence, extrinsic asthma without status asthmaticus and normal delivery in donor B. Family history included cerebrovascular disease, depression, and atherosclerotic coronary artery disease in donor B.</p>

Table 7

Program	Description	Reference	Parameter Threshold
ABIFACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1998) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less Signal peptide hits: Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:

- 5 a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54,
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-53,
- 10 c) a polypeptide consisting essentially of a naturally occurring amino acid sequence at least 91% identical to the amino acid sequence of SEQ ID NO:54,
- d) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, and
- e) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-54.

15 2. An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54.

20 3. An isolated polynucleotide encoding a polypeptide of claim 1.

 4. An isolated polynucleotide encoding a polypeptide of claim 2.

25 5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108.

 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

30 7. A cell transformed with a recombinant polynucleotide of claim 6.

 8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

 9. A method of producing a polypeptide of claim 1, the method comprising:

- 35 a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant

polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

- b) recovering the polypeptide so expressed.

5 10. A method of claim 9, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-54.

11. An isolated antibody which specifically binds to a polypeptide of claim 1.

10 12. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:55-108,
b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of
15 SEQ ID NO:55-108,
c) a polynucleotide complementary to a polynucleotide of a),
d) a polynucleotide complementary to a polynucleotide of b), and
e) an RNA equivalent of a)-d).

20 13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.

14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

- 25 a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
30 b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.

35 16. A method of detecting a target polynucleotide in a sample, said target polynucleotide

having a sequence of a polynucleotide of claim 12, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

18. A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-54.

19. A method for treating a disease or condition associated with decreased expression of functional SECP, comprising administering to a patient in need of such treatment the composition of claim 17.

20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with decreased expression of functional SECP, comprising administering to a patient in need of such treatment a composition of claim 21.

23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.

25. A method for treating a disease or condition associated with overexpression of functional SECP, comprising administering to a patient in need of such treatment a composition of claim 24.

26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:
- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
 - b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

10

27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- 15 b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

20

28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

25

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

30

29. A method of assessing toxicity of a test compound, the method comprising:

- a) treating a biological sample containing nucleic acids with the test compound,
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions

35

whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,

c) quantifying the amount of hybridization complex, and

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

30. A diagnostic test for a condition or disease associated with the expression of SECP in a biological sample, the method comprising:

a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and

b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

31. The antibody of claim 11, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a $F(ab')_2$ fragment, or
- e) a humanized antibody.

32. A composition comprising an antibody of claim 11 and an acceptable excipient.

33. A method of diagnosing a condition or disease associated with the expression of SECP in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. A composition of claim 32, wherein the antibody is labeled.

35. A method of diagnosing a condition or disease associated with the expression of SECP in a subject, comprising administering to said subject an effective amount of the composition of claim

34.

36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from said animal, and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54.

37. A polyclonal antibody produced by a method of claim 36.

38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-54, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal;
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54.

40. A monoclonal antibody produced by a method of claim 39.

41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant

immunoglobulin library.

44. A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54 in a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54 in the sample.

45. A method of purifying a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54 from a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) separating the antibody from the sample and obtaining the purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-54.

46. A microarray wherein at least one element of the microarray is a polynucleotide of claim

13.

47. A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim 12.

49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.

52. An array of claim 48, which is a microarray.

53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.

54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.

56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

5 64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

10 66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

15 69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

20 71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.

73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.

25 74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.

75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.

30 76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.

77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.

78. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:23.

35 79. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:24.

80. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:25.

81. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:26.

5 82. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:27.

83. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:28.

84. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:29.

10 85. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:30.

86. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:31.

15 87. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:32.

88. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:33.

89. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:34.

20 90. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:35.

91. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:36.

25 92. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:37.

93. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:38.

94. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:39.

30 95. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:40.

96. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:41.

35 97. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:42.

98. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:43.

99. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:44.

5 100. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:45.

101. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:46.

102. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:47.

10 103. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:48.

104. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:49.

15 105. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:50.

106. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:51.

107. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:52.

20 108. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:53.

109. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:54.

25 110. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:55.

111. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:56.

30 112. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:57.

35 113. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:58.

114. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:59.

115. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
5 NO:60.

116. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:61.

10 117. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:62.

118. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:63.

15 119. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:64.

120. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
20 NO:65.

121. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:66.

25 122. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:67.

123. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:68.

30 124. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:69.

125. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
35 NO:70.

126. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:71.

127. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
5 NO:72.

128. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:73.

129. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
10 NO:74.

130. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:75.

15 131. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:76.

132. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
20 NO:77.

133. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:78.

25 134. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:79.

135. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:80.

30 136. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:81.

137. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
35 NO:82.

138. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:83.

139. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
5 NO:84.

140. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:85.

10 141. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:86.

142. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:87.
15

143. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:88.

144. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
20 NO:89.

145. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:90.

25 146. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:91.

147. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:92.
30

148. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:93.

149. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
35 NO:94.

150. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:95.

151. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
5 NO:96.

152. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:97.

10 153. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:98.

154. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:99.

15 155. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:100.

156. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
20 NO:101.

157. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:102.

25 158. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:103.

159. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:104.

30 160. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:105.

35 161. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:106.

162. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:107.

163. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
5 NO:108.

<110> INCYTE GENOMICS, INC.
 GRIFFIN, Jennifer A.
 YAO, Monique G.
 DUGGAN, Brendan M.
 YUE, Henry
 DING, Li
 LAL, Preeti G.
 LEE, Ernestine A.
 RAMKUMAR, Jayalaxmi
 THANGAVELU, Kavitha
 XU, Yuming
 LEE, Sally
 TANG, Y. Tom
 NGUYEN, Danniel B.
 WARREN, Bridget A.
 HONCHELL, Cynthia D.
 GIETZEN, Kimberly J.
 BAUGHN, Mariah R.
 GANDHI, Ameena R.
 ARVIZU, Chandra
 WALIA, Narinder K.
 LU, Yan
 ELLIOTT, Vicki S.
 LU, Dyung Aina M.
 HAFALIA, April J.A.
 AZIMZAI, Yalda
 KHAN, Farrah A.
 UYEN, K. Tran

<120> SECRETED PROTEINS

<130> PI-0345 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/255,639; 60/257,852; 60/260,105; 60/262,932; 60/263,096;
 60/263,090; 60/265,926

<151> 2000-12-13; 2000-12-21; 2001-01-05; 2001-01-18; 2000-01-18;
 2001-01-19; 2001-02-02

<160> 108

<170> PERL Program

<210> 1

<211> 235

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 095765CD1

<400> 1

Met	Pro	Arg	Ser	Cys	Cys	Ser	Arg	Ser	Gly	Ala	Leu	Leu	Leu	Ala
1				5					10					15
Leu	Leu	Leu	Gln	Ala	Ser	Met	Glu	Val	Arg	Gly	Trp	Cys	Leu	Glu
			20						25					30
Ser	Ser	Gln	Cys	Gln	Asp	Leu	Thr	Thr	Glu	Ser	Asn	Leu	Leu	Glu
			35						40					45
Cys	Ile	Arg	Ala	Cys	Lys	Pro	Asp	Leu	Ser	Ala	Glu	Thr	Pro	Met
			50						55					60

```

Phe Pro Gly Asn Gly Asp Glu Gln Pro Leu Thr Glu Asn Pro Arg
      65      70      75
Lys Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe Gly Arg Arg
      80      85      90
Asn Ser Ser Asp Gly Ala Lys Pro Gly Pro Arg Glu Gly Lys Arg
      95     100     105
Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys
     110     115     120
Lys Arg Arg Pro Val Lys Val Tyr Pro Asn Gly Ala Glu Asp Glu
     125     130     135
Ser Ala Glu Ala Phe Pro Leu Glu Phe Lys Arg Glu Leu Thr Gly
     140     145     150
Gln Arg Leu Arg Glu Gly Asp Gly Pro Asp Gly Pro Ala Asp Asp
     155     160     165
Gly Ala Gly Ala Gln Ala Asp Leu Glu His Ser Leu Leu Val Ala
     170     175     180
Ala Glu Lys Lys Asp Glu Gly Pro Tyr Arg Met Glu His Phe Arg
     185     190     195
Trp Gly Ser Pro Pro Lys Asp Lys Arg Tyr Gly Gly Phe Met Thr
     200     205     210
Ser Glu Lys Ser Gln Thr Pro Leu Val Thr Leu Phe Lys Asn Ala
     215     220     225
Ile Ile Lys Asn Ala Tyr Lys Lys Gly Glu
     230     235

```

<210> 2
 <211> 689
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6399886CD1

```

<400> 2
Met Ala Ala Arg Thr Leu Gly Arg Gly Val Gly Arg Leu Leu Gly
  1      5      10      15
Ser Leu Arg Gly Leu Ser Gly Gln Pro Ala Arg Pro Pro Cys Gly
     20      25      30
Val Ser Ala Pro Arg Arg Ala Ala Ser Gly Pro Ser Gly Ser Ala
     35      40      45
Pro Ala Val Ala Ala Ala Ala Ala Gln Pro Gly Ser Tyr Pro Ala
     50      55      60
Leu Ser Ala Gln Ala Ala Arg Glu Pro Ala Ala Phe Trp Gly Pro
     65      70      75
Leu Ala Arg Asp Thr Leu Val Trp Asp Thr Pro Tyr His Thr Val
     80      85      90
Trp Asp Cys Asp Phe Ser Thr Gly Lys Ile Gly Trp Phe Leu Gly
     95     100     105
Gly Gln Leu Asn Val Ser Val Asn Cys Leu Asp Gln His Val Arg
    110     115     120
Lys Ser Pro Glu Ser Val Ala Leu Ile Trp Glu Arg Asp Glu Pro
    125     130     135
Gly Thr Glu Val Arg Ile Thr Tyr Arg Glu Leu Leu Glu Thr Thr
    140     145     150
Cys Arg Leu Ala Asn Thr Leu Lys Arg His Gly Val His Arg Gly
    155     160     165
Asp Arg Val Ala Ile Tyr Met Pro Val Ser Pro Leu Ala Val Ala
    170     175     180
Ala Met Leu Ala Cys Ala Arg Ile Gly Ala Val His Thr Val Ile
    185     190     195
Phe Ala Gly Phe Ser Ala Glu Ser Leu Ala Gly Arg Ile Asn Asp
    200     205     210

```

Ala Lys Cys Lys	Val Val Ile Thr Phe	Asn Gln Gly Leu Arg	Gly
215	220	225	
Gly Arg Val Val	Glu Leu Lys Lys Ile	Val Asp Glu Ala Val	Lys
230	235	240	
His Cys Pro Thr	Val Gln His Val Leu	Val Ala His Arg Thr	Asp
245	250	255	
Asn Lys Val His	Met Gly Asp Leu Asp	Val Pro Leu Glu Gln	Glu
260	265	270	
Met Ala Lys Glu	Asp Pro Val Cys Ala	Pro Glu Ser Met Gly	Ser
275	280	285	
Glu Asp Met Leu	Phe Met Leu Tyr Thr	Ser Gly Ser Thr Gly	Met
290	295	300	
Pro Lys Gly Ile	Val His Thr Gln Ala	Gly Tyr Leu Leu Tyr	Ala
305	310	315	
Ala Leu Thr His	Lys Leu Val Phe Asp	His Gln Pro Gly Asp	Ile
320	325	330	
Phe Gly Cys Val	Ala Asp Ile Gly Trp	Ile Thr Gly His Ser	Tyr
335	340	345	
Val Val Tyr Gly	Pro Leu Cys Asn Gly	Ala Thr Ser Val Leu	Phe
350	355	360	
Glu Ser Thr Pro	Val Tyr Pro Asn Ala	Gly Arg Tyr Trp Glu	Thr
365	370	375	
Val Glu Arg Leu	Lys Ile Asn Gln Phe	Tyr Gly Ala Pro Thr	Ala
380	385	390	
Val Arg Leu Leu	Leu Lys Tyr Gly Asp	Ala Trp Val Lys Lys	Tyr
395	400	405	
Asp Arg Ser Ser	Leu Arg Thr Leu Gly	Ser Val Gly Glu Pro	Ile
410	415	420	
Asn Cys Glu Ala	Trp Glu Trp Leu His	Arg Val Val Gly Asp	Ser
425	430	435	
Arg Cys Thr Leu	Val Asp Thr Trp Trp	Gln Thr Glu Thr Gly	Gly
440	445	450	
Ile Cys Ile Ala	Pro Arg Pro Ser Glu	Glu Gly Ala Glu Ile	Leu
455	460	465	
Pro Ala Met Ala	Met Arg Pro Phe Phe	Gly Ile Val Pro Val	Leu
470	475	480	
Met Asp Glu Lys	Gly Ser Val Met Glu	Gly Ser Asn Val Ser	Gly
485	490	495	
Ala Leu Cys Ile	Ser Gln Ala Trp Pro	Gly Met Ala Arg Thr	Ile
500	505	510	
Tyr Gly Asp His	Gln Arg Phe Val Asp	Ala Tyr Phe Lys Ala	Tyr
515	520	525	
Pro Gly Tyr Tyr	Phe Thr Gly Asp Gly	Ala Tyr Arg Thr Glu	Gly
530	535	540	
Gly Tyr Tyr Gln	Ile Thr Gly Arg Met	Asp Asp Val Ile Asn	Ile
545	550	555	
Ser Gly His Arg	Leu Gly Thr Ala Glu	Ile Glu Asp Ala Ile	Ala
560	565	570	
Asp His Pro Ala	Val Pro Glu Ser Ala	Val Ile Gly Tyr Pro	His
575	580	585	
Asp Ile Lys Gly	Glu Ala Ala Phe Ala	Phe Ile Val Val Lys	Asp
590	595	600	
Ser Ala Gly Asp	Ser Asp Val Val Val	Gln Glu Leu Lys Ser	Met
605	610	615	
Val Ala Thr Lys	Ile Ala Lys Tyr Ala	Val Pro Asp Glu Ile	Leu
620	625	630	
Val Val Lys Arg	Leu Pro Lys Thr Arg	Ser Gly Lys Val Met	Arg
635	640	645	
Arg Leu Leu Arg	Lys Ile Ile Thr Ser	Glu Ala Gln Glu Leu	Gly
650	655	660	
Asp Thr Thr Thr	Leu Glu Asp Pro Ser	Ile Ile Ala Glu Ile	Leu
665	670	675	
Ser Val Tyr Gln	Lys Cys Lys Asp Lys	Gln Ala Ala Ala Lys	

680

685

<210> 3
 <211> 584
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6024420CD1

<400> 3
 Met Asp Leu Leu Trp Met Pro Leu Leu Leu Val Ala Ala Cys Val
 1 5 10 15
 Ser Ala Val His Ser Ser Pro Glu Val Asn Ala Gly Val Ser Ser
 20 25 30
 Ile His Ile Thr Lys Pro Val His Ile Leu Glu Glu Arg Ser Leu
 35 40 45
 Leu Val Leu Thr Pro Ala Gly Leu Thr Gln Met Leu Asn Gln Thr
 50 55 60
 Arg Phe Leu Met Val Leu Phe His Asn Pro Ser Ser Lys Gln Ser
 65 70 75
 Arg Asn Leu Ala Glu Glu Leu Gly Lys Ala Val Glu Ile Met Gly
 80 85 90
 Lys Gly Lys Asn Gly Ile Gly Phe Gly Lys Val Asp Ile Thr Ile
 95 100 105
 Glu Lys Glu Leu Gln Gln Glu Phe Gly Ile Thr Lys Ala Pro Glu
 110 115 120
 Leu Ser Cys Phe Leu Arg Ala Thr Arg Ser Glu Pro Ile Ser Cys
 125 130 135
 Lys Gly Val Val Glu Ser Ala Ala Leu Val Val Trp Leu Arg Arg
 140 145 150
 Gln Ile Ser Gln Lys Ala Phe Leu Phe Asn Ser Ser Glu Gln Val
 155 160 165
 Ala Glu Phe Val Ile Ser Arg Pro Leu Val Ile Val Gly Phe Phe
 170 175 180
 Gln Asp Leu Glu Glu Glu Val Ala Glu Leu Phe Tyr Asp Val Ile
 185 190 195
 Lys Asp Phe Pro Glu Leu Thr Phe Gly Val Ile Thr Ile Gly Asn
 200 205 210
 Val Ile Gly Arg Phe His Val Thr Leu Asp Ser Val Leu Val Phe
 215 220 225
 Lys Lys Gly Lys Ile Val Asn Arg Gln Lys Leu Ile Asn Asp Ser
 230 235 240
 Thr Asn Lys Gln Glu Leu Asn Arg Val Ile Lys Gln His Leu Thr
 245 250 255
 Asp Phe Val Ile Glu Tyr Asn Thr Glu Asn Lys Asp Leu Ile Ser
 260 265 270
 Glu Leu His Ile Met Ser His Met Leu Leu Phe Val Ser Lys Ser
 275 280 285
 Ser Glu Ser Tyr Gly Ile Ile Ile Gln His Tyr Lys Leu Ala Ser
 290 295 300
 Lys Glu Phe Gln Asn Lys Ile Leu Phe Ile Leu Val Asp Ala Asp
 305 310 315
 Glu Pro Arg Asn Gly Arg Val Phe Lys Tyr Phe Arg Val Thr Glu
 320 325 330
 Val Asp Ile Pro Ser Val Gln Ile Leu Asn Leu Ser Ser Asp Ala
 335 340 345
 Arg Tyr Lys Met Pro Ser Asp Asp Ile Thr Tyr Glu Ser Leu Lys
 350 355 360
 Lys Phe Gly Arg Ser Phe Leu Ser Lys Asn Ala Thr Lys His Gln
 365 370 375
 Ser Ser Glu Glu Ile Pro Lys Tyr Trp Asp Gln Gly Leu Val Lys-

	380		385		390
Gln Leu Val Gly	Lys Asn Phe Asn Val	Val Val Phe Asp Lys	Glu		
	395		400		405
Lys Asp Val Phe	Val Met Phe Tyr Ala	Pro Trp Ser Lys Lys	Cys		
	410		415		420
Lys Met Leu Phe	Pro Leu Leu Glu Glu	Leu Gly Arg Lys Tyr	Gln		
	425		430		435
Asn His Ser Thr	Ile Ile Ile Ala Lys	Ile Asp Val Thr Ala	Asn		
	440		445		450
Asp Ile Gln Leu	Met Tyr Leu Asp Arg	Tyr Pro Phe Phe Arg	Leu		
	455		460		465
Phe Pro Ser Gly	Ser Gln Gln Ala Val	Leu Tyr Lys Gly Glu	His		
	470		475		480
Thr Leu Lys Gly	Phe Ser Asp Phe Leu	Glu Ser His Ile Lys	Thr		
	485		490		495
Lys Ile Glu Asp	Glu Asp Glu Leu Leu	Ser Val Glu Gln Asn	Glu		
	500		505		510
Val Ile Glu Glu	Glu Val Leu Ala Glu	Glu Lys Glu Val Pro	Met		
	515		520		525
Met Lys Lys Glu	Leu Pro Glu Gln Gln	Ser Pro Glu Leu Glu	Asn		
	530		535		540
Met Thr Lys Tyr	Val Ser Lys Leu Glu	Glu Pro Ala Gly Lys	Lys		
	545		550		555
Lys Thr Ser Glu	Glu Val Val Val Val	Val Ala Lys Pro Lys	Gly		
	560		565		570
Pro Pro Val Gln	Lys Lys Lys Pro Lys	Val Lys Glu Glu Leu			
	575		580		

<210> 4

<211> 1049

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7481067CD1

<400> 4

Met Lys Ala Leu Leu	Pro Leu Thr Phe Leu	Phe Phe Ile Ser Ser
1	5	10 15
Pro Gly Trp Ala Ile	Asp Arg His Cys Tyr	Ile Gly Ile Glu Glu
	20	25 30
Ser Ile Trp Asn Tyr	Ala Pro Ser Gly Lys	Asn Met Leu Asn Glu
	35	40 45
Lys Pro Phe Ser Glu	Asp Leu Glu Phe Leu	Gln Gly Gly Gln Ala
	50	55 60
Arg Lys Ser Phe Val	Phe Lys Lys Ala Leu	Tyr Phe Gln Tyr Thr
	65	70 75
Asp Asn Thr Phe Gln	Arg Ile Ile Glu Lys	Pro Ser Trp Leu Gly
	80	85 90
Phe Leu Gly Pro Met	Ile Lys Ala Glu Thr	Gly Asp Phe Ile Tyr
	95	100 105
Val His Val Lys Asn	Asn Ala Ser Arg Ala	Tyr Ser Tyr His Pro
	110	115 120
His Gly Leu Thr Tyr	Ser Lys Glu Asn Glu	Gly Ala Ile Tyr Pro
	125	130 135
Asp Asn Thr Thr Gly	Leu Gln Lys Glu Asp	Glu Tyr Leu Glu Pro
	140	145 150
Gly Lys Gln Tyr Thr	Tyr Lys Trp Tyr Val	Glu Glu His Gln Gly
	155	160 165
Pro Gly Pro Asn Asp	Ser Asn Cys Val Thr	Arg Ile Tyr His Ser
	170	175 180
His Ile Asp Thr Ala	Arg Asp Val Ala Ser	Gly Leu Ile Gly Pro

Ile Leu Thr Cys	185	190	195
Lys Arg Gly Thr Leu	200	Asn Gly Asp Thr Glu	Lys
Asp Ile Asp Arg Ser Ser Phe Leu Met	215	205	210
Ser Arg Ser Trp Tyr Ser Asp Glu Asn	230	220	225
Ser Gly Lys Ile Asn Thr Ser Asp Pro	245	Ile Arg Ala Phe Thr	Glu
Ser Met Gln Ala Ile Asn Gly Tyr Ile	260	235	240
Leu Thr Met Cys Ala Glu Asp Arg Val	275	250	255
Met Gly Gly Val Ala Asp Ile His Pro	290	Tyr Gly Asn Leu Pro	Asn
Thr Leu Ile Ser Arg Asn His Arg Lys	305	265	270
Pro Ser Ser Leu Glu Asp Ala Phe Met	320	280	285
Val Trp Met Leu Gly Cys Gln Ile His	335	295	300
Phe Phe Lys Val Ser Asn Cys Gln Lys	350	310	315
Val Thr Gly Thr His Val Ile His Tyr	365	325	330
Ile Leu Trp Asn Tyr Ala Pro Ser Gly	380	340	345
Lys Asn Leu Thr Ala Ala Gly Ser Lys	395	355	360
Arg Ser Pro Thr Arg Ile Gly Gly Thr	410	370	375
Arg Glu Tyr Thr Asp Ala Ser Phe Gln	425	385	390
Glu His Leu Gly Ile Leu Gly Pro Val	440	400	405
Gln Thr Ile Lys Ile Thr Phe Tyr Asn	455	415	420
Ser Ile Gln Pro Pro Gly Leu His Tyr	470	430	435
Leu Phe Tyr Glu Thr Pro Gly Gly Thr	485	445	450
Val Ser Pro Gly Thr Thr Phe Val Tyr	500	460	465
Asp Val Gly Pro Thr Ser Thr Asp Pro	515	475	480
Tyr Tyr Ser Ser Val Asn Gly Lys Lys	530	490	495
Leu Gly Pro Leu Leu Ile Cys Arg Asn	545	505	510
Gly Lys Gln Lys Gly Val Asp Lys Glu	560	520	525
Ile Phe Asp Glu Asn Glu Ser Asn Leu	575	535	540
Thr Phe Ile Thr Glu Pro Glu Asn Ile	590	550	555
Cys Gln Ala Ser Asn Lys Met Tyr Ser	605	565	570
Gly Asn Leu Pro Gly Leu Asp Thr Cys	620	580	585
Trp His Val Phe Ser Val Gly Ser Val	635	595	600
Tyr Phe Ser Gly Asn Thr Phe Thr Ser	650	610	615
		625	630
		640	645
		655	660

Thr	Ile	Pro	Met	Phe	Pro	Tyr	Thr	Ser	Gln	Thr	Leu	Leu	Met	Thr	
				665					670					675	
Pro	Asp	Ser	Ile	Gly	Thr	Phe	Asp	Leu	Val	Cys	Met	Thr	Ile	Lys	
				680					685					690	
His	Asn	Leu	Gly	Gly	Met	Lys	His	Lys	Tyr	His	Val	Arg	Gln	Cys	
				695					700					705	
Gly	Lys	Pro	Asn	Pro	Asp	Gln	Thr	Gln	Tyr	Gln	Glu	Glu	Lys	Ile	
				710					715					720	
Ile	Ile	Thr	Ile	Ala	Ala	Glu	Glu	Met	Glu	Trp	Asp	Tyr	Ser	Pro	
				725					730					735	
Ser	Arg	Lys	Trp	Glu	Asn	Glu	Leu	His	His	Leu	Arg	Arg	Glu	Gln	
				740					745					750	
Thr	Ser	Met	Tyr	Val	Asp	Arg	Ser	Gly	Thr	Leu	Leu	Gly	Ser	Lys	
				755					760					765	
Tyr	Lys	Lys	Val	Leu	Tyr	Arg	Gln	Tyr	Asp	Asp	Asn	Thr	Phe	Thr	
				770					775					780	
Asn	Gln	Thr	Lys	Arg	Asn	Glu	Gly	Glu	Lys	His	Leu	Asp	Ile	Leu	
				785					790					795	
Gly	Pro	Leu	Ile	Leu	Leu	Asn	Pro	Gly	Gln	Ile	Ile	Gln	Ile	Ile	
				800					805					810	
Phe	Lys	Asn	Lys	Ala	Ala	Arg	Pro	Tyr	Ser	Ile	His	Ala	His	Gly	
				815					820					825	
Val	Lys	Thr	Asn	Asn	Ser	Thr	Val	Val	Pro	Thr	Gln	Pro	Gly	Glu	
				830					835					840	
Ile	Gln	Ile	Tyr	Thr	Trp	Gln	Ile	Pro	Asp	Arg	Thr	Gly	Pro	Thr	
				845					850					855	
Ser	Leu	Asp	Phe	Glu	Cys	Ile	Pro	Trp	Phe	Tyr	Tyr	Ser	Thr	Val	
				860					865					870	
Ser	Val	Ala	Lys	Asp	Leu	His	Ser	Gly	Leu	Val	Gly	Pro	Leu	Ser	
				875					880					885	
Val	Cys	Arg	Lys	Asp	Ile	Asn	Pro	Asn	Ile	Val	His	Arg	Val	Leu	
				890					895					900	
His	Phe	Met	Ile	Phe	Asp	Glu	Asn	Glu	Ser	Trp	Tyr	Phe	Glu	Asp	
				905					910					915	
Ser	Ile	Asn	Thr	Tyr	Ala	Ser	Lys	Pro	Asn	Lys	Val	Asp	Lys	Glu	
				920					925					930	
Asn	Asp	Asn	Phe	Gln	Leu	Ser	Asn	Gln	Met	His	Ala	Ile	Asn	Gly	
				935					940					945	
Arg	Leu	Phe	Gly	Asn	Asn	Gln	Gly	Ile	Thr	Phe	His	Val	Gly	Asp	
				950					955					960	
Val	Val	Asn	Trp	Tyr	Leu	Ile	Gly	Ile	Gly	Asn	Glu	Ala	Asp	Leu	
				965					970					975	
His	Thr	Val	His	Phe	His	Gly	His	Ser	Phe	Glu	Tyr	Lys	Asn	Arg	
				980					985					990	
Gly	Val	Tyr	Gln	Ser	Asp	Val	Tyr	Asp	Leu	Pro	Pro	Gly	Val	Tyr	
				995					1000					1005	
Arg	Thr	Val	Lys	Met	Tyr	Arg	Arg	Asp	Val	Gly	Thr	Trp	Leu	Phe	
				1010					1015					1020	
Tyr	Cys	His	Val	Phe	Glu	His	Ile	Gly	Ala	Gly	Met	Glu	Ser	Thr	
				1025					1030					1035	
Tyr	Thr	Val	Leu	Glu	Arg	Lys	Gly	Leu	Met	Glu	Gln	Asn	Leu		
				1040					1045						

<210> 5

<211> 383

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3378720CD1

<400> 5

Met	Phe	Trp	Thr	Phe	Lys	Glu	Trp	Phe	Trp	Leu	Glu	Arg	Phe	Trp
1				5					10					15
Leu	Pro	Pro	Thr	Ile	Lys	Trp	Ser	Asp	Leu	Glu	Asp	His	Asp	Gly
				20					25					30
Leu	Val	Phe	Val	Lys	Pro	Ser	His	Leu	Tyr	Val	Thr	Ile	Pro	Tyr
				35					40					45
Ala	Phe	Leu	Leu	Leu	Ile	Ile	Arg	Arg	Val	Phe	Glu	Lys	Phe	Val
				50					55					60
Ala	Ser	Pro	Leu	Ala	Lys	Ser	Phe	Gly	Ile	Lys	Glu	Thr	Val	Arg
				65					70					75
Lys	Val	Thr	Pro	Asn	Thr	Val	Leu	Glu	Asn	Phe	Phe	Lys	His	Ser
				80					85					90
Thr	Arg	Gln	Pro	Leu	Gln	Thr	Asp	Ile	Tyr	Gly	Leu	Ala	Lys	Lys
				95					100					105
Cys	Asn	Leu	Thr	Glu	Arg	Gln	Val	Glu	Arg	Trp	Phe	Arg	Ser	Arg
				110					115					120
Arg	Asn	Gln	Glu	Arg	Pro	Ser	Arg	Leu	Lys	Lys	Phe	Gln	Glu	Ala
				125					130					135
Cys	Trp	Arg	Phe	Ala	Phe	Tyr	Leu	Met	Ile	Thr	Val	Ala	Gly	Ile
				140					145					150
Ala	Phe	Leu	Tyr	Asp	Lys	Pro	Trp	Leu	Tyr	Asp	Leu	Trp	Glu	Val
				155					160					165
Trp	Asn	Gly	Tyr	Pro	Lys	Gln	Pro	Leu	Leu	Pro	Ser	Gln	Tyr	Trp
				170					175					180
Tyr	Tyr	Ile	Leu	Glu	Met	Ser	Phe	Tyr	Trp	Ser	Leu	Leu	Phe	Arg
				185					190					195
Leu	Gly	Phe	Asp	Val	Lys	Arg	Lys	Asp	Phe	Leu	Ala	His	Ile	Ile
				200					205					210
His	His	Leu	Ala	Ala	Ile	Ser	Leu	Met	Ser	Phe	Ser	Trp	Cys	Ala
				215					220					225
Asn	Tyr	Ile	Arg	Ser	Gly	Thr	Leu	Val	Met	Ile	Val	His	Asp	Val
				230					235					240
Ala	Asp	Ile	Trp	Leu	Glu	Ser	Ala	Lys	Met	Phe	Ser	Tyr	Ala	Gly
				245					250					255
Trp	Thr	Gln	Thr	Cys	Asn	Thr	Leu	Phe	Phe	Ile	Phe	Ser	Thr	Ile
				260					265					270
Phe	Phe	Ile	Ser	Arg	Leu	Ile	Val	Phe	Pro	Phe	Trp	Ile	Leu	Tyr
				275					280					285
Cys	Thr	Leu	Ile	Leu	Pro	Met	Tyr	His	Leu	Glu	Pro	Phe	Phe	Ser
				290					295					300
Tyr	Ile	Phe	Leu	Asn	Leu	Gln	Leu	Met	Ile	Leu	Gln	Val	Leu	His
				305					310					315
Leu	Tyr	Trp	Gly	Tyr	Tyr	Ile	Leu	Lys	Met	Leu	Asn	Arg	Cys	Ile
				320					325					330
Phe	Met	Lys	Ser	Ile	Gln	Asp	Val	Arg	Ser	Asp	Asp	Glu	Asp	Tyr
				335					340					345
Glu	Glu	Glu	Glu	Glu	Glu	Glu	Glu	Glu	Glu	Ala	Thr	Lys	Gly	Lys
				350					355					360
Glu	Met	Asp	Cys	Leu	Lys	Asn	Gly	Leu	Gly	Ala	Glu	Arg	His	Leu
				365					370					375
Ile	Pro	Asn	Gly	Gln	His	Gly	His							
				380										

<210> 6

<211> 72

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 938824CD1

<400> 6

```

Met Pro Ala Ser Leu Trp Ala Phe Pro Arg Lys Lys His Trp Phe
 1          5          10          15
Leu Ser Ile Val Pro Trp Leu Val Leu Phe Leu Thr Leu Gly Leu
          20          25          30
Cys Val Arg Asn Lys Ala Ala Lys Leu His Val Val Ile Gln Gln
          35          40          45
Lys Glu Tyr Ser Asp Leu Ser Phe Ile Leu Leu Ile Val Pro Ser
          50          55          60
Thr Pro Ala Ala Ala Pro Ala Lys Tyr Tyr His Pro
          65          70

```

<210> 7

<211> 91

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1683721CD1

<400> 7

```

Met Met Leu Gly Trp Gly Trp Lys Ala Leu Leu Leu Lys Ser Leu
 1          5          10          15
Ala Phe Pro Thr Gln Gly Tyr Pro Glu Gly Tyr Glu Glu Leu Leu
          20          25          30
Arg Lys Val Thr Gly Ala Asp Leu Thr Trp Ser Pro Gly Asp Gly
          35          40          45
Ile Gln Phe Gln Val Pro Gly Thr Arg Lys Thr Lys Gln Tyr Cys
          50          55          60
Glu Phe Glu Asn Glu Ile Asn Phe Ile Met Pro His Met Lys Ile
          65          70          75
Gln Ser Leu Leu Phe Leu Leu Gly Phe Tyr Val Lys Asp Pro Ser
          80          85          90
Gln

```

<210> 8

<211> 160

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1694122CD1

<400> 8

```

Met Pro Lys Arg Trp Arg Cys Ile Leu Ala Pro Ser Arg Pro Trp
 1          5          10          15
Arg Ser Met Thr Trp Arg Gly Ile Tyr Trp Ile Leu Glu Pro Arg
          20          25          30
Cys Lys Glu Phe Met Gly Ile Met Thr Leu Gly Cys Leu Pro Thr
          35          40          45
Pro Ala Pro Leu His Leu Phe Phe Ser Leu Ser Pro Ala Arg Val
          50          55          60
Leu Arg Ala Pro Tyr Gly Ala Gln Glu Lys Lys Gly Arg Arg Val
          65          70          75
Arg Thr Thr Pro Trp Arg Arg Pro Pro Trp Arg Thr Ser Gly His
          80          85          90
Trp Gly Arg Asp Pro Ile Arg Glu Asn Cys Pro Gln Gln Ser Glu
          95          100          105
Glu Leu Ser Trp Pro Trp Ile Leu Arg Trp Ala Leu Leu Cys Ala
          110          115          120
Leu Arg Gln Ala Thr Cys Pro Leu Ser Leu Ser Phe Leu Ile Cys

```

Thr Thr Gly Pro	125		130		135
Ile Ser Leu Thr Ser		Gln Val Ala Leu Gly	Asp		
	140		145		150
Arg Cys Ala Trp His		Ile Val Gly Val	Gln		
	155		160		

<210> 9
 <211> 95
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1970615CD1

<400> 9
 Met Gly Val Gln Cys Pro Cys Leu Pro Leu Thr Gln Leu Trp Phe
 1 5 10 15
 Ile Leu Leu Val Cys Leu His Arg Pro Asp Ala Arg Val Pro Cys
 20 25 30
 Leu Ile Leu His Leu Ser His Trp Gly Ser Leu Pro Ser Asp
 35 40 45
 Ala Leu Ala Lys Ile Ala Leu Val Cys Ser Arg Lys Glu Gly Gln
 50 55 60
 Ile Pro Gly Ile Val Arg Ala Ala Glu Leu Tyr Arg Ile Gly Leu
 65 70 75
 Pro Phe Pro Pro Val Trp Leu Ala Leu His Ser Leu Gln Ile Pro
 80 85 90
 Pro Thr Ser Thr Gln
 95

<210> 10
 <211> 92
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2314152CD1

<400> 10
 Met Val Met Thr Ser Gly His Pro Leu Leu Ser Leu Arg Leu Leu
 1 5 10 15
 Pro Leu Trp Ser Gln Glu Gly Ser Ser Arg Ser Arg Asn His Val
 20 25 30
 Tyr Leu Ser Lys Arg Gln Glu Val Glu Arg Cys Gly Tyr Met Lys
 35 40 45
 Pro Ser Leu Asn Thr Ile Ser Ser Pro Glu Ser His Pro Val Thr
 50 55 60
 Ser His Ile His Thr Ser Gln Asp Arg Arg Lys Trp Pro Ala Leu
 65 70 75
 Ala Cys Lys Lys Gly Trp Glu Met Glu Ala Phe Phe Tyr Tyr Tyr
 80 85 90
 Tyr Phe

<210> 11
 <211> 71
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature

<223> Incyte ID No: 2886225CD1

<400> 11

Met	Asp	Arg	Trp	Gly	Gln	Asn	Gly	Leu	Phe	Pro	Arg	Arg	Arg	His
1				5					10					15
Leu	Phe	Ala	Pro	Phe	Leu	Asn	Leu	Ile	Ser	Ser	Val	Phe	Leu	His
				20					25					30
Arg	Phe	Cys	Thr	Leu	Gly	Thr	Lys	Lys	Pro	Ser	Gly	Thr	Leu	Leu
				35					40					45
Arg	Lys	Asp	Cys	Arg	Arg	Glu	Asp	Gln	Arg	Glu	Ile	Tyr	Lys	Tyr
				50					55					60
Phe	Arg	Asp	His	Gly	Ile	Tyr	Ser	Arg	Gly	Asn				
				65					70					

<210> 12

<211> 100

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6144418CD1

<400> 12

Met	Asn	Ser	Ala	Val	Gly	Gly	Leu	Ser	Arg	Pro	Phe	Ser	Val	Pro
1				5					10					15
Leu	Thr	Phe	Ser	Ala	Leu	Ile	Pro	Ser	Leu	Leu	Leu	His	Ala	Ser
				20					25					30
Val	Leu	Phe	Cys	Thr	Gly	Trp	Tyr	His	Asp	Phe	Gln	Glu	Gly	Glu
				35					40					45
Ser	Lys	Arg	Glu	Thr	Ser	Gln	Leu	Lys	Gln	Lys	His	Pro	Gly	Thr
				50					55					60
Arg	Glu	Asp	Glu	Val	Asn	Asn	Asp	Ser	Met	Trp	Asp	Thr	Ile	Ser
				65					70					75
His	Cys	His	Ser	Ala	Cys	Ser	Ser	Thr	Asn	Lys	Thr	Ile	Leu	Thr
				80					85					90
Lys	His	Pro	Trp	Ile	Ile	Gly	Ser	His	Asp					
				95					100					

<210> 13

<211> 122

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6834184CD1

<400> 13

Met	Gln	Gly	Val	Pro	Cys	Leu	Gly	Trp	Leu	Leu	Ser	Ser	Ala	Phe
1				5					10					15
Ser	Leu	Met	Ser	Trp	Gly	Ser	Leu	His	Gly	Cys	Ala	Leu	Leu	Leu
				20					25					30
Ala	Leu	Cys	Ser	Gly	Thr	Phe	Glu	Val	Glu	Lys	Ile	Leu	Val	Gly
				35					40					45
Val	Gly	Ala	Asp	Glu	Cys	Gln	Ala	Ser	Ala	Leu	Val	Trp	Glu	Ala
				50					55					60
Thr	Met	Leu	Thr	Phe	Gln	Leu	His	Pro	Arg	Gly	Ser	Thr	Ser	Gln
				65					70					75
Pro	Pro	Glu	Pro	Asp	Cys	Ser	Ala	Ala	Val	Leu	Gly	Lys	Leu	Leu
				80					85					90
Thr	Phe	Leu	Cys	Leu	Ser	Phe	Phe	Ile	Cys	Glu	Leu	Gly	Val	Ile
				95					100					105

Ala Ser Asn Glu Ser Lys Gly Leu Gly Thr Val Thr Lys Leu Trp
 110 115 120
 Leu Val

<210> 14
 <211> 113
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6951005CD1

<400> 14
 Met Val Leu Pro Gly Phe Pro Ser Val Pro Ser Pro Leu Pro His
 1 5 10 15
 Pro Leu Trp Leu Leu Pro Leu Ala Pro Ser Ile Leu Asp Gln Phe
 20 25 30
 Ser Leu Gly Pro Thr Leu Arg Ser Pro Ala Phe Ile Pro Ser Arg
 35 40 45
 Asp Ser Pro Ala Ser Ile Ala Val Thr Asp Ile Thr Ile His Ile
 50 55 60
 Gln Ile Val Leu Leu Ala Thr Leu Leu Ala Ser Ser Phe Thr Lys
 65 70 75
 Ser Pro Asp Phe Ser Tyr Asn Pro Asp Leu Ser Phe Thr Ser Ser
 80 85 90
 Tyr Met Thr Ser Gly Met Leu Leu Asp Ile Ser Glu Leu Gln Tyr
 95 100 105
 Pro Tyr Val Gln Ser Glu Thr Ile
 110

<210> 15
 <211> 85
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7250331CD1

<400> 15
 Met Trp Pro Glu Pro Pro Leu Gly Pro Leu Ser Pro Leu Leu Cys
 1 5 10 15
 Leu Leu Ser Leu Ser Cys Leu Pro Glu Val Arg Leu Phe Arg Gly
 20 25 30
 Gln Cys Val Thr Cys Gln Leu Pro His His Pro Pro Pro Ser Leu
 35 40 45
 Pro Pro Leu Leu Pro Gln Gly Pro Pro Pro Ile Ser Gly Ser Gln
 50 55 60
 Ala Ile Asn Leu Glu Thr Glu Met Gly Leu Leu Ser Ile Leu Trp
 65 70 75
 Pro Leu Phe Leu Ser Leu Gln Phe Val Pro
 80 85

<210> 16
 <211> 256
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1758413CD1

<400> 16

```

Met Ala Pro Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Ala Leu
 1          5          10          15
Leu Cys Leu Pro Trp Leu Gln Glu Ala Gly Ala Val Gln Thr Val
          20          25          30
Pro Leu Ser Arg Leu Phe Asp His Ala Met Leu Gln Ala His Arg
          35          40          45
Ala His Gln Leu Ala Ile Asp Thr Tyr Gln Glu Phe Glu Glu Thr
          50          55          60
Tyr Ile Pro Lys Asp Gln Lys Tyr Ser Phe Leu His Asp Ser Gln
          65          70          75
Thr Ser Phe Cys Phe Ser Asp Ser Ile Pro Thr Pro Ser Asn Met
          80          85          90
Glu Glu Thr Gln Gln Lys Ser Asn Leu Glu Leu Leu Arg Ile Ser
          95          100          105
Leu Leu Leu Ile Glu Ser Trp Leu Glu Pro Val Arg Phe Leu Arg
          110          115          120
Ser Met Phe Ala Asn Asn Leu Val Tyr Asp Thr Ser Asp Ser Asp
          125          130          135
Asp Tyr His Leu Leu Lys Asp Leu Glu Gly Ile Gln Thr Leu
          140          145          150
Met Gly Val Arg Val Ala Pro Gly Val Thr Asn Pro Gly Thr Pro
          155          160          165
Leu Ala Ser Arg Ala Gly Gly Glu Lys Tyr Cys Cys Pro Leu Phe
          170          175          180
Ser Ser Lys Ala Leu Thr Gln Glu Asn Ser Pro Tyr Ser Ser Phe
          185          190          195
Arg Leu Val Asn Pro Pro Gly Leu Ser Leu His Pro Glu Gly Glu
          200          205          210
Gly Gly Lys Trp Ile Asn Glu Arg Gly Arg Glu Gln Cys Pro Ser
          215          220          225
Ala Trp Pro Leu Leu Leu Phe Leu His Phe Ala Glu Ala Gly Arg
          230          235          240
Arg Gln Pro Pro Asp Trp Ala Asp Pro Gln Ala Asp Leu Gln Gln
          245          250          255
Val

```

<210> 17

<211> 287

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7011042CD1

<400> 17

```

Met Arg Gln Thr Leu Pro Leu Leu Leu Leu Thr Val Leu Arg Pro
 1          5          10          15
Ser Trp Ala Asp Pro Pro Gln Glu Lys Val Pro Leu Phe Arg Val
          20          25          30
Thr Gln Gln Gly Pro Trp Gly Ser Ser Gly Ser Asn Ala Thr Asp
          35          40          45
Ser Pro Cys Glu Gly Leu Pro Ala Ala Asp Ala Thr Ala Leu Thr
          50          55          60
Leu Ala Asn Arg Asn Leu Glu Arg Leu Pro Gly Cys Leu Pro Arg
          65          70          75
Thr Leu Arg Ser Leu Asp Ala Ser His Asn Leu Leu Arg Ala Leu
          80          85          90
Ser Thr Ser Glu Leu Gly His Leu Glu Gln Leu Gln Val Leu Thr
          95          100          105
Leu Arg His Asn Arg Ile Ala Ala Leu Arg Trp Gly Pro Gly Gly

```


Pro Ala Gly Leu	110	115	120
His Thr Leu Asp Leu Ser Tyr Asn Gln Leu Ala			
125	130	135	
Ala Leu Pro Pro Cys Thr Gly Pro Ala Leu Ser Ser Leu Arg Ala			
140	145	150	
Leu Ala Leu Ala Gly Asn Pro Leu Arg Ala Leu Gln Pro Arg Ala			
155	160	165	
Phe Ala Cys Phe Pro Ala Leu Gln Leu Leu Asn Leu Ser Cys Thr			
170	175	180	
Ala Leu Gly Arg Gly Ala Gln Gly Gly Ile Ala Glu Ala Ala Phe			
185	190	195	
Ala Gly Glu Asp Gly Ala Pro Leu Val Thr Leu Glu Val Leu Asp			
200	205	210	
Leu Ser Gly Thr Phe Leu Glu Arg Val Glu Ser Gly Trp Ile Arg			
215	220	225	
Asp Leu Pro Lys Leu Thr Ser Leu Tyr Leu Arg Lys Met Pro Arg			
230	235	240	
Leu Thr Thr Leu Glu Gly Asp Ile Phe Lys Met Thr Pro Asn Leu			
245	250	255	
Gln Gln Leu Asp Cys Gln Asp Ser Pro Ala Leu Ala Ser Val Ala			
260	265	270	
Thr His Ile Phe Gln Asp Thr Pro His Leu Gln Val Leu Leu Phe			
275	280	285	
Gln Lys			

<210> 18

<211> 366

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7427362CD1

<400> 18

Met Leu Asp Gly Ser Pro Leu Ala Arg Trp Leu Ala Ala Ala Phe		
1	5	10
Gly Leu Thr Leu Leu Leu Ala Ala Leu Arg Pro Ser Ala Ala Tyr		
20	25	30
Phe Gly Leu Thr Gly Ser Glu Pro Leu Thr Ile Leu Pro Leu Thr		
35	40	45
Leu Glu Pro Glu Ala Ala Ala Gln Ala His Tyr Lys Ala Cys Asp		
50	55	60
Arg Leu Lys Leu Glu Arg Lys Gln Arg Arg Met Cys Arg Arg Asp		
65	70	75
Pro Gly Val Ala Glu Thr Leu Val Glu Ala Val Ser Met Ser Ala		
80	85	90
Leu Glu Cys Gln Phe Gln Phe Arg Phe Glu Arg Trp Asn Cys Thr		
95	100	105
Leu Glu Gly Arg Tyr Arg Ala Ser Leu Leu Lys Arg Gly Phe Lys		
110	115	120
Glu Thr Ala Phe Leu Tyr Ala Ile Ser Ser Ala Gly Leu Thr His		
125	130	135
Ala Leu Ala Lys Ala Cys Ser Ala Gly Arg Met Glu Arg Cys Thr		
140	145	150
Cys Asp Glu Ala Pro Asp Leu Glu Asn Arg Glu Ala Trp Gln Trp		
155	160	165
Gly Gly Cys Ser Glu Asp Ile Glu Phe Gly Gly Met Val Ser Arg		
170	175	180
Glu Phe Ala Asp Ala Arg Glu Asn Arg Pro Asp Ala Arg Ser Ala		
185	190	195
Met Asn Arg His Asn Asn Glu Ala Gly Arg Gln Val Ile Lys Ala		

	200		205		210
Gly Val Glu Thr	Thr Cys Lys Cys His	Gly Val Ser Gly Ser Cys			
	215	220			225
Thr Val Arg Thr	Cys Trp Arg Gln Leu	Ala Pro Phe His Glu Val			
	230	235			240
Gly Lys His Leu	Lys His Lys Tyr Glu	Thr Ala Leu Lys Val Gly			
	245	250			255
Ser Thr Thr Asn	Glu Ala Ala Gly Glu	Ala Gly Ala Ile Ser Pro			
	260	265			270
Pro Arg Gly Arg	Ala Ser Gly Ala Gly	Gly Ser Asp Pro Leu Pro			
	275	280			285
Arg Thr Pro Glu	Leu Val His Leu Asp	Asp Ser Pro Ser Phe Cys			
	290	295			300
Leu Ala Gly Arg	Phe Ser Pro Gly Thr	Ala Gly Arg Arg Cys His			
	305	310			315
Arg Glu Lys Asn	Cys Glu Ser Ile Cys	Cys Gly Arg Gly His Asn			
	320	325			330
Thr Gln Ser Arg	Val Val Thr Arg Pro	Cys Gln Cys Gln Val Arg			
	335	340			345
Trp Cys Cys Tyr	Val Glu Cys Arg Gln	Cys Thr Gln Arg Glu Glu			
	350	355			360
Val Tyr Thr Cys	Lys Gly				
	365				

<210> 19

<211> 416

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7485304CD1

<400> 19

Met Leu Ala Val	Val Met Ala Asp Leu	Ala Ser Leu Met Cys Trp			
1	5	10			15
Val Cys Lys Gln	Lys Leu Pro Gly Leu	Ala Ala Trp Ser Ala Ala			
	20	25			30
Val Arg Gln Glu	Val Gly Leu Cys Leu	Glu Arg Gln Ser Leu Gln			
	35	40			45
Leu Asp Pro Ala	Leu Ser Ser Leu Ser	Gln Gly Trp Pro Leu Arg			
	50	55			60
Arg Pro Leu Pro	Phe Ile Cys Pro Ser	Pro Pro Ser Pro Arg Leu			
	65	70			75
Thr Cys Leu Pro	Pro Leu Ala Leu Ser	Leu Thr Gly Arg Glu			
	80	85			90
Val Leu Thr Pro	Phe Pro Gly Leu Gly	Thr Ala Ala Ala Pro Ala			
	95	100			105
Gln Gly Gly Ala	His Leu Lys Gln Cys	Asp Leu Leu Lys Leu Ser			
	110	115			120
Arg Arg Gln Lys	Gln Leu Cys Arg Arg	Glu Pro Gly Leu Ala Glu			
	125	130			135
Thr Leu Arg Asp	Ala Ala His Leu Gly	Leu Leu Glu Cys Gln Phe			
	140	145			150
Gln Phe Arg His	Glu Arg Trp Asn Cys	Ser Leu Glu Gly Arg Met			
	155	160			165
Gly Leu Leu Lys	Arg Gly Phe Lys Glu	Thr Ala Phe Leu Tyr Ala			
	170	175			180
Val Ser Ser Ala	Ala Leu Thr His Thr	Leu Ala Arg Ala Cys Ser			
	185	190			195
Ala Gly Arg Met	Glu Arg Cys Thr Cys	Asp Asp Ser Pro Gly Leu			
	200	205			210
Glu Ser Arg Gln	Ala Trp Gln Trp Gly	Val Cys Gly Asp Asn Leu			

	215		220		225
Lys Tyr Ser Thr	Lys Phe Leu Ser Asn	Phe Leu Gly Ser Lys	Arg		
	230		235		240
Gly Asn Lys Asp	Leu Arg Ala Arg Ala	Asp Ala His Asn Thr	His		
	245		250		255
Val Gly Ile Lys	Ala Val Lys Ser Gly	Leu Arg Thr Thr Cys	Lys		
	260		265		270
Cys His Gly Val	Ser Gly Ser Cys Ala	Val Arg Thr Cys Trp	Lys		
	275		280		285
Gln Leu Ser Pro	Phe Arg Glu Thr Gly	Gln Val Leu Lys Leu	Arg		
	290		295		300
Tyr Asp Ser Ala	Val Lys Val Ser Ser	Ala Thr Asn Glu Ala	Leu		
	305		310		315
Gly Arg Leu Glu	Leu Trp Ala Pro Ala	Arg Gln Gly Ser Leu	Thr		
	320		325		330
Lys Gly Leu Ala	Pro Arg Ser Gly Asp	Leu Val Tyr Met Glu	Asp		
	335		340		345
Ser Pro Ser Phe	Cys Arg Pro Ser Lys	Tyr Ser Pro Gly Thr	Ala		
	350		355		360
Gly Arg Val Cys	Ser Arg Glu Ala Ser	Cys Ser Ser Leu Cys	Cys		
	365		370		375
Gly Arg Gly Tyr	Asp Thr Gln Ser Arg	Leu Val Ala Phe Ser	Cys		
	380		385		390
His Cys Gln Val	Gln Trp Cys Cys Tyr	Val Glu Cys Gln Gln	Cys		
	395		400		405
Val Gln Glu Glu	Leu Val Tyr Thr Cys	Lys His			
	410		415		

<210> 20

<211> 871

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1422394CD1

<400> 20

Met Lys Tyr Ser Cys	Cys Ala Leu Val	Leu Ala Val Leu Gly Thr
1	5	10 15
Glu Leu Leu Gly Ser	Leu Cys Ser Thr	Val Arg Ser Pro Arg Phe
	20	25 30
Arg Gly Arg Ile Gln	Gln Glu Arg Lys	Asn Ile Arg Pro Asn Ile
	35	40 45
Ile Leu Val Leu Thr	Asp Asp Gln Asp	Val Glu Leu Gly Ser Leu
	50	55 60
Gln Val Met Asn Lys	Thr Arg Lys Ile	Met Glu His Gly Gly Ala
	65	70 75
Thr Phe Ile Asn Ala	Phe Val Thr Thr	Pro Met Cys Cys Pro Ser
	80	85 90
Arg Ser Ser Met Leu	Thr Gly Lys Tyr	Val His Asn His Asn Val
	95	100 105
Tyr Thr Asn Asn Glu	Asn Cys Ser Ser	Pro Ser Trp Gln Ala Met
	110	115 120
His Glu Pro Arg Thr	Phe Ala Val Tyr	Leu Asn Asn Thr Gly Tyr
	125	130 135
Arg Thr Ala Phe Phe	Gly Lys Tyr Leu	Asn Glu Tyr Asn Gly Ser
	140	145 150
Tyr Ile Pro Pro Gly	Trp Arg Glu Trp	Leu Gly Leu Ile Lys Asn
	155	160 165
Ser Arg Phe Tyr Asn	Tyr Thr Val Cys	Arg Asn Gly Ile Lys Glu
	170	175 180
Lys His Gly Phe Asp	Tyr Ala Lys Asp	Tyr Phe Thr Asp Leu Ile

	185		190		195
Thr Asn Glu Ser	Ile Asn Tyr Phe Lys	Met Ser Lys Arg Met	Tyr		
	200		205		210
Pro His Arg Pro	Val Met Met Val Ile	Ser His Ala Ala Pro	His		
	215		220		225
Gly Pro Glu Asp	Ser Ala Pro Gln Phe	Ser Lys Leu Tyr Pro	Asn		
	230		235		240
Ala Ser Gln His	Ile Thr Pro Ser Tyr	Asn Tyr Ala Pro Asn	Met		
	245		250		255
Asp Lys His Trp	Ile Met Gln Tyr Thr	Gly Pro Met Leu Pro	Ile		
	260		265		270
His Met Glu Phe	Thr Asn Ile Leu Gln	Arg Lys Arg Leu Gln	Thr		
	275		280		285
Leu Met Ser Val	Asp Asp Ser Val Glu	Arg Leu Tyr Asn Met	Leu		
	290		295		300
Val Glu Thr Gly	Glu Leu Glu Asn Thr	Tyr Ile Ile Tyr Thr	Ala		
	305		310		315
Asp His Gly Tyr	His Ile Gly Gln Phe	Gly Leu Val Lys Gly	Lys		
	320		325		330
Ser Met Pro Tyr	Asp Phe Asp Ile Arg	Val Pro Phe Phe Ile	Arg		
	335		340		345
Gly Pro Ser Val	Glu Pro Gly Ser Ile	Val Pro Gln Ile Val	Leu		
	350		355		360
Asn Ile Asp Leu	Ala Pro Thr Ile Leu	Asp Ile Ala Gly Leu	Asp		
	365		370		375
Thr Pro Pro Asp	Val Asp Gly Lys Ser	Val Leu Lys Leu Leu	Asp		
	380		385		390
Pro Glu Lys Pro	Gly Asn Arg Phe Arg	Thr Asn Lys Lys Ala	Lys		
	395		400		405
Ile Trp Arg Asp	Thr Phe Leu Val Glu	Arg Gly Lys Phe Leu	Arg		
	410		415		420
Lys Lys Glu Glu	Ser Ser Lys Asn Ile	Gln Gln Ser Asn His	Leu		
	425		430		435
Pro Lys Tyr Glu	Arg Val Lys Glu Leu	Cys Gln Gln Ala Arg	Tyr		
	440		445		450
Gln Thr Ala Cys	Glu Gln Pro Gly Gln	Lys Trp Gln Cys Ile	Glu		
	455		460		465
Asp Thr Ser Gly	Lys Leu Arg Ile His	Lys Cys Lys Gly Pro	Ser		
	470		475		480
Asp Leu Leu Thr	Val Arg Gln Ser Thr	Arg Asn Leu Tyr Ala	Arg		
	485		490		495
Gly Phe His Asp	Lys Asp Lys Glu Cys	Ser Cys Arg Glu Ser	Gly		
	500		505		510
Tyr Arg Ala Ser	Arg Ser Gln Arg Lys	Ser Gln Arg Gln Phe	Leu		
	515		520		525
Arg Asn Gln Gly	Thr Pro Lys Tyr Lys	Pro Arg Phe Val His	Thr		
	530		535		540
Arg Gln Thr Arg	Ser Leu Ser Val Glu	Phe Glu Gly Glu Ile	Tyr		
	545		550		555
Asp Ile Asn Leu	Glu Glu Glu Glu Glu	Leu Gln Val Leu Gln	Pro		
	560		565		570
Arg Asn Ile Ala	Lys Arg His Asp Glu	Gly His Lys Gly Pro	Arg		
	575		580		585
Asp Leu Gln Ala	Ser Ser Gly Gly Asn	Arg Gly Arg Met Leu	Ala		
	590		595		600
Asp Ser Ser Asn	Ala Val Gly Pro Pro	Thr Thr Val Arg Val	Thr		
	605		610		615
His Lys Cys Phe	Ile Leu Pro Asn Asp	Ser Ile His Cys Glu	Arg		
	620		625		630
Glu Leu Tyr Gln	Ser Ala Arg Ala Trp	Lys Asp His Lys Ala	Tyr		
	635		640		645
Ile Asp Lys Glu	Ile Glu Ala Leu Gln	Asp Lys Ile Lys Asn	Leu		
	650		655		660

Arg	Glu	Val	Arg	Gly	His	Leu	Lys	Arg	Arg	Lys	Pro	Glu	Glu	Cys	
				665					670					675	
Ser	Cys	Ser	Lys	Gln	Ser	Tyr	Tyr	Asn	Lys	Glu	Lys	Gly	Val	Lys	
				680					685					690	
Lys	Gln	Glu	Lys	Leu	Lys	Ser	His	Leu	His	Pro	Phe	Lys	Glu	Ala	
				695					700					705	
Ala	Gln	Glu	Val	Asp	Ser	Lys	Leu	Gln	Leu	Phe	Lys	Glu	Asn	Asn	
				710					715					720	
Arg	Arg	Arg	Lys	Lys	Glu	Arg	Lys	Glu	Lys	Arg	Arg	Gln	Arg	Lys	
				725					730					735	
Gly	Glu	Glu	Cys	Ser	Leu	Pro	Gly	Leu	Thr	Cys	Phe	Thr	His	Asp	
				740					745					750	
Asn	Asn	His	Trp	Gln	Thr	Ala	Pro	Phe	Trp	Asn	Leu	Gly	Ser	Phe	
				755					760					765	
Cys	Ala	Cys	Thr	Ser	Ser	Asn	Asn	Asn	Thr	Tyr	Trp	Cys	Leu	Arg	
				770					775					780	
Thr	Val	Asn	Glu	Thr	His	Asn	Phe	Leu	Phe	Cys	Glu	Phe	Ala	Thr	
				785					790					795	
Gly	Phe	Leu	Glu	Tyr	Phe	Asp	Met	Asn	Thr	Asp	Pro	Tyr	Gln	Leu	
				800					805					810	
Thr	Asn	Thr	Val	His	Thr	Val	Glu	Arg	Gly	Ile	Leu	Asn	Gln	Leu	
				815					820					825	
His	Val	Gln	Leu	Met	Glu	Leu	Arg	Ser	Cys	Gln	Gly	Tyr	Lys	Gln	
				830					835					840	
Cys	Asn	Pro	Arg	Pro	Lys	Asn	Leu	Asp	Val	Gly	Asn	Lys	Asp	Gly	
				845					850					855	
Gly	Ser	Tyr	Asp	Leu	His	Arg	Gly	Gln	Leu	Trp	Asp	Gly	Trp	Glu	
				860					865					870	

Gly

<210> 21
 <211> 100
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1336022CD1

<400> 21															
Met	Lys	Ser	Val	Asn	Asp	Thr	Leu	Leu	Ala	His	Phe	Leu	Val	Leu	
1				5					10					15	
Leu	Val	Ile	Leu	Pro	Pro	Ala	Pro	Val	Lys	Pro	Val	Pro	Gly	His	
				20					25					30	
Ile	Thr	Gln	Leu	Pro	Ala	Gln	Leu	Leu	Arg	Glu	Lys	Thr	Met	His	
				35					40					45	
Phe	Thr	Ser	Thr	Ser	Pro	Ala	Thr	Gly	Thr	Gln	Met	Val	Asn	Ala	
				50					55					60	
Ala	Ala	Asn	Gly	Leu	Gly	Ala	Glu	Pro	Met	Glu	Ser	Phe	Lys	Gln	
				65					70					75	
Ala	Tyr	Arg	His	Cys	Ile	Lys	Ile	Pro	Asp	Phe	Lys	Ile	Pro	Ser	
				80					85					90	
Gln	Gly	Ser	His	Lys	Thr	Ile	Ile	Phe	Ser						
				95					100						

<210> 22
 <211> 102
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature

<400> 22

<210> 23

<211> 117

<212> PRT

<213> Homo sapiens

<220>

```
<221> misc feature
```

<223> Incyte ID No: 7475846CD1

<400> 23

Met	Cys	His	Gly	Ser	Pro	Thr	Leu	Cys	Gln	Pro	Val	Cys	Ala	Met
1				5					10					15
Ala	Pro	Asp	Pro	Val	Pro	Ala	His	Val	Cys	His	Gly	Ser	Pro	Thr
				20					25					30
Leu	Cys	Gln	Pro	Val	Trp	Ala	Met	Ala	Pro	Pro	Asn	Pro	Cys	Gln
				35					40					45
Pro	Ala	Cys	Ala	Met	Gly	Ser	Thr	Asp	Pro	Val	Pro	Ala	Arg	Val
				50					55					60
Arg	His	Gly	Phe	Pro	Asp	Pro	Met	Pro	Ala	Arg	Val	Cys	Ala	Met
				65					70					75
Ala	Pro	Pro	Thr	Pro	Cys	Gln	Pro	Ala	Cys	Val	Met	Thr	Pro	Pro
				80					85					90
Arg	Val	Arg	His	Gly	Phe	Pro	Asp	Pro	Met	Pro	Ala	Arg	Val	Arg
				95					100					105
His	Gly	Ser	Thr	Asp	Pro	Val	Pro	Ala	Ser	Ala	Gly			
				110					115					

<210> 24

<211> 150

<212> PRT

<213> Homo sapiens

<220>

```
<221> misc_feature
```

<223> Incyte ID No: 7475860CD1

<400> 24

Met	Ala	Ala	Ser	Gln	Cys	Leu	Cys	Cys	Ser	Lys	Phe	Leu	Phe	Gln
1				5					10					15
Arg	Gln	Asn	Leu	Ala	Cys	Phe	Leu	Thr	Asn	Pro	His	Cys	Gly	Ser
				20					25					30
Leu	Val	Asn	Ala	Asp	Gly	His	Gly	Glu	Val	Trp	Thr	Asp	Trp	Asn
				35					40					45
Asn	Met	Ser	Lys	Phe	Phe	Gln	Tyr	Gly	Trp	Arg	Cys	Thr	Thr	Asn
				50					55					60

Glu	Asn	Thr	Tyr	Ser	Asn	Arg	Thr	Leu	Met	Gly	Asn	Trp	Asn	Gln	
				65					70					75	
Glu	Arg	Tyr	Asp	Leu	Arg	Asn	Ile	Val	Gln	Pro	Lys	Pro	Leu	Pro	
				80					85					90	
Ser	Gln	Phe	Gly	His	Tyr	Phe	Glu	Thr	Thr	Tyr	Asp	Thr	Ser	Tyr	
				95					100					105	
Asn	Asn	Lys	Met	Pro	Leu	Ser	Thr	His	Arg	Phe	Lys	Arg	Glu	Pro	
				110					115					120	
His	Trp	Phe	Pro	Gly	His	Gln	Pro	Glu	Leu	Asp	Pro	Pro	Arg	Tyr	
				125					130					135	
Lys	Cys	Thr	Glu	Lys	Ser	Thr	Tyr	Met	Asn	Ser	Tyr	Ser	Lys	Pro	
				140					145					150	

<210> 25

<211> 89

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7950941CD1

<400> 25

Met	Ala	Pro	Asn	Pro	Ala	Arg	Leu	His	Ser	His	Leu	Asp	Leu	Val	
1				5					10					15	
Ser	Pro	Ser	Val	Pro	Arg	Ser	Leu	Gly	Phe	Gln	Leu	Pro	Ile	Gly	
				20					25					30	
Arg	Lys	Gln	Ser	Arg	Asn	Val	Leu	Ser	His	Gln	Asp	Gly	His	Ile	
				35					40					45	
Leu	Gln	Cys	Ser	Phe	Arg	Pro	Asp	Arg	Arg	Met	Lys	Arg	Lys	Ala	
				50					55					60	
Glu	Ser	Pro	Glu	Asn	Asn	Gln	Leu	Arg	Cys	His	Leu	Pro	Cys	Gln	
				65					70					75	
Gly	Gly	Asp	Pro	Ala	Met	Leu	Pro	Ser	Arg	Phe	Gln	Asn	Cys		
				80					85						

<210> 26

<211> 287

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7485334CD1

<400> 26

Met	Ala	Leu	Gly	Leu	Leu	Ile	Ala	Val	Pro	Leu	Leu	Leu	Gln	Ala	
1				5					10					15	
Ala	Pro	Pro	Gly	Ala	Ala	His	Tyr	Glu	Met	Leu	Gly	Thr	Cys	Arg	
				20					25					30	
Met	Ile	Cys	Asp	Pro	Tyr	Ser	Val	Ala	Pro	Ala	Gly	Gly	Pro	Ala	
				35					40					45	
Gly	Ala	Lys	Ala	Pro	Pro	Pro	Gly	Pro	Ser	Thr	Ala	Ala	Leu	Glu	
				50					55					60	
Val	Met	Gln	Asp	Leu	Ser	Ala	Asn	Pro	Pro	Pro	Pro	Phe	Ile	Gln	
				65					70					75	
Gly	Pro	Lys	Gly	Asp	Pro	Gly	Arg	Pro	Gly	Lys	Pro	Gly	Pro	Arg	
				80					85					90	
Gly	Pro	Pro	Gly	Glu	Pro	Gly	Pro	Pro	Gly	Pro	Arg	Gly	Pro	Pro	
				95					100					105	
Gly	Glu	Lys	Gly	Asp	Ser	Gly	Arg	Pro	Gly	Leu	Pro	Gly	Leu	Gln	
				110					115					120	

<400>	27														
Met	Asp	Gly	Glu	Ala	Thr	Val	Lys	Pro	Gly	Glu	Gln	Lys	Glu	Val	
1				5					10					15	
Val	Arg	Arg	Gly	Arg	Glu	Val	Asp	Tyr	Ser	Arg	Leu	Ile	Ala	Gly	
				20					25					30	
Thr	Leu	Pro	Gln	Ser	His	Val	Thr	Ser	Arg	Arg	Ala	Gly	Trp	Lys	
				35					40					45	
Met	Pro	Leu	Phe	Leu	Ile	Leu	Cys	Leu	Leu	Gln	Gly	Ser	Ser	Phe	
				50					55					60	
Ala	Leu	Pro	Gln	Lys	Arg	Pro	His	Pro	Arg	Trp	Leu	Trp	Glu	Gly	
				65					70					75	
Ser	Leu	Pro	Ser	Arg	Thr	His	Leu	Arg	Ala	Met	Gly	Thr	Leu	Arg	
				80					85					90	
Pro	Ser	Ser	Pro	Leu	Cys	Trp	Arg	Glu	Glu	Ser	Ser	Phe	Ala	Ala	
				95					100					105	
Pro	Asn	Ser	Leu	Lys	Gly	Ser	Arg	Leu	Val	Ser	Gly	Glu	Pro	Gly	
				110					115					120	
Gly	Ala	Val	Thr	Ile	Gln	Cys	His	Tyr	Ala	Pro	Ser	Ser	Val	Asn	
				125					130					135	
Arg	His	Gln	Arg	Lys	Tyr	Trp	Cys	Arg	Leu	Gly	Pro	Pro	Arg	Trp	
				140					145					150	
Ile	Cys	Gln	Thr	Ile	Val	Ser	Thr	Asn	Gln	Tyr	Thr	His	His	Arg	
				155					160					165	
Tyr	Arg	Asp	Arg	Val	Ala	Leu	Thr	Asp	Phe	Pro	Gln	Arg	Gly	Leu	
				170					175					180	
Phe	Val	Val	Arg	Leu	Ser	Gln	Leu	Ser	Pro	Asp	Asp	Ile	Gly	Cys	
				185					190					195	
Tyr	Leu	Cys	Gly	Ile	Gly	Ser	Glu	Asn	Asn	Met	Leu	Phe	Leu	Ser	
				200					205					210	

Leu	Leu	Leu	His	Ala	Leu	Leu	Leu	Phe	Val	Ala	Asp	Ala	Ala	Phe
				20					25					30
Thr	Glu	Val	Pro	Lys	Asp	Val	Thr	Val	Arg	Glu	Gly	Asp	Asp	Ile
				35					40					45
Glu	Met	Pro	Cys	Ala	Phe	Arg	Ala	Ser	Gly	Ala	Thr	Ser	Tyr	Ser
				50					55					60
Leu	Glu	Ile	Gln	Trp	Trp	Tyr	Leu	Lys	Glu	Pro	Pro	Arg	Glu	Leu
				65					70					75
Leu	His	Glu	Leu	Ala	Leu	Ser	Val	Pro	Gly	Ala	Arg	Ser	Lys	Val
				80					85					90
Thr	Asn	Lys	Asp	Ala	Thr	Lys	Ile	Ser	Thr	Val	Arg	Val	Gln	Gly
				95					100					105
Asn	Asp	Ile	Ser	His	Arg	Leu	Arg	Leu	Ser	Ala	Val	Arg	Leu	Gln
				110					115					120
Asp	Glu	Gly	Val	Tyr	Glu	Cys	Arg	Val	Ser	Asp	Tyr	Ser	Asp	Asp
				125					130					135
Asp	Thr	Gln	Glu	His	Lys	Ala	Gln	Ala	Met	Leu	Arg	Val	Leu	Ser
				140					145					150
Arg	Phe	Ala	Pro	Pro	Asn	Met	Gln	Ala	Ala	Glu	Ala	Val	Ser	His
				155					160					165
Ile	Gln	Ser	Ser	Gly	Pro	Arg	Arg	His	Gly	Pro	Ala	Ser	Ala	Ala
				170					175					180
Asn	Ala	Asn	Asn	Ala	Gly	Ala	Ala	Ser	Arg	Thr	Thr	Ser	Glu	Pro
				185					190					195
Gly	Arg	Gly	Asp	Lys	Ser	Pro	Pro	Pro	Gly	Ser	Pro	Pro	Ala	Ala
				200					205					210
Ile	Asp	Pro	Ala	Val	Pro	Glu	Ala	Ala	Ala	Ala	Ser	Ala	Ala	His
				215					220					225
Thr	Pro	Thr	Thr	Thr	Val	Ala	Ala	Ala	Ala	Ala	Ala	Ser	Ser	Ala
				230					235					240
Ser	Pro	Pro	Ser	Gly	Gln	Ala	Val	Leu	Leu	Arg	Gln	Arg	His	Gly
				245					250					255
Ser	Gly	Lys	Gly	Arg	Ser	Tyr	Thr	Thr	Asp	Pro	Leu	Leu	Ser	Leu
				260					265					270
Leu	Leu	Leu	Ala	Leu	His	Lys	Phe	Leu	Arg	Leu	Leu	Leu	Gly	His
				275					280					285

<210> 29
 <211> 72
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 346472CD1

Met	Val	Phe	Ile	Phe	Phe	Leu	Phe	Ser	Gly	Cys	Leu	Leu	Cys	Phe
1				5					10					15
Ser	Phe	Leu	Gln	Ser	Asn	Phe	Gln	His	Ser	Asp	Lys	Pro	Phe	Glu
				20					25					30
Arg	Asn	Arg	Leu	Arg	Ile	Pro	Tyr	Ser	Gln	Asn	Cys	Gly	Ile	Phe
				35					40					45
Lys	Pro	Gln	Arg	Lys	Pro	Arg	Asp	Pro	Arg	Arg	Leu	Phe	Cys	Gly
				50					55					60
Cys	Gly	Lys	Phe	Lys	Tyr	Pro	Pro	Arg	Leu	His	Ser			
				65					70					

<210> 30
 <211> 72
 <212> PRT
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 643526CD1

<400> 30

Met	Thr	Thr	Leu	Tyr	Leu	Pro	Ala	Phe	Ala	Ala	Val	Leu	Ser	Leu	
1				5					10					15	
Ser	Gln	Cys	Ser	Glu	Ser	Val	Gly	Ser	Phe	Pro	Thr	Gln	Val	Leu	
				20					25					30	
Ala	Ala	Asp	Leu	Gly	Leu	Ala	Leu	Leu	Asp	Val	Ile	Leu	Gln	Pro	
				35					40					45	
Arg	Gly	Lys	Leu	Ser	Leu	Tyr	Val	Pro	Ser	Thr	Ala	Trp	Gly	Gln	
				50					55					60	
Thr	Arg	Thr	Leu	Thr	Val	Ala	Met	Ala	Glu	Gly	Leu				
				65					70						

<210> 31

<211> 149

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1483418CD1

<400> 31

Met	Arg	Pro	Thr	Gly	Gly	Ser	Gly	Gln	Arg	Gly	Pro	Arg	Tyr	Thr	
1				5					10					15	
Thr	Ser	Leu	Leu	Phe	His	Cys	Leu	Leu	Pro	Cys	Ser	Asp	His	Ser	
				20					25					30	
Ser	Gly	Ala	Val	Ser	Gln	Ala	Trp	Ala	Ser	Phe	Asn	Ile	Phe	Tyr	
				35					40					45	
Leu	Ala	Leu	His	Gly	Ala	Ala	Pro	Ala	Met	Val	Pro	Gln	Gly	Phe	
				50					55					60	
Phe	Ser	Gln	Val	Ser	Ser	Leu	Glu	Arg	Ser	Pro	Arg	Phe	Pro	Val	
				65					70					75	
Lys	Gln	Pro	Cys	Ser	Leu	Cys	Leu	Ser	Gln	Pro	His	His	Pro	Val	
				80					85					90	
Ala	Ser	Phe	Thr	Ala	Cys	Leu	Thr	Ile	Cys	Asn	His	Leu	Ser	Val	
				95					100					105	
Cys	Arg	Leu	Val	Asp	Leu	Leu	Pro	Pro	His	Cys	Gln	Leu	Leu	Gly	
				110					115					120	
Asn	Arg	Asp	Trp	Phe	Val	Tyr	Cys	Ala	Ser	Leu	Val	Pro	Arg	Thr	
				125					130					135	
Gly	His	Gly	Ile	Leu	Leu	Val	His	Asn	Lys	Tyr	Gly	Gly	Asn		
				140					145						

<210> 32

<211> 100

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2683477CD1

<400> 32

Met	Pro	Phe	Ser	Asn	Pro	Met	Ala	Ser	Ser	Ser	Pro	Ser	Gly	Trp	
1				5					10					15	
Pro	Arg	Ala	Ala	Gly	Lys	Ala	Leu	Met	Val	Trp	Val	Val	Leu	Phe	
				20					25					30	
Pro	Trp	Ala	Glu	Leu	Gly	Trp	Arg	Thr	Leu	Ser	Arg	Val	Ala	Ala	
				35					40					45	

Ser	Leu	Trp	Gly	Pro	Tyr	Leu	Gly	Thr	Tyr	Thr	Asp	Gln	Ala	Val
				50					55					60
Cys	Leu	Cys	Ser	Leu	Ser	Asn	His	Asn	Tyr	Ser	Gln	Lys	Ala	Cys
				65					70					75
Gly	Leu	Glu	Ser	Thr	Thr	Val	Lys	Pro	Gly	Arg	Met	Cys	Tyr	Pro
				80					85					90
Val	Pro	Glu	Arg	Leu	Leu	Val	Cys	Val	Leu					
				95					100					

<210> 33
 <211> 78
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5580991CD1

Met	Asn	Ile	Met	Pro	Tyr	Leu	Leu	Gln	Leu	Ser	Phe	Phe	Leu	Leu
1				5					10					15
Leu	Phe	Ser	Leu	Pro	Phe	Ser	Leu	Cys	Pro	Ser	Ser	Leu	Ser	Leu
				20					25					30
Leu	Phe	Phe	Leu	Leu	Ala	Val	Gly	Phe	Tyr	Phe	Phe	Phe	Glu	Thr
				35					40					45
Ser	Leu	Ala	Leu	Ser	Pro	Arg	Leu	Glu	Cys	Ser	Gly	Ala	Ile	Ser
				50					55					60
Ala	His	Cys	Lys	Leu	Cys	Leu	Pro	Gly	Ser	Cys	Tyr	Ser	Trp	Ala
				65					70					75
Ser	Ala	Cys												

<210> 34
 <211> 75
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5605931CD1

Met	Gly	Ser	Pro	Ala	Leu	Gln	Met	Cys	Val	Leu	Thr	Leu	Cys	Leu
1				5					10					15
Asp	Leu	Phe	Leu	Leu	Gly	Leu	Arg	Thr	Phe	Cys	Pro	Gln	Met	Ser
				20					25					30
Pro	Leu	Val	Thr	Val	Cys	Leu	Arg	Ala	Leu	Gly	Leu	Ala	Gly	Trp
				35					40					45
Glu	Gln	Thr	Gln	Leu	Cys	Gly	Gly	His	Gln	Val	Val	Pro	Phe	Ile
				50					55					60
Ser	Ser	Gly	Leu	Ser	Leu	Leu	Glu	Cys	Gly	Arg	Cys	Gln	Lys	Gln
				65					70					75

<210> 35
 <211> 111
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6975241CD1

```

<400> 35
Met Val Ser Ser Val Ser Ile Arg Gln Ser Gln Val Leu Val Leu
  1          5          10          15
Cys Leu Cys Leu Cys Leu Glu Gln Lys Leu Val Pro Gly Val Ile
          20          25          30
Cys Lys Gln Glu Ile Leu Arg Glu Met Gly Met Trp Glu Asp Thr
          35          40          45
Gly Val Ala Arg Ser Ser Cys Thr Glu Val Asn Lys Asn Pro Ala
          50          55          60
Gly Ser Ser Trp Met Gly Ile Gln Gln Thr Arg Ala His Asn Ser
          65          70          75
Gly Arg Ala Thr Tyr Thr Gly Ala Cys Asp Trp Leu Gln Trp Ser
          80          85          90
Pro Leu Arg Ala Arg Asp Pro Ala Ala Ile Lys Gln Glu Lys Leu
          95          100          105
Gln Val Gly Ser Arg Phe
          110

```

```

<210> 36
<211> 72
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 6988529CD1

```

```

<400> 36
Met Gln Ser Leu Leu Leu Leu Gly Ala Val Val Thr Val Ile Ala
  1          5          10          15
Glu Thr Glu Ile Ala Lys Pro Val Leu Tyr Lys Glu Cys Ala Ser
          20          25          30
Ala Ile Glu Asp Thr Ala Arg Ile Gly Cys Trp Ser Ser Ala Gly
          35          40          45
Pro Ala Val Ile Thr Arg Val Gln Gln Arg Glu Ser Pro Pro Leu
          50          55          60
Pro Ser Leu Thr Gln His Leu Thr Leu Ser His Ser
          65          70

```

```

<210> 37
<211> 90
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 6996808CD1

```

```

<400> 37
Met Phe Cys Ala Phe Leu Phe Leu Pro Phe Ser Gln Asp Val Leu
  1          5          10          15
Cys Met Cys Phe Gly Lys Val Val Leu Val Met Phe Ile Leu Leu
          20          25          30
Cys Ile Cys Ser Val Leu Glu Leu Phe Phe Ser Ser Gly Arg Cys
          35          40          45
Phe Glu Ser Thr Leu Phe Ile Val Ala His Val Ser Asn Leu Ile
          50          55          60
Ser Lys Ile Leu Gln Val Tyr Ser Leu Arg Arg Ile Leu Phe Ile
          65          70          75
Tyr Cys Thr Asp Met Leu Cys Thr Arg His Cys Ala Met Ala Asn
          80          85          90

```

<210> 38
 <211> 283
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472689CD1

<400> 38
 Met Trp Glu Gly Asn Ala Ala Glu Gly Gly Phe Val Thr Glu Gly
 1 5 10 15
 Gly Lys Ser Glu Gly Met Lys Leu Trp Pro Leu Val Ile Phe Leu
 20 25 30
 Ser Tyr Phe Pro Gly Lys Pro Gly Glu Leu Thr Leu Phe Ser Val
 35 40 45
 Leu Pro Glu Leu Ser Gln Ser Leu Gly Leu Arg Glu Gln Glu Leu
 50 55 60
 Gln Val Val Arg Ala Ser Gly Lys Glu Ser Ser Gly Leu Val Leu
 65 70 75
 Leu Ser Ser Cys Pro Gln Thr Ala Ser Arg Leu Gln Lys Tyr Phe
 80 85 90
 Thr His Ala Arg Arg Ala Gln Arg Pro Thr Ala Thr Tyr Cys Ala
 95 100 105
 Val Thr Asp Gly Ile Pro Ala Ala Ser Glu Gly Lys Ile Gln Ala
 110 115 120
 Ala Leu Lys Leu Glu His Ile Asp Gly Val Asn Leu Thr Val Pro
 125 130 135
 Val Lys Ala Pro Ser Arg Lys Asp Ile Leu Glu Gly Val Lys Lys
 140 145 150
 Thr Leu Ser His Phe Arg Val Val Ala Thr Gly Ser Gly Cys Ala
 155 160 165
 Leu Val Gln Leu Gln Pro Leu Thr Val Phe Ser Ser Gln Leu Gln
 170 175 180
 Val His Met Val Leu Gln Leu Cys Pro Val Leu Gly Asp His Met
 185 190 195
 Tyr Ser Ala Arg Val Gly Thr Val Leu Gly Gln Arg Phe Leu Leu
 200 205 210
 Pro Ala Glu Asn Asn Lys Pro Gln Arg Gln Val Leu Asp Glu Ala
 215 220 225
 Leu Leu Arg Arg Leu His Leu Thr Pro Ser Gln Ala Ala Gln Leu
 230 235 240
 Pro Leu His Leu His Leu His Arg Leu Leu Leu Pro Gly Thr Arg
 245 250 255
 Ala Arg Asp Thr Pro Val Glu Leu Leu Ala Pro Leu Pro Pro Tyr
 260 265 270
 Phe Ser Arg Thr Leu Gln Cys Leu Gly Leu Arg Leu Gln
 275 280

<210> 39
 <211> 566
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 876751CD1

<400> 39
 Met Asp Phe Leu Leu Ala Leu Val Leu Val Ser Ser Leu Tyr Leu
 1 5 10 15
 Gln Ala Ala Ala Glu Phe Asp Gly Ser Arg Trp Pro Arg Gln Ile
 20 25 30

Val	Ser	Ser	Ile	Gly	Leu	Cys	Arg	Tyr	Gly	Gly	Arg	Ile	Asp	Cys
				35					40					45
Cys	Trp	Gly	Trp	Ala	Arg	Gln	Ser	Trp	Gly	Gln	Cys	Gln	Pro	Val
				50					55					60
Cys	Gln	Pro	Arg	Cys	Lys	His	Gly	Glu	Cys	Ile	Gly	Pro	Asn	Lys
				65					70					75
Cys	Lys	Cys	His	Pro	Gly	Tyr	Ala	Gly	Lys	Thr	Cys	Asn	Gln	Asp
				80					85					90
Leu	Asn	Glu	Cys	Gly	Leu	Lys	Pro	Arg	Pro	Cys	Lys	His	Arg	Cys
				95					100					105
Met	Asn	Thr	Tyr	Gly	Ser	Tyr	Lys	Cys	Tyr	Cys	Leu	Asn	Gly	Tyr
				110					115					120
Met	Leu	Met	Pro	Asp	Gly	Ser	Cys	Ser	Ser	Ala	Leu	Thr	Cys	Ser
				125					130					135
Met	Ala	Asn	Cys	Gln	Tyr	Gly	Cys	Asp	Val	Val	Lys	Gly	Gln	Ile
				140					145					150
Arg	Cys	Gln	Cys	Pro	Ser	Pro	Gly	Leu	Gln	Leu	Ala	Pro	Asp	Gly
				155					160					165
Arg	Thr	Cys	Val	Asp	Val	Asp	Glu	Cys	Ala	Thr	Gly	Arg	Ala	Ser
				170					175					180
Cys	Pro	Arg	Phe	Arg	Gln	Cys	Val	Asn	Thr	Phe	Gly	Ser	Tyr	Ile
				185					190					195
Cys	Lys	Cys	His	Lys	Gly	Phe	Asp	Leu	Met	Tyr	Ile	Gly	Gly	Lys
				200					205					210
Tyr	Gln	Cys	His	Asp	Ile	Asp	Glu	Cys	Ser	Leu	Gly	Gln	Tyr	Gln
				215					220					225
Cys	Ser	Ser	Phe	Ala	Arg	Cys	Tyr	Asn	Val	Arg	Gly	Ser	Tyr	Lys
				230					235					240
Cys	Lys	Cys	Lys	Glu	Gly	Tyr	Gln	Gly	Asp	Gly	Leu	Thr	Cys	Val
				245					250					255
Tyr	Ile	Pro	Lys	Val	Met	Ile	Glu	Pro	Ser	Gly	Pro	Ile	His	Val
				260					265					270
Pro	Lys	Gly	Asn	Gly	Thr	Ile	Leu	Lys	Gly	Asp	Thr	Gly	Asn	Asn
				275					280					285
Asn	Trp	Ile	Pro	Asp	Val	Gly	Ser	Thr	Trp	Trp	Pro	Pro	Lys	Thr
				290					295					300
Pro	Tyr	Ile	Pro	Pro	Ile	Ile	Thr	Asn	Arg	Pro	Thr	Ser	Lys	Pro
				305					310					315
Thr	Thr	Arg	Pro	Thr	Pro	Lys	Pro	Thr	Pro	Ile	Pro	Thr	Pro	Pro
				320					325					330
Pro	Pro	Pro	Pro	Leu	Pro	Thr	Glu	Leu	Arg	Thr	Pro	Leu	Pro	Pro
				335					340					345
Thr	Thr	Pro	Glu	Arg	Pro	Thr	Thr	Gly	Leu	Thr	Thr	Ile	Ala	Pro
				350					355					360
Ala	Ala	Ser	Thr	Pro	Pro	Gly	Gly	Ile	Thr	Val	Asp	Asn	Arg	Val
				365					370					375
Gln	Thr	Asp	Pro	Gln	Lys	Pro	Arg	Gly	Asp	Val	Phe	Ile	Pro	Arg
				380					385					390
Gln	Pro	Ser	Asn	Asp	Leu	Phe	Glu	Ile	Phe	Glu	Ile	Glu	Arg	Gly
				395					400					405
Val	Ser	Ala	Asp	Asp	Glu	Ala	Lys	Asp	Asp	Pro	Gly	Val	Leu	Val
				410					415					420
His	Ser	Cys	Asn	Phe	Asp	His	Gly	Leu	Cys	Gly	Trp	Ile	Arg	Glu
				425					430					435
Lys	Asp	Asn	Asp	Leu	His	Trp	Glu	Pro	Ile	Arg	Asp	Pro	Ala	Gly
				440					445					450
Gly	Gln	Tyr	Leu	Thr	Val	Ser	Ala	Ala	Lys	Ala	Pro	Gly	Gly	Lys
				455					460					465
Ala	Ala	Arg	Leu	Val	Leu	Pro	Leu	Gly	Arg	Leu	Met	His	Ser	Gly
				470					475					480
Asp	Leu	Cys	Leu	Ser	Phe	Arg	His	Lys	Val	Thr	Gly	Leu	His	Ser
				485					490					495
Gly	Thr	Leu	Gln	Val	Phe	Val	Arg	Lys	His	Gly	Ala	His	Gly	Ala

Ala Leu Trp Gly	500	Arg Asn Gly Gly His	505	Gly Trp Arg Gln Thr	510
	515		520		525
Ile Thr Leu Arg	530	Gly Ala Asp Ile Lys	535	Ser Val Val Phe Lys	540
	545		550		555
Glu Lys Arg Arg	560	Gly His Thr Gly Glu	565	Ile Gly Leu Asp Asp	
Ser Leu Lys Lys		Gly His Cys Ser Glu		Glu Arg	

<210> 40

<211> 1093

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2512510CD1

<400> 40

Met Ala Arg Pro Val	Arg Gly Gly Leu	Gly Ala Pro Arg Arg	Ser
1	5	10	15
Pro Cys Leu Leu Leu	Leu Trp Leu Leu	Leu Leu Arg Leu Glu	Pro
	20	25	30
Val Thr Ala Ala Ala	Gly Pro Arg Ala	Pro Cys Ala Ala Ala	Cys
	35	40	45
Thr Cys Ala Gly Asp	Ser Leu Asp Cys	Gly Gly Arg Gly Leu	Ala
	50	55	60
Ala Leu Pro Gly Asp	Leu Pro Ser Trp	Thr Arg Ser Leu Asn	Leu
	65	70	75
Ser Tyr Asn Lys Leu	Ser Glu Ile Asp	Pro Ala Gly Phe Glu	Asp
	80	85	90
Leu Pro Asn Leu Gln	Glu Val Tyr Leu	Asn Asn Asn Glu Leu	Thr
	95	100	105
Ala Val Pro Ser Leu	Gly Ala Ala Ser	Ser Ser His Val Val	Ser
	110	115	120
Phe Leu Gln His Asn	Lys Ile Arg Ser	Val Glu Gly Ser Gln	Leu
	125	130	135
Lys Ala Tyr Leu Ser	Leu Glu Val Leu	Asp Leu Ser Leu Asn	Asn
	140	145	150
Ile Thr Glu Val Arg	Asn Thr Cys Phe	Pro His Gly Pro Pro	Ile
	155	160	165
Lys Glu Leu Asn Leu	Ala Gly Asn Arg	Ile Gly Thr Leu Glu	Leu
	170	175	180
Gly Ala Phe Asp Gly	Leu Ser Arg Ser	Leu Leu Thr Leu Arg	Leu
	185	190	195
Ser Lys Asn Arg Ile	Thr Gln Leu Pro	Val Arg Ala Phe Lys	Leu
	200	205	210
Pro Arg Leu Thr Gln	Leu Asp Leu Asn	Arg Asn Arg Ile Arg	Leu
	215	220	225
Ile Glu Gly Leu Thr	Phe Gln Gly Leu	Asn Ser Leu Glu Val	Leu
	230	235	240
Lys Leu Gln Arg Asn	Asn Ile Ser Lys	Leu Thr Asp Gly Ala	Phe
	245	250	255
Trp Gly Leu Ser Lys	Met His Val Leu	His Leu Glu Tyr Asn	Ser
	260	265	270
Leu Val Glu Val Asn	Ser Gly Ser Leu	Tyr Gly Leu Thr Ala	Leu
	275	280	285
His Gln Leu His Leu	Ser Asn Asn Ser	Ile Ala Arg Ile His	Arg
	290	295	300
Lys Gly Trp Ser Phe	Cys Gln Lys Leu	His Glu Leu Val Leu	Ser
	305	310	315
Phe Asn Asn Leu Thr	Arg Leu Asp Glu	Glu Ser Leu Ala Glu	Leu

Ser Ser Leu Ser	320	325	330
Val Leu Arg Leu Ser	335	340	345
Ile Ala Glu Gly	350	355	360
Asp Leu Asp His	365	370	375
Gly Ala Phe Ser	380	385	390
Gly Asn Lys Ile	395	400	405
Glu Gly Leu Glu	410	415	420
Val Gln Phe Asp	425	430	435
His Ile Ser Ser	440	445	450
Leu Pro Pro Trp	455	460	465
Ala Thr Cys Ala	470	475	480
Ser Val Pro Pro	485	490	495
Gln Ile Ile Thr	500	505	510
Asp Ile Arg Phe	515	520	525
Met Thr Phe Ala	530	535	540
Asp Met Glu Asn	545	550	555
Met Glu Tyr Thr	560	565	570
His Glu Gly Arg	575	580	585
Thr Tyr Ser His	590	595	600
Phe Thr Lys Thr	605	610	615
Ala Arg Leu Glu	620	625	630
Ala Trp Gln Lys	635	640	645
Arg Arg Met His	650	655	660
Asp Val Lys Ile	665	670	675
Asn Ser Ala Gly	680	685	690
Glu Thr Pro Ser	695	700	705
Val Gly Glu Thr	710	715	720
Pro Pro Arg Ile	725	730	735
Thr Glu Arg His	740	745	750
Gln Asn Val Val	755	760	765
Ser Asn Thr Leu	770	775	780
Leu Pro Ala Ala	785	790	795

Phe Thr Ile Ala Val Val Ser Ser Ile Val Leu Thr Ser Leu Val	800	805	810
Trp Val Cys Ile Ile Tyr Gln Thr Arg Lys Lys Ser Glu Glu Tyr	815	820	825
Ser Val Thr Asn Thr Asp Glu Thr Val Val Pro Pro Asp Val Pro	830	835	840
Ser Tyr Leu Ser Ser Gln Gly Thr Leu Ser Asp Arg Gln Glu Thr	845	850	855
Val Val Arg Thr Glu Gly Gly Pro Gln Ala Asn Gly His Ile Glu	860	865	870
Ser Asn Gly Val Cys Pro Arg Asp Ala Ser His Phe Pro Glu Pro	875	880	885
Asp Thr His Ser Val Ala Cys Arg Gln Pro Lys Leu Cys Ala Gly	890	895	900
Ser Ala Tyr His Lys Glu Pro Trp Lys Ala Met Glu Lys Ala Glu	905	910	915
Gly Thr Pro Gly Pro His Lys Met Glu His Gly Gly Arg Val Val	920	925	930
Cys Ser Asp Cys Asn Thr Glu Val Asp Cys Tyr Ser Arg Gly Gln	935	940	945
Ala Phe His Pro Gln Pro Val Ser Arg Asp Ser Ala Gln Pro Ser	950	955	960
Ala Pro Asn Gly Pro Glu Pro Gly Gly Ser Asp Gln Glu His Ser	965	970	975
Pro His His Gln Cys Ser Arg Thr Ala Ala Gly Ser Cys Pro Glu	980	985	990
Cys Gln Gly Ser Leu Tyr Pro Ser Asn His Asp Arg Met Leu Thr	995	1000	1005
Ala Val Lys Lys Lys Pro Met Ala Ser Leu Asp Gly Lys Gly Asp	1010	1015	1020
Ser Ser Trp Thr Leu Ala Arg Leu Tyr His Pro Asp Ser Thr Glu	1025	1030	1035
Leu Gln Pro Ala Ser Ser Leu Thr Ser Gly Ser Pro Glu Arg Ala	1040	1045	1050
Glu Ala Gln Tyr Leu Leu Val Ser Asn Gly His Leu Pro Lys Ala	1055	1060	1065
Cys Asp Ala Ser Pro Glu Ser Thr Pro Leu Thr Gly Gln Leu Pro	1070	1075	1080
Gly Lys Gln Arg Val Pro Leu Leu Leu Ala Pro Lys Ser	1085	1090	

<210> 41
 <211> 915
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7486326CD1

<400> 41
Met Pro Ser Leu Pro Ala Pro Pro Ala Pro Leu Leu Leu Leu Gly
1 5 10 15
Leu Leu Leu Leu Gly Ser Arg Pro Ala Arg Gly Ala Gly Pro Glu
20 25 30
Pro Pro Val Leu Pro Ile Arg Ser Glu Lys Glu Pro Leu Pro Val
35 40 45
Arg Gly Ala Ala Gly Cys Thr Phe Gly Gly Lys Val Tyr Ala Leu
50 55 60
Asp Glu Thr Trp His Pro Asp Leu Gly Glu Pro Phe Gly Val Met
65 70 75
Arg Cys Val Leu Cys Ala Cys Glu Ala Pro Gln Trp Gly Arg Arg
80 85 90

Thr	Arg	Gly	Pro	Gly	Arg	Val	Ser	Cys	Lys	Asn	Ile	Lys	Pro	Glu
				95					100					105
Cys	Pro	Thr	Pro	Ala	Cys	Gly	Gln	Pro	Arg	Gln	Leu	Pro	Gly	His
				110					115					120
Cys	Cys	Gln	Thr	Cys	Pro	Gln	Glu	Arg	Ser	Ser	Ser	Glu	Arg	Gln
				125					130					135
Pro	Ser	Gly	Leu	Ser	Phe	Glu	Tyr	Pro	Arg	Asp	Pro	Glu	His	Arg
				140					145					150
Ser	Tyr	Ser	Asp	Arg	Gly	Glu	Pro	Gly	Ala	Glu	Glu	Arg	Ala	Arg
				155					160					165
Gly	Asp	Gly	His	Thr	Asp	Phe	Val	Ala	Leu	Leu	Thr	Gly	Pro	Arg
				170					175					180
Ser	Gln	Ala	Val	Ala	Arg	Ala	Arg	Val	Ser	Leu	Leu	Arg	Ser	Ser
				185					190					195
Leu	Arg	Phe	Ser	Ile	Ser	Tyr	Arg	Arg	Leu	Asp	Arg	Pro	Thr	Arg
				200					205					210
Ile	Arg	Phe	Ser	Asp	Ser	Asn	Gly	Ser	Val	Leu	Phe	Glu	His	Pro
				215					220					225
Ala	Ala	Pro	Thr	Gln	Asp	Gly	Leu	Val	Cys	Gly	Val	Trp	Arg	Ala
				230					235					240
Val	Pro	Arg	Leu	Ser	Leu	Arg	Leu	Leu	Arg	Ala	Glu	Gln	Leu	His
				245					250					255
Val	Ala	Leu	Val	Thr	Leu	Thr	His	Pro	Ser	Gly	Glu	Val	Trp	Gly
				260					265					270
Pro	Leu	Ile	Arg	His	Arg	Ala	Leu	Ala	Ala	Glu	Thr	Phe	Ser	Ala
				275					280					285
Ile	Leu	Thr	Leu	Glu	Gly	Pro	Pro	Gln	Gln	Gly	Val	Gly	Gly	Ile
				290					295					300
Thr	Leu	Leu	Thr	Leu	Ser	Asp	Thr	Glu	Asp	Ser	Leu	His	Phe	Leu
				305					310					315
Leu	Leu	Phe	Arg	Gly	Leu	Leu	Glu	Pro	Arg	Ser	Gly	Gly	Leu	Thr
				320					325					330
Gln	Val	Pro	Leu	Arg	Leu	Gln	Ile	Leu	His	Gln	Gly	Gln	Leu	Leu
				335					340					345
Arg	Glu	Leu	Gln	Ala	Asn	Val	Ser	Ala	Gln	Glu	Pro	Gly	Phe	Ala
				350					355					360
Glu	Val	Leu	Pro	Asn	Leu	Thr	Val	Gln	Glu	Met	Asp	Trp	Leu	Val
				365					370					375
Leu	Gly	Glu	Leu	Gln	Met	Ala	Leu	Glu	Trp	Ala	Gly	Arg	Pro	Gly
				380					385					390
Leu	Arg	Ile	Ser	Gly	His	Ile	Ala	Ala	Arg	Lys	Ser	Cys	Asp	Val
				395					400					405
Leu	Gln	Ser	Val	Leu	Cys	Gly	Ala	Asp	Ala	Leu	Ile	Pro	Val	Gln
				410					415					420
Thr	Gly	Ala	Ala	Gly	Ser	Ala	Ser	Leu	Thr	Leu	Leu	Gly	Asn	Gly
				425					430					435
Ser	Leu	Ile	Tyr	Gln	Ala	Val	Gly	Ile	Cys	Pro	Gly	Leu	Gly	Ala
				440					445					450
Arg	Gly	Ala	His	Met	Leu	Leu	Gln	Asn	Glu	Leu	Phe	Leu	Asn	Val
				455					460					465
Gly	Thr	Lys	Asp	Phe	Pro	Asp	Gly	Glu	Leu	Arg	Gly	His	Val	Ala
				470					475					480
Ala	Leu	Pro	Tyr	Cys	Gly	His	Ser	Ala	Arg	His	Asp	Thr	Leu	Pro
				485					490					495
Val	Pro	Leu	Ala	Gly	Ala	Leu	Val	Leu	Pro	Pro	Val	Lys	Ser	Gln
				500					505					510
Ala	Ala	Gly	His	Ala	Trp	Leu	Ser	Leu	Asp	Thr	His	Cys	His	Leu
				515					520					525
His	Tyr	Glu	Val	Leu	Leu	Ala	Gly	Leu	Gly	Gly	Ser	Glu	Gln	Gly
				530					535					540
Thr	Val	Thr	Ala	His	Leu	Leu	Gly	Pro	Pro	Gly	Thr	Pro	Gly	Pro
				545					550					555
Arg	Arg	Leu	Leu	Lys	Gly	Phe	Tyr	Gly	Ser	Glu	Ala	Gln	Gly	Val

Val Lys Asp Leu	560	Pro Glu Leu Leu	565	Arg His Leu Ala Lys	570
	575		580		585
Met Ala Ser Leu	590	Leu Ile Thr Thr Lys	595	Gly Ser Pro Arg Gly	600
Leu Arg Gly Gln	605	Val His Ile Ala Asn	610	Gln Cys Glu Val Gly	615
Leu Arg Leu Glu	620	Ala Ala Gly Ala Glu	625	Gly Val Arg Ala Leu	630
Ala Pro Asp Pro	635	Ala Ser Ala Ala Pro	640	Pro Val Val Pro Gly	645
Pro Ala Leu Ala	650	Pro Ala Lys Pro Gly	655	Gly Pro Gly Arg Pro	660
Asp Pro Asn Thr	665	Cys Phe Phe Glu Gly	670	Gln Gln Arg Pro His	675
Ala Arg Trp Ala	680	Pro Asn Tyr Asp Pro	685	Leu Cys Ser Leu Cys	690
Cys Gln Arg Arg	695	Thr Val Ile Cys Asp	700	Pro Val Val Cys Pro	705
Pro Ser Cys Pro	710	His Pro Val Gln Ala	715	Pro Asp Gln Cys Cys	720
Val Cys Pro Glu	725	Lys Gln Asp Val Arg	730	Asp Leu Pro Gly Leu	735
Arg Ser Arg Asp	740	Pro Gly Glu Gly Cys	745	Tyr Phe Asp Gly Asp	750
Ser Trp Arg Ala	755	Ala Gly Thr Arg Trp	760	His Pro Val Val Pro	765
Phe Gly Leu Ile	770	Lys Cys Ala Val Cys	775	Thr Cys Lys Gly Gly	780
Gly Glu Val His	785	Cys Glu Lys Val Gln	790	Cys Pro Arg Leu Ala	795
Ala Gln Pro Val	800	Arg Val Asn Pro Thr	805	Asp Cys Cys Lys Gln	810
Pro Val Gly Ser	815	Gly Ala His Pro Gln	820	Leu Gly Asp Pro Met	825
Ala Asp Gly Pro	830	Arg Gly Cys Arg Phe	835	Ala Gly Gln Trp Phe	840
Glu Ser Gln Ser	845	Trp His Pro Ser Val	850	Pro Pro Phe Gly Glu	855
Ser Cys Ile Thr	860	Cys Arg Cys Gly Ala	865	Gly Val Pro His Cys	870
Arg Asp Asp Cys	875	Ser Leu Pro Leu Ser	880	Cys Gly Ser Gly Lys	885
Ser Arg Cys Cys	890	Ser Arg Cys Thr Ala	895	His Arg Arg Pro Ala	900
Glu Thr Arg Thr	905	Asp Pro Glu Leu Glu	910	Lys Glu Ala Glu Gly	915

<210> 42

<211> 113

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1221545CD1

<400> 42

Met Ala Trp Thr	Leu Ala Cys Val Cys Val	Leu Gly Ser Ile Leu
1	5	10
Val Leu Asp Ser	Gly Met Cys Val Arg Ala	Gly Glu Cys Leu Asp
	20	25
		30

Gly Asp Val Val Ser Leu Leu His Phe Trp His Ser Val Thr Thr
 35 40 45
 Gln Glu Asn Gln Ile Glu Asn Leu Glu Ser Val Leu Gln Trp Ile
 50 55 60
 Glu Thr Gly Leu Gln Ser Leu Arg Lys Lys Ser Lys Gln Asn Thr
 65 70 75
 Gln Glu Phe Arg Glu Asn Ile Phe Leu Pro Lys Asn Asn Phe Ser
 80 85 90
 Phe Met Leu Phe Leu Ile Trp Val Asn Thr Pro Met Glu Lys Ile
 95 100 105
 Asp Arg Leu Val Lys Ser Ser Ile
 110

<210> 43
 <211> 91
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 124737CD1

<400> 43
 Met Gly Lys Gly Arg Trp Ala Thr Val Gly Val Ser Pro Cys Leu
 1 5 10 15
 Pro Pro Leu Trp Ala Ala Ala Gly Ala His Ala Ser Lys Ser Ser
 20 25 30
 Leu Arg Glu Arg Glu Leu Arg Cys Leu Tyr Pro Ser Ser Val Arg
 35 40 45
 His Trp Leu Asn Val His Thr Pro Gly Ser Pro Pro Leu Ile Leu
 50 55 60
 Met Met Ser His Gly Pro His Phe Thr Ser Glu Leu Trp Val His
 65 70 75
 Gly Glu His Gln Ser His Pro Gly Ser Val Pro Gln Leu Ser Leu
 80 85 90
 Thr

<210> 44
 <211> 83
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1510784CD1

<400> 44
 Met Arg Met Phe Pro Leu Pro Leu Pro Val Cys Leu Pro Leu Gly
 1 5 10 15
 Val His Leu Gln Ser Thr Ser Pro Pro Phe Pro Ala Ser His Thr
 20 25 30
 Gln Val Ser Leu Ser Asp Ser His Thr Cys Leu Thr Ala Ser Pro
 35 40 45
 Ala Lys Val Leu Phe Lys Cys Leu Phe Ser Val Cys Leu Cys His
 50 55 60
 Ser Gln Cys Asp His Ser Cys Ser Ala Val Ser Gln Gln Glu Asp
 65 70 75
 Arg Cys Arg Ser Ser Ser Cys Ser
 80

<210> 45
 <211> 128

<212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1901257CD1

<400> 45
 Met Pro Tyr Ala Leu His Met Ser Phe Gln Arg Leu Trp Val Trp
 1 5 10 15
 Ile Leu Leu Pro Thr Val Ala Asn Ile Ala Leu Ser Ser Ser Arg
 20 25 30
 Thr Gly Arg Ser Lys Glu His Thr Gln Asp Asp Ala Thr Ala Tyr
 35 40 45
 Met Leu Ser Arg His Leu His Ala Leu Ser Ala Pro Thr Cys Ser
 50 55 60
 Leu Gly Ser Leu His Ala Leu Ser Ala Ala Tyr Thr Leu Ser Trp
 65 70 75
 His Val Gln Gln Val Leu Gln Pro Cys Pro Gly Gly Leu Gly Leu
 80 85 90
 Arg Gly Leu Ser Leu Ser Trp Val Leu Asp Leu Pro Pro His Phe
 95 100 105
 His His Cys Asn Phe Cys Phe Thr Cys Trp Lys Gly Ala Ser Tyr
 110 115 120
 Asn Met Pro Leu Lys Glu Lys Asp
 125

<210> 46
 <211> 84
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2044370CD1

<400> 46
 Met Ala Leu Leu Trp Trp Ile Ser Thr Val Ala Ile Leu Leu Phe
 1 5 10 15
 Thr Ser Thr Ile Leu Gly Thr Tyr Val Glu Ala Gly Ala Ala Lys
 20 25 30
 Ser Asn Glu Glu Glu Ile Val Asn Lys Ser Glu Phe Gly Arg Phe
 35 40 45
 Pro Arg Gly Ser Arg Lys Asp Ala Ser Gly Cys His Lys Pro Gly
 50 55 60
 Tyr Pro Val Pro Pro His Ser Arg Cys Pro Pro Pro Pro His Val
 65 70 75
 Gln Arg Pro Arg Pro Ile Leu His Ala
 80

<210> 47
 <211> 109
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2820933CD1

<400> 47
 Met Gly Trp Pro Pro Pro Pro Gly Ser Ser Phe Cys Leu Cys Phe
 1 5 10 15
 Ile His Gly Ala Phe Ser Ser Phe Ser Pro His Pro Pro Ser His

	20		25		30
Glu Cys Ser Ser	Arg Cys Cys Ser Leu Cys	Leu Ala Arg Phe Leu			
	35		40		45
Ala Ser Pro Leu Pro	Trp Ser Asn Ser Glu Ser Ser Ser Thr Leu				
	50		55		60
Tyr Leu Lys Ser Arg	Leu Ala Gly Ser Leu Ser Gly Ser Ala His				
	65		70		75
Cys Ser Pro Thr Ser	Leu Pro Phe Ser Leu Gly Thr Leu Ile Thr				
	80		85		90
Pro Glu Thr Val Asp	Ser Ser Pro Lys Tyr Ser Phe Trp Leu Ile				
	95		100		105
Val Gly Ala Gln					

<210> 48
 <211> 159
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2902793CD1

<400> 48	
Met Trp Ser Val Ser	Ser Trp Ala Leu Cys Leu Leu Cys Ala Ile
1	5 10 15
His Val Leu Ser Leu	Ser Cys Ala Gln Cys Asn Cys Val His Val
	20 25 30
Phe Leu Ile Pro Pro	Pro Ala Leu Pro Ala Arg Phe Thr Glu Gly
	35 40 45
Leu Arg Asn Glu Glu	Ala Met Glu Gly Ala Thr Ala Thr Leu Gln
	50 55 60
Cys Glu Leu Ser Lys	Ala Ala Pro Val Glu Trp Arg Lys Gly Leu
	65 70 75
Glu Ala Leu Arg Asp	Gly Asp Lys Tyr Ser Leu Arg Gln Asp Gly
	80 85 90
Ala Val Cys Glu Leu	Gln Ile His Gly Leu Ala Met Ala Asp Asn
	95 100 105
Gly Val Tyr Ser Cys	Val Cys Gly Gln Arg Thr Ser Ala Thr
	110 115 120
Leu Thr Val Arg Gly	Lys Asp Pro Met Trp Pro Cys Gly Leu Val
	125 130 135
Ala Trp Cys Ile His	Leu Ser Val Ser Pro Pro Ser Ala Ser Lys
	140 145 150
Cys Gly Thr Ser Pro	Val Glu Thr Leu
	155

<210> 49
 <211> 242
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7486536CD1

<400> 49	
Met Pro Arg Gly Phe	Thr Trp Leu Arg Tyr Leu Gly Ile Phe Leu
1	5 10 15
Gly Val Ala Leu Gly	Asn Glu Pro Leu Glu Met Trp Pro Leu Thr
	20 25 30
Gln Asn Glu Glu Cys	Thr Val Thr Gly Phe Leu Arg Asp Lys Leu
	35 40 45

Gln	Tyr	Arg	Ser	Arg	Leu	Gln	Tyr	Met	Lys	His	Tyr	Phe	Pro	Ile	
				50					55					60	
Asn	Tyr	Lys	Ile	Ser	Val	Pro	Tyr	Glu	Gly	Val	Phe	Arg	Ile	Ala	
				65					70					75	
Asn	Val	Thr	Arg	Leu	Gln	Arg	Ala	Gln	Val	Ser	Glu	Arg	Glu	Leu	
				80					85					90	
Arg	Tyr	Leu	Trp	Val	Leu	Val	Ser	Leu	Ser	Ala	Thr	Glu	Ser	Val	
				95					100					105	
Gln	Asp	Val	Leu	Leu	Glu	Gly	His	Pro	Ser	Trp	Lys	Tyr	Leu	Gln	
				110					115					120	
Glu	Val	Glu	Thr	Leu	Leu	Leu	Asn	Val	Gln	Gln	Gly	Leu	Thr	Asp	
				125					130					135	
Val	Glu	Val	Ser	Pro	Lys	Val	Glu	Ser	Val	Leu	Ser	Leu	Leu	Asn	
				140					145					150	
Ala	Pro	Gly	Pro	Asn	Leu	Lys	Leu	Val	Arg	Pro	Lys	Ala	Leu	Leu	
				155					160					165	
Asp	Asn	Cys	Phe	Arg	Val	Met	Glu	Leu	Leu	Tyr	Cys	Ser	Cys	Cys	
				170					175					180	
Lys	Gln	Ser	Ser	Val	Leu	Asn	Trp	Gln	Asp	Cys	Glu	Val	Pro	Ser	
				185					190					195	
Pro	Gln	Ser	Cys	Ser	Pro	Glu	Pro	Ser	Leu	Gln	Tyr	Ala	Ala	Thr	
				200					205					210	
Gln	Leu	Tyr	Pro	Pro	Pro	Pro	Trp	Ser	Pro	Ser	Ser	Pro	Pro	His	
				215					220					225	
Ser	Thr	Gly	Ser	Val	Arg	Pro	Val	Arg	Ala	Gln	Gly	Glu	Gly	Leu	
				230					235					240	
Leu	Pro														

<210> 50

<211> 542

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 8137305CD1

<400> 50

Met	Pro	Arg	Arg	Gly	Leu	Ile	Leu	His	Thr	Arg	Thr	His	Trp	Leu	
1				5					10					15	
Leu	Leu	Gly	Leu	Ala	Leu	Leu	Cys	Ser	Leu	Val	Leu	Phe	Met	Tyr	
				20					25					30	
Leu	Leu	Glu	Cys	Ala	Pro	Gln	Thr	Asp	Gly	Asn	Ala	Ser	Leu	Pro	
				35					40					45	
Gly	Val	Val	Gly	Glu	Asn	Tyr	Gly	Lys	Glu	Tyr	Tyr	Gln	Ala	Leu	
				50					55					60	
Leu	Gln	Glu	Gln	Glu	Glu	His	Tyr	Gln	Thr	Arg	Ala	Thr	Ser	Leu	
				65					70					75	
Lys	Arg	Gln	Ile	Ala	Gln	Leu	Lys	Gln	Glu	Leu	Gln	Glu	Met	Ser	
				80					85					90	
Glu	Lys	Met	Arg	Ser	Leu	Gln	Glu	Arg	Arg	Asn	Val	Gly	Ala	Asn	
				95					100					105	
Gly	Ile	Gly	Tyr	Gln	Ser	Asn	Lys	Glu	Gln	Ala	Pro	Ser	Asp	Leu	
				110					115					120	
Leu	Glu	Phe	Leu	His	Ser	Gln	Ile	Asp	Lys	Ala	Glu	Val	Ser	Ile	
				125					130					135	
Gly	Ala	Lys	Leu	Pro	Ser	Glu	Tyr	Gly	Val	Ile	Pro	Phe	Glu	Ser	
				140					145					150	
Phe	Thr	Leu	Met	Lys	Val	Phe	Gln	Leu	Glu	Met	Gly	Leu	Thr	Arg	
				155					160					165	
His	Pro	Glu	Glu	Lys	Pro	Val	Arg	Lys	Asp	Lys	Arg	Asp	Glu	Leu	
				170					175					180	


```
<210> 51
<211> 105
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<223> Incyte ID No: 3793128CD1
```

```
<400> 51
Met Ser His Leu Leu Ala Pro Asn Leu Phe Phe Val Leu Leu Asn
  1           5           10           15
```

Leu	Val	Thr	Ser	Leu	Leu	Arg	Leu	Ile	Gly	Val	Gln	His	Lys	Ser
				20					25					30
Phe	Arg	Ser	Tyr	Leu	Ala	Thr	Pro	Arg	Pro	Phe	Ala	Phe	Leu	Lys
				35					40					45
Glu	Glu	Ile	Ile	Gly	Thr	Leu	Leu	Leu	Asn	Gly	Thr	Tyr	Thr	Ala
				50					55					60
Val	Val	Cys	Tyr	Phe	Tyr	Lys	Gly	Ser	Gln	Ala	Phe	Thr	Cys	Phe
				65					70					75
Pro	His	Phe	Asn	Leu	Pro	Cys	Ala	Cys	Arg	Val	Ile	Val	Arg	Asp
				80					85					90
Phe	Arg	Asn	Pro	Arg	Ser	Trp	Val	Pro	Phe	Trp	Thr	Leu	Cys	His
				95					100					105

<210> 52

<211> 102

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4001243CD1

<400> 52

Met	Arg	Leu	Arg	His	Arg	Gln	Arg	Ala	Leu	Pro	Thr	Thr	Leu	Ala
1				5					10					15
Thr	Ala	Ser	Lys	Pro	Leu	Phe	Met	Pro	Gly	Thr	Ala	Pro	Lys	Asp
				20					25					30
Leu	Ala	His	Ala	Trp	Asp	Arg	Pro	Gln	Gly	Pro	His	Trp	Leu	Gln
				35					40					45
Ser	Ala	Ala	Gly	Arg	Val	Val	Gly	Glu	Gly	Met	Asp	Thr	Pro	Trp
				50					55					60
Ala	Gly	Ala	Gly	Arg	Thr	Arg	Pro	Ile	Ile	Gly	His	Leu	Val	Ala
				65					70					75
Met	Ala	Thr	Thr	Gln	Gly	Cys	Leu	Arg	Leu	Lys	Ile	Cys	Gly	Leu
				80					85					90
Gln	Gly	Ala	Pro	Ala	Leu	Ala	Leu	Ala	Glu	Ser	Gln			
				95					100					

<210> 53

<211> 129

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6986717CD1

<400> 53

Met	Val	Ile	Pro	Gly	Leu	Thr	Thr	Leu	Leu	Ile	Lys	Thr	Thr	Phe
1				5					10					15
Trp	Gly	Phe	Arg	Phe	Gly	Glu	Leu	Gly	Met	Gly	Arg	Gly	Ser	Thr
				20					25					30
Ser	Ser	Arg	Cys	Leu	Val	Ser	Pro	Ser	Phe	Ser	Leu	Leu	His	Val
				35					40					45
Gly	Gly	Arg	Leu	Asp	Gln	Leu	Ala	Cys	Thr	Leu	Pro	Lys	Glu	Leu
				50					55					60
Arg	Gly	Lys	Asp	Met	Arg	Met	Val	Pro	Met	Glu	Met	Phe	Asn	Tyr
				65					70					75
Cys	Ser	Gln	Leu	Glu	Asp	Glu	Asn	Ser	Ser	Ala	Gly	Leu	Asp	Ile
				80					85					90
Leu	Gly	His	Pro	Ala	Pro	Arg	Pro	Val	Gln	Ser	Leu	Leu	Ser	Pro
				95					100					105

Ser Pro Gly Leu Ser Arg Ser Arg Ser Pro Ala Gln Pro Ala His
 110 115 120
 Arg Ser Arg Gly Thr Gly Arg Arg Ala
 125

<210> 54
 <211> 1070
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7503512CD1

<400> 54
 Met Ala Arg Pro Val Arg Gly Gly Leu Gly Ala Pro Arg Arg Ser
 1 5 10 15
 Pro Cys Leu Leu Leu Leu Trp Leu Leu Leu Leu Arg Leu Glu Pro
 20 25 30
 Val Thr Ala Ala Ala Gly Pro Arg Ala Pro Cys Ala Ala Ala Cys
 35 40 45
 Thr Cys Ala Gly Asp Ser Leu Asp Cys Gly Gly Arg Gly Leu Ala
 50 55 60
 Ala Leu Pro Gly Asp Leu Pro Ser Trp Thr Arg Ser Leu Asn Leu
 65 70 75
 Ser Tyr Asn Lys Leu Ser Glu Ile Asp Pro Ala Gly Phe Glu Asp
 80 85 90
 Leu Pro Asn Leu Gln Glu Val Tyr Leu Asn Asn Asn Glu Leu Thr
 95 100 105
 Ala Val Pro Ser Leu Gly Ala Ala Ser Ser His Val Val Ser Leu
 110 115 120
 Phe Leu Gln His Asn Lys Ile Arg Ser Val Glu Gly Ser Gln Leu
 125 130 135
 Lys Ala Tyr Leu Ser Leu Glu Val Leu Asp Leu Ser Leu Asn Asn
 140 145 150
 Ile Thr Glu Val Arg Asn Thr Cys Phe Pro His Gly Pro Pro Ile
 155 160 165
 Lys Glu Leu Asn Leu Ala Gly Asn Arg Ile Gly Thr Leu Glu Leu
 170 175 180
 Gly Ala Phe Asp Gly Leu Ser Arg Ser Leu Leu Thr Leu Arg Leu
 185 190 195
 Ser Lys Asn Arg Ile Arg Leu Ile Glu Gly Leu Thr Phe Gln Gly
 200 205 210
 Leu Asn Ser Leu Glu Val Leu Lys Leu Gln Arg Asn Asn Ile Ser
 215 220 225
 Lys Leu Thr Asp Gly Ala Phe Trp Gly Leu Ser Lys Met His Val
 230 235 240
 Leu His Leu Glu Tyr Asn Ser Leu Val Glu Val Asn Ser Gly Ser
 245 250 255
 Leu Tyr Gly Leu Thr Ala Leu His Gln Leu His Leu Ser Asn Asn
 260 265 270
 Ser Ile Ala Arg Ile His Arg Lys Gly Trp Ser Phe Cys Gln Lys
 275 280 285
 Leu His Glu Leu Val Leu Ser Phe Asn Asn Leu Thr Arg Leu Asp
 290 295 300
 Glu Glu Ser Leu Ala Glu Leu Ser Ser Leu Ser Val Leu Arg Leu
 305 310 315
 Ser His Asn Ser Ile Ser His Ile Ala Glu Gly Ala Phe Lys Gly
 320 325 330
 Leu Arg Ser Leu Arg Val Leu Asp Leu Asp His Asn Glu Ile Ser
 335 340 345
 Gly Thr Ile Glu Asp Thr Ser Gly Ala Phe Ser Gly Leu Asp Ser
 350 355 360

Leu	Ser	Lys	Leu	Thr	Leu	Phe	Gly	Asn	Lys	Ile	Lys	Ser	Val	Ala
				365					370					375
Lys	Arg	Ala	Phe	Ser	Gly	Leu	Glu	Gly	Leu	Glu	His	Leu	Asn	Leu
				380					385					390
Gly	Gly	Asn	Ala	Ile	Arg	Ser	Val	Gln	Phe	Asp	Ala	Phe	Val	Lys
				395					400					405
Met	Lys	Asn	Leu	Lys	Glu	Leu	His	Ile	Ser	Ser	Asp	Ser	Phe	Leu
				410					415					420
Cys	Asp	Cys	Gln	Leu	Lys	Trp	Leu	Pro	Pro	Trp	Leu	Ile	Gly	Arg
				425					430					435
Met	Leu	Gln	Ala	Phe	Val	Thr	Ala	Thr	Cys	Ala	His	Pro	Glu	Ser
				440					445					450
Leu	Lys	Gly	Gln	Ser	Ile	Phe	Ser	Val	Pro	Pro	Glu	Ser	Phe	Val
				455					460					465
Cys	Asp	Asp	Phe	Leu	Lys	Pro	Gln	Ile	Ile	Thr	Gln	Pro	Glu	Thr
				470					475					480
Thr	Met	Ala	Met	Val	Gly	Lys	Asp	Ile	Arg	Phe	Thr	Cys	Ser	Ala
				485					490					495
Ala	Ser	Ser	Ser	Ser	Ser	Pro	Met	Thr	Phe	Ala	Trp	Lys	Lys	Asp
				500					505					510
Asn	Glu	Val	Leu	Thr	Asn	Ala	Asp	Met	Glu	Asn	Phe	Val	His	Val
				515					520					525
His	Ala	Gln	Asp	Gly	Glu	Val	Met	Glu	Tyr	Thr	Thr	Ile	Leu	His
				530					535					540
Leu	Arg	Gln	Val	Thr	Phe	Gly	His	Glu	Gly	Arg	Tyr	Gln	Cys	Val
				545					550					555
Ile	Thr	Asn	His	Phe	Gly	Ser	Thr	Tyr	Ser	His	Lys	Ala	Arg	Leu
				560					565					570
Thr	Val	Asn	Val	Leu	Pro	Ser	Phe	Thr	Lys	Thr	Pro	His	Asp	Ile
				575					580					585
Thr	Ile	Arg	Thr	Thr	Thr	Met	Ala	Arg	Leu	Glu	Cys	Ala	Ala	Thr
				590					595					600
Gly	His	Pro	Asn	Pro	Gln	Ile	Ala	Trp	Gln	Lys	Asp	Gly	Gly	Thr
				605					610					615
Asp	Phe	Pro	Ala	Ala	Arg	Glu	Arg	Arg	Met	His	Val	Met	Pro	Asp
				620					625					630
Asp	Asp	Val	Phe	Phe	Ile	Thr	Asp	Val	Lys	Ile	Asp	Asp	Ala	Gly
				635					640					645
Val	Tyr	Ser	Cys	Thr	Ala	Gln	Asn	Ser	Ala	Gly	Ser	Ile	Ser	Ala
				650					655					660
Asn	Ala	Thr	Leu	Thr	Val	Leu	Glu	Thr	Pro	Ser	Leu	Val	Val	Pro
				665					670					675
Leu	Glu	Asp	Arg	Val	Val	Ser	Val	Gly	Glu	Thr	Val	Ala	Leu	Gln
				680					685					690
Cys	Lys	Ala	Thr	Gly	Asn	Pro	Pro	Pro	Arg	Ile	Thr	Trp	Phe	Lys
				695					700					705
Gly	Asp	Arg	Pro	Leu	Ser	Leu	Thr	Glu	Arg	His	His	Leu	Thr	Pro
				710					715					720
Asp	Asn	Gln	Leu	Leu	Val	Val	Gln	Asn	Val	Val	Ala	Glu	Asp	Ala
				725					730					735
Gly	Arg	Tyr	Thr	Cys	Glu	Met	Ser	Asn	Thr	Leu	Gly	Thr	Glu	Arg
				740					745					750
Ala	His	Ser	Gln	Leu	Ser	Val	Leu	Pro	Ala	Ala	Gly	Cys	Arg	Lys
				755					760					765
Asp	Gly	Thr	Thr	Val	Gly	Ile	Phe	Thr	Ile	Ala	Val	Val	Ser	Ser
				770					775					780
Ile	Val	Leu	Thr	Ser	Leu	Val	Trp	Val	Cys	Ile	Ile	Tyr	Gln	Thr
				785					790					795
Arg	Lys	Lys	Ser	Glu	Glu	Tyr	Ser	Val	Thr	Asn	Thr	Asp	Glu	Thr
				800					805					810
Val	Val	Pro	Pro	Asp	Val	Pro	Ser	Tyr	Leu	Ser	Ser	Gln	Gly	Thr
				815					820					825
Leu	Ser	Asp	Arg	Gln	Glu	Thr	Val	Val	Arg	Thr	Glu	Gly	Gly	Pro

Gln Ala Asn Gly	830	835	840
His Ile Glu Ser Asn		Gly Val Cys Pro Arg	Asp
845	850	855	
Ala Ser His Phe Pro	Glu Pro Asp Thr	His Ser Val Ala Cys	Arg
860	865	870	
Gln Pro Lys Leu Cys	Ala Gly Ser Ala	Tyr His Lys Glu Pro	Trp
875	880	885	
Lys Ala Met Glu Lys	Ala Glu Gly Thr	Pro Gly Pro His Lys	Met
890	895	900	
Glu His Gly Gly Arg	Val Val Cys Ser	Asp Cys Asn Thr Glu	Val
905	910	915	
Asp Cys Tyr Ser Arg	Gly Gln Ala Phe	His Pro Gln Pro Val	Ser
920	925	930	
Arg Asp Ser Ala Gln	Pro Ser Ala Pro	Asn Gly Pro Glu Pro	Gly
935	940	945	
Gly Ser Asp Gln Glu	His Ser Pro His	His Gln Cys Ser Arg	Thr
950	955	960	
Ala Ala Gly Ser Cys	Pro Glu Cys Gln	Gly Ser Leu Tyr Pro	Ser
965	970	975	
Asn His Asp Arg Met	Leu Thr Ala Val	Lys Lys Lys Pro Met	Ala
980	985	990	
Ser Leu Asp Gly Lys	Gly Asp Ser Ser	Trp Thr Leu Ala Arg	Leu
995	1000	1005	
Tyr His Pro Asp Ser	Thr Glu Leu Gln	Pro Ala Ser Ser Leu	Thr
1010	1015	1020	
Ser Gly Ser Pro Glu	Arg Ala Glu Ala	Gln Tyr Leu Leu Val	Ser
1025	1030	1035	
Asn Gly His Leu Pro	Lys Ala Cys Asp	Ala Ser Pro Glu Ser	Thr
1040	1045	1050	
Pro Leu Thr Gly Gln	Leu Pro Gly Lys	Gln Arg Val Pro Leu	Leu
1055	1060	1065	
Leu Ala Pro Lys Ser			
1070			

<210> 55

<211> 1315

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 095765CB1

<400> 55

gaagaagagc	cgcgaccgag	agaggccgcc	gagcgctcccc	gccctcagag	agcagcctcc	60
cgagacagag	cctcagcctg	cctggaagat	gccgagatcg	tgctgcagcc	gctcgggggc	120
cctgttgctg	gccttgctgc	ttcaggcctc	catggaagtg	cgtaggctgg	gcctggagag	180
cagccagtgt	caggacctca	ccacggaaag	caacctgctg	gagtgcattc	gggcctgcaa	240
gcccgaacctc	tgggccgaga	ctcccatggt	cccgggaaat	ggcgacgagc	agcctctgac	300
cgagaacccc	cggaagtacg	tcatgggcca	cttcgctggg	gaccgattcg	gccgccgcaa	360
cagcagcgat	ggtgccaagc	cgggcccgcg	cgaggggcaag	cgctcctact	ccatggagca	420
cttcgcgtgg	ggcaagccgg	tgggcaagaa	gcggcgccca	gtgaagggtg	accctaacgg	480
cgccgaggac	gagtcggccg	aggccttccc	cctggagttc	aagaggggagc	tgactggcca	540
gcgactccgg	gaggggagatg	gccccgacgg	ccctgcccgt	gacggcgcag	gggcccaggc	600
cgacctggag	cacagcctgc	tggtggcgcc	cgagaagaag	gacgagggcc	cctacaggat	660
ggagcacttc	cgctggggca	gcccgcctca	ggacaagcgc	tacggcggtt	tcatgacctc	720
cgagaagagc	cagacgcccc	tggtgacgct	gttcaaaaac	gccatcatca	agaacgccta	780
caagaagggc	gagtgagggc	acagcggggc	cccagggtca	ccctccccc	ggaggtcgac	840
cccaaagccc	cttgctctcc	cctgcctctg	tgccgcctcc	cagcctgggg	ggctggtggc	900
gataatcagc	ctcttaaagc	tgctgttagt	taggaaataa	aacctttcaa	atttcacctt	960
tccagaagtg	gtgcacacga	tacctgctcc	gtcctcctca	ctgaatttgt	cctgagatca	1020
ggtgtggctg	tgaatattaa	acatgcggat	tgcaacccta	gacagagctc	ccttgagcgg	1080
ttgagcagat	gcagccaggt	gtggcgctcc	gctgtggggc	gaggggggtca	cacggggggc	1140

```

agtggcttca gcgacgagtc catagggaca tggctgaggt cccggcgtgg tgaggacaca 1200
ggggttgccg gcaggtcagg ccaatgcagg gtccgcatgg cggtgtaggg tccactcatt 1260
ttgccccggg ggcgtctcat tctcccatth gtctgccaag ctgtaaacga cggtta 1315

```

<210> 56

<211> 3796

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6399886CB1

<400> 56

```

gctgctcccc tcttcctaag cggccccccc tctccccgggc agcagaagaa ggggtgggac 60
ccggggcgggc tccgggaggg ggccctggag gaatggatgg tggcggaagg gcggagcagg 120
ggcgggggccc gcggagactc cacggggcgc cccgggcgtg aggcacccac tctgggagca 180
cagagagctc aggtagcctg cctagatggc ggcgcgcacc ctgggcccgc gcgtcgggag 240
gctgctgggc agcctgcgag ggctctcggg gcagcccgcg cggccgcctg gcgggggtgag 300
cgcgcgcgcg agggcggcct cgggaccctc gggcagcgct cccgcagttg cagcagcagc 360
agcacagcca ggctcgtatc ccgcgctgag tgcacaggca gcccgggagc cggccgcctt 420
ctggggggcct ctggcgcggg acactctcgt gtgggacacc ccctaccaca ccgtctggga 480
ctgcgacttc agcactggca agatcggctg gtctctggga ggccagttaa atgtctctgt 540
caactgcttg gaccagcatg ttcggaagtc ccccgagagc gttgctttga tctgggagcg 600
cgatgagcct ggaacggaag tgaggatcac ctacaggga ctactggaga ccacgtgccg 660
cctggccaac acgctgaaga ggcattggag ccaccgtggg gaccgtgttg ccatctacat 720
gcccgtgtcc ccattggctg tggcagcaat gctggcctgt gccaggatcg gagctgtcca 780
cacagtcatac tttgctggct tcagtgcgga gtccttggct gggaggatca atgatgccaa 840
gtgcaagggtg gttatcacct tcaaccaagg actccgggtg gggcgcgtgg tggagctgaa 900
gaaaatagtg gatgaggctg tgaagcactg cccaccgtg cagcatgtcc tgggtggctca 960
caggacagac aacaaggctc acatggggga tctggacgtc ccgctggagc aggaaatggc 1020
caaggaggag cctgttttgc cccagagag catgggcagt gaggacatgc tcttcagtgc 1080
gtacacctca gggagcaccg gaatgccaa gggcatcgtc catacccagg caggctacct 1140
gctctatgcc gccctgactc acaagcttgt gtttgaccac cagccagggtg acatcttttg 1200
ctgtgtggcc gacatcgggt ggattacagg acacagctac gtggtgtatg ggcctctctg 1260
caatggtgcc accagcgtcc tttttgagag caccacagtt tatcccaatg ctggtcggta 1320
ctgggagaca gtagagaggt tgaagatcaa tcagttctat ggcgccccaa cggctgtccg 1380
gctgttgctg aaatacgggt atgcctgggt gaagaagtat gatcgctcct cctgcccagc 1440
cctgggggtc gtgggagagc ccatcaactg tgaggcctgg gagtggcttc acagggtggg 1500
gggggacagc aggtgcagc tggtggacac ctggtggcag acagaaacag gtggcatctg 1560
catcgcacca cggccctcgg aagaaggggc ggaatcctc cctgccatgg cgatgaggcc 1620
cttctttggc atcgtccccg tctctatgga tgagaagggc agcgtcatgg agggcagcaa 1680
cgtctccggg gccctgtgca tctcccaggc ctggccgggc atggccagga ccatctatgg 1740
cgaccaccag cgattttgtg acgcctactc caaggcctac ccaggctatt acttactgtg 1800
agacggggct taccgaactg agggcggcta ttaccagatc acagggcgga tggatgatgt 1860
catcaacatc agtggccacc ggctggggac cgcagagatt gaggacgcca tcgccacca 1920
ccctgcagta ccagaaagt ctgtcatttg ctacccccac gacatcaaag gagaagctgc 1980
ctttgccttc attgtggtga aagatagtgc gggtgactca gatgtggtgg tgcaggagct 2040
caagtccatg gtggccacca agatcgccaa atatgctgtg cctgatgaga tcctggtggg 2100
gaaacgtctt ccaaaaacca ggtctgggaa ggtcatgcgg cggctcctga ggaagatcat 2160
cactagttag gccaggagc tgggagacac taccaccttg gaggaccca gcatcatcgc 2220
agagatcctg agtgtctacc agaagtcaa ggacaagcag gctgctgcta agtgagctgg 2280
caccttgttg ggctcttggg atgggcgggc acccaagccc tggttgttcc tccccagaag 2340
gtacccttga ggttggcgtc ttcctacgtc ccagaagcag cccccacccc acacatgacc 2400
cacaccgccc tcacgtgaag ctgggctgag agccctttct cccatccatt ggaggtccca 2460
ggagtgtcac ccatggagag gctatgcgac atggctaggg ctggttctgc catctgagtt 2520
tggtttcttg gaatgaaaag gcattgccat ctccactcct ctgccctctt gagccagcac 2580
aggaaggttg ggccctggga tagcgcgcct gctcagataa cacagagcta gtttagctagt 2640
agcaaccgtg ttttctccag atctgtctag atacaaaggt cagaaatctt atttttatac 2700
ttttatattg tggagaaca gcatgcaaca ctacatgta gtgtgtggat ttacttgaac 2760
atgttctttt taacatgtag ttatgaaaat ctctttttt gcctctactg gtgaggaaac 2820
atgaggatca gaggccacat ttttaattat tgttagtgta tttggaagtc tgaattggag 2880
atgtttgtac ctctgtctaa acagttccct tgagaacctc caagcctccg gcatcttttc 2940

```

```

ctggtgagtg tttctcctgt gcttggttgt gtataatgga gctaactcct aagcgggtggg 3000
gtgaatgtgg ccgccttagt tctgaagcta ctccagttat gttctgtttc ttcaagctgt 3060
gatccagaaa gattttttgtg cccccagatg cctcttgata ggagaggcaa catactccaa 3120
atagttgggt tcttcagggg agctattaga aactcaggtg acttggttaga gcactaactt 3180
ggtcagagcc aaatcctggc aaacgctgcc tgaccttcac tctgtggttg gggcagtgag 3240
aaccactgag gtccaatgat gagacttgga ggtctggatc cagtctctct ttgttttaat 3300
gtgacttagg tgctgtcaac attagcaaga taatggaaat cacgacgcca gtgggtgctt 3360
acctccctgc taggcatgca ggggctggcg gttggcaggg gaaggaggcc cagtgaaggc 3420
ggtccttagg gggagggaga gtttgtctc tttgccccac agtctacctt tcagggcctt 3480
gtggcagtg cagtgttcgg ggggtgtctg ggccactgag taccactcgt gtcgtggttg 3540
tgctggcctc ttgggtgagt gaacctgtga agcccaggag gtggtgttggt ctgcagggtg 3600
cacaaatact gagtgggtgg cttttgttac aggcttagca acaaagctgt gccctgggca 3660
tggtgggctg tagtgtagct acagttgtgc gtttgtgaaa tggcttagct ttccatgttg 3720
ctgagaggaa cctggacatg gtcccgggca tctgaatgat ctgtagggga gggagtcaa 3780
ataaagcttt attttg 3796

```

<210> 57

<211> 2983

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6024420CB1

<400> 57

```

ccctgggagt ggccttggct tctgagga cagccatgga cctactctgg atgcccctgc 60
tgctggtggc cgcttgtgtc tctgctgtcc acagctcacc agaggttaac gccggtgttt 120
ccagcatcca cataaccaag cctgtgcaca tctggagga acgcagtctc ctagtgtctaa 180
cgcccgctgg cctgaccag atgctgaacc agaccgctt cctcatggtg cttttccaca 240
acccatcctc aaagcaatcc aggaacttgg cggaagagct gggcaaagct gtggagatca 300
tggtgcaaagg caagaatggg atcggtcttg gcaaagtgga cattaccata gagaaggagc 360
ttcagcagga gtttgggatt accaaggccc cggagttag ctgttttttg agggcaacaa 420
ggtcagagcc catcagctgc aaaggagtgg ttgaatctgc tgccttagtc gtttgggtga 480
gacgacaaat tagccagaaa gcatttttgt tcaacagcag cgagcaggtg gcagagtttg 540
tgatatccag gcccttggct atcggtggct tctccagga ttttagaggaa gaagtagcag 600
agttgttcta tgatgtgatc aaagactttc cagagctaac gtttggagtc ataacgattg 660
gcaatgtcat tgggcgtttc cacgtcacc ttagacagcg cctggtgttc aaaaagggaa 720
aaattgtgaa ccgccaaaag cttattaatg acagtaccaa caaacaggaa ctcaatcgtg 780
tcataaaaca gcaccttaca gattttgtga tcgaatacaa cactgagaat aaggatctga 840
tttccgagtt gcacatcatg agtcacatgc tgctgtttgt ctccaaaagc tccgagtcac 900
atggtatcat aattcagcat tataagctgg catcaaagga attccaaaac aagatccttt 960
tcatccttgt ggatgcagac gaaccagaa atggacgtgt cttcaagtac ttccgggtca 1020
cagagggtcg tatcccatcc gtccaaatcc taaacttag ctctgacgcc aggtacaaaa 1080
tgccctcaga tgacataacc tacgaaagcc tcaagaatt tgcccgagc ttcctgagta 1140
aaaatgccac aaaacatcaa tccagtgaag agattccaaa atactgggac cagggactgg 1200
ttaagcagct cgtggggaag aacttcaacg tagtcgtctt tgacaaagaa aaggacgtgt 1260
ttgtgatgtt ctatgcaccc tgggtctaaa agtgcaagat gctgttccca ctgttgagg 1320
aattgggcag aaaatatcaa aaccactcca caattatcat tgccaagatc gatgtcacag 1380
caaatgacat tcagctgatg tacctggacc ggtacccatt cttcaggctg ttccccagcg 1440
gctctcaaca agctgtcctg tataaggagg aacacaccct gaagggtctt tctgacttcc 1500
tggaaagcca catcaaaact aagattgagg ataggatga gctgttgtct gttgagcaaa 1560
atgaagtgat agaagaggaa gtgctagctg aggaaaagga ggtgcctatg atgaagaaag 1620
agttacctga acagcagtcg cctgagctgg agaactgac caagtacgta tccaagctgg 1680
aagagcccg cgggaagaag aaaacatctg aggaggtggt ggtggtggtg gctaagccaa 1740
agggacctcc agtgcaaaag aagaaaacaa aagtcaagga agaactttag cttctccaat 1800
accaggaaaa aagatgctta ttttccagat cctggcatca ttttctgaat ggattgattc 1860
caataaaagc tatatcatt gtggtagggt aggtggggcg ggggtagggg tgataataa 1920
agcctctgag ttcaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa 1980
aaaaaaaaa aaaaaaaaaa aaacaacaca aacacacaaa caacaacaaa acacaaaaca 2040
ccgcgggggg cgagcgaaga acaacaccac acccgcacag aacaccacac cagagagaga 2100
gagaggaatg gaacaagcac acaccaccaa caaacaacaa aagagaagag aacacccgac 2160
gagcgacaga agacggaaaa agaaacacac gacgcacgag cgaaacagaa agtcacaaca 2220

```

```

gaacaaaaaa gaacaaacac aaagcaacag agaaaacata agcagaaaaga aaagcagaaa 2280
gaaaaggaga aacgagagaa acacacaaca gacaacggaa aaaaacaaaa gacaaaaaca 2340
ccaaatataa aaaaacataa aaataagaat aaaaagaaca aataaagaaa agaaaactaa 2400
aaaaaagcaa gagatagaaa agtaattgaa aaaaaaaga' gtaaaatgaa caaacacagg 2460
aatagtacaa ctaaataata agacataata aaaccgcaaa cagacacaac aaacaaagag 2520
aacacaacga gcaaacacac aacaaacaca acagccaaga acaacacaca gaagtacgag 2580
agagaaaagc gagagatagc gcagagacaa ccagaaaaaa gagaacagcc aaaaccaaga 2640
ggaaacaagg ataacaaaac ggaaagagag aagaggggag cgggagcgaa agagccgaga 2700
agacacgagc acagccgagg aacagcacga ccgaagaagc cgaagcggga aaacagaacg 2760
agacaacaag gaaacagaag agaagtacag ccagagaaac gcagaacgac acatactagt 2820
gagaaagagg cgcagtagac acaccacgag acaggagaag cacggtagca cgaacaagtg 2880
cgagacgaag agcgaagaga gacaagcaga ggagaacaga cgagaaaaaagg 2940
agacaagaag gaacgacgag cgaggaagag cagagcggga gag 2983

```

<210> 58

<211> 3840

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7481067CB1

<400> 58

```

atgaaggcac ttttaccatt gacctttctg ttttttatta gttctccagg ttgggcaata 60
gataggcact gctacatagg cattgaagaa agcatttggg actatgctcc ttctggtaaa 120
aatatgctca atgaaaagcc tttttctgaa gacctagaat ttctacaagg aggtcaagcg 180
aggaagagct ttgtttttta aaaggctttg ttttttcaat atactgataa tacatttcaa 240
aggatcattg aaaaaccatc ctgggtggga ttttttaggtc caatgattaa agcagagact 300
ggagacttca tttatgtaca tgtaaaaaat aatgcttcaa gagcttatag ttatcatcct 360
catgggctca cctactccaa agaaaatgaa ggtgctatct atcctgataa tacgacaggc 420
ctgcaaaagg aagatgaata tctggagcca gggaacaat atacctaca gtggtatgta 480
gaagaacatc agggacctgg cccaatgac agtaattgtg tgacaagaat ttaccattcc 540
catatagaca ctgcaagaga tgtagcttcg ggacttattg gaccaatact gacttgtaaa 600
agaggtacac tgaatggaga cactgaaaaa gatattgaca ggtcttcttt tctgatgttt 660
tctacaactg atgaaagcag aagctgggat agtgatgaaa atattcgtgc atttactgaa 720
tctggcaaga ttaatactag tgatccccgt tttgaggaga gcatgagcat gcaagcaata 780
aatggataca tctatggaaa tctgcccatt ctcaccatgt gtgctgaaga tagggctccag 840
tggtattttg ttggcatggg tggcgtggct gacatacacc ccgtctacct ccgcggaaca 900
actctgatct ctcggaatca cagaaaggac accattatgc tcttccccct ctcactggaa 960
gatgccttca tgggtggcaa ggccccctgga gtgtggatgc tgggatgcca gatacatggt 1020
aagagtatgc aggcattttt caaagtaagt aattgccaga aaccttcaac agaagccttt 1080
gttactggga cacatgttat acattactat attgctgcta aagaaattct ttggaactat 1140
gctccatctg gtatagattt cttcactaaa aaaaatttaa cagcagctgg aagtaaattc 1200
cagttatttt ttgaacgaag tccaaccaga attggaggaa ctaacaaaaa actgatttac 1260
cgtgaatata cagatgcttc cttccaaaca cagaaggcaa gagaagaaca ccttgggaatc 1320
ctaggccccg ttattaaggc agaggtgaga cagaccatca aaatcacttt ctataacaat 1380
gcttccctgc cactcagcat tcagcctcct ggactgcatt acaacaagag cttagagggc 1440
ttattctacg aaacacctgg aggtaccocct ccaccctctt cacatgtaag tcctggcaca 1500
acatttgtct atacatggga agttccaaaa gatgtgggtc ccacctccac agatcccaac 1560
tgcttgacct ggttctatta ctcttcagta aatgggaaaa aagacatcaa cagtggcctt 1620
ctggggcctc tccttatatg tagaaatgga agtcttggag acgatggcaa acagaaagga 1680
gtagacaaag agttttacct acttgccaca atatttgatg aaaatgaaag taatctcttg 1740
gatgaaaata tcagaacatt tatcacagag cctgaaaaca tagataaaga ggatacagac 1800
tgccaagcct caaataagat gtactccata aatggataca tgtatggaaa tctgcctgga 1860
ttggacacgt gcttaggaga caacgttttg tggcacgttt ttagtgtagg atcagtggaa 1920
gatttacacg ggatatattt ttcaggaaat accttcactt ctttaggagc aagaagggag 1980
acaataccta tgtttcetta tacttctcag acgcttttga tgacacctga ttctatagga 2040
acttttgatt tggtttgcac gacaataaag cacaatctag gaggcattga acataaatat 2100
cacgtgaggg aatgtgggaa gccaaaccct gatcaaacac aataccagga ggagaaaata 2160
attattacca ttgcagccga ggaaatggaa tgggattatt ctctagtag aaagtgggag 2220
aatgaactcc accacttacg aagagagcaa acgagcatgt atgtggacag aagtggaaaca 2280
cttcttgggt ccaaatacaa gaaagtctta tatcgtcaat atgatgataa caggttcaca 2340

```



```

aatcaaaciaa aaaggaatga aggtgaaaaa catctcgata tactaggtcc attaatatgt 2400
ctcaaccctg gtcaaataat tcaaattatc tttaaaaata aagccgcaag accgtattct 2460
attcatgctc atggagtgaa aacaaataat tccactgttg ttccaactca gccaggagag 2520
attcaaatat atacttgga gatacctgat agaactgggtc ctacctcact ggactttgaa 2580
tgcatacctt gggtttacta ttcaactgta tctgtggcta aggaccttca cagtggactg 2640
gtaggccctc tctctgtatg ccgcaaagac atcaacccca acatagttca ccgtgttctc 2700
cacttcatga tatttgatga gaatgaatcc tgggtacttcg aagacagtat caacacctat 2760
gcttcaaaac caaacaaggt ggacaaggaa aatgataatt ttcaactcag caaccaaatg 2820
cacgcaatta acggaagact gtttggaat aaccaaggta taacattcca tgttggggat 2880
gtagtgaatt ggtatctgat tggcataggg aatgaagctg acctgcacac agttcacttt 2940
catggccata gctttgaata caagaatagg ggagtgtatc aatctgatgt ttatgacctt 3000
cctcctgggg tctatcgaac tgtaaaaatg tatcgaagag atgttggaac ctgggtattt 3060
tattgccatg tttttgagca cattgggtgt ggaatggaaa gcacttacac tgtacttgaa 3120
agaaaagggc tgatggagca gaacctctga agcagacaaa ggagagtcag catgaacagt 3180
ttctcagaat cttctctcaa tatcaggact acatttgtca acaaaaccaa aaactgatta 3240
gccaccgata taatttttac ctacaacatc ctattaatgt caataatatc attattgata 3300
caattctaata aatcactacc cttatttcta tcagtgttca tgtacattct tagtaaaaga 3360
gactttgggt cgctgtccat gaaataaatc cccattgtct aacattcttt ctttggaaaa 3420
gtagattttg catttcaaag aatataaagt caaattggat tggatttaca ggatcatctgt 3480
tcccacagaa ggggtgatatt gatgttgcta ttgataagta aactttttgt ggcaaaagtg 3540
atggtagtta ttttaaggat gttcccaaga ctaataataa ttttgtattt attcctaaa 3600
tgtatgtaat cattttagct tagtatttta acctagaact gcatgctatt atataatatt 3660
acctattttt gaaacttcct tttctacagc ataaatatat gatatgatat gaatatgac 3720
aagcttacaa gccaaaggtaa agctgccaaa gaaggaaaac tccagggacc aaggagtctg 3780
ggaggaacca gctaaagact ttcatgacaa tgtaccaggg agactagttt gagatcaagg 3840

```

<210> 59

<211> 1570

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3378720CB1

<400> 59

```

gagaacgaag ctgggttgaa cggttggaagc tgctctctga ctacacttca caagcaaggg 60
gcaccttttg tggactgaca ttccagaaag ggatgttggt aaacaaaagc tgacatttat 120
atatatatac atatatacag tatttgagtt cctcagtaga aagctatcat atatactcag 180
aatgtttttg acgttttaag aatggttctg gttggaaaga ttctggcttc ctccaacaat 240
aaagtgggtc gatcttgagg atcacgatgg actcgtcttt gtaaaacctt ctcatattata 300
cgtgacaatt ccatatgctt ttctcttctg gattatcagg cgtgtatttg aaaaatttgt 360
tgcttcacct ctagcaaaat catttggtcat taaagagaca gttcgaaagg ttacaccaa 420
tactgtctta gagaattttt tcaaacattc cacaaggcaa ccattgcaaa ctgatattta 480
tggactggca aagaagtgtt acttgacgga gcgccaggtg gaaagatggt ttaggagtcg 540
gcggaatcaa gagaggcctt ccaggctgaa gaaattccag gaagcttgct ggagatttgc 600
attttactta atgatcactg ttgctggaat tgcgtttctt tatgataaac cttggctata 660
tgacttatgg gaggtttgga atggctatcc caaacagccc ctgctgccat cccagtactg 720
gtactacatt ttagaaatga gtttttattg gtctctgtta tttagacttg gctttgatgt 780
caagagaaag gattttctag ctcatatcat ccaccacctg gctgctatta gtctgatgag 840
cttctcttgg tgtgctaatt atattcgagc tgggaccctc gtgatgattg tacacgatgt 900
ggctgacatt tggctggagt ctgctaagat gttttcttat gctggatgga cgcagacctg 960
taacaccctg tttttcatct tctccaccat atttttcatc agccgctca ttgtttttcc 1020
ttcttgattt ttatattgca cgctgatctt gcctatgtat cacctcgagc ctttcttttc 1080
atacatcttc ctcaacctac agctcatgat cttgcaggtc cttcaccttt actgggggta 1140
ttacatcttg aagatgtcga acagatgtat attcatgaag agcatccagg atgtgaggag 1200
tgatgacgag gattatgaag aggaagagga agaggaagaa gaagaggcta ccaaaggcaa 1260
agagatggat tgtttaaaga acggcctcgg ggctgagagg cacctcatte ccaatggcca 1320
gcatggccat tagctggaag cctacaggac tcccattgga cagcatgctg caagtactgt 1380
tggcagcctg gcttccagga cccacacaga cccacatc tgcccttccc tctttctcac 1440
caccgccttc cctccacct aagatgtgtt taccaaatg ttgttaactt gtgttaaaat 1500
gttaaatata agcatgcccc tggattttta ctgcagttag gactcagact ggtcaaagat 1560
ttcaaagatt

```

<210> 60
 <211> 409
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 938824CB1

<400> 60
 cagtctttttc cccactttac cagtgtgtga ggcctctctc ccacttccctc cacttaccac 60
 ctctccaaga tgccagcctc actgtgggct ttccctagaa agaaacactg gtttctttct 120
 atcgtgccct ggtagtggt gtttctcaca ttaggcctct gtgttagaaa taaagctgct 180
 aaactccatg tcgttatata acaaaaggaa tacagtgacc tatccttcat tcttctgata 240
 gttccctcaa ctccagctgc agccctgcc aaatactatc atccttaaaa gatagacagt 300
 gatccagca ctgtgggagg ccaaggcagc tagatcactt gagtccggga gttcaagacc 360
 agcctgggca acatggtgaa ccccatctct actgagaaaa ttataacaa 409

<210> 61
 <211> 953
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1683721CB1

<400> 61
 aagagcgatt ataattgagt atgatgtgtg cagtaagagc aacacaagat gatgatagtg 60
 gtgggtggtac ttgtcatttg cttgatgcc a ggcacacttc taggtgctta catgcacctt 120
 ctcatgaat tccccaacag tcctatgaag taggctcttt tcatcccat tgatagatga 180
 agaactccag gcccaactg gtttaagtta ttgggttaaaa gtcacacaga aaatggccaa 240
 gccaggattt gaacctataa tctctgctct gcccttaaga gatagtacaa actggcggt 300
 tcgggaagcc tcacagagaa ggcagcattt gaaccaggac tgaaggatca ataagatgaa 360
 ttctggcatc aggaaaggaa aggcactccc tgcagttagga atgggagggg caaaggcaga 420
 gaggcgggac catggctcag catggctcact gattaggtga gtgtggctgg aaccgtgaca 480
 gggaacagca ggagatgatg ctgggttggg gatggaaggc tctgctcctg aagagccttg 540
 ctttccccac tcagggtat cctgagggtc atgaggagct acttaggaaa gtgacaggag 600
 cagatttgac ttggtcacct ggagatggaa tccaattcca ggttcctggc accaggaaga 660
 caaagcagta ttgtgaattt gaaaatgaaa tcaactttat catgccccac atgaaaattc 720
 agtcgctctt atttttgctt ggcttttatg taaaagacct aagccaatga aactgcctgc 780
 cattagtcaa ggtcagagt aaacttgta gaaaaacttc cttaggtctc tctactgacac 840
 tacaagttat tgccaacctg agagctcctc cacagaaatt accatttgga gactgtccac 900
 agtgggattt cagataggct ccaacccctc acgggaacct ccccccccg cca 953

<210> 62
 <211> 890
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1694122CB1

<400> 62
 accacgcgtc cgcgagcgcg tgggtggcca aagtgcagga ttaccggcag gccaggtcg 60
 agaggctgga gaccaaggtg gtcaaccccc tgaagctcta cggggcacag atcaagcaga 120
 caggggtga gatcaagaaa ttcaaactg tccaaatca tgagatcaaa caactggaaa 180
 aactggagaa actgaggcag aagtcacct cggtacagca aatgatctcc caggcagaga 240
 ccagagtga gagggccgct gtggactcca gccgcaccac cctccagctg gaggagactg 300
 tggatggctt ccagaggcag aagctcaagg acctgcagaa atttttttgt gactttgtaa 360
 ctattgagat ggttttccat gccaaagcgg tggaggtgta ttctagcgcc ttccagacct 420
 tggagaagta tgacctggag agggatctac tggattttag agccaagatg caaggagttt 480

```

atgggcatta tgacactcgg ctgcttgcca acaccagccc ccctccatct gttcttcagt 540
ctctcgccag ccagagtgtc cagagcacca tatggagccc agggaaaagaa ggggaggaga 600
gtgaggacaa ctccatggag gaggcccccg tggaggacct caggggcactg gggcagggac 660
cccataagag agaactgccc acaacagtca gaagaactta gctggccttg gatcctcagg 720
tgggctctgc tgtgtgccct caggcaagcc acgtgtcctc tgagcctcag tttcctcatc 780
tgtacaacag ggccaatatc actcacttca caggttgctc tgggggatcg ctgtgcctgg 840
catatagtag gtgttcaata aatgcctgt gactctcaaa aaaaaaaaaa 890

```

<210> 63

<211> 1960

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1970615CB1

<400> 63

```

cggctcgagca caggcaggtg gtcaaaacaa ctttcaacca gaatctactg atatggatag 60
atgctgtccc ttatggaggg acgcagactt cagaactgtg cccatgactg ctgactgcca 120
ccaccaaggc cctcaggtac acagcctgcc tcctgcagga tgatgtgggc agatttcagc 180
cctagttaac agaagagtcc ccaggagggt agggggcccc catcactgga gacatgccag 240
cagagcctct gccaccta ccaggagggt ttctgaaatg actatacgag gtaaagaagt 300
agtaccagat ggtcccaaag ttccctttta gcctgaaagc ttttctttgt cctccttag 360
tgaatctgtg ttccgagccc tactctaaag ttcagtgtgc aatacaatag tccaccaaga 420
gactgggaat gattagaagt gaaattgggt cctccttacc aaggaggggc agatgatctc 480
cattgcacag ggcgattaga ttctggagct gaggtgggga ctgcaggagg ccacctagtc 540
tggtagggtt caacccaagc tgtgtacatt agaattccct tgggagcgtg caggaaatac 600
agatgcccat gccacattcc agaccaactg aagctgaatc tccagagtag ggcctgtatg 660
ttcatataag ctccacaggt gatctgcagt acagtgaaga tgggaagactg catgtgtacc 720
tatttgcaat aaagatgaag aggacagcaa gctccagaca ggagctggga ctcaaccag 780
atctcttaag tcctgcctgg tggctcctta aaagtccaga agtgttgccc caagccctcc 840
ctcaacatct ctgggaaccg cagctgcagc acgatggggg ttcagtggcc ctgtttggcc 900
cttaccagc tgtggtttat tctgcttgta tgtctgcaca ggccggatgc tctgttccct 960
tgtcttattc tccatttact cagtcactgg ggctcactcc cgtctgatgc actagccaag 1020
attgccttag tgtgtctcag aaaagaaggc caaatccag gcattgtcag ggcagcagag 1080
ctctacagga taggcttacc tttcccacct gtgtggctag cacttcacag tttacaaatt 1140
cctcccacct ccactcagtg acacatgctg ttctaacaca ggtcaggcag gcattacagt 1200
ccccatgttc agaatacaag acctagcctc agagaagtga agaaacatca tgccaaggtc 1260
attgactgcc aagcggtaga ggtggggttg catccagaga gcttcccggg atgcctctgc 1320
acaatgccat tccttggcca gctccctcca cccaaggga ccagactgc acacttaaca 1380
aacaggacac aggtgtcttt gaacaaactt ttttgtatta ttatttttac atctagaata 1440
aattatttaa attatttcac agcaaggag agggatagggt aatttttatc agatattttt 1500
ttaaacatc tgttttttaa attacatttt tgtttatgtt cttgagctga tgtagtggaa 1560
cttgccctagc acattcaggt ccagccagt tggcagagca tgctctcatc tccttattcc 1620
ataccctggg cgtccccttt ctgttgactc aggaactttc tgagaatgag gacagcacta 1680
ggagatgagc tttggcaggt atccacctta acgtacaat aattgtgctt cctgaaacaa 1740
aacttgagat tgtatcatag aaggaaacag gaagtcagaa atcaaatcta tgcttttaat 1800
tgaaaccgtg cctgaaacag tttgaatgat tgttttaatg ttgtttctga aattccttgt 1860
acctttgtga aaaataatga taataaataa aagtgaaaat aaatagatgt ggaatatgca 1920
atggaaataa tgtaacaaaa taataaacat ctgcaagtag 1960

```

<210> 64

<211> 832

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2314152CB1

<400> 64

```

gggtttttttt tttttttttt ttttttttaa atgtcagtat ctatatattaa tttcatttgc 60

```

```

tcaaaacata tatatgtatg tatatacata aatttataaaa ctgacagaat gacaaagatt 120
tttcagcaat acataatcat ggtgggagag tttaacatac ctctctcaat aaatgctaga 180
tcacagatca acattttataa atgtgtagat ggttttttaa cacatttgct tgatctagca 240
gacatttgta gaatacaata cattgatttc aaccatccat gaagcattta taaaaactga 300
catatactaa gtgcatcagt taggaattat attcaggtga aataaacctc ccaccaaaaa 360
caaaaacaaa caaaagaaaa ctgtaccagt aagaagtgc tatttttcat gtatgggaca 420
tccagaaata aatagtccag ggctgctgca atcacataaa tatgccaatt ctattaaatc 480
tatcctaaat attttttaga ttacagaagc aagatgggta tgacttccgg ccaccctctt 540
cttagcttgc ggcttttacc cttatgggtc caggagggct cctctaggct tagaaatcat 600
gtctacttgt ccaaaaggca agaagtggag agatgtggct acatgaaacc atccctgaac 660
acaatatctt cccagagctc acatccagtg acttctcata ttcatactag ccaggaccgg 720
aggaaatggc ctgcccttgc ttgcaagaag ggctgggaga tgggaagctt tttttattat 780
tattattttt gagacagagt ctcatgctgt caccagggct ggattgcagt gg 832

```

<210> 65

<211> 546

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2886225CB1

<400> 65

```

caatgtacga gctcggcatc atagtacggg ccgcagtgtg ctggaaagga aatcacagcc 60
tgagtgtgtc tcagtcagcg cagcagaatt cagcgcgagg aagctgaatg caacccttgg 120
tgcaggaagg gaggcttttc ctgaggaccg ggagaggatt ttaagtacat agaaggaagc 180
ttctggagat cctgctccgt cgccccagtg ttcagactac ctgttcagga caatgccgtt 240
gtacagtagt ctgcacattg gttagactgg gcaagggaga gcaacgccat ggaccgctgg 300
ggacaaaatg ggctgttttc aaggagaaga catttgtttg ctccctttttt gaatctcata 360
tccagtgttt ttcttcacag gttttgcaca ctaggggacca agaagccctc ggggacactg 420
ctgagaaaag actgccgaag ggaagaccag cgggagatat acaaattatt tagggatcat 480
ggaatctatt ccagaggaaa ctaaccaaca gtgagcatct tcaactaaaa ctacccttgg 540
atgtaa 546

```

<210> 66

<211> 890

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6144418CB1

<400> 66

```

gtacttttga atcaagcagg tgttacagat ctccctctcc tagggagctt gcagtatttt 60
acccagtttg tggagttcca tttgaggatt gctgggggtt gtggaccatc cagagatctt 120
tccatggtaa agatcaagca tcgtgggttg ccatgatcta ttgtcagatt gagtctcact 180
ctgttgccca ggctggagca cagtggcgtg atcttggtc actgcaacct ccagggttca 240
agggaaacctg taaaggaaac cagttagctta tctgtaccag tggcatatct gtataatctc 300
ttagaaaatc aagggttcaa aatcaaacac cttgctagtt tgcgattcag tgattcaaga 360
atgaattctg cagttggagg actctctagg cccttcagtg ttccacttac tttttctgct 420
cttattccct ctcttcttct acacgccagc gtccctcttct gcaactggatg gtatcatgat 480
tttcaggaag gagagtcaaa aagggaacaa agtcagctca agcaaaaaca tcctggcaca 540
cgggaggacg aagtaaataa tgatagtatg tgggacacca ttagtcattg tcattctgca 600
tgctccagca ccaataaaaac catcttaacc aaacaccctt ggataatttg ttcccatgac 660
taatacatag ccactgatcc agagcctaag gagtgtgaat gacaaacaat aaacctgctt 720
gggataacgt gattgattgt aattccattt gaaataaatg taacaaacag caatgagcca 780
tctagttaac catgcagcac aacttaattg ttacgggtcg tcatttcatt cccagtgctc 840
ctttccagaa acacaaaaaa agggggcgga aaaggaggcg gagaccggat 890

```

<210> 67

<211> 807

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 6834184CB1

<400> 67
agagagagaa acataaggga attagggagg gtctctgggg tggtagacatt taagccaaag 60
ccagaaggac aggaaggaca cagctacgca gacagctgga ggaagagcat tccagacaga 120
gggaactgtg tactcacagg ctccaaggaa gaacagaact aggtgttgga gggattgagg 180
ggaacccacc tctgtgtgtg gcttcgggtc ccggacaagg gggctgagat agaacgaaga 240
gggagaggag ggcagagcct gggatcatgca gggagttccc tgcctgggct ggctgctctc 300
tagtgctttt tccctcatgt cctggggggag tctgcacggg tgtgccctgt tgttggcatt 360
gtgctcaggg acctttgaag ttgagaaaat actagtgggt gtgggggctg acgagtgcc 420
ggcatcagcc ctgggtctggg aggtaccat gctcaccttc cagctgcacc cacggggctc 480
cacctcgag cctccagagc cagactgctc tgcctgagtg ctgggcaaat tgttaacctt 540
tctgtgcctt agtttcttca tctgtgaatt ggggtaata gcatccaatg agagcaaagg 600
gcttggtaca gtaactaagc tttggttagt atgagcaaag ggctgagtg agacatagtg 660
cactcactcc gtgagcattg ttcctgtggc tgtggatggc tccgtggatg tgtgtgtttc 720
tagcatagag gacagaggct gtctccagac ccggaccctg acttgccctg tgcctcctgt 780
ggcactcatt agcctcttgt gctcact 807

<210> 68
<211> 677
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 6951005CB1

<400> 68
attgtcacat gtttttttgt ttgtttgttt gtttgtttct gtttttgttt tgctgtggat 60
agattaaaaa gttgggaagt ttctgtttta gtttgtcttt ctgtactgcc aagctgggaa 120
gtaaaaaatgc cacttcccat ttctctataa ctaacacaa acatttccaaa tcatagtaag 180
actatcttct gaaaactgag ctctctccca aattctctac attgctaatt gttttgccag 240
ggttcccatc agtcccctct cccctgcccc atcctctgtg gcttcttctt ctggcccat 300
ccatactgga tcaatttctc ctaggtccca ctctgagatc tccagcattc attccctctc 360
gtgattctcc tgcctcaatt gcagttacag atattactat tcatatccag atagtacttc 420
tagtactct tctggcctct agtttcacaa agtccccga cttcagttac aatcctgatc 480
tgtcatttac cagcagctat atgacctcag gaatgttgtt ggacatttct gagctgcaat 540
atccctatgt gcaaagtga actattta atttttctca cagggctgtt ctccagaatca 600
gaggaatatg gagataaata tatatatata catataaagc tggtaaggta ccaagggcta 660
gcacagtaga gccagaa 677

<210> 69
<211> 617
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7250331CB1

<400> 69
tgggctgcac cactcacaga gctccctccc ccaggcactt agttggggcc cagcactgac 60
ctttcccttg agcccaggat gtggccagag cccctctctg gaccctctc gcccttctc 120
tgccctctca gcttgagctg cctgcccga gttcggctgt tccggggcca gtgtgtcacc 180
tgcacaactc cacatcacc tctccctcg ctccctctc tccctccca aggacctcc 240
cccatttctg gcagccaagc cattaatctg gagacagaaa tgggtttgct atcgattctc 300
tggccacttt ttctttcatt acaatttgta ccgtgattct tctcaccctt ctctgcgtcc 360
atgcatttaa agagttgtct ctttaaatgt tgaagcttcc ggaagcctga tgctattctg 420

```

tgtctccttt caaaggaaga aggggggggcc cagctatggg tgaggactca agttattagt 480
ttggaaatag agcaactatg tgtacagccc accttagagg tcatgttacc cccttcctgt 540
taaattttac aattaatttt ggttcaggaa atgtaataaa atttgtaaat tacaatatgc 600
aaaaaaaaaa aaaaagg 617

```

```

<210> 70
<211> 795
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 1758413CB1

```

```

<400> 70
atggctccag gctcccggac gtccctgctc ctggcttttg cctgctctg cctgccctgg 60
cttcaagagg ctggtgccgt ccaaaccgtt cegttatcca ggctttttga ccacgctatg 120
ctccaagccc atcgcgcgca ccagctggcc attgacacct accaggagtt tgaagaaacc 180
tatatcccaa aggaccagaa gtattcattc ctgcatgact ccagacctc cttctgcttc 240
tcagactcta ttccgacacc ctccaacatg gaggaaacgc aacagaaatc caatctagag 300
ctgctccgca tctccctgct gctcatcgag tegtggctgg agcccgctgc gttcctcagg 360
agtatgttcg ccaacaacct ggtgtatgac acctcggaca gcgatgacta tcacctcta 420
aaggacctag aggaaggcat ccaaaccgtg atgggggtga ggggtggcgc aggggtcacc 480
aatcctggaa cccactggc ttcgagggct gggggagaga aatactgctg ccctcttttt 540
agcagtaagg cgctgaccca agagaactca ccttattctt catttcgcct ggtgaatcct 600
ccaggccttt ctctacaccc tgaaggggag ggaggaaaat ggataaatga gagagggagg 660
gaacagtgcc caagcgcttg gcctctcctt ctcttccttc actttgcaga ggctggaaga 720
cggcagccgc cggactgggc agatcctcaa gcagacctac agcaagtttg acacaaactc 780
gcacaaccat gacgc 795

```

```

<210> 71
<211> 1677
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 7011042CB1

```

```

<400> 71
ggggagggaag agcaggggggt atcaccgtgc tcctagggga gacgacaggg caaaagcaga 60
caggggagagag gtcactgcac actaggcgac tctgggaacg tctccccgcc ctgcagggaa 120
catccagcgc ctgtgctcct cctcagagcc ctggaggtag ggttgggacg cgcactctgac 180
tctttgtgcg ggggttctct tggatttgat gggcgctcct ctgttctctc ccagacgcc 240
atgcggcaaa cctacccgct gctgctgctg acggtgctgc gccccagctg ggcagaccct 300
ccccaggaga aggtcccgtt cttccgggtc actcagcagg gccctggggg gagcagtggc 360
agcaacgcca ccgactcgcc ctgcgagggg ctgcccgcgc cggatgcgac ggccttgacc 420
ctggcgaacc gcaacctgga gcgcctgccc ggctgcctac cgcgcacact gcgcagcctc 480
gacgccagcc acaacctgct gcgcgccttg agcacttccg agctcggcca cctggagcag 540
ctgcaggtgc tgacctgctg ccacaaccgc atcgccgcgc tgcgctgggg cccgggtggg 600
ccggcggggc tgcacaccct ggacctcagc tacaaccage tggccgctct gccgccgtgc 660
accggggccc cgctgagcag cctccgcgcc ctggcgctcg ccgggaatcc gctgcgggcg 720
ctgcagcccc gggccttcgc ctgcttcccc gcgctgcage tctcaacct ctctgcacc 780
gcgctgggtc gcggagccca ggggggcate gccgagggcg cgttcgctgg agaggatggc 840
gcgcccctgg tcacgctcga agtctggat ctacagcgga cgttccttga acgggttgag 900
tcagggtgga tcagagacct gccgaagctc acatccctct acctgaggaa gatgcctcgg 960
ctgacgaccc tggagggggga cattttcaag atgaccccca acctgcagca gctggactgt 1020
caggactccc cagcacttgc ttctgtcgcc acacacatct ttcaagatac tccacatcta 1080
caggtccttc tgttccagaa gtaagtgtt ctgaggcaca tcttcatac atgactgatt 1140
tttgccatt acgttatgtt gaattttata gaacaaacca gaccttaatt tttctcccac 1200
tactcttcca aatcctctct ggggctttgt tttccccac cctttgggtg atatcttggg 1260
taggtcccag atagtcacc cagcccatct agccttgcaa ctcagtcag ttcagagtag 1320
cattagaacg caaaactcct atgcctttta agtttatttt aagcccagtc ttagaaatct 1380

```

```

acagtgggaa gaggtgagga ggacctcagg tctcctctct gtctggatct gctttcttcc 1440
ccacatgtca tgcaagttca gtcccttcca gaatttgagt ggggtctaggg atgaaagtat 1500
tgatattgtt agaaaaatccc ttggaagtct atgggcaggc cctgttagtc ctcttttaca 1560
caatgcagtc actaaagatg gaattattct tctaaaagga tgaacaactt ttcaaagcaa 1620
aggcagaacc attcactcat tctgtccttt attcaataaa tagctattga gcacaaa 1677

```

<210> 72

<211> 1402

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7427362CB1

<400> 72

```

ggcgcgcgcg gctcggggttt cggcccgccc cggggcgccg cgtgatcccc tcccggggcg 60
ggggcggggc cgggcccagc tggccgcgct cggggcgcta taagagggcg gcggccgccc 120
cgcgccctgc gcggagctgg gagcgcgatg gtcggccgcc gaggcgcggc aagatgctgg 180
atgggtcccc gctggcgcg cggctggccg cggccttcgg gctgacgctg ctgctcgccg 240
cgctgcgccc ttcggccgcc tacttcgggc tgacgggcag cgagccctg accatcctcc 300
cgctgacctt ggagccagag gcggctgccc agggcacta caaggcctgc gaccggctga 360
agctggagcg gaagcagcgg cgcattgtgc gccgggaccc gggcgtggca gagacgctgg 420
tggaggccgt gagcatgagt gcgctcgagt gccagtcca gttccgcttt gagcgctgga 480
actgcacgct ggagggccgc taccgggcca gcctgctcaa gcgaggcttc aaggagactg 540
ccttcctcta tgccatctcc tcggctggcc tgacgcacgc actggccaag gcgtgcagcg 600
cgggcccgcg ggagcgctgt acctgcgatg aggcacccga cctggagaac cgtgaggcct 660
ggcagtgggg gggctgtagc gaggacatcg agtttggtgg gatgggtgtc cgggagttcg 720
ccgacgcccc ggagaaccgg ccagatgccc gctcagccat gaaccgccac aacaacgagg 780
ctgggcccga ggtgatcaag gctggggtgg agaccacctg caagtgccac ggcgtgtcag 840
gctcatgcac ggtgcggacc tgctggcgcc agttggcgcc tttccatgag gtgggcaagc 900
atctgaagca caagtatgag acggcactca aggtgggcag caccaccaat gaagctgccg 960
gcgagggcagg tgccatctcc ccaccacggg gccgtgcctc gggggcaggt ggcagcgacc 1020
cgctgccccg cactccagag ctggtgcacc tggatgactc gcctagcttc tgcctggctg 1080
gccgcttctc cccgggcacc gctggccgta ggtgccaccg tgagaagaac tgagagagca 1140
tctgctgtgg ccgcgcccat aacacacaga gccgggtggt gacaaggccc tgccagtgcc 1200
aggtgcgttg gtgctgctat gtggagtgca ggcagtgcac gcagcgtag gaggtctaca 1260
cctgcaaggg ctgagttccc aggcctgcc agcctgctg cacaggggtg aggcattgca 1320
cacggtgtga aggttctaca cctgcacagg ctgagctcct gggctcgacc agcccagctg 1380
cgtggggtac aggcattgca ca 1402

```

<210> 73

<211> 1251

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7485304CB1

<400> 73

```

atgcttgetg tggatgatggc tgatttggtt tccttgatgt gctgggtctg caagcagaaa 60
ctgccaggct tggcagcctg gctcgcggtg gtgagacagg aagtggggct gtgcttgagg 120
agacaaagcc tacagctgga cccggctctt tcctctctga gtcagggatg gcccctgagg 180
aggcccttc ccttcatttg cccctcacca ccattcccaa ggctcacctg tctccctcct 240
ctcgctctct ctacgctgac cgggcgggaa gtctgacgc ccttcccagg attgggcaact 300
gcggcagccc cggcacaggg cggggcccac ctgaagcagt gtgacctgct gaagctgtcc 360
cggcggcaga agcagctctg ccggagggag cccggcctgg ctgagaccct gagggatgct 420
gcgcacctcg gcctgcttga gtgccagttt cagttccggc atgagcgctg gaactgtagc 480
ctggagggga ggatgggcct gctcaagaga ggcttcaaag agacagcttt cctgtacgcg 540
gtgtcctctg ccgcccctac ccacacctg gcccgggcct gcagcgctgg gcgcatggag 600
cgctgcacct gtgatgactc tccggggctg gagagccggc aggcctggca gtggggcgctg 660
tgcggtgaca acctcaagta cagcaccaag tttctgagca acttcctggg gtccaagaga 720

```

```

ggaaacaagg acctgcgggc acgggcagac gccacaata cccacgtggg catcaaggct 780
gtgaagagtg gcctcaggac cacgtgtaag tgccatggcg tatcaggctc ctgtgccgtg 840
cgcacctgct ggaagcagct ctccccgttc cgtgagacgg gccagggtgct gaaactgcgc 900
tatgactcgg ctgtcaagggt gtccagtgcc accaatgagg ccttggggccg cctagagctg 960
tggggccctg ccaggcaggg cagcctcacc aaaggcctgg ccccaaggctc tggggacctg 1020
gtgtacatgg aggactcacc cagcttctgc cggcccagca agtactcacc tggcacagca 1080
ggtaggggtgt gctcccggga ggccagctgc agcagcctgt gctgcggggc gggctatgac 1140
accagagacc gcctggtggc cttctcctgc cactgccagg tgcagtgggt ctgctacgtg 1200
gagtgccagc aatgtgtgca ggaggagctt gtgtacacct gcaagcacta g 1251

```

<210> 74

<211> 4961

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1422394CB1

<220>

<221> unsure

<222> 4929

<223> a, t, c, g, or other

<400> 74

```

ccgtcttcat cttgcgaaca cttcgcagac cgtcgctaata gaatcttggg gccggtgtcg 60
ggccggggcg gcttgatcgg caactaggaa accccaggcg cagaggccag gagcgagggc 120
agcgaggatc agaggccagg ccttcccggc tgccggcgct cctcggagggt cagggcagat 180
gaggaacatg actctcccc ttcggaggag gaaggaagtc ccgctgccac cttatctctg 240
ctcctctgcc tcctccctgt tcccagagct ttttctctag agaagatttt gaaggcggct 300
tttggtattct tcacttctct tgaacaagga actcactcag agactaacac aaaggaagta 360
atctcttacc tggtcattat ttagtctaca ataagttcat ccttcttcag tgtgaccagt 420
aaattcttcc catactcttg aagagagcat aattggaatg gagagggtgt gacggccacc 480
caccatcatc taaagaagat aaacttggca aatgacatgc aggttcttca aggcagaata 540
attgcagaaa atcttcaaag gacctatct gcagatgttc tgaataacct tgagaataga 600
gattgattat tcaaccagga tacctaattc aagaactcca gaaatcagga gacggagaca 660
ttttgtcagt tttgcaacat tggacaaat acaatgaagt attcttgtgt tgctctggtt 720
ttggctgtcc tgggcacaga attgctggga agcctctgtt cgactgtcag atccccgagg 780
ttcagaggac ggatacagca ggaacgaaaa aacatccgac ccaacattat tcttgtgctt 840
accgatgatc aagatgtgga gctgggttcc ctgcaagtca tgaacaaaac gagaaagatt 900
atggaacatg gggggggccac cttcatcaat gcctttgtga ctacacccat gtgctgccc 960
tcacggctct ccatgtcac cggaagtat gtgcacaatc acaatgtcta caccaacaac 1020
gagaactgct cttccccctc gtggcaggcc atgcatgagc ctccggacttt tgctgtatat 1080
cttaacaaca ctggctacag aacagccttt tttggaaaat acctcaatga atataatggc 1140
agctacatcc cccctgggtg gcgagaatgg cttggattaa tcaagaattc tcgcttctat 1200
aattacatg tttgtcgcaa tggcatcaaa gaaaagcatg gatttgatta tgcaaggac 1260
tacttcacag acttaatcac taacgagagc attaattact tcaaaatgtc taagagaatg 1320
tatccccata ggcccgttat gatggtgatc agccacgctg cgccccacgg ccccgaggac 1380
tcagccccac agttttctaa actgtacccc aatgcttccc aacacataac tcctagtatt 1440
aactatgcac caaatatgga taaacactgg attatgcagt acacaggacc aatgctgccc 1500
atccacatgg aatttacaaa cattctacag cgcaaaaggc tccagacttt gatgtcagt 1560
gatgattctg tggagaggct gtataacatg ctctgggaga cgggggagct ggagaatact 1620
tacatcattt acaccgccga ccatggttac catattgggc agtttggact ggtcaagggg 1680
aaatccatgc catatgactt tgatattcgt gtgccttttt ttattcgtgg tccaagtgt 1740
gaaccaggat caatagtccc acagatcgtt ctcaacattg acttggcccc caccgatcct 1800
gatattgctg ggctcgacac acctcctgat gtggacggca agtctgtcct caaacttctg 1860
gaccagaaa agccaggtaa caggtttcga acaaacaaga aggccaaaat ttggcgtgat 1920
acattcctag tggaaagagg caaatttcta cgtaagaagg aagaatccag caagaatata 1980
caacagtcaa atcacttgcc caaatatgaa cgggtcaaaag aactatgcca gcaggccagg 2040
taccagacag cctgtgaaca accggggcag aagtggcaat gcattgagga tacatctggc 2100
aagcttcgaa ttcacaagtg taaaggaccc agtgacctgc tcacagtccg gcagagcacg 2160
cggaacctct acgctcgcg cttccatgac aaagacaaa agtgacgttg tagggagtct 2220
ggttaccgtg ccagcagaag ccaaagaaag agtcaacggc aattcttgag aaaccagggg 2280

```



```

actccaaagt acaagcccg agttgtccat actcggcaga cacgttcctt gtccgtcgaa 2340
tttgaaggtg aaatatatga cataaatctg gaagaagaag aagaattgca agtggtgcaa 2400
ccaagaaaca ttgctaagcg tcatgatgaa ggccacaagg ggccaagaga tctccaggct 2460
tccagtgggtg gcaacagggg caggatgctg gcagatagca gcaacgccgt gggccacact 2520
accactgtcc gagtgacaca caagtgtttt attcttccca atgactctat ccattgtgag 2580
agagaactgt accaatcggc cagagcgtgg aaggaccata aggcatacat tgacaaagag 2640
attgaagctc tgcaagataa aattaagaat ttaagagaag tgagaggaca tctgaagaga 2700
aggaagcctg aggaatgtag ctgcagtaaa caaagctatt acaataaaga gaaaggtgta 2760
aaaaagcaag agaaattaaa gagccatctt caccattca aggaggctgc tcaggaagta 2820
gatagcaaac tgcaactttt caaggagaac aaccgtagga ggaagaagga gaggaaggag 2880
aagagacggc agaggaaggg ggaagagtgc agcctgcctg gcctcacttg cttcacgcac 2940
gacaacaacc actggcagac agccccgttc tggaaacctg gatctttctg tgcttgacag 3000
agttctaaca ataacaccta ctggtgtttg cgtacagtta atgagacgca taattttctt 3060
ttctgtgagt ttgtactagg ctttttgag ttttttgata tgaatacaga tccttatcag 3120
ctcacaataa cagtgcacac ggtagaacga ggcattttga atcagctaca cgtacaacta 3180
atggagctca gaagctgtca aggatataag cagtgcacac caagacctaa gaatcttgat 3240
gttggaataa aagatggagg aagctatgac ctacacagag gacagttatg ggatggatgg 3300
gaaggttaat cagccccgtc tcaactgcaga catcaactgg caaggcctag aggagctaca 3360
cagtgtgaat gaaaacatct atgagtacag acaaaactac agacttagtc tgggtggactg 3420
gactaattac ttgaaggatt tagatagagt atttgcactg ctgaagagtc actatgagca 3480
aataaaaaca aataagactc aaactgctca aagtgcaggg ttcttggttg tctctgctga 3540
gcacgctgtg tcaatggaga tggcctctgc tgactcagat gaagaccaa ggcataaggt 3600
tgggaaaaca cctcatttga ccttgccagc tgaccttcaa accctgcatt tgaaccgacc 3660
aacattaagt ccagagagta aacttgaatg gaataacgac attccagaag ttaatcattt 3720
gaattctgaa cactggagaa aaaccgaaaa atggacgggg catgaagaga ctaatcatct 3780
ggaaaccgat ttcagtggcg atggcatgac agagctagag ctcgggcccga gcccaggt 3840
gcagcccatt cgcaggcacc cgaaagaact tcccagtat ggtggtcctg gaaaggacat 3900
ttttgaagat caactatata ttcctgtgca ttccgatgga atttcagttc atcagatgtt 3960
caccatggcc accgcagaac accgaagtaa ttccagcata gcggggaaga tgttgaccaa 4020
ggtggagaag aatcacgaaa aggagaagtc acagcaccta gaaggcagcg cctcctcttc 4080
actctcctct gattagatga aactgttacc ttaccctaaa cacagtattt ctttttaact 4140
tttttatattg taaactaata aaggtaatca cagccacca cattccaagc taccctgggt 4200
acctttgtgc agtaagagct agtgagcatg tgagcaagcg gtgtgcacac ggagactcat 4260
cggtataatt tactatctgc caagagtaga aagaaaggct ggggatattt ggggtggctt 4320
ggttttgatt ttttgcttgt ttgtttgttt tgtactaaaa cagtattatc ttttgaatat 4380
cgtagggaca taagtatata catgttatcc aatcaagatg gctagaatgg tgcctttctg 4440
agtgtctaaa acttgacacc cctggtaaact ctttcaacac acttccactg cctgcgtaat 4500
gaagttttga ttcattttta accactggaa tttttcaatg ccgtcatttt cagttagatg 4560
attttgcact ttgagattaa aatgccatgt ctatttgatt agtcttattt ttttattttt 4620
acaggcttat cagtctcact gttggctgtc attgtgacaa agtcaaataa accccaagg 4680
acgacacaca gtatggatca catattgttt gacattaagc ttttgccaga aaatgttgca 4740
tgtgttttac ctgcacttgc taaaatcgat tagcagaaag gcatggctaa taatgttgg 4800
ggtgaaaata aataaataag taaaacaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4860
aaaaaaaaaa aaaaaaaaaa caaaaaaagc tgccgccaca gttagatgaa gaagcatgag 4920
gatccgagng ggtcgccctc ttgagtgggt agggagtcgc g 4961

```

<210> 75

<211> 3298

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1336022CB1

<220>

<221> unsure

<222> 76

<223> a, t, c, g, or other

<400> 75

```

ataaagttgg ccaacggtgg agctcccat tgtgaaaccc aagctttggg cattggaaat 60
ctcatttgag aaacantgat gagcagtagg cataacatca atagtttact gggcacatac 120

```

tggttagtat	tgccattttt	tagtttcccta	ttgatttttta	ctttttttatt	ttttaattttt	180
tttttctttt	ttttttttatt	taattttattt	gaggagtgcc	agacaatctt	tttattgttc	240
actgaaaaat	gcaggtctgc	aaagagtcaa	ttgcattgta	tattgaatgc	aagggtctgat	300
attgcaagta	tatatgacat	ggtataacat	ataaaatatt	acatatttta	cacagtgcaca	360
gtacccgccf	cttctaaca	ctaaaattta	atagaatgaa	gtaaaaagcc	tattaaataa	420
gaaacaaaca	ctgcaatcat	aaacaaaatg	cactaagcaa	aatactttta	aattgttgtg	480
tgtgacatct	atcttgtcta	cctggaggtta	ggaatgggtg	agcccagaaa	aaaactgagc	540
taacaaaaac	agccaacacc	ctccaggaac	tcttccctgg	aatcaggccg	ctggtgcccc	600
tcacaggctg	cccccatctg	atgacccagc	caggcttcag	ggctgcctga	gggcccacac	660
tgaatgctaa	cgctgtctg	gggctgggct	gagggtgaatg	ggaggagtac	caggtaggaa	720
gaagcttctc	tcccaactgc	ttattctgca	tccatgctat	ggatatgaac	acctagtgtt	780
tctggtgtga	atctgccact	ctccacaaac	attgaaatgt	gattgagaag	aaaatgttaa	840
cgctgggaac	aaaagccatt	ttctacgcag	tctgcagata	tcattcattaa	ttcctttcat	900
ccatgttttc	attaagatgc	tctaaaagag	gctgctgcta	ttatacagcc	agtcaggcaa	960
gccaggatag	aggtaacaaa	atttctccag	ttataactag	taattcaaat	gaatcaaaaa	1020
taaatatagc	ttatactaga	gagcaacaca	gtctctatta	ttcacatggg	aatatatattca	1080
agaattgcaa	caatattcac	aattctctaa	ggtcaacata	tttccctcca	agcagaaaat	1140
cctgaatgga	agggagtgtg	taacatcaat	aactcctgtt	tgtctcacat	aatatcaggg	1200
ctcagaaagc	tatttataga	taacaaatgc	aaaaataaaa	aaaaaaagca	tttcaatata	1260
tgtacagcaa	cagaggaaga	ctaggccctc	cctctggggc	tccttggcat	aaggcaaagc	1320
atggctattt	gcgacaacag	tgtctaagct	gactctggaa	aggctcatgt	tttacgataa	1380
atcagaatta	caaagttcct	tcattcacag	gttaacaaag	attattaaat	aatttctctga	1440
actaagacaa	cagtctcacc	atcaaagaaa	attttcttct	catctgagtt	tttataaatg	1500
agatttttaca	ataccagct	tttttagtta	atatgaaacc	atcggcgtac	agagaacatc	1560
ctcaaagctc	aagatgagta	aagctaatat	tctcagattt	tccacactct	acagagcagc	1620
aaatattttta	tcagaatatc	catttaacac	agtttttaagt	ccataataac	caactatgta	1680
tttttcttat	tcaaagaaga	ccatgttttg	ataagaataa	tccagtttg	atgagtatcc	1740
tattccctt	gatgttgtac	aataaatgtc	actgttgagt	ctctatatcc	ttgactcttc	1800
cagtcaaagg	aaaatcctgt	ataaagctgg	aaaactgcaa	actccagcgg	aagcactagt	1860
gtagtgctg	aagtaaaact	taggggaata	accacagctc	cttatcagac	tgtttacagc	1920
attgatagaa	gccctcctct	tcttttatct	ctattatctc	taaacattct	aatattttta	1980
acatgggggt	tcaactgat	cgataaagg	ctagttcatg	agtaaggttt	tgggtctctg	2040
aatgatgtgt	ggctagccca	aaacactggc	tatgttagct	ttaaactatga	tcattcttct	2100
tcccaccaca	atctgtcaaa	cccgccatc	cgctctgcc	ctgtcactcc	cccagccct	2160
caggattgct	gctcctctct	tctgaatgtt	ctactgcattg	tatgggtattc	actgagacat	2220
cacttttaatg	tataggtcat	ttgcatttca	tgccaccagc	tccccaaaag	acatcaactg	2280
ggaacaattt	ctaatagtaa	aggcacgatt	tgccagaatt	ttccctttat	aaaggaaatc	2340
aaaggacctg	tctggaagct	gaaagaacac	cttgggtatt	cctgtaaagg	gaacgctgta	2400
tctgctacca	aaaccagag	acactgacta	gatctaaaga	gcatatggat	tatgcaatag	2460
tgtgagattt	ggcagtttaa	gatctatttc	caatattaca	ttaagccatt	tgggtgaaaag	2520
tgttggttagt	atcacaggag	caaataaaaa	gtgtcaatga	cacccttttg	gctcatttcc	2580
ttgtgcttct	gggtataact	ccaccagctc	cagtgaagcc	tgtcccagg	cacatcactc	2640
agctccccgc	acagctgctc	agagagaaaa	caatgcactt	cacctcaact	agtccagcaa	2700
ctggcactca	gatggtgaac	gctgcagcca	acggccttgg	ggcagagccc	atggaaaagct	2760
ttaaacaggc	ttatagacat	tgcataaaaa	ttcctgattt	taaaataacct	tcccaaggaa	2820
gtcacaaaa	aatcattttt	agtttaataa	atgtaatcta	tactcaaaaa	caatgtaatg	2880
cctcagaaag	caaaacctgg	aatggaagca	cttcagaaaa	atacggctta	atcagtatct	2940
tactttggct	aagttaccac	agtcagcgta	atttattatt	gcatttagaa	gccaaccta	3000
cogtgttctc	ctaagatgg	gaagtacacg	caaacagtga	gcaggggtga	tagcccttta	3060
gccttttgtg	acttcagaac	ttaggaagat	aaacgataac	caggatttga	cattcagata	3120
cttacttgct	cagcagcagt	tgagtttagga	aacagctaaa	gaccagattc	tcattccatt	3180
aagggtgttc	caggaagctc	ctatttggat	accaaacag	tgggtctcaa	catggctgca	3240
catcagaatc	acctgggaag	cttttaaaaa	tcaccacgta	gccaccattg	ccaatacc	3298

<210> 76

<211> 833

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473674CB1

```

<400> 76
cacggcgctct gctggcgggcc gcggagacgc agagtcttga gcagcgcggc aggcaccatg 60
ttcctgactg cgctcctctg gcgcggccgc attcccggcc gtcagtggat cggaagcac 120
cgggcgccgc ggttcgtgtc gttgcgcgcc aagcagaaca tgatccgccg cctggagatc 180
gaggcgagga accattactg gctgagcatg ccctacatga cccgggagca ggagcgcggc 240
cacgcgcgcg tgcgcaggag ggaggccttc gaggccataa aggcggccgc cacttccaag 300
ttccccccgc atagattcat tgcggaccag ctgcaccatc tcaatgtcac caagaaatgg 360
tcctaatect gagtcgtcac ccttggattt tatggatcac ggagctgacc atctttacct 420
ggctcctgga ctgaaaaact gtagcttggtg tgaaaatgag cctttggacc agtctttatt 480
aaaacaaaca aacatgagta gtctgcatac cgaatatcta gagctctaaa ccccccaata 540
cttaaaagtc taattgctgt cctgtgggtt cattagtctg ataggaagat agggatttcc 600
tcagtcacag atgataattt gaaggaaagc tgcaataaag ccacaatgat ttgagggtctt 660
tgcttaagta tgagatactt gatgggggct ttatcatgca acattagttt gcttacctta 720
agaattgccc aaaaatgaaa gaaaatatga gcttttcagt taaacatact ctaaaaaaca 780
ttttccggga ttttactact aaaattggac atttaagcga agtaaaagag gcc 833

```

<210> 77

<211> 920

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7475846CB1

<400> 77

```

cacaccaacc ggcccaggcc ccgctggctt cagcctggtc acgacctcca cggcgcgggc 60
ctgtctgtct ttggccgggc catcctgtcc tggccctccc tgccacggc tccgggaagg 120
gctctgccaa gagacttctc cattcccacc cgtcactttt gaggatccgg ctccccggtc 180
cctcctgtgc cagccagcat gtgccatggc tccccgacct tgtgccagcc cgtgtgtgcc 240
atggctcccc accccgtgcc agcccatgtg tgccatggct ccccaaccct gtgccagccc 300
gtgtgggcca tggccccacc gaaccctgtc caaccgcgt gtgccatggg ttccaccgac 360
cccgtgccag cccgcgtgcg ccatggcttc cctgatccca tgccagccc cgtgtgcgcc 420
atggctcccc cgaccccggt ccagcccgcg tgcgtcatga ccccaccgcg tgtgcgccat 480
ggcttccccg accccatgcc agcccgctg cgccatgggt ccaactgacc tgtgccagcc 540
agtgcgggct gatctgtgtc ccagctgtgg gcgtcctgaa ccccaggccg tgggacaact 600
tgggccggga gagaagatct ttcactttga tttggggcat aggtggaggc tccccctacg 660
gccctgtgtg gaggacctg tttcctgggt gctgtgatgc cactggcctc gaccctggct 720
cctcatgcgt gtcgcctgcg ggcgtgaggt ccgtgcagag gaaggaagaa agaggaagta 780
agacgtgagc tcggccagcc ccgggtgcag gaggagtggg cgaagcgggc gacagggtcc 840
catgccttcc ccttccttcc tcaggcccg cctccatctc tcccaccaca ccaggcgctt 900
gctgggtgat ggccgggtca

```

<210> 78

<211> 964

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7475860CB1

<400> 78

```

cccatggcgc ctggttgtct agacgagccg gtgtaccgac tccccgggtg atgataacta 60
tgagtgcaaa agcaagacgc gcactttcct gtcacctcgc cttttcacc cctcgggaag 120
atcaaagtgt ctttagccca agcatggcct tgagcgactt catcacacct gcatgaggtc 180
acaagcagtc actagcgcag gggggtgagg cgagttcttg gtgaaagaaa cggggcgggg 240
ctgaggccaa ggaagagggt ggactgtgtc tccatgtctc ctgacgcaga aggttttgaa 300
ccttttttca cctcgtctga aatggctgcc tcccagtgtc tctgctgctc aaaatttctc 360
ttccagagac agaacctcgc ctgtttctc acaaacccac actgtggcag ccttggttaat 420
gcagatggcc atggtgaagt gtggacagat tggaataata tgtccaagtt tttccagtat 480
ggatggcgat gcaccactaa tgagaatacc tattcaaacc gtaccctgat gggcaactgg 540
aaccaggaaa gatatgacct gaggaatata gtgcagccca aacccttgcc ttcccagttt 600

```

```

ggacactact ttgaaacaac atatgataca agctacaaca acaaaatgcc actttcaaca 660
catagattta agcgagagcc tcaactgggtc ccaggacatc aacctgaact ggatcctccc 720
cgatacaaat gcacagaaaa gtcaacttac atgaatagct attcaaagcc ttaaattggg 780
catcactcag gatgtgtata agatcttaat attgactagt ttcacatcca ggtttctaag 840
aaatgataag atacttcact tttccagagt gaaatgtagg agggagcaca ttctaagtac 900
agctaaaaat ttagctcact gtaacacagt ttcactctct gaataaataa agcaaaaaaac 960
acag

```

<210> 79

<211> 701

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7950941CB1

<400> 79

```

ccgctactgc gctatgagaa accagcaca ttatagcctt gagcattcta agcattttac 60
agttttacaaa taatcctttt atgatgttaa cagcttctct atttattaag tgcctagcat 120
gtgtcagacc tcatgttagg tattgtgtag gctttacctc acttaattct ggaaggtaga 180
tattctaatt ctttccattt tatagatgag gaaacaggct cagagagact aagttattgg 240
ataaggctac acagctcata aatgggtggag ctggatctca aaccagagc ctctgggtgt 300
aagtcctgaa ttttaggaagc atctggaagc cctatcaagg gtgtagacac caagagtcac 360
cagaatggct ccaaateccag ctcgtttgca cagtcatttg gatttagtga gtccatccgt 420
accaaggtct ctgggctttc aacttcctat aggcaggaag cagtcaagaa atgtgctaag 480
ccaccaagat gggcatattc tccaatgttc ctttaggcca gacaggagga tgaaaaggaa 540
ggctgagagc ccagagaaca atcaactgag gtgccatctc ccatgccagg gtggggaccc 600
agccatgttg cccagcagat ttcagaattg ctgaggacca gtgactgccg atgccctttc 660
cagcacatgg cggccgtaca agtgatgcga gctcgtacca g
701

```

<210> 80

<211> 1742

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7485334CB1

<400> 80

```

tcgttgaaat agttgggtgg ctaagagagg ggtctccacg tcgggggacgc ggagggggacc 60
tgccgagttg gcgctccgaac gcatagagcg gggccacccg cgccgctcca ccattacctc 120
cccaggcggc aaggaggagc tgggtggcgg cgccctcccg ctgtggcagc ggcggcgccg 180
cgcttgcttg gcgccgctcg gcgtgctctt ggccatggca ctggggctgc tgatcgcggt 240
gcctctgctg ctgcaggcgg cgccccccg agcggctcac tacgagatgc tgggcacctg 300
ccgcatgata tgtgacccat acagcgctgc tcccgaggg ggaccgcgg gcgccaaggc 360
tccaccgccc ggaccagta ccgctgccct ggaagttatg caggacctca gcgccaaccc 420
cccgcctccg tttatccagg gaccaaagg tgatccgggg cgaccaggca agccagggcc 480
tcgggggtcct cctggagagc cagggcctcc tggggcccagg ggtcccccg gagagaaagg 540
agactcgggg aggcagggc taccgggact gcagttgaca accagcgcg cggtggcgt 600
tggagtgggt agtggcgaa ccggggggcg tggcgacacg gagggagaag tgaccagtgc 660
gctgagcgcc gccttcagcg gtcccaagat cgccttctac gtgggactca agagcccca 720
cgaaggctac gaggtgctca agttcgacga cgtggtcacc aacctcgga atcactatga 780
ccccaccacg ggcaagttca gctgccaggt gcgcggcatc tacttcttca cctaccacat 840
cctcatgcgc ggcggcgacg gcaccagcat gtgggcggac ctctgcaaga acgggcaggt 900
ccggggccagc gccattgcac aggacgcga ccagaactac gactacgcca gtaacagcgt 960
gggtgctgcac ttggattcag gggacgaagt gtatgtgaag ctggatggcg ggaaggctca 1020
cggaggcaat aataacaagt acagcacgtt ctcgggcttt cttctgtacc cggattaggg 1080
gcgcgggggg tgcgaggcgg ggtggctgca ggccgcccgg tctccgccc ggcgcggctc 1140
cttggcaaaag gccactctcg attcataaca cttcctgaca tctcctttgg aaaagacaaa 1200
tccctgcgtc ctccctgccc cgctcctggc ctcagtgcgt ctgcgaccca ccacgctcag 1260
ggctgtgctc ctgggtctcca tccccatccc ggcaaggag gaagggacgc ccgagccctt 1320

```

```

gaggcggcgg cacagacttt gcaaacctga ttagcctgga caggcagggc cgggagcctg 1380
ccctcctcag acagcctcct cccagtgcct agaagcggag ggctccgggc cctggccagg 1440
gaggtaggcc agaggggagcg cgggcttcct ggggcgtcct tctttgtgac ccgaaatact 1500
tgtgcagatt tccctgtcca tcagccaaaa cccacccac agcagaattc cagcaaacag 1560
aaaattcacc tctccacacc gcattccctc ctgactcaga ctaccgcga tgcattaaat 1620
tatgttttta gaaaaaaaaa agaacaaaaa aaaagcaaaa aaaaaaagga aagggaaaca 1680
caaataccga gagacaaggc ggtgccagaa aaaaaaaaaa gggggggggc ctcttttatt 1740
ta

```

<210> 81

<211> 2295

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7220001CB1

<400> 81

```

ggaaggatat ggatcagtgt tttctttttt gaagctactg ttaccactcc tggaaaagtt 60
cttcaggaat aagtgcagct aagaatgaca agggattagg actggcttcc tcttataaat 120
aataaaatcc aaagagaagt gacttgagtc tccaggttta aagaagagca actagaagtc 180
gtccaaacac ctgcattctca taaggagaag aaaagtccac ctggatcttg tttctggact 240
gagatggatg gagaggccac agtgaagcct ggagaacaaa aggaagtggg gaggagagga 300
agagaagtgg actactccag gctcattgct ggcactttac cacaattctca cgtcaccagc 360
aggagggcag gatggaaaat gcccctcttc ctcatactgt gcctgctaca aggttcttct 420
ttcgcccttc cacaaaaaag accccatccg agatggctgt gggagggctc tctcccctcc 480
aggacccttc tccgggcat gggaaacact aggccttcct cgcccctctg ctggcggggag 540
gagagctcct ttgcagctcc aaattcattg aagggtctca ggctgggtgc aggggagcct 600
ggaggagctg tcaccatcca gtgccattat gcccctcat ctgtcaacag gcaccagagg 660
aagtactggg gccgtctggg gcccccaaga tggatctgcc agaccattgt gtccaccaac 720
cagtatactc accatcgcta tcgtgaccgt gtggccctca cagactttcc acagagaggc 780
ttgtttgtgg tgaggctgtc ccaactgtcc ccgatgaca tcgatgcta cctctgcggc 840
atttgaagtg aaaaacaact gctgttctta agcatgaatc tgaccatctc tgcaggtccc 900
gccagcaccc tccccacagc cactccagct gctggggagc tcaccatgag atcctatgga 960
acagcgtctc cagtggccaa cagatggacc ccaggaagcc acccagacct taggacaggg 1020
gacagcatgg gacacatgtt gcttccacat ccaggaacca gcaagactac agcttcagct 1080
gagggaaagc gaacccagg agcaaccagg ccagcagctc cagggacagg cagctgggca 1140
gagggttctg tcaaagcacc tgctccgatt ccagagagtc caccttcaaa gagcagaagc 1200
atgtccaata caacagaagg tgttcgggag ggcaccagaa gctcgggtgac aaacagggct 1260
agagccagca aggacaggag ggagatgaca actaccaagg ctgataggcc aagggaggac 1320
atagaggggg tcaggatagc tcttgatgca gccaaaaagg tcctaggaac cattgggcca 1380
ccagctctgg tctcagaaac tttggcctgg gaaatcctcc cacaagcaac gccagtttct 1440
aagcaacaat ctccagggtc cattggagaa acaactccag ctgcaggcat gtggaccttg 1500
ggaactccag ctgcagatgt gtggatcttg ggaactccag ctgcagatgt gtggaccagc 1560
atggaggcag catctgggga aggaagcgtc gcaggggacc tagatgctgc cactggagac 1620
agaggtcccc aagcaacact gagccagacc ccggcagtag gaccctgggg acccctggc 1680
aaggagtcc cctgaagcgt tacttttcca gaagatgaaa gcagctctcg gaccctggct 1740
cctgtctcta ccatgctggc cctgtttatg cttatggctc tggttctatt gcaaaggaag 1800
ctctggagaa ggaggacctc tcaggaggca gaaaggggtc ctttaattca gatgacacat 1860
tttctggaag tgaaccccca agcagaccag ctgccccatg tggaaagaaa gatgctccag 1920
gatgactctc ttcctgctgg ggccagcctg actgccccag agagaaatcc aggacctga 1980
gggacagaga gatgaactgc tcagttacca tgggagaagg accaagatca aaggccttca 2040
ggacccagc ctctttccat catccttctc ccacctgtgg gaagagaagc tgatgcagcc 2100
ggtgctccac ccatggaaga aaggctggct gtccttgggc ccaagaaagt caagcattat 2160
ccacgtccag aaggtgacaa gatgactcaa aggagacttc aagaacagtg tatgaaacac 2220
tggaagaggt cacctaggaa aagcatgaaa tttccagggg atccactagt tctaggcgcc 2280
gccccgcgtg gctcc

```

<210> 82

<211> 911

<212> DNA

<213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5956275CB1

<400> 82
 gccgctctcc gctccccgggc cccccgccggg cagcgcgccc cccgcgggag atggaacagc 60
 ggaaccggct cggtgccctc ggatacctgc cgcctctgct gctgcatgcc ctgctgctct 120
 tcgtggccga cgctgcattc acagaagtc ccaaagatgt gacagtacgg gagggagacg 180
 acatcgaaat gccctgcgcg ttccggggcca gcgagaccac ctctgtattc ctggagattc 240
 agtggtggta cctcaaggag ccaccccggg agctgctgca cgagctggcg ctcagcgtgc 300
 cgggcgcccc gagcaaggta acaaataagg atgcaactaa aatcagcacc gtacgcgtcc 360
 agggcaatga catctcacac cggcttcggc tgtctgccgt gcggctgcag gacgagggcg 420
 tgtacgagtg ccgcgtgtcg gactacagcg acgacgacac gcaggagcac aaggcccagg 480
 cgtgctcgcg cgtgctctcg cgcttcgcgc cgcccaacat gcaggccgcc gaggccgtgt 540
 cccacatcca gagcagcggc ccgcgtcgcc acggcccagc cagcgccgcc aacgcccaaca 600
 acgcggggcg cgcgagccgt accacctccg agcccggccg cggcgacaag agcccgcgcg 660
 ccgggagccc tcccgcgcgc atcgatcccg cagtccccga ggccgcggca gcctcggcgg 720
 cccacacgcc caccaccaca gtcgcggcag ctgctgctgc ctctcagcg tcgccgccat 780
 cgggacagge ggtcctgctg cgccagaggc acggctcggg taaggagcgt agctacacca 840
 cagaccact cttgtccctg ctctgttag ctctgcataa gttcctgcgc ctgctcttgg 900
 gacattgaca g 911

<210> 83
 <211> 1806
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 346472CB1

<400> 83
 aaggctcctca ggtgtttgaa gagatagttc taagtaaattg aaaacaagca caaaaataag 60
 cacaagcatg gatgctttac atgagattac aaagagggga gagaggattg atggctccac 120
 agtttagcct aagggtagac tgggaattgat ggggtctgag gcctgctggg cttctctaac 180
 aggtggtcac tgtggacccc gggccttctt ctctctgatt ttaggtcatc ctcagtcctc 240
 agagagtaga ccatcttaga ggcaggaccc caggtaccct gaaattaccc tccagctccc 300
 taggtctgca gtctgtctct cactgacagt ttctcctga agagaagcat cttcccctgt 360
 cctgactcag tgtctcagtt ggagcgctgt ggtctccct ttcctcgggt tggctctcga 420
 gaactacctg ggaggtgct gggtaactccc catctcttcc tgcactcagag cctgtgctcc 480
 ccttttgggc tgtccctggg gtttgtttct ctgttgaggg aggacactcc cagctctctg 540
 cacttttgag cagcagagat gtggagacac tgtcactggg tccagcagct ggctcagggt 600
 acagcccacc cacttctctg ggagattgtc tttagctcat tgcccataatg gtcccagggc 660
 aagggtgggc ctattgtttg tcttttaatt aaaattttat aaaatatgat gttttaata 720
 tcccaggat ttgcatactt cccaccagga attaagaggg ctgttttgct atagtttaag 780
 cccattgtaa agtaattgat aaaaaaatcc agtgccatga gttgagaggg ttagaaaaat 840
 aatagaaatc tttgttaata ctactctta tatttattta aatctacata gtgaatcttc 900
 cctgcctttt acccaacgat tctttccata aagaaaaata attaggttaa tgcaactgta 960
 attcaaagca aatatggtat tcatcttttt tcttttttct ggatgccttt tatgttttag 1020
 tttcttacia agcaatttcc agcactcaga taaaccattt gagaggaaca gacttagaat 1080
 tccatattca cagaactgtg ggatttttaa accacaaagg aaacctagag atcctagaag 1140
 actgttctgt ggatgtggaa agttcaaata tcccccaaga ctgcacagct aattagaggc 1200
 agagctgggg taaggactca ggtttcctgg ctctcaactc aaatctcttt ccaatatcat 1260
 ttctcaaatt ctaagatcag aagttgaatg aaacgattcg cttcacattt cttgtggttt 1320
 gaaacatgag cttctcagaa tctccagctt cagtggggtc agggtaacgt attggctgct 1380
 actgatggag gccagacaga gcccgggcca ggttgggggtc aggaatgtcg ttaggagaga 1440
 gggattcccac atttaagctg cagagagagc agtgagtgat gatagaagca ggaaatgcc 1500
 gaggccccag gggtcgggcc aggtgaggaa acaggtacct ccaactcgctc cttttagggtg 1560
 ggccctgccct gctgcccagg gctaagtggc tccccacagt ggctcagaaa catcaccgta 1620
 accccagtgt ttggaggaga tcatttcaac taaggaggaaa aaacttttct ttttttaagt 1680
 aaaaaggatc tatttgaaat ttgtcattcc aaactagact tggagacagt tgtaaatctc 1740
 actcttttta ttctgggagc actctgtgct tttctagctc attctgttaa aaagaaaaaa 1800
 aaaagg 1806

<210> 84
<211> 603
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 643526CB1

<400> 84
gtagtcagtt accttcattt ctcgatgttt tcagagggct aatgctttgt gcaggggtatt 60
tattttagtc tgaattattg tccttggttt cacagaggat atattaaagt atttttttgt 120
gttgaagttt gggctgtgat ccagtagatg gtgcttaagc atgctggctg ataggtagac 180
tggtgttcag tcacatgact actctgtatt tgcccgcat tgcagctgtg ctctctctct 240
ctcagtgtct tgagagtgtg ggctcctttc ccactcaagt gctggctgca gatctgggtt 300
tggcactcct ggacgtcata ctacagcccc ggggtaagct cagcctttat gttccctcca 360
cagcatgggg gcaaacacga accttgacag tggcaatggc agagggcctt taatttgtct 420
cttggggctc tatcccagag acatgcagaa ctgctgtcaa tcagagtgtg tggccttgtg 480
tgggggtggt gcattgtggg ctcaagcctg ggggcccatg gggaacacag actggcctct 540
tcttacagca actgcagcat gctggagggtg tgagtaaggc actcaggggt ctctgtttct 600
tcc 603

<210> 85
<211> 1888
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1483418CB1

<400> 85
atgaaagggtg tgtggaaagt ggccagcatt ctgcctgcag accctgagca ctgagtcaac 60
aaggtttgtg atgatgtctg tactagttag ctattgttat taacaagatc tccatggcag 120
acaagctaaa gcatctgect aagtcgtgag tctgtgggtt ggctcagggt aagctgagct 180
tggctgggct tggcagcaag tctcagattt gatcaagtca tattcgtttt cttcttcggc 240
tggtgggcta cccagagcga gcacgcttct ctcggtgtca tgccaagaac acaggagggt 300
gagtctaaca agcacacctc aagcctctgc ttgggtcaca ttgccaatgt cctctcagcc 360
catacaagtg gcaggaccag gcccaatatt aaggagtggg aaagtgtagg ctgcccttgg 420
tgaagtgtg acaagggagt gaccatccat cccctccaca ggagggtgag gaattgggac 480
aggaattcc agccaatacc tgggtccatag ttcttcacat tgtgagtata tgaatacggg 540
gaaatagaac cccctcccca ccacctacac acatgctgtt ttaccttcca agaataggac 600
atgtgcaaaa actaggcttc cagatcgtga ggctggggag cattctaggt accatttatt 660
atctactgcg ttctcggtcag tagctgttgt aggtacccgc atcagccctt gttcctaagg 720
atgtgtggag cccaggctgt actctttgac attccacagg tcagtctgcg tgaaagccct 780
ttgtggggag ttccaagcc agtgtcgttt ttgcactggt ttccacctca ctgtcagata 840
ttgttctttt gatatgcagt ttccagccct ccaatgagtc cccagcacag atctcaggct 900
tgtggctggg aataagccca gctgagcagg tggggatctc agccagcctc ccagactgca 960
cctcttctat tgcctctctc tgtccaccgt tccaggcagc agcactcca cctggctgct 1020
ctgatgtcct cgctccctcc attcctgcct ctccacctgc acgcatccat tgtccacaca 1080
cacacaacca gataatcttc tgaaagtgtg actcagatga tgcctccaac cctgtggcta 1140
cccttcacac ttacaggcct aaccccagca ggacctgcca gctgcttcat gaacaagtcc 1200
ctgcctcatg ttaattgcaa gcactcattt cactctccct gtgtgccagg caatagcata 1260
agcatgggaa gaatacagat gttatagtga gtcctacaat agccctggaa ggcaagagct 1320
gtttcctttc catttctaca atgagtcaat tgcagatgat gctataacac ttccagtgtt 1380
tctgacactt ccctgaagct atacctgcta ccttcattgg ccgagcttgc ccttatgagg 1440
cccacagggt gcagtgggca gaggggaccc cgctatacca cctcgctgct gttccactgt 1500
ctgctcccggt gttctgacca cagctctggg gccgtttctc aagcctgggc ttcatccaac 1560
attttctatc tagctcttca tgggtgctgt cccgctatgg ttccacaggg cttctctctg 1620
caggtcagct ccttagagag gtctccagaa ttcccgttaa agcagccctg cagcctctgt 1680
ctctctcage cgcacacccc tgttgcttcc ttccacagcat gtctcaccat ctgcaaccat 1740
ctttctgttt gtcgtcttgt tgatttgcgt cctccacact gtcagctcct tgggaacaga 1800
gattgggttg tttactgtgc atccctgggtg cccagaacag ggcatggcat attgttgggt 1860

cataataaat atggtggaaa ctaaaaaa

1888

<210> 86

<211> 1576

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2683477CB1

<400> 86

```

aaacaaatta gcaatgtaaa gaacatttgt tgagttcagt gttggagaga gcagttcaca 60
gagctgccga gaagccacag ctgacccttt cctctctcct cttggttagga gccagctgca 120
aggagagggg cctaagggtg tagagggaat ggctccctcc tccacagctc tgcattgcgtc 180
agcccccaaa atagaaatgc ggggaccaag ttgtgatggc agggaaacag cagaaagagg 240
tgaggctgcc tgtgctccct gccctccagg cctccacagg ccaacctgtg acctcactgg 300
tgggcctcca gaagcaggga aagacagagg cccagcatca cctttccatt tccgcatttg 360
ttttctcttc cttgctggtg tgcattgact ctgtggtcac tgttctccat gtcagcacat 420
tcaaaaattgc tgactgtcaa cactgaaggc agcgtggctg ctactgaaga agccacaagg 480
aaaacagctt tgggcaatgg tggatgttct tgggtgtgaca ctttctagc tcccagcaca 540
ggccctttac aaagaacagg gctttgtggt ttgggttagga tggggagaaa gaaagaggga 600
gggagagaga gaaggaggct tggcttgttg agatcttttg ttaaggaaat aaatattggg 660
ttcctagaat ttgaacagct gaaatgggag attggcagta agcaaaatgt gattgtaaca 720
atcaaaccce cgtgcagaca gaagtgggga gtcattaggg caatgagggt gttcttcacg 780
atcttgggag gaaagaaaag gtgacccaaa tgccatttag taaccgatg gcctcttcaa 840
gcccttcagg ctggcccaga gctgcaggca aagctttgat ggtgtgggtg gtgctgttcc 900
cttgggcaga gcttggctgg aggactctta gcagggtggc cgcaagtctc tggggccctc 960
acttggggac ttacacagac caggctgtat gtctttgtag cttgtcaaac cacaactatt 1020
cacagaaggc gtgtggttta gaatctacca cagtcaaacc cgggagaatg tgttaccag 1080
ttccagaaaag gttgctagtt tgtgtgctgt aatggaaagt ggccaacttt atcttttctt 1140
ataagaacta caatgggcaa tcaggatgga ggcttgatct acaggactct ctactgaggg 1200
tctcctgtga aaaagggtgat aggagggagg tgctggttgt attaatacaga gtcctctaga 1260
gacagaacaa atagaggata aagagagaaat tcattttaaa gaactggctt atttgactgt 1320
gggggctggc aagtccaaaa tctgtagacc agactaccag gctagaattt caagtgatct 1380
gcccgttca gcctcccaaa gtgttaggat tacaggtgtg agccactgca cgcagcctaa 1440
tagcccttcg taagctttta tttaatggct ccatccttct tcaccccttg gcccccttaa 1500
tactagactt gctaccaga aattttctgg gatctttttt tgcttacaa actttcctgc 1560
tactggagac aaaaaa 1576

```

<210> 87

<211> 415

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5580991CB1

<400> 87

```

ctttcccaga aagccttttg aaacctgtt ttattatgaa aatattcaaa cattcacaaa 60
actagagaaa atacctattc ctagattcaa cagtgatgaa cataatgcca tatttgcttc 120
aactttcatt ctctctctc cttttctccc tccctttttc tctctgcect tcttctctct 180
ctctattgtt ttttcttttg gctgtggggt tttatttttt ttttgagacg agtcttgctc 240
tgtcaccag gctggaatgc agtgggtgcaa tctcggctca ctgcaagctc tgccctcccg 300
gttcattgcta ttcttggggt tcagcctgct gagtagctgg ggctacaggt gccaccacc 360
acgcccggcc aatttttggg atttttagta gagatggggg ttcactgtat tggcc 415

```

<210> 88

<211> 762

<212> DNA

<213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5605931CB1

<400> 88
 ttttgtgggtt gttttttgtg ttttttgatt tgtgttgttg tgccaggtaa taatgtagtg 60
 ccatgcctgt gttcttcttc ttctttttta aatagagaca gattcttgct atggctatgg 120
 ctacagtctt acccaagctc ttcttgaagc cccggcctca agtgatcctc ccacctcaac 180
 ctcccaaggt gctgagatta caggcatgag ccatcatgtc cagccttcaa ccagatttct 240
 tgacagcacc tttatatgtg attcttacac caatcttcat tgttaacccc attttaaaga 300
 agcagaaacc aaggcccagg gaggctacat aacttgccag agctctcaga gccaaaaagc 360
 aacagatgtg gaattcaaac ccgggcattc agatgcccaa gtcccttgca ctcccactct 420
 cccaaactgc ctcagcctga gcaagcccaa cctgaagcct tcctcctgga gtccaaagtc 480
 cagccaggaa tgtgacatgg gctcccagc cctccagatg tgtgtgctca cactttgtct 540
 ggacttggtc ctccttgcc ttctgaacgt ctgccctcag atgtcccat tagtcacagt 600
 ctgtctgaga gccctcggat tagctggatg ggagcagacg caactttgtg gtgggtcatca 660
 gggtgtccca ttcatacagc caggcctgag cctgctggag tgtgggtcgt gccagaaaca 720
 ataactctta ggaaagaaaa ccagcctcgt gccgaattct tg 762

<210> 89
 <211> 654
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6975241CB1

<400> 89
 gtttaaaccgc gcacccccag ggcgagacct ggggttaaagc aaaagggcta acaagggcaa 60
 cccagaatcc ggcagggctg cagtgaaccc tgcccagcac actctctgct gtgaccttg 120
 cgtgattcta ggttcacacc ttcccatcag tgctgtgagc tcctgggtgct gtcagcgatg 180
 gtttcatctg tttccattag acaaagtcag gttctagttt tgtgcctgtg tctgtgccta 240
 gaacagaaat tgggtaccagg tgtgatttgc aagcaagaga tcctcagaga aatgggtatg 300
 tgggaggaca ctggagttgc cagatctagt tgtactgaag tcaataaaaa tccagctgg 360
 tcttcctgga tgggaatcca gcagaccagg gtcacaaca gcggaagagc tacatacact 420
 ggtgcctgtg attggctgca atggagccca ttgagggcaa gagatccagc tgccataaaa 480
 caggagaagc tacaggtagg gagccgattc taatgcatgg agaactacta ggctagagca 540
 aaggcccagc ttctccatgc aacgcgcaga agggttccta gagcttcag cattatgctg 600
 agagaatctt ttctaaggct cccgtgtgtc atagcagaaa accagaggca aaac 654

<210> 90
 <211> 505
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6988529CB1

<400> 90
 ttttagccaaa gaatcaaagc attggtgaag aattgaagat tggaagttac acattttttg 60
 ctaagggaag taatagagaa agaaaaatat tcctggaggt aaatcttcag tttggattaa 120
 tgtgaacatg aagaaacctg tagaaacctt catttctcaa gacaaagctc aaattcaagg 180
 ttgtgaggaa tgcagtcact gcttttggtt ggggcagttg tgacagtgat tgcagaaact 240
 gagattgcaa agcccgtatt atataaagaa tgtgcaagt ccatagaaga cactgcaagg 300
 attgggtgct ggagcagtgc tggacctgcc gtcataacca gagtgagca gagagaatct 360
 cctcctttgc catcactaac ccagcacttg actttgtccc actcctaaaa gatcttgga 420
 ggaattaaag gtgcttggtg gttcttcatt ccagcataac cttacttggc ctgaccatga 480
 accatgcatt agtctttgga caggg 505

<210> 91
 <211> 841

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 6996808CB1

<400> 91
ttcaatgagg gtgactcatt ttgtgactga gacaaacatt cacatgtgga ccatgttaaa 60
aataaataaa taaatggcag gtgctgcttg gctaaattct gtgttttaaat gctgtaattt 120
cctgccgtaa ggggttcacgt cttgtataat gtctactcag cctctgtaat cactagccca 180
atatatctaa tgcacctcaa ttcattgcta ctcatttctt gattatttat tttagttcct 240
aagggctttt tgaattgtaa caatgtgatt tcaacaggga agccaaggaa tggatggggg 300
ggagccacag ttagccggaa aacaaagagt gacacataag ctgtagcaaa aggacatgtt 360
ctgtgctttt ctgtttttgc cattttccca agatgttttg tgcattgtgt ttggtaaagt 420
tgtcttagtt atgtttatatt tattatgtat atgttcagta ttggagctct ttttctcaag 480
tggaagatgc tttgaaagca ctctcttcat tgtggcccat gtatcaaate taatctcaaa 540
aattttacia gtctactctc tcaggagaat tctgtttatt tattgtacag atatgctatg 600
tactaggcac tgtgctatgg caaactaaag caggcggtgg cactatctt cttgaaactt 660
tttcagatct gtttggggag ttacgtacta ccacaaatac atcctcacgc aaattgaatt 720
gcaaattacg cacatcacta cgtaggtaag taaggatctc taaatatgca ttagttacct 780
gagtggtaga tgaggtggcg gaagaagcct agttggtgcc gcaaagggaa atcgttggga 840
a 841

<210> 92
<211> 1367
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472689CB1

<400> 92
agacattaga ttggagattc agacctctcc gtgatgtgac atttgagcca agatgatagg 60
gagccagacc tgggaaattt ggggacagga aacagcaagt gccgaggctc tgaggtggca 120
gaggaacaga aagaagtga atttggtctg gggtagttaa ctcattgtctg agagtcataa 180
tggggacatg tgctaagatg cgtgagaaag tgctctggaa actctttagt gctgcataaa 240
gggttaaccgt tgcttttget gatgttcgtg tgatgtatgt ttcaggacct ctagtgaagt 300
tgaacaagcc acagggtcta ccagtgcag gtatgggccc gggatgtggg aaggggaatgc 360
agcgggaagg ggtttcgtga ctgagggagg gaaaagtga ggcatgaagc tttggcctct 420
tgtaattttt ctttcttact ttccaggaaa accaggagag ctgacgttgt tctcagtgtc 480
gccagagctg agccagtcct tagggctcag ggagcaggag cttcagggtt tccgagcatc 540
tgggaaagaa agctctgggc ttgtactcct ctccagctgt cccagacag ctagtcgcct 600
ccagaagtac ttcacccatg cacggagagc ccaaaggccc acagccacct actgtgctgt 660
cactgatggg atcccagctg cttctgaggg gaagatccag gctgccctga aactggaaca 720
cattgatggg gtcaatctca cagttccagt gaaggcccca tcccgaagg acatcctgga 780
aggtgtcaag aagactctca gtcactttcg tgtggtagcc acaggctctg gctgtgccct 840
ggtccagctg cagccactga cagtgttctc cagtcaacta caggtgcaca tggtagtaca 900
gctctgccct gtgcttgggg accacatgta ctctgcccgt gtgggcactg tcttgggcca 960
gcatattctg ctgccagctg agaacaacaa gcccacaaaga caggctcctgg atgaagccct 1020
cctcagagcg cttccactga cccctccca ggtgcccag ctgcccttg accctcacct 1080
acatcggtc cttctcccag gcaccagggc caggacacc cctgttgagc tcttggcacc 1140
actgccccct tatttctcca ggaccctaca gtgcctgggg ctccgcttac aatagtcctc 1200
cctctgttcc tgacccctc acacacactg gaaagtgagg gtgggggctc tgcagtcaga 1260
caaacctaag atcacatcct ggacaggcca cttgcttget gtgtggcatt gggcaagtaa 1320
ctttacctct ctggacttgt gataataaaa gttcctacct caaaaaa 1367

<210> 93
<211> 4595
<212> DNA
<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 876751CB1

<400> 93

```

gaggggggctc cggggcgccgc gcagcagacc tgctccggcc gcgcgcctcg ccgctgtcct 60
ccgggagcgcg cagcagtagc ccgggcgccg agggctgggg gttcctcgag actctcagag 120
gggcgccctcc catcggcgcc caccacccca acctgttctt cgcgcgccac tgcgctgcgc 180
cccaggacccc gctgcccac atggattttt tcttggcgct ggtgctggta tctctgctct 240
acctgcaggc ggccgcccag ttcgacggga gtaggtggcc caggcaaata gtgtcatcga 300
ttggcctatg tctgttatgg gggaggattg actgctgctg gggctgggct cgccagtctt 360
ggggacagtg tcagcctgtg tgccaaccac gatgcaaaca tgggtgaatgt atcgggccaa 420
acaagtgcaa gtgtcatctt ggttatgtcg gaaaaacctg taatcaagat ctaaagtagt 480
gtggcctgaa gccccggccc tgtaagcaca ggtgcatgaa cacttacggc agctacaagt 540
gctactgtct caacggatat atgtcatgac cggatgggtt ctgctcaagt gccctgacct 600
gtcccatggc aaactgtcag tatggctgtg atgttggtta aggacaaata cggtgccagt 660
gcccattccc tggcctgcag ctggctcctg atgggaggac ctgtgtagat gttgatgaat 720
gtgctacagg aagagcctcc tgccctagat ttaggcaatg tgtcaacact tttgggagct 780
acatctgcaa gtgtcataaa ggcttcgac tcatgtatat tggaggcaaa tatcaatgtc 840
atgacataga cgaatgtcca ctgggtcagt atcagtgca cagctttgct cgatgttata 900
acgtacgtgg gtccatacaag tgcaaatgta aagaaggata ccagggtgat ggactgactt 960
gtgtgtatat cccaaaagtt atgattgaac ctccagggtc aattcatgta ccaaagggaa 1020
atggtaccat tttaaagggt gacacaggaa ataataattg gattcctgat gttggaagta 1080
cttgggtggc tccgaagaca ccatatattc ctctatcat taccaacagg cctacttcta 1140
agccaacaac aagacctaca ccaaagccaa caccaattcc tactccacca ccaccaccac 1200
ccctgccaac agagctcaga acacctctac cacttacaac ccagaaaagg ccaaccaccg 1260
gactgacaac tatagcacca gctgccagta cacctccagg agggattaca gttgacaaca 1320
gggtacagac agacctcag aaaccacag gagatgtgtt cattccacgg caaccttcaa 1380
atgacttggt tgaaatattt gaaatagaaa gaggagtcag tgcagacgat gaagcaaagg 1440
atgatccagg tgttctggta cacagttgta attttgacca tggactttgt ggatggatca 1500
gggagaaaaga caatgacttg cactgggaac caatcaggga ccagcagggt ggacaatatc 1560
tgacagtgtc ggcagccaaa gccccagggt gaaaagctgc acgcttggtg acggtgctgc 1620
gctcctctat gccttcagg gacctgtgct gtctattcag gcacaagggt acggggctgc 1680
actctggcac actccagggt tttgtgagaa aacacgggtg ccacggagca gccctgtggg 1740
gaagaaatgg tggccatggc tggaggcaaa cacagatcac cttgcgagg gctgacatca 1800
agagcgctgt cttcaaagg gaaaaaagg gtggtcacac tggggagatt ggattagatg 1860
atgtgagctt gaaaaaagg cactgctctg aagaacgcta acaactccag aactaacaat 1920
gaactcctat gttgctctat cctctttttt caattctcat cttctctct cttctccctt 1980
ttatcaggcc taggagaaga gtgggtcagt gggtcagaag gaagtctatt tggtgacca 2040
ggtttttctg gctgtctttt gtgcaatccc aatgaacagt gataccctcc ttgaaataca 2100
ggggcatcgc agacacatca aagccatctg tgggtgttgc cttccatctt gtgtctcttt 2160
cagggaaggc ttcagcatgc gtgagccata ccactctcca tcttgattac aagggtgctc 2220
ttgtagcaaa ttatgagagt gagttacggg agcagttttt aaaagaaatc tttgcagatg 2280
gctatgatgt tatgtgttcg gtgtgttacc atgagtatga ttgacttccc ttgagatag 2340
atgtacaatg tgcttgtgaa attgacttac cctcttcaat taagttagtt ctggcctgac 2400
ctgaactctg actttttact ccattcactt tataaaataa ggggtgtgtaa catatcaaga 2460
tacattttat tttatctgtt tttttttttc ctgttaaaga caattatgta gagtgggcac 2520
gtaatccctc cttagtagta ttgtgttttg tgtaaatgtg ctattgatat taagtattta 2580
catgttccaa atattttacg actctagtgt caaggtaaa ggcagcttgt gatctcaaaa 2640
aaatacatgg tgaaatgtca tccagttcca tgaccttata ttggcagcag taggaaattg 2700
gcagaagtgt tgggttgtgg taacggagtg atgaattttt ttttaattgg cttgagtttg 2760
atctctgcaa aggataggaa acccttagga agacaagaaa ctgcagttaa tttagaactg 2820
tactgttttc aagttacact ttaaaaccac agctttttacc atcataacat ggctctggta 2880
atatgtagga agctttataa aagttttggg tgattcagaa aaaggatcct gttgcagagt 2940
gagaggaagc atagggggaa actccattgg aacagatttt cacacaacgt tttaaattga 3000
tataagttta ggcagttgta gttcataact catgttgctc atgttggtgt gtgtcaggat 3060
gggataggaa gcaagtccca tgcttagagg catgggatgt gttggaacgg gatttacaca 3120
cactgggcaa gcagggcaag ttggaattct aagatccatg aacccccaac tgtatttctt 3180
ccctgcata tttaccaata tattaataaa caatgtaact tttaaaaggc atcattcctg 3240
aggtttgtct taattttctg ttaagtaatc agaataattt ctgctgtttt tgccaggaat 3300
caciaaagatg attaaagggt tggaaaaaaa gatctatgat ggaaaattaa aggaactggg 3360
attattgagc ctggagaaga gaagactgag gggcaaacca ttgatggttt tcaagtatat 3420
gaagggttgg cacagagagg gtggcgacca gctgttctcc atatgcacta agaatagaac 3480

```

```

aagaggaaac tggccttagac tagagtataa gggagcattt cttggcaggg gccattgtta 3540
gaataacttca taaaaaaaga agtgtgaaaa tctcagtatc tctctctctt tctaaaaaat 3600
tagataaaaaa tttgtctatt taagatggtt aaagatgttc ttaccaagg aaaagtaaca 3660
aattatagaa tttcccaaaa gatgttttga tcctactagt agtatgcagt gaaaatcttt 3720
agaactaaat aatttggaca aggccttaatt taggcatttc cctcttgacc tcctaattga 3780
gagggattga aaggggaaga gcccaccaa tgctgagctc actgaaatat ctctccctta 3840
tggcaatcct agcagtatta aagaaaaaag gaaactatct attccaaatg agagtatgat 3900
ggacagatat tttagtatct cagtaatgtc ctagtgtggc ggtgggtttt aatgtttctt 3960
catgttaaag gtataagcct ttcatttgtt caatggatga tgtttcagat tttttttttt 4020
ttaagagatc cttcaaggaa cacagttcag agagattttc atcgggtgca ttctctctgc 4080
ttcgtgtgtg acaagttatc ttggctgctg agaaagagtg ccctgccccca caccggcaga 4140
cctttccttc acctcatcag tatgattcag tttctcttat caattggact ctcccagggt 4200
ccacagaaca gtaatatttt ttgaacaata ggtacaatag aaggtcttct gtcatttaac 4260
ctggtaaaag cagggctgga gggggaaaaa aaatcattaa gcctttgagt aacggcagaa 4320
tatatggctg tagatccatt tttaattggtt catttccttt atggtcatat aactgcacag 4380
ctgaagatga aaggggaaaa taaatgaaaa ttttactttt cgatgccaat gatacattgc 4440
actaaactga tggaagaagt tatccaaagt actgtataac atcttgttta ttatttaatg 4500
ttttctaaaa taaaaaatgt tagtggtttt ccaaatggcc taataaaaaac aattattttg 4560
aataaaaaac actgttagta ataaaaaaa aaaaa 4595

```

<210> 94
 <211> 4759
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2512510CB1

```

<400> 94
atggcgcgcc cgggtccggg agggctcggg gccccgcgcc gctcgccttg ccttctcctt 60
ctctggctgc ttttgcttcg gctggagccg gtgaccgccg cggccggccc gcgggcgccc 120
tgcgcggccg cctgcacttg cgctggggac tcgctggact gcggtgggcg cgggctggct 180
gcgttgcccg gggacctgcc ctccctggacg cggagcctaa acctgagtta caacaaactc 240
tctgagattg acctgctgg ttttgaggac ttgccgaacc tacaggaagt gtacctcaat 300
aataatgagt tgacagcggg accatccctg ggcgctgctt catcacatgt cgtctctctc 360
tttctgcagc acaacaagat tcgcagcgtg gaggggagcc agctgaaggc ctacctttcc 420
ttagaagtgt tagatctgag tttgaacaac atcacggaag tgcggaacac ctgctttcca 480
cacggaccgc ctataaagga gctcaacctg gcaggcaatc ggattggcac cctggagtgt 540
ggagcatttg atggtctgtc acggctcgtg ctaactcttc gcctgagcaa aaacaggatc 600
acctcagctc ctgtaagagc attcaagcta cccaggctga cacaactgga cctcaatcgg 660
aacaggattc ggctgataga gggcctcacc ttccaggggc tcaacagctt ggagggtgctg 720
aagcttcagc gaaacaacat cagcaaaactg acagatgggg ccttctgggg actgtccaag 780
atgcatgtgc tgcacctgga gtacaacagc ctggtagaag tgaacagcgg ctgcgtctac 840
ggcctcacgg ccctgcatac gctccacctc atgacaatt ccategctcg cattcacccg 900
aagggtgga gcttctgcca gaagctgcat gagttggtcc tgtccttcaa caacctgaca 960
cggctggacg aggagagcct ggccgagctg agcagcctga gtgtcctgcg tctcagccac 1020
aattccatca gccacattgc ggagggtgcc ttcaaggac tcaggagcct gcgagtcttg 1080
gatctggacc ataacgagat ttccgggcaca atagaggaca cgagcggcgc cttctcaggg 1140
ctcgacagcc tcagcaagct gactctgttt ggaacaaga tcaagtctgt ggctaagaga 1200
gcattctcgg ggctggaagg cctggagcac ctgaaccttg gagggaatgc gatcagatct 1260
gtccagtttg atgcctttgt gaagatgaag aatcttaag agctccatat cagcagcgac 1320
agcttctctg gtgactgcca gctgaagtgg ctgccccgt ggctaattgg caggatgctg 1380
caggcctttg tgacagccac ctgtgcccac ccagaatcac tgaagggtca gagcattttc 1440
tctgtgccac cagagagttt cgtgtgcgat gacttcttga agccacagat catcacccag 1500
ccagaaacca ccattggctat ggtgggcaag gacatccggt ttacatgctc agcagccagc 1560
agcagcagct cccccatgac ctttgctctg aagaagaca atgaagtctt gaccaatgca 1620
gacatggaga actttgtcca cgtccacgcg caggagggg aagtgatgga gtacaccacc 1680
atcctgcacc tccgtcaggt cactttcggg cagcagggcc gctaccaatg tgtcatcacc 1740
aaccactttg gctccaccta ttcacataag gccaggctca ccgtgaatgt gttgccatca 1800
ttcacaaaaa cgcgccacga cataaccatc cggaccacca ccatggccc cctcgaatgt 1860
gctgccacag gtcacccaaa ccctcagatt gcctggcaga aggatggagg cacggatttc 1920
cccgtgccc gtgagcgacg catgcattgc atgcccgatg acgacgtgtt tttcatcact 1980

```

```

gatgtgaaaa tagatgacgc aggggtttac agctgtactg ctccagaactc agccgggttct 2040
atctcagcta atgccaccct gactgtccta gagaccccat ccttggtggt ccccttgga 2100
gaccgtgtgg tatctgtggg agaaacagtg gccctccaat gcaaagccac ggggaaccct 2160
ccgccccgca tcacctggtt caagggggac cgcccgctga gcctcactga gcggcaccac 2220
ctgacccttg acaaccagct cctggtggtt cagaacgtgg tggcagagga tgcgggccga 2280
tatacctgtg agatgtccaa caccctgggc acggagcgag ctccacagcca gctgagcgct 2340
ctgcccgcag caggctgcag gaaggatggg accacggtag gcatcttcac cattgctgtc 2400
gtgagcagca tcgtcctgac gtcactgggc tgggtgtgca tcatctacca gaccaggaag 2460
aagagtgaag agtacagtgt caccaacaca gatgaaaccg tcgtgccacc agatgttcca 2520
agctacctct cttctcaggg gaccctttct gaccgacaag aaaccgtggt caggaccgag 2580
gggtggccctc agggcaatgg gcacattgag agcaatgggt tgtgtccaag agatgcaagc 2640
cactttccag agcccagcac tcacagcggt gcctgcaggc agccaaagct ctgtgctggg 2700
tctgcgtatc acaaagagcc gtggaaagcg atggagaaag ctgaaggggac acctggggcca 2760
cataagatgg aacacggtgg ccgggtcgta tgcagtgcac gcaacaccga agtggactgt 2820
tactccaggg gacaagcctt ccaccccag cctgtgtcca gagacagcg acagccaagt 2880
gcgccaatg gcccgagacc ggggtgggagt gaccaagagc attctccaca tcaccagtgc 2940
agcaggactg ccgctgggtc ctgccccgag tgccaagggt cgctctaccc cagtaaccac 3000
gatagaatgc tgacggctgt gaagaaaaag ccaatggcat ctctagatgg gaaaggggat 3060
tcttccctgga ctttagcaag gttgtatcac ccggactcca cagagctaca gcctgcactc 3120
tcattaactt caggcagtc agagcgcgc gaagccagc acttgcttgt ttccaatggc 3180
cacctcccca aagcatgtga cgccagtc cactgacagg acactcccc 3240
gggaaacaga ggggtgccact gctgttggca ccaaaaagct aggttttgtc tacctcagtt 3300
cttgtcatac caatctctac gggaaagaga ggtaggagag gctgcgagga agcttgggtt 3360
caagcgtcac tcactgttac atagttgtaa ctcccatgtg gagtatcagt cgctcacagg 3420
acttgatct gaagcacagt aaacgcaaga ggggatttgt gtacaaaagg caaaaaaagt 3480
atcttgatgc attgtacata agagttttca gagatttcat atatatcttt tacagaggct 3540
atcttaactt ttagtgcac gttaacagaa aaaaattata caattttgac aatattattt 3600
ttcgtatcag gttgctgttt aattttggag ggggtgggga aatagttctg gtgccttaac 3660
gcatggctgg aatttataga ggctacaacc acatttgttc acaggagttt ttggtgcggg 3720
gtgggaagga tggaaggcct tggatttata ttgcacttca tagacccta ggctgctgtg 3780
cggtgggact ccacatgcgc cggaaggagc ttcaggtgag cactgctcat gtgtggatgc 3840
ccctgcaaca ggcttccctg tctgtagagc caggggtgca agtgccatcc acacttgcag 3900
tgaatggctt ttccttttag gtttaagtcc tctctgtctg taaggcgtag aatctgtccg 3960
tctgtaagga gtagaatgag ggtgtttaat ccatacacaag caaaaggcca gaacagttaa 4020
acactgcctt tcctcctcct cttattttat gataaaagca aatgtggcct tctcagtatc 4080
attcgattgc tatttgagac ttttaaatta aggtaaaggc tgctgggtgtt ggtacctgtg 4140
gatttttcta tactgatgtt ttcgttttgc caatataatg agtattacat tggccttggg 4200
ggacagaaag gaggaagttc tgacttttca gggctacctt atttctacta aggaccaga 4260
gcaggcctgt ccattgccatt ccttcgcaca gatgaaactg agctgggact ggaaaggaca 4320
gcccttgacc tgggttctgg gtataatttg cacttttgag actggtagct aacctctta 4380
tgagtgccaa tgtgtcattt agtaaaactt aaatagaaac aaggctcttc aaatgttctc 4440
ttggccaaaa gctgaaggga gttactgaga aaatagttta caattactgt caggtgtcat 4500
cactgttcaa aaggtaagca catttagaat tttgttcttg acagttaact gactaatctt 4560
acttccacaa aatatgtgaa tttgctgctt ctgagaggca atgtgaaaga gggagtatta 4620
cttttatgta caaagttatt tatttataga aattttggta cagtgtacat tgaaaacct 4680
gtaaaatatt gaagtgtcta acaaatggca ttgaagtgtc ttaataaag gttcatttat 4740
aaatgtcaaa aaaaaaaaaa 4759

```

<210> 95

<211> 3203

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7486326CB1

<400> 95

```

ccctcctccc cagctgtccc gttcgcgtca tgccgagcct cccggccccg cccgccccgc 60
tgetgtctct cgggctgctg ctgctcggct cccggccggc ccgcgcgccc ggcccagagc 120
ccccgtgct gccatccgt tctgagaagg agccgctgcc cgctcgggga gcggcaggct 180
gcaccttcgg cgggaaggct tatgccttgg acgagacgtg gcacccggac ctaggggagc 240
cattcggggg gatgcgctgc gtgctgtgct cctgcgaggc gcctcagtgg ggtcgccgta 300

```

```

ccagggggccc tggcaggggtc agctgcaaga acatcaaacc agagtgccca accccggcct 360
gtggggcagcc gcgccagctg ccggggacact gctgccagac ctgccccccag gagcgagca 420
gttcggagcgc gcagccgagc ggccctgtcct tcgagtatcc gcggggaccgc gagcatcgca 480
gttatagcga ccgcgggggag ccagggcgctg aggagcgggc ccgtgggtgac ggccacacgg 540
acttcgtggc gctgctgaca gggccgaggt cgcaggcggt ggcacgagcc cgagtctcgc 600
tgctgcgctc tagcctccgc ttctctatct cctacaggcg gctggaccgc cctaccagga 660
tccgcttctc agactccaat ggcagtgctc tgtttgagca cctgcagcc cccaccgaag 720
atggcctggg ctgtgggggtg tggcgggcag tgccctcggt gtctctgcgc ctccttaggg 780
cagaacagct gcatgtggca cttgtgacac tcactcacc ttcaggggag gtctgggggc 840
ctctcatccg gcaccgggccc ctggctgcag agaccttcag tgccatcctg actctagaag 900
gccccccaca gcaggggcgta gggggcatca ccctgtcac tctcagtgc acagaggact 960
ccttgcattht tttgctgctc ttccgagggc tgctggaacc caggagtggg ggactaacc 1020
aggttccctt gaggtccag attctacacc aggggcagct actgcgagaa cttcaggcca 1080
atgtctcagc ccaggaacca ggctttgtct aggtgtgccc caacctgaca gtccaggaga 1140
tggactggct ggtgctgggg gagctgcaga tggccctgga gtgggcaggc agggccagggc 1200
tgcgcatcag tggacacatt gctgccagga agagctgcga cgtcctgcaa agtgtccttt 1260
gtggggctga tgccctgatc ccagtccaga cgggtgctgc cggctcagcc agcctcacgc 1320
tgctaggaaa tggtccctg atctatcagg ccgtgggtat ctgccctggg ctgggtgccc 1380
gaggggctca tatgctgctg cagaatgagc tcttcttgaa tgtgggcacc aaggacttcc 1440
cagacggaga gcttcggggg cactggctg ccctgcceta ctgtgggcat agcgcccgc 1500
atgacagct ccccgctgcc ctacgaggag ccctgggtgt accccctgtg aagagccaag 1560
cagcaggggca cgcctggctt tccttgata cccactgtca cctgcactat gaagtgtctg 1620
tggctgggct tgggtggctc gaacaaggca ctgtcactgc ccacctcctt gggcctcctg 1680
gaacgccagg gcctcggcgg ctgctgaagg gattctatgg ctgagaggcc cagggtgtgg 1740
tgaaggacct ggagccggaa ctgctgcggc acctggcaaa aggcattggc tccctgctga 1800
tcaccaccaa gggtagcccc agaggggagc tccgagggca ggtgcacata gccaaccaat 1860
gtgaggttgg cggactgcgc ctggaggcgg ccggggccga ggggggtgcg gcgctggggg 1920
ctccggatcc agcctctgct gcgcgcgctg tgggtgctgg tctcccggcc ctagegccc 1980
ccaaacctgg tggctcctgg cgccccgag accccaacac atgcttcttc gaggggcagc 2040
agcgccccca cggggctcgc tgggcgccc actacgacct gctctgctca ctctgcacct 2100
gccagagacg aacgggtgatc tgtgaccgg tgggtgtgcc accgcccagc tgcccacacc 2160
cggtcaggcc tcccgaccag tgctgcctg tttgccctga gaaacaagat gtcagagact 2220
tgccagggt cccaaggagc cgggaccag gagagggctg ctattttgat ggtgaccgga 2280
gctggcgggc agcgggtacg cgggtggcacc ccgttgtgcc cccctttggc ttaattaagt 2340
gtgctgtctg cacctgcaag gggggcactg gagaggtgca ctgtgagaag gtgcagtgtc 2400
cccggctggc ctgtgcccag cctgtgcgtg tcaaccccac cgactgctgc aaacagtgtc 2460
cagtgggggtc gggggccccc ccccagctgg gggaccccat gcaggctgat gggccccggg 2520
gctgccgttt tgctgggagc tggttcccag agagtgcagag ctggcaccct tcagtgcctc 2580
cgtttgagga gatgagctgt atcacctgca gatgtggggc aggggtgcct cactgtgagc 2640
gggatgactg ttcactgccca ctgtcctgtg gctcggggaa ggagagtcga tgetgttccc 2700
gctgcacggc ccaccggcgg ccagccccag agaccagaac tgatccagag ctggagaaag 2760
aagccgaagg ctcttaggga gcagccagag ggccaagtga ccaagaggat ggggcctgag 2820
ctgggggaagg ggtggcatcg aggaccttct tgcattctcc tgtgggaagc ccagtgcctt 2880
tgctcctctg tcctgcctct actcccaccc ccaactacct tgggaaccac agctccaca 2940
gggggagagg cagctgggccc agaccgaggt cacagccact ccaagtcctg cctgcccacc 3000
ctcggcctct gtcctggaag cccaccctt ttctcctgt acataatgtc actggcttgt 3060
tgggattttt aatttatctt cactcagcac caagggcccc cgacactcca ctctgctgc 3120
ccctgagctg agcagagtca ttattggaga gttttgtatt tattaataa tttctttttc 3180
agtcaaaaaa aaaaaaaaaa aaa 3203

```

<210> 96

<211> 1681

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1221545CB1

<400> 96

```

tttaataatc aaacactctg ataacctatg acaaaggatt agtatacaat taaatgaagt 60
aatgcataaa gaggttgggc atataataaa gacttacctc atgtgagcta aaaccactat 120
caaggcagtt tctaggacca agagcacaag tgaccttaaa tgccactgaa agctcccttg 180

```

```

gaggtgttct caccaggagg attagagaag ccaaaacaac caggtgaata tctctgtcaa 240
tgatagacaa cttgggtata acaggaaaag attctagaat ttatgggatt atggaacaat 300
aaatagagtt aacttttagaa aggagattta caaaataagt agcgggtatg gatattgcta 360
gtccgtagct gattaaggct ctgattaagt gaattgcccc aagtctcaga gcagacatag 420
gcctagtcca aacttagagc tcatattact tgcagtggat gtttgttctc ttggctgtcc 480
agcaggccac cttttccttc aggacactgc tctcccactg catttcacat gtgactcgtt 540
tggggctgcc aaaatatatt tggttatctt tttttttttt ttcagtaagc taatacaaaa 600
ttactgtttc ttcaataatt actttgcatt tattgtcatc atttcactcc caaatgtatc 660
aaaattaaag ttttaagaggg aggaaaaaag gataagtaga agatcctgat taccttttag 720
taacatagatg tttcattatg ttatctttta ggggtctggaa tacactgacc agtgtattag 780
acaaaatttt atgagaattg gttaaagata tagggaagaa atgtatttgg aaaaaaaca 840
accaaaccac accaaaacaa aacaaaaacc attattttga gagtaaatac ttgggggggaa 900
gaagcttgca agccaccoga atatggcctg gactctggcg tgtgtgtgcg tgctggggag 960
tatcttggtg ttggactctg gcatgtgtgt gcggtgctggg gagtgtcttg atggtgatgt 1020
tgtgtcattg cttcattttt ggcactcagt cactactcaa gaaaaccaga ttgaaaattt 1080
ggaatctctg cttcagtggg ttgaaactgg cctccagtca ctaaggaaaa aatcaaaaaca 1140
aaacacacaa gaatttagag agaattttt tctgccaaaa aataattttt cttttatgct 1200
atctcttatt tgggtcaata ctccaatgga aaaaatagat agattgggtc agagtccaat 1260
ataattttct gtgacatttg aactaaagta actcataaaa acttaaacac aggaaattgt 1320
atcctctcct gctgatgtat gtgtgactat ttgtctctct taaaagaaaa aagtagaaga 1380
agagaattaa ttgaatggta ttttgtttta cttgagatgt taaactaatg tcaactaat 1440
ttatttattc aataaatatt tattaagcac ctactacatg ctgggtactac aagccaggtg 1500
tagatgtctg ggaatttatta atgagcaaaa caaaaccagt agcaaaactg tacacgcaga 1560
taagggtttc aaatattgtt ggcattgggc aggtgcaatg gatcacacct gtaatttctt 1620
ttctcttctt ttctctgctt ctttcttctc ttcttctctc ccttcttctt ttcttctcgc 1680
c

```

<210> 97

<211> 1207

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 124737CB1

<400> 97

```

ccaaataact ctggaaccct ttaactgtcc agcagggaga tccaactacc ttgaaaccca 60
ccaagctgga aaagccccac agggcagcca cctctgtggc acaatcccca gctgaaacct 120
tgcccttcca gactgtccct gtcaaagatg cccaggcaat gtgaataaag cccatcatgg 180
accctctaaa ccagactgcc caccagcagg gtaccatctg gcagccacat ggagggcagt 240
ccaccttctt gactccacaa ttcaaatgct gatctaatac agaaacactc tcacagacac 300
agtggttagt ctgggcaccc cacagtgcac ttaagtggac acataaaaatt aaccatccca 360
gggagtgaga tgggtaaggg aagatgggcc acagtgggtg tgtctccatg cctaccccca 420
ctgtgggcag ctgctggagc acacgcctca aagtcttccc tgagggagag ggagctgagg 480
tgtttatata ccagctctgt caggcatttg ctgaatgtcc acactcctgg atcaccgcct 540
ctcactctca tgatgtccca tggtcctcat ttcacaagtg agctctgggt acatggggag 600
catcagtcac accctgggtc agtacctcag ctgtctctca catgacatcc tcattatcca 660
cactgcaaag ccaaccatcc ctatgatggg ttcatgtggg atcatgactt agtgggtcaa 720
gagtttggaa gtggctcagc tgggcgggtc ttctgtccca tgtggctgcc agatgggtacc 780
ctgctgggtg gcagtctggt ctgaggggtc catgatggct ttactcacat gcctggcatc 840
ttgacagggg cagctggaag gcaagggtca gctgggactg tccacagagc tctcctctgt 900
ggcctttcca gcatgggtgg ctgagggtag ctggacttcc tgcattgacag ctgagggtcc 960
ccagagctac tgtcccaaga gatagaaggt ggaactgcc agtctcttag gctaggacca 1020
gaaaccagca cccctgcacc cacagccttt tggtagtgat gaaataaaca taagatttat 1080
cattttaatc attcgtaagt gggattaaat acatttaca tattgtgtaa ccacggcac 1140
tgtctatata taaaactttt tcatcatctg caataaaaaa tctgtatgca ttaaaaaaaa 1200
aaaaaaa
1207

```

<210> 98

<211> 1544

<212> DNA

<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1510784CB1

<400> 98
tgacgggtgtg tggagcattc ctgacctttg tccccagccc tgcctctctc tgtcctgcag 60
cctgcatctt tgctgagttc tcagggcctt ccagctagaa gttctgccat ctgttaaag 120
cgtatgtttc ctctcccgtc gctgtctgc ctccctctcg gactgcacct acagagcact 180
agccctccat tccctgccag ccacacccag gtctccctct ctgactccca cacctgcctc 240
actgccagcc cagctaaggc tctcttcaaa tgtctgtttt ctgtctgcct ctgccattcc 300
cagtgtgacc actcgtgtc agccgtatct cagcaggagg acaggtgccg gagcagctcg 360
tgcagctaag cagccaactg cagaaacgtc aggtgggtgg tgcattcgca ggcatgctga 420
agaagcagtt ccaggcatgg gccgccggca gagaggctgg ctgcagcacc ccccaccacc 480
atgcacatcg tgctttgctt ctctctagag ttagcggctt tggcaggcca tgccttgctt 540
gtgttcacag cctgcctgtc aggagcgaag acagaacgtc tgacttttgg atccgtaaca 600
gggggtgggg ctccccagaa gagaagaggc tttgggtcct ggccagtgtc cactactcag 660
tcaaacattc agaaacttac atgattcttc atcgtcccaa gcaagtctga cttggggcct 720
ttattgaaac tctgtttcct ctcccgtgc ctgtctgcct cctctctcga gtgcacctac 780
tgagcaccag cctccattc cctgccagcc acaccagaa agcaatgggg ctttctggga 840
aggcagaaat attctgtgac ctgggctatt cagaggggtg gcgtgagtcg tgtgtgccta 900
gcaaacactc aggacatggc cgtgagaca gaagggtga gcttttgtcc tagctaata 960
attaattaat tcattcatta tttattttga gacggagtct ctctgtcgcc caggctggac 1020
tgcagttgag cagtcttggc tcaactgcaac ctctgcctcc taggttcaag caattctccc 1080
gcctcagcta cttgggaggc tggggcagaa gaatcgcttg aaccaggag gcggagggtg 1140
cagtgcagcc agattgcgcc actgcactcc agcctgtgag acagagttag actccgtctc 1200
aaaataaata atgaatgaat taattaatat attagctagg acaaaagctc agcccttctg 1260
tctcaccggc catgtcctga gtgtttgcta ggcacacac actcacgcca cccctctgaa 1320
tagccagggt cacagaatat ttctgccttc ccagaaagcc ccattgcttt ctgggtgtgg 1380
ctggcaggga atggagggtt ggtgctcagt aggtgcactc cgagaggag gcagacaggc 1440
agcgggagag gaaacagagt ttcaataaag ggcccaagtc agacttgctt gggacgatga 1500
agaatcatgt aagtttctga atgtttgact gagtagtggg gctg 1544

<210> 99
<211> 1519
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1901257CB1

<400> 99
aagcctccaa gggaggcatc caattcactt ttgggttaaga tcaatacttt cttcttctac 60
aatccccctc tgattaattt ttttaattgg ctttcagaag aaagcaaata tcaaagttgc 120
ttctaaacat cactgatttt gctagctcta tcacttcatt ttttctatc aagttttaa 180
gataaccttg tgtgactcag gccattcctt gtttgcacgt tcaccatcaa tacaagttag 240
ccaagacgag tgtcgctaga gcttccagtg tctttcacat tctagccctc ttcaaccaca 300
aattataaaa acgtggctct gctcaagcac acgtttttaa ttaaaccttt ttgtttttta 360
catgaatttt ttaggtcttt ttttcagggt attattttct gagacagtc aataaaaatt 420
tatttttaaaa tgtattttgt gtaatttgat gacagcctca aaaaaatcac ataattagga 480
ttttattaca aaagtcaaca gttcagtttg tgttctggaa gtggggaatg gaaggaggga 540
aagaggagga gcaggagag aaaagatgag gaacctggta actgcaaaaa acaattcaag 600
cagttatatt tcaccatgta cagtctggaa agaagagttt tctagaatca aggaagaaaa 660
taaaagctct gttagtttgc tcttgcattt gctatgcctt tctaattaaa tgattggaag 720
gacttcatta ttgactcctg ctggccgaca tgacactaaa atgatatgca tctcaatctg 780
catactccaa gccaaaaccc aacatgccat atgcattgca catgtccttc caaaggcttt 840
gggtctggat cctccttccc accgtggcca acattgcttt gtctctatca agaactggca 900
gatccaagga gcatacccaa gatgacgcca cagctacat gctctctcgg cacctacatg 960
ctctctcgcc acctacatgc tctctcgcca gctacatgc tctctcgcca gcctacacgc 1020
tctcttggca tgtacagcag gttcttcagc cgtgcccagg aggcctgggg ctccgtgggtc 1080
tatctctgag ctgggttcta gacctccac cccacttcca ccaactgcaac ttctgtttta 1140
catgttggaagg gggggttct tataatatgc cacttaaaga aaaagactga atttttttta 1200
aataaaaaat atactggcct atgtcattaa aatgaaatat atcccaataa agttgtaaag 1260


```

caaaaagcaa actcttttcaa atcttatttta ctgcaaaaaca ttttagaaac tttcctcaat 1320
tgccaccgat tttccaaagc agacctgtga aagccagcaa tgaaaaattt aagggtatta 1380
ctcatacctg gctcttttgg aagaaggctg gacattagct acttcattct gtttcagttt 1440
gggaggtagt cttatactct gcaattaaaa tattgtcgac ttttaattcaa tcaatctact 1500
aagtaataca gtagcttcc 1519

```

<210> 100
 <211> 525
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2044370CB1

```

<400> 100
agagttcctt tttctaggct gattagggtta tacattgttg aagtatagtt tgcagttaga 60
attggtcatt ttattttcag tgtttcacag aaatcgaaga agacagaaat ggcgcttctg 120
tggtggatat ctacagtagc aatactgttg tttacttcga cgattttggg aacatacgtt 180
gaagctgggtg ccgctaagtc taacgaagaa gagattgtga acaaaagcga atttggaaga 240
tttccacgag ggctcgagaaa ggatgcatcg ggggtgccaca agccgggcta ccctgtaccc 300
cctcattctc gctgccctcc acctcccat gtgcagcgtc ctgcctctat tctgcatgct 360
tagtctaaca ccatacaggct cgtttatctt ttctgtcatt gatctcacca ggagcaaata 420
actagtgcgt gcttctgatt caggtaacgt agtatgtaaa taaatgtcag tgatattatg 480
aattggtaaa acatttctgt tatctaaata aaacagtga agttt 525

```

<210> 101
 <211> 1062
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2820933CB1

```

<400> 101
agtcgagaat caatctagca tccactctta gatattctatt aaaaggaggt aagaaacata 60
tgtccactca gacttatagg caaatcagtc gtagcaccat aattcactat agtgtgacaa 120
caggaaacaa ttcagggtgcc cctcaactga caaatatata aacaaatgta ttatatccat 180
gcaatgggat actgttcagc aattttacaa aggactagtg atgcctgcaa caacatggat 240
gatcctcaaa atgagctaag tgaaagaaac cagacacaga agatacatat taaatgattc 300
cattcacatg aaatttctag aaaaggcaaa actatagaag caaaagcagg tcagtgcctg 360
ggaatggcat tgacagcaag tgggcacaag aaaatttggg ggtgataaaa atgttctaaa 420
actagattgt gatgatagtt gcacaactgt gtacatttac taaggctcat caaactgtgc 480
ccataaaatg ggtagatatt gtgttattta aatgacacct taattaaggt gtttaaaaga 540
aaaattcccc tgagtttctc ctgcttgcac ttgaagtga aaccagctc ctcatgggg 600
ggccacctcc ccccggcagc tctttctgtc tctgcttcat ccattggggt ttctccagtt 660
tctcacccca cctccttcc catgagtgtc ccagcaggtg ctgttccctc tgcttgccac 720
gctttcttgc ttctccactt ccttggagta actcagagtc ttcttcaact ctctacctca 780
agtcacgtct cgcaggaagc ctctctggct ctgcccactg cagtctacc tccctgccct 840
tctccttggg gacactcatc actcctgaaa ctgttgactc ttctcctaag tacagcttct 900
ggctcatagt ggggtgctcaa taaatatttc ataaaataat gtctgaataa tcatctgaat 960
tgttctgaga agcccatgat aaacaaacct gtttaacttt gtgtaaccag tgtatctgag 1020
gcatgttttc acaagaacct cacttttttt tttaatgggt cc 1062

```

<210> 102
 <211> 2155
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2902793CB1

<400> 102

```

gcctgaggag cccacgaagg ggctccttcg tggttacttc gtgatgttac caggctgaac 60
agagggaatc tacagcctgt gcttggcata ccctgcatgt ggtctgtgtc cagttgggct 120
ttgtgtcttc tctgtgccat ccatgtcctg tctctttcat gtgctcaatg taattgtgtc 180
catgtctttc tgatccctcc accagccctg cctgccaggt tcacagaggg tctgaggaat 240
gaagaggcca tggaaggggc cacagccaca ctgcaatgtg agctgagcaa ggcagccctc 300
gtggagtggg ggaagggcct tgaggctctc agagatgggg acaaatacag cctgagacaa 360
gacggggctg tgtgtgagct gcagattcat ggctgggcta tggcagataa cgggggtgtac 420
tcatgtgtgt gtgggcagga gaggacctca gctacactca ctgtcagggg taaagatcct 480
atgtggccat gtgggcttgt ggcttggtgt atacacctct ctgtgtcacc acctctgtcc 540
tccaaatgtg gcacatctcc tgtggaaaacc ctgtgattgt ctgtcctcta actggggccc 600
tctaggtatc tctgcctcc ccttctcatc agtagatgtc ctctgtctca tgcattgtcc 660
tgtgtgttct ctgtgcctcc tgggccattt gccttctcat tgtttatata ttgctcatct 720
agctatggtc ctttggttgt ttgtgtggct ccttattggg gtccatgttc tgtccgaaaa 780
atcctccaga cagtctgatg atatcagtga ctggttggtc cttctcagcc ctgcctgcca 840
gattcataga ggaatagaga aaccagaagg ggctacagtc acattgcaat 900
gtaagctgag aaaggcggcc cccgtggagt ggagaaaggg gcccaacacc ctcaaagatg 960
gggacaggta cagcctgaag caggatggga ccagttgtga gctgcagatt cgtggcctgg 1020
tcatagcaga tgctggagaa tactcgtgca tatgtgagca ggagaggacc tcggccacgc 1080
tactgtcag gggtaaagac cacatgtgac cacctgagtg acttctgtct tccccactt 1140
aaccacatg ttctgtgctc tcccagtgct tctcagtgct gttgacattt tattcagtca 1200
ctcatctttg tggctccatct cacaatgca tgtcaggac ccacttggat ggcctaactc 1260
agggcctggg catacagacc ccaagggtag atagtgcagg gtccccaggt gtcaggacag 1320
ggagagcagc aggcaggtgt cagggtccag gagagctgtc tggggccctc gccatcttgc 1380
aaaggcctgt ggatgtccac cagctcttga gcctcaggca tggaggtcag gaaatgtatg 1440
tcctttgaca gacatagcga tggctcaggc caggccctc ttcaggctgg tgagtgttct 1500
gattgatcct tgtggtcatt ccaagcttct aaaggagtat tgtcttcac tgcctcaggt 1560
aacgtaacaa agcactgcag acagggtggc tcaaataaca cagatttatt ttctcagaag 1620
tatggggctg aaatctcaag atcaagatgt cagctcctct cttctttag acagctgtct 1680
tctccccatg tcttcacatg gatgtccctc tgtgtgcatg tgtgtgtcct aacctctttt 1740
tataagagca ccagtcatac tggatttgga accaccctaa caacctcatt ttctctttca 1800
atgattgtct ttaaatacag tgatattctg acgtgtactg ggggttagga cttcaacata 1860
tgcatttttt ctgaggcaca attcagacca taacactcca ccactctgat tctcaaaatt 1920
catggccttc tcacgtgcaa aatatgttta cttcttcta acagtcccaa atcttagccc 1980
atttcaatat caactagtcc aaatcacctc taaatatcat ctgagtcaac tgtgagggag 2040
ataaagtgtg acttatacag aggcaaaatt tttcttcatc tgtgaggctg tgaaatcaga 2100
caagttattt gttttgaagt cacaatgggt ggacaggcat aggatggaca ttctg 2155

```

<210> 103

<211> 1777

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7486536CB1

<400> 103

```

gcctggactg tgggttgggg gcagcctcag cctctccaac ctggcaccca ctgcccgtgg 60
cccttaggca cctgcttggg gtccctggagc cccttaaggc caccagcaaa tccctaggaga 120
ccgagtcttg gcacgtgaac agagccagat ttcacactga gcagctgcag tcggagaaat 180
cagagaaagc gtcacccagc cccagattcc gaggggacct ccagggaactc tctcctcctg 240
ctccttggaa aggaagaccc cgaaagaccc ccaagccacc ggctcagacc tgcttctggg 300
ctgccattgg acttgcgggc accgcccccc ggcgtgtcctc cacgctgccg ggcagataag 360
ggcagctgct gcccttgggg cacctgtctc ctcccgagc ccagccactc ctccagggcc 420
agcccttccc tgactgagtg accacctctg ctgccccgag gccatgtagg ccgtgcttag 480
gcctctgtgg acacactgct ggggacggcg cctgagctct cagggggagc aggaacacca 540
cgatgccccg gggcttcacc tggctgcgct atcttgggat cttccttggc gtggccttgg 600
ggaatgagcc tttggagatg tggcccttga cgcagaatga ggagtgcact gtcacgggtt 660
ttctgcggga caagctgcag tacaggagcc gacttcagta catgaaacac tacttcccc 720
tcaactacaa gatcagtgtg ccttacgagg ggggtgttcag aatcgccaac gtcaccaggc 780
tgacagaggg ccaggtgagc gagcgggagc tgcggtatct gtgggtcttg gtgagcctca 840
gtgccactga gtcggtgcag gacgtgctgc tcgagggcca cccatcctgg aagtacctgc 900

```

```

aggaggtgga gacgctgctg ctgaatgtcc agcagggcct cacggatgtg gaggtcagcc 960
ccaaggtgga atccgtgttg tccctcttga atgccccagg gccaaacctg aagctgggtgc 1020
ggcccaaagg cctgctggac aactgcttcc gggatcatgga gctgctgtac tgctcctgct 1080
gtaaacaaag ctccgtccta aactggcagg actgtgaggt gccaaagtcct cagtcttgca 1140
gccagagacc ctcatcgcag tatgcggcca cccagctgta ccctccgccc ccgtgggtccc 1200
ccagctcccc gcctcactcc acgggctcgg tgaggccggg cagggcacag ggcgagggcc 1260
tcttgccctg agcacctcgg atggtgactg cggatagggg cagccagacc agctcccaca 1320
ggagttcaac tgggtctgag acttcaaggg gtgggtgggtg gagccccct tgggagagga 1380
cccctgggaa ggggtgtttt cctttgaggg ggattctgtg ccacagcagg gctcagcttc 1440
ctgccttcca tagctgtcat ggctcacct ggagcggagg ggacctgggg acctgaaggt 1500
ggatggggac acagctcctg gcttctcctg gtgctgccct cactgtcccc ccgcctaaag 1560
ggggtactga gcctcctgtg gcccgagca gtgagggcac agctgtgggt tgcaggggag 1620
acagccagca cggcgtggcc attctatgac cccccagcct ggagactgg ggagctgggg 1680
gcagagggcg gtgccaaagt ccacatcttg ccatagtggg tgctcttcca gtttcttttt 1740
tctattaaac accccacttc ctttgaaaaa aaaaaaa 1777

```

<210> 104

<211> 2587

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 8137305CB1

<400> 104

```

aggcgccggc gggcccaagg cgtgaggcgc cgcccggtg tccccgggc gcaggaggcg 60
gtggagcgca gagcgggcga ggcgaaaaa tcactaccaa tataatggat tttatatatc 120
agattgcttt attctggata tcatggtaac aatacagaaa gtatacataa tttcccattt 180
ctgcaagtag tcatgactgc tgaagaaaga aaaacttaaa gctacggcag aattatttta 240
tggaatttct gattttgttt ttaatttttg ataacttttt actaaaggta tgaacacaca 300
aagagcttat tttgttaggc aaatacacat taataagaat gcctagaaga ggactgattc 360
ttcacacccg gaccactgg ttgctgttg gccttgcttt gctctgcagt ttggtattat 420
ttatgtacct cctggaatgt gccccccaga ctgatggaaa tgcattctct cctgggtgtg 480
ttggggaaaa ttatggtaaa gagtattatc aagccctcct acaggaacaa gaagaacatt 540
atcagaccag ggcaaccagt ctgaaacgcc aaattgcccc actaaaacaa gaattacaag 600
aatgagtga gaagatgcgg tcaactgcaag aaagaaggaa ttagggggt aatggcatag 660
gctatcagag caacaaagag caagcaccta gtgatctttt agagtttctt cattcccaa 720
ttgacaaagc tgaagtttagc atagggggcca aactaccag tgagtatggg gtcattccct 780
ttgaaagttt taccttaatg aaagtatttc aattggaaat gggctcact cgccatcctg 840
aagaaaggcc agttagaaaa gacaaacgag atgaattggg ggaagtattt gaagcgggct 900
tggaggtcat taataatcct gatgaagatg atgaacaaga agatgaggag ggtcccttgg 960
gagagaaact gatatttaat gaaaatgact tcgtagaagg ttattatcgc actgagagag 1020
ataagggcac acagtatgaa ctctttttta agaaagcaga ccttacggaa tatagacatg 1080
tgacctctt ccgccccttt ggacctctca tgaaagtgaa gagtgagatg attgacatca 1140
ctagatcaat tattaatatc attgtgccac ttgctgaaag aactgaagca tttgtacaat 1200
ttatgcagaa cttcagggat gtttgatttc atcaagacaa gaagattcat ctcacagtgg 1260
tgtatttttg taaagaagga ctgtctaaag tcaagtctat cctagaatct gtcaccagtg 1320
agtctaattt tcacaattac accttgggtc cattgaatga agaatttaat cgtggacgag 1380
gactaaatgt ggggtgcccg gcttgggaca agggagaggt cttgatgttt ttctgtgatg 1440
ttgatattct tttctcagcc gaattcctta acagctgccg gttaaattgt gagccaggta 1500
agaaggtgtt ttaccctgtg gtgttcagtc tttacaatcc tgccattgtt tatgccaacc 1560
aggaagtggc accacctgtg gagcagcagc tggttcacaa aaaggattct ggcttttggc 1620
gagattttgg ctttggaatg acttgctcagt atcggttcaga tttcctgacc attggtggat 1680
ttgacatgga agtgaaaggt tgggggtggag aagatgttca tctttatcga aaatacttac 1740
atggtgacct cattgtgatt cggactccgg ttctgtgtct tttccacctc tggcatgaaa 1800
agcgtgtgtc tgatgagctg acccccgagc agtaccgcat gtgcatccag tctaaagcca 1860
tgaatgaggc ctctcactcc cacctgggaa tgctggctct cagggaggaa atagagacgc 1920
atcttcataa acaggcatac aggacaaaca gtgaagctgt tgggtgaaat cataattaat 1980
gcgttactgt atgaaccaca aaacagcact atttatttag cttacttct acttccagat 2040
gcagtgcctc ttttgagaa gacatgttta tttttcatgt tctttctgac attactttag 2100
caattcaact tgatgtgaga agaaaaaaca aatgtttcaa cacaaaatct ctgttttgtg 2160
agaatactgc actatggaat aattgacaaa ttgaaatctc atatttgtcc caaaagtgtg 2220

```

```

tttgagttag ttctacctgg tgcccatggt ctgatttgtg tgtgggattg catgggtgtcc 2280
tgatgcatct aggtggagcg gatggaaatg tgctggagcc actgttgggt gagaagcaag 2340
aacgatactt accagaagga gattggagcg ttagtgagca ataggtatgt agggaatagg 2400
gtatctatca aacgtgcaca gaacactgaa ataccagcct tacttggaat tgatagcttg 2460
aaagaatcaa ttaagccaca tgaagtagaa ggatactaaa gttggaacaa ttgaaaagcc 2520
ccaaataata aagcaaagca aagggagaac tcaaaagcca ataaataatg gaggttacac 2580
ccagcaa 2587

```

<210> 105
 <211> 1490
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3793128CB1

```

<400> 105
gtaagcccct tataaaacca catgtctcat ttgctggctc caaatctctt ctttgtcctc 60
ttgaacctgg taacttccct attgagggtta ataggggttc agcacaagag ctttaggagt 120
tatttggcta caccagggcc atttgctttt ctcaagggaag agataattgg cacactactc 180
ttaaatggca cctacactgc agtgggtgtgt tatttttaca agggaagtca agccttcacc 240
tgtttccctc actttaactt accttgtgcc tgcagggtaa ttgtcagaga cttcagaaat 300
ccaagatcct ggggtccctt ttggacattg tgtcattgag gcatgtccct aggaacatgt 360
aagatgaagc catgataggc tattcaggac agttaccag aggaaatatt gattcacttt 420
ttatgcacaa catctgggta atggtttcta caatgagggt tatataattg gaatagggtga 480
ccagaaattt attgttaacc ttgtccgaag ttttaaagaa cactttcaca gctctcaaag 540
ctgaatgatg agtctcaact atttgactca cgtgaaatag aaaatctggt agcttttagac 600
tttctactag ccagtcatga tgggtatctgt gccattactg gcaatctgtg ttacacatga 660
ataaatacta ttagccaagt acaatgctct tctaaactga gggggtcagc cacttgactc 720
tccaaggaat atcctcctag attctagaca tattttcttg tcttgggttc agtaatttct 780
gtatatggct tggaggcatt ctgcaaagtt cagtctcac tcttctactt tgtgtgcatc 840
ttcaatcttc catgcttccg tgcagccact gtcacatcag atgatcgaaa atctcatccc 900
ttaacaaaat acacaaaata atagacactg atttaagttt agacactcta aaccttaaaa 960
aaaaaagatg ataatatcag ggctcatgac agtgatgtaa atctggaatg atactgcttt 1020
tgtggccaac cctttggcct ggcgaaaaga cggccaaaag ctgttgagac cagaactaga 1080
aagaccacct cctgttgtca cttgtgtgat tagaaccaca aaatatctta tgaatttcat 1140
aacactttca tctttgctca gaatctcacc tagttgcata agtctttaa aaatcaacca 1200
gttcaaagat ttgctctcct tttatcccag tctattacct ttctgagttt aatccataag 1260
aaataaaaat ggtatatgca cttcctgtaa tgagatgcca atttagagtt gattccttat 1320
gttctctctt gccaaagtaa gtgaatgaaa gccagttggc ttacatcata atagctttca 1380
tttaaggcac aggccttcaa ctttgtgtca ctgaaaatat ctaaagttaa tttacctgtg 1440
taattatcta aattatgctt ttcaagtttc tgtgcatctt cgggtgtcgca 1490

```

<210> 106
 <211> 1174
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 4001243CB1

```

<400> 106
cgggacaaca ggaccctatg aagggtgggcc cacagcaaaa ggagagatga ttctagagca 60
tccagtcttc tagggcagca aaacaaccta aattttctaa gagggcaccc agctgagggt 120
gccccgggg agggctgagg cgtcagggtg acgggtccac tgcccactca cctgcgacct 180
caaagcccct ctctccttg ggggtgctct gacagccacc tccagggcag gcgagtggcg 240
ctgggacaaa ggctggcccc actgcgcccc acccaagcag acggtccttc cccagacct 300
ggcgccaaac tggagtgaac gcccgaccac cgtgtctcac agggaaaactg acaccagatg 360
cgaacttcca aatggatccc tccctgcaag tgtggagctg gcgctaccag gcactgctct 420
ggccatgctg ctaagacaca ggcagagggc gctgcccacc acgctggcga cggcctcaaa 480
gccctgttc atgcctggga cagcgcccaa ggaccttgct catgcctggg acaggcccca 540

```

```

gggccccccac tggctgcagt cagcagcggg cagggtgggtg ggggaaggta tggacactcc 600
gtggggccgga gctgggagaa caaggcctat tattggacac ctggtggcca tggcaaccac 660
acaaggatgc ctgagactga aaatctgtgg gcttcaagga gctccagctc ttgcaactggc 720
tgagtcacag tgactatata actcttactc ccacttttgg gacacttttt gagaggggaca 780
gggatcctat ctaactacac gggacagaca tcgccaaga ccgtcctgag caagcctgga 840
cgctgtgacc ctaacgatga aggtgtcccg cagacaatgt ccggggcagg caccatgctc 900
tcccaacctt ccacagccag atgtttttgt aaagaacaat aaaaatgaat tactagaaaa 960
gcaaagactt aaaatacaca aaaaaaaaaa caagggggag gccgccgaat atagaggacc 1020
cggaagaccg gggaattaat cccgaaccgg taccgtgggg gcgctccaag gattcccata 1080
tatagggagc cacattaaga acttgggaaa tcgaggccaa tgcgtgacct cgtgttgcca 1140
atgtaaccgg acaattccca caaccaaaca aagg                                     1174

```

<210> 107

<211> 818

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6986717CB1

<400> 107

```

ctgggctcac agacaggtga tgagcaggca gattcggggg cagagagtgt ggcaggacgc 60
tcagctctct aatgacagcc ctttcctggg aacctcccca tgtagcact gccttactct 120
gtgggtctgt ttggcctggg agaggacagg ccgatggaa gtggctgctg gcttctctat 180
aaaatgggaa taaagacaat atccatttca catggcttct gcgaggatga aatggcacga 240
tatacgtaac tcactgtgga cttggctcaa tcaatgctgt ttccctcct ccgcttcctc 300
ttctatagat ggtgattcca ggattgacta cattgctgat aaaaactacc ttctggggct 360
tccgttttgg ggagctgggg atggggagag ggagtacaag ttctagatgc ctggtcagcc 420
cctctttttc tcttctgcat gtagggggac gcttgacca gcttgctgc accctgcca 480
aggagctgag ggggaaggac atgcgatgg tcccatgga gatgttcaac tactgctccc 540
agctggagga cgagaatagc tcagctgggc tggatattct gggccaccct gcaccaaggc 600
cagtccagag cctgctaagc ccaagcccg ggctgagccg gagccggagc ccagcacagc 660
ctgcccacag aagcagaggc accggccggc gagcgtgagg cgagccatgg gcacggtgat 720
cattgcaggg gtcgtgtgcg gcgtcgtctg catcatgatg gtggtggccg ctgcctatgg 780
ctgcatctac gcctccctca tggccaagta ccaccgag                                     818

```

<210> 108

<211> 4717

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7503512CB1

<400> 108

```

atggcgcggc cgggtccgggg agggctcggg gccccgcgcc gctcgccttg ccttctcctt 60
ctctggctgc ttttgcttcg gctggagccg gtgaccgccg cggccggccc gcgggcgcc 120
tgcgcgcccg cctgcacttg cgctggggac tcgctggact gcggtgggcg cgggctggct 180
gcgttgcccc gggacctgcc ctccctggac cggagcctaa acctgagtta caacaaactc 240
tctgagattg accctgctgg ttttgaggac ttgccgaacc tacaggaagt gtacctcaat 300
aataatgagt tgacagcggg accatccctg ggcgctgctt catcacatgt cgtctctctc 360
tttctgcagc acaacaagat tcgcagcgtg gaggggagcc agctgaaggc ctacctttcc 420
ttagaagtgt tagatctgag tttgaacaac atcacggaag tgcggaacac ctgctttcca 480
cacggaccgc ctataaagga gctcaacctg gcaggcaatc ggattggcac cctggagttg 540
ggagcatttg atggtctgtc acggtcgtcg ctaactcttc gcctgagcaa aaacaggatt 600
cggctgatag agggcctcac cttccagggg ctcaacagct tggaggtgct gaagcttcag 660
cgaaacaaca tcagcaaaact gacagatggg gccttctggg gactgtccaa gtactctgtg 720
ctgcacctgg agtacaacag cctggtagaa gtgaacagcg gctcgtctta cggcctcacg 780
gccctgcac agctccacct cagcaacaat tccatcgctc gcattcaccg caagggctgg 840
agcttctgcc agaagctgca tgagttggtc ctgtccttca acaacctgac acggctggac 900
gaggagagcc tggccgagct gagcagcctg agtgtcctgc gtctcagcca caattccatc 960

```

agccacattg	cggagggtgc	cttcaaggga	ctcaggagcc	tgcgagtctt	ggatctggac	1020
cataacgaga	tttcgggcac	aatagaggac	acgagcggcg	ccttctcagg	gctcgacagc	1080
ctcagcaagc	tgactctgtt	tggaaacaag	atcaagtctg	tggctaagag	agcattctcg	1140
gggctggaag	gcctggagca	cctgaacctt	ggagggaatg	cgatcagatc	tgtccagttt	1200
gatgcctttg	tgaagatgaa	gaatcttaaa	gagctccata	tcagcagcga	cagcttctcg	1260
tgtgactgcc	agctgaagtg	gctgcccccg	tggctaattg	gcaggatgct	gcaggccttt	1320
gtgacagcca	cctgtgcccc	cccagaatca	ctgaagggtc	agagcatttt	ctctgtgcc	1380
ccagagagtt	togtgtgcga	tgacttctcg	aagccacaga	tcatacccca	gccagaaacc	1440
accatggcta	tgggtgggcaa	ggacatccgg	tttcatgtct	cagcagccag	cagcagcagc	1500
tcccccatga	cctttgcttg	gaagaaagac	aatgaagtcc	tgaccaatgc	agacatggag	1560
aactttgtcc	acgtccacgc	gcaggacggg	gaagtgtatg	agtacaccac	catcctgcac	1620
ctccgtcagg	tcacttttcg	gcacgagggc	cgctaccaat	gtgtcatcac	caaccacttt	1680
ggctccacct	attcacataa	ggccaggctc	accgtgaatg	tgttgccatc	attcaccaaa	1740
acgccccacg	acataaccat	ccggaccacc	accatggccc	gcctcgaatg	tgtgtgccca	1800
ggtcacccaa	accctcagat	tgcttggcag	aaggatggag	gcacggattt	ccccgctgcc	1860
cgtgagcgac	gcatgcatgt	catgccggat	gacgacgtgt	ttttcatcac	tgatgtgaaa	1920
atagatgacg	caggggttta	cagctgtact	gctcagaact	cagccgggtc	tatttcagct	1980
aatgccaccc	tgactgtcct	agagacccca	tccttgggtg	tccccttgga	agaccgtgtg	2040
gtatctgtgg	gagaaacagt	ggccctccaa	tgcaaagcca	cggggaaccc	tccgccccgc	2100
atcacctggt	tcaaggggga	ccgcccgtcg	agcctcactg	agcggcacca	cttgaccctt	2160
gacaaccagc	tcctgggtgt	tcagaacgtg	gtggcagagg	atgcccccg	atatacctgt	2220
gagatgtcca	acaccctggg	cacggagcga	gtcacagccc	agctgagcgt	cctgcccgc	2280
gcaggctgca	ggaaggatgg	gaccacggta	ggcatcttca	ccattgctgt	cgtgagcagc	2340
atcgctcctga	cgctactggt	ctgggtgtgc	atcatctacc	agaccaggaa	gaagagttaa	2400
gagtacagtg	tcaccaacac	agatgaaacc	gtcgtgccac	cagatgttcc	aagctacctc	2460
tcttctcagg	ggaccctttc	tgaccgacaa	gaaaccgtgg	tcaggaccga	gggtggccct	2520
caggccaatg	ggcacattga	gagcaatggt	gtgtgtccaa	gagatgcaag	ccactttcca	2580
gagcccgcga	ctcacagcgt	tgcttgcagg	cagccaaagc	tctgtgctgg	gtctgcgtat	2640
cacaaagagc	cgtggaaagc	gatggagaaa	gctgaaggga	cacctggggc	acataagatg	2700
gaacacggtg	gccgggtcgt	atgcagtgc	tgcaacaccg	aagtggactg	ttactccagg	2760
ggacaagcct	tccaccccca	gcctgtgtcc	agagacagcg	cacagccaag	tgcgccaaat	2820
ggccccggagc	cgggtggggg	tgaccaagag	cattctccac	atcaccagtg	cagcaggagt	2880
gccgctgggtg	cctgcccaga	gtgccaaagg	tcgctctacc	ccagtaacca	cgtagcaatg	2940
ctgacggctg	tgaagaaaaa	gccaatggca	tctctagatg	ggaaagggga	ttcttctctg	3000
acttttagcaa	ggttgtatca	cccggactcc	acagagctac	agcctgcac	ttcattaact	3060
tcaggcagtc	cagagcgcgc	ggaagcccag	tacttgcttg	tttccaatgg	ccacctcccc	3120
aaagcatgtg	acgccagtc	cgagtccacg	ccactgacag	gacagctccc	cgggaaacag	3180
agggtgccac	tgctgttggc	acaaaaagc	taggttttgt	ctacctcagt	tcttgtcata	3240
ccaatctcta	cgggaaagag	aggtaggaga	ggctgcgagg	aagcttgggt	tcaagcgtca	3300
ctcatctgta	catagttgta	actccatgt	ggagtatcag	tcgtccacag	gacttggatc	3360
tgaagcacag	taaacgcaag	aggggatttg	tgtacaaaag	gcaaaaaaag	tatttgatat	3420
cattgtacat	aagagttttc	agagatttca	tatatatctt	ttacagaggc	tattttaatc	3480
tttagtgc	ggtttaacaga	aaaaaattat	acaattttga	caatattatt	tttcgtatca	3540
ggttgctgtt	taatttttga	gggggtgggg	aaatagttct	ggtgccttaa	cgcatggctg	3600
gaatttatag	aggctacac	cacatttgtt	cacaggagt	tttgggtcgg	ggtgggaagg	3660
atggaaggcc	ttggatttat	attgcacttc	atagaccctt	aggctgctgt	gcgggtgggac	3720
tccacatg	ccggaaggag	cttcagggtg	gcactgctca	tgtgtggatg	cccctgcaac	3780
aggcttccct	gtctgtagag	ccagggggtg	aagtgccatc	cacacttgca	gtgaatggct	3840
tttcctttta	ggtttaagtc	ctgtctgtct	gtaaggcgta	gaatctgtcc	gtctgtaagg	3900
cgtagaatga	gggttgttaa	tccatcacaa	gcaaaaggtc	agaacagtta	aacactgcct	3960
ttcctctctc	tcttatttta	tgataaaaagc	aaatgtggcc	ttctcagtat	cattcgattg	4020
ctatttgaga	ccttttaaatt	aaggtaaagg	ctgctgggtg	tggtaacctg	ggatttttct	4080
atactgatgt	tttcgttttg	ccaatataat	gagtattaca	ttggccttgg	gggacagaaa	4140
ggaggaagtt	ctgacttttc	agggctacct	tatttctact	aaggaccag	agcaggcctg	4200
tccatgccat	tccttcgcac	agatgaaact	gagctggggc	tggaaaggac	agcccttgac	4260
ctgggttctg	ggtataattt	gcacttttga	gactgggtagc	taaccatctt	atgagtgcga	4320
atgtgtcatt	tagtaaaact	taaatagaaa	caaggctcct	caaatgttcc	tttgccaaa	4380
agctgaaggg	agttactgag	aaaatagtta	acaattactg	tcagggtgtca	tactgtttca	4440
aaaggtaagc	acatttagaa	ttttgttctt	gacagttaac	tgactaatct	tacttccaca	4500
aaatatgtga	atttgctgct	tctgagaggc	aatgtgaaag	agggagtatt	acttttatgt	4560
acaaagttat	ttatttatag	aaattttggt	acagtgtaca	ttgaaaacca	tgtaaaatat	4620
tgaagtgtct	aacaaatggc	attgaagtgt	ctttaataaa	ggttcattta	taaagtgtca	4680
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	atcggtc			4717